[
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied include Ewing's sarcoma/soft tissue sarcoma, neuroblastoma, and brain tumors. The corresponding ICDCodes for these diseases are C71.7, C71.9, C79.31, D33.0, D33.1, D33.2, and D49.6. The drugs being used in the trial are plerixafor. \n\nThe eligibility criteria for this trial include:\n- Age between 2 to less than 18 years during stage 1 and 1 to less than 18 years during stage 2.\n- Diagnosis of Ewing's sarcoma, soft tissue sarcoma, lymphoma, neuroblastoma, brain tumors, or other malignancy (excluding leukemia) requiring high dose chemotherapy and autologous transplant as rescue therapy.\n- Eligibility for autologous transplantation.\n- Recovery from all acute significant toxic effects of prior chemotherapy.\n- Adequate performance status.\n- Specific blood count requirements.\n- Specific liver function requirements.\n- Signed informed consent from the patient or their parent/legal guardian.\n- Sexual activity requires abstinence or the use of contraception during plerixafor treatment and for at least 3 months following any plerixafor treatment.\n\nThe exclusion criteria for this trial include:\n- Any form of leukemia.\n- High-risk co-morbid condition.\n- Previous stem cell transplantation.\n- Prohibited marrow involvement prior to mobilization.\n- Ongoing toxicities from prior chemotherapy.\n- Acute infection or fever.\n- HIV seropositivity, AIDS, hepatitis C, or active hepatitis B infections.\n- Positive pregnancy test in post-pubertal girls.\n- History of clinically significant cardiac abnormality or arrhythmia.\n- Use of investigational drugs not approved in any indication within 2 weeks prior to the first dose of G-CSF.\n- Inability to adhere to the study requirements, as determined by the investigator.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 1. The diseases being studied are \"renal impairment\" and \"heart failure\". The corresponding ICDCodes for these diseases are \"M10.38\", \"M10.30\", \"M10.311\", \"M10.312\", \"M10.319\", \"M10.321\", \"M10.322\" for renal impairment, and \"I50.814\", \"I09.81\", \"I50.82\", \"I50.89\", \"I50.9\", \"T86.22\", \"I11.0\" for heart failure. The drugs being tested are \"mk-7145\", \"furosemide\", and \"torsemide\". \n\nThe eligibility criteria for this sample include various inclusion and exclusion criteria. The inclusion criteria state that participants must be of non-child bearing potential or agree to use at least 2 acceptable contraceptive measures if they are of child-bearing potential. They must also have a Body Mass Index (BMI) between 17.5 and 38 kg/m^2, no present history of clinically significant uncontrolled arrhythmias on electrocardiogram (ECG), and be a nonsmoker or a light smoker consuming up to an average of 20 cigarettes (or equivalent tobacco product) per day. \n\nThe exclusion criteria include factors such as being mentally or legally institutionalized and/or incapacitated, having significant emotional problems or a history of clinically significant psychiatric disorder over the last 5 years, being diagnosed with acute coronary syndrome or acute cardiovascular (CV) event, having unstable angina pectoris, requiring high dose peroxisome proliferator-activated receptor (PPAR) antagonist for diabetes, having infectious disease requiring concomitant use of aminoglycosides, having low plasma potassium (hypokalemia), having a recent history of stroke, uncontrolled seizures, or uncontrolled major neurological disorder, having urinary retention, hydronephrosis or hydroureter, having active nephrocalcinosis, nephrolithiasis, or hypercalciuria, having functional disability that can interfere with rising from a semi-recumbent position to the standing position, having a history of malignant neoplastic disease, being unable to refrain from the use of certain medications, consuming excessive amounts of alcohol or caffeine, having had major surgery, donated or lost 1 unit of blood, or participated in another investigational study within 4 weeks, and being a regular user of any illicit drugs or having a history of drug (including alcohol) abuse within approximately 6 months.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease mentioned is small cell lung cancer. The ICDCodes associated with this disease are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The drug mentioned is chloroquine. The eligibility criteria for this trial include various factors such as histologically or cytologically confirmed stage I-III small cell lung cancer, measurable disease site, WHO performance status, blood counts, renal and hepatic function, previous treatments, lung function, medical history, cardiac conditions, infectious diseases, other active malignancies, recent surgeries or treatments, and various other factors. The exclusion criteria are the opposite of the inclusion criteria.",
    "The sample provided is a record from a table that contains information about clinical trials. The table has several columns, including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of the diseases being studied, \"icdcodes\" which lists the corresponding ICD-10 codes for the diseases, \"drugs\" which lists the names of the drugs being used in the trial, and \"criteria\" which provides the eligibility criteria for participants.\n\nIn this specific sample, the phase of the trial is phase 1. The diseases being studied include non-Hodgkin's lymphoma, multiple myeloma, mycosis fungoides, and Hodgkin's lymphoma. The corresponding ICD-10 codes for these diseases are also provided. The drug being used in the trial is dasatinib.\n\nThe eligibility criteria for participants are listed under \"criteria.\" The inclusion criteria include being recipients of first ASCT (autologous stem cell transplantation) for the treatment of hematologic malignancies, being between 100 to 180 days after ASCT, having a performance status of at least 60%, and meeting certain laboratory values such as total bilirubin, hepatic enzymes, serum creatinine, hemoglobin, absolute neutrophil counts, and platelet counts. The participant should also be able to provide signed written informed consent and be able to take oral medication.\n\nThe exclusion criteria include evidence of disease progression before day 100 after ASCT, certain restrictions for women of childbearing potential, medical history and concurrent diseases that may increase the risk of toxicity, history of significant bleeding disorder unrelated to cancer, previous history of severe toxicity to dasatinib, and prohibited treatments and therapies.\n\nOverall, this sample provides information about a phase 1 clinical trial studying the use of dasatinib in the treatment of various hematologic malignancies. It outlines the diseases being studied, the eligibility criteria for participants, and the exclusion criteria.",
    "The sample from the table is for a Phase 1 clinical trial focused on alcohol dependence. The trial is looking for participants who are U.S. Veterans and meet the DSM-IV diagnostic criteria for alcohol dependence. They should also have reported drinking at least 48 standard drinks in a 30-day period before enrollment, with at least 2 days of heavy drinking. The trial also includes a control group of healthy individuals who do not have any Axis I DSM-IV diagnosis (except for nicotine dependence) and have reported drinking less than 10 drinks weekly over the past 90 days.\n\nThere are various exclusion criteria for both the alcohol dependence group and the healthy control group. For example, individuals currently receiving treatment for alcohol problems or with a history of treatment in the 30 days before enrollment are excluded. Additionally, individuals with a current diagnosis of dependence on any psychoactive substances other than alcohol and nicotine are excluded.\n\nOther exclusion criteria apply to all subjects, including a current diagnosis of certain mental illnesses, current use of psychoactive drugs (except occasional marijuana use), significant physical abnormalities, abnormal ECG results, history of epilepsy or severe head trauma, and recent treatment with certain medications. Pregnancy, nursing, refusal to use reliable birth control methods (for females), presence of metal fragments or devices that could interfere with an MRI scan, recent radiation exposure, elevated breath-alcohol levels, abnormal vital signs, suicidal ideation, and previous exposure to ionizing radiation are also exclusion criteria.\n\nThe sample description provides detailed information about the eligibility criteria and exclusion criteria for participants in the clinical trial.",
    "The sample is a phase 1 clinical trial for the treatment of cystic fibrosis. The trial is looking for participants who are homozygous for the F508del-CFTR gene, have a sweat chloride level of at least 60 mEq/L, weigh at least 40 kg, have a forced expiratory volume in one second (FEV1) of at least 40% predicted, have an oxygen saturation of at least 90% while breathing ambient air, and have no clinically significant abnormalities in their blood and urine tests. Women of childbearing potential must have a negative pregnancy test and be willing to follow contraception requirements. \n\nExclusion criteria include previous enrollment in another cohort for this study, any acute infection or change in chronic therapies for CF lung disease within 4 weeks of the study, low blood hemoglobin or serum albumin levels, abnormal liver function, abnormal renal function, history of ventricular tachycardia or other ventricular arrhythmias, history of prolonged QT and/or QTcF interval, history of solid organ or hematological transplantation, recent intranasal medication changes, required use of continuous or nocturnal supplemental oxygen, and concomitant use of any inhibitors or inducers of CYP3A4.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The diseases being studied are non-small cell lung cancer, non-small-cell lung carcinoma, lung cancer, and NSCLC. The corresponding ICDCodes for these diseases are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The drug being tested is theophylline. \n\nThe eligibility criteria for this trial include the following inclusion criteria:\n- The patient must have histologically confirmed NSCLC, stage IIIB with malignant pleural effusion, stage IV, or recurrent disease.\n- There should be at least one site of measurable disease.\n- If the patient has brain metastasis, it must be stable by CT scan or MRI for at least 4 weeks after treatment.\n- The patient must have received and failed at least one line of palliative therapy (chemotherapy or biological therapy).\n- The patient must be 18 years or older.\n- The ECOG performance status should be between 0-2.\n- The patient's life expectancy should be at least 3 months.\n- Various laboratory parameters such as hemoglobin levels, ANC, platelets, creatinine clearance, total and direct bilirubin, and liver function tests should meet certain criteria.\n- The patient must have signed informed consent.\n\nThe exclusion criteria for this trial include:\n- Patients with active or symptomatic cardiac disease such as congestive heart failure, angina pectoris, or recent myocardial infraction. Patients with a history of these conditions who are stable taking cardiac medications are also excluded.\n- Pregnant or lactating women are excluded, and a negative pregnancy test is required for women of childbearing potential.\n- Patients with known HIV infection are excluded.\n- Patients with uncontrolled or untreated brain or spinal cord metastases are excluded.\n- Patients with active infection are excluded.\n- Patients receiving concomitant steroid or other immunosuppressive therapy are excluded.\n- Other active malignancies within the past three years, except for basal and/or squamous cell carcinoma(s) or in situ cervical cancer, are exclusion criteria.\n- Meningeal carcinomatosis is an exclusion criterion.\n- Patients who have undergone chemotherapy, radiation therapy, or other anti-tumor therapy in the last three weeks are excluded.\n- Patients with immune deficiency syndromes such as rheumatoid arthritis, systemic lupus erythematousus, Sjogren's disease, sarcoidosis, vasculitis, polymyositis, or glomerulonephritis are excluded.\n- Patients with compromised lung function, indicated by FeV1 < 30% of the predicted value, DLCO < 30% of the predicted value, or PCO2 > 45 mmHg, are excluded.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is \"infections, bacterial.\" The ICDCodes associated with this disease are ['A49.9', 'A04.9', 'A04.8', 'A49.8']. The drugs being tested in this trial are 'gsk1322322 1200 mg', 'gsk1322322 3000 mg', 'placebo', and 'moxifloxacin'. \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" Inclusion criteria include being healthy, being between 18 and 65 years old, having specific body weight and BMI ranges, and meeting certain laboratory parameters. Exclusion criteria include having a history of certain cardiac diseases or procedures, having conditions that could interfere with the study drugs, having certain medical conditions or sensitivities, and being unable to follow the study procedures.\n\nOverall, this sample provides information about the phase, diseases, ICDCodes, drugs, and eligibility criteria for a specific clinical trial.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is divided into different phases, and this particular record is from phase 1/phase 2. The trial focuses on the treatment of cancer, specifically grade four Glioblastoma Multiforme. The trial requires patients to meet certain eligibility criteria, such as being 18 years or older, having a confirmed diagnosis of Glioblastoma Multiforme, and showing evidence of tumor progression after radiation and first-line chemotherapy. Other criteria include having a Karnofsky performance scale of 60% or greater, being willing to comply with study requirements, and allowing their primary care practitioner and consultant to be notified of their participation. \n\nThere are also exclusion criteria, which specify conditions that would disqualify a patient from participating in the trial. These include having Glioblastoma Multiforme secondary to low-grade glioma or anaplastic glioma, currently receiving treatment for recurrent Glioblastoma Multiforme, and having undergone certain surgeries or procedures within a specific timeframe. Other exclusion criteria include having a history of different malignancies, using cannabis or cannabinoid-based medications within 30 days of study entry, having a history of substance abuse or psychiatric disorders, and having certain cardiac disorders or toxicities. \n\nAdditionally, there are criteria related to pregnancy, contraception, and previous use of investigational medicinal products. The sample also mentions that patients should not have any significant diseases or disorders that could put them at risk or influence the study results. Other factors that would disqualify a patient include planned travel outside the country of residence during the study, previous enrollment in the same study, known hypersensitivity to cannabinoids or the investigational medicinal product, intolerance to Temozolomide, physical abnormalities that would prevent safe participation, and unwillingness to abstain from blood donation during the study.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2, and the diseases being studied are Crohn's disease and Crohn disease. The corresponding ICD-10 codes for these diseases are provided. The drug being tested is high-dose cyclophosphamide. The eligibility criteria for participants are listed, including age requirements, specific disease severity criteria, previous treatment history, and willingness to participate in the trial. There are also exclusion criteria, such as pregnancy or nursing, certain medical conditions, history of allergic reactions, recent malignancy, and other factors that would make a patient ineligible.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease being studied is metastatic melanoma. The icd-10 codes associated with this disease are C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, and C43.4. The drugs being used in the trial are ipilimumab and isoniazid. The eligibility criteria for participants in this trial include having histologically confirmed stage III or stage IV melanoma, having a minimum of 1 metastatic lesion, having a performance status of Eastern Cooperative Oncology Group 0-1, meeting specific laboratory parameter ranges, having an estimated life expectancy of at least 4 to 6 months, having fully recovered from surgery, being at least 18 years old, and being able and willing to give written informed consent. The exclusion criteria include having active cerebral metastases, having another known malignancy within the past 3 years (except for non-melanoma skin cancer and cervical carcinoma in situ), having a history of tuberculosis or hypersensitivity to BCG, having contraindications to the use of isoniazid, having generalized skin disease, having autoimmune diseases (with some exceptions), having underlying medical or psychiatric conditions that may make the administration of ipilimumab hazardous, having received prior immunotherapy or systemic adjuvant therapy for melanoma, having received prior treatment with a CTLA-4 inhibitor, receiving concomitant therapy with certain medications, having certain infections, having received chemotherapy or radiation therapy within the past 4 weeks (6 weeks for nitrosourea drugs), lacking availability for follow-up assessments, participating in another clinical trial involving an investigational agent within the past 4 weeks, having mental impairment that may compromise the ability to give informed consent or comply with study requirements, being pregnant or breastfeeding, and being unwilling or unable to use contraception during the study period. Prisoners or patients who are compulsorily detained for treatment are also excluded from the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase is Phase 1. The diseases listed include various types of acute myeloid leukemia, chronic myelogenous leukemia, and recurrent adult acute myeloid leukemia. The ICDCodes associated with these diseases are also provided. The drugs mentioned are metformin hydrochloride and cytarabine. The eligibility criteria include specific requirements for patients with relapsed/refractory disease, previously untreated AML, chronic myelogenous leukemia, and other medical conditions. Exclusion criteria are also listed, such as recent chemotherapy or radiotherapy, history of diabetes mellitus treated with metformin, pregnancy or breastfeeding, and active infections or other medical problems.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 1. The disease mentioned is \"pancreatic neoplasms\" and its corresponding ICDCodes is \"C25.3\". The drugs being used in this trial are \"ascorbate\" and \"gemcitabine\". \n\nThe eligibility criteria for this trial include the following:\n- Patients must have a histologically or cytologically diagnosed pancreatic adenocarcinoma, with documentation of disease extent by CT scan.\n- The patient must be at least 18 years old.\n- The patient's ECOG performance status should be 0, 1, or 2 (Karnofsky > 50%).\n- The patient's blood count and differential must meet certain criteria, such as ANC \u2265 1500 cells per mm3, platelets \u2265 100,000 per mm3, and leukocytes \u2265 3,000 per mm3.\n- The patient's serum blood chemistries should also meet certain criteria, such as creatinine \u2264 1.5 x UIHC upper limit of normal, total bilirubin \u2264 2 x UIHC upper limit of normal, ALT \u2264 2.5 times the UIHC upper limit of normal, AST \u2264 2.5 times the UIHC upper limit of normal, and PT/INR within normal limits (UIHC).\n- The patient should be able to tolerate a test dose of ascorbate.\n- The patient should not be pregnant.\n- The patient should have the ability to understand and sign a written informed consent document.\n\nThe exclusion criteria for this trial include the following:\n- G6PD deficiency.\n- Prior abdominal radiotherapy that would result in overlap of fields.\n- Adjuvant therapy (including radiation therapy) within 2 calendar weeks.\n- Patients actively receiving insulin.\n- Patients who are on certain drugs and cannot have a drug substitution, such as flecainide, methadone, amphetamines, quinidine, and chlorpropamide.\n- Second malignancy other than non-melanoma skin cancers within the past 5 years.\n- Other investigational agents/therapy with the intention to treat the disease under study.\n- Uncontrolled intercurrent illness.\n- Pregnant or lactating women.\n- Known HIV-positive individuals.\n\nOverall, this sample provides specific information about the phase, disease, ICDCodes, drugs, and eligibility criteria for a clinical trial related to pancreatic neoplasms.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is \"multiple myeloma in relapse.\" The ICDCodes associated with this disease are \"C90.02.\" The drug being used in the trial is \"combination therapy.\" The eligibility criteria for participants in this trial include being over 18 years old, having relapsed or progressive multiple myeloma, having received 1 to 4 prior treatment regimens for multiple myeloma, having an ECOG performance status of 0-2, and having adequate organ and marrow function. There are also specific criteria related to pregnancy, contraception, prior therapy, and exclusion criteria such as recent chemotherapy or radiotherapy, ongoing infections, and certain medical conditions.",
    "The sample from the table represents a phase 1 clinical trial for the treatment of cutaneous T-cell lymphoma. The trial includes patients with biopsy-proven, measurable, Stage IB-IVB relapsed or refractory cutaneous T-cell lymphoma after 2 lines of skin-directed therapy or one prior line of systemic therapy. The eligibility criteria include being able to understand and voluntarily sign an informed consent form, being at least 18 years old, and being able to adhere to the study visit schedule and other protocol requirements.\n\nThe sample also includes a list of diseases, which in this case are lymphoma, T-cell lymphoma, and cutaneous lymphoma. The corresponding ICD-10 codes for these diseases are also provided. Additionally, there is a list of drugs being used in the trial, which are istodax and doxil.\n\nThe criteria for inclusion in the trial include specific laboratory test results, such as absolute neutrophil count, platelet count, total bilirubin, aspartate aminotransferase, and creatinine levels. The criteria also state that participants must be disease-free of prior malignancies for at least 5 years, except for certain specified conditions. Other criteria include negative serum pregnancy test for females of childbearing potential, use of effective contraceptive methods, and a life expectancy of more than 90 days.\n\nThe exclusion criteria include any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form. Pregnant or breastfeeding females are also excluded, as well as individuals with certain medical conditions or prior treatments that would place them at unacceptable risk or confound the ability to interpret data from the study. The use of any other experimental drug or therapy within 28 days of baseline, prior allogeneic hematopoietic cell transplant, prior solid organ transplant, and cumulative anthracycline exposure greater than 300 mg/m2 doxorubicin equivalents are also exclusion criteria.\n\nFurthermore, the sample includes exclusion criteria related to viral infections, cardiac abnormalities, and the use of certain medications. Patients with known active viral infections with HIV, HBV, or HCV are excluded, except for those who are seropositive due to prior hepatitis B virus vaccination. Various cardiac abnormalities, such as congenital long QT syndrome, baseline QTc interval, myocardial infraction, and other significant ECG abnormalities, are also exclusion criteria. Patients with certain cardiac conditions, uncontrolled hypertension, or taking drugs leading to significant QT prolongation are excluded as well. Finally, concomitant use of CYP3A4 inhibitors or inducers is an exclusion criterion unless the medication(s) can be stopped prior to starting study therapies.",
    "The sample from the table represents a clinical trial for phase 1 of a drug study. The trial focuses on patients with various types of acute myeloid leukemia (AML) who have relapsed after induction therapy or are refractory to induction chemotherapy. The eligibility criteria include having an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, serum creatinine levels within a certain range, normal bilirubin levels, and specific limits for AST/ALT and alkaline phosphatase. Participants must also be registered in the Revlimid assistance program and comply with its requirements. Female participants of childbearing potential must have negative pregnancy tests and commit to using two forms of birth control. The exclusion criteria include not undergoing concurrent radiotherapy, chemotherapy, or immunotherapy, not having received prior lenalidomide therapy, and not having severe concurrent diseases or serious organ dysfunction. Pregnant or nursing patients and those with HIV infection are also excluded from the study.",
    "The sample provided is a schema definition of a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. The table has several columns including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of diseases, \"icdcodes\" which lists the ICDCodes (ICD-10 codes) associated with the diseases, \"drugs\" which lists the names of drugs, and \"criteria\" which provides the eligibility criteria for the trial.\n\nThe sample data in the table includes information for different cohorts and steps within the trial. It includes details such as the inclusion criteria, exclusion criteria, and specific requirements for each cohort and step. The inclusion criteria include factors such as HIV-1 infection, specific medication history, laboratory values, and negative test results for certain diseases. The exclusion criteria include factors such as a history of malignancy, active infections, autoimmune disorders, and certain medication use. The sample also mentions requirements for pregnancy testing, contraception, and performance scores.\n\nOverall, the table provides a structured format for organizing and storing information related to clinical trial phases, diseases, drugs, and eligibility criteria.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease mentioned is \"advanced solid tumors,\" and the corresponding ICDCodes are ['K74.02', 'G47.22', 'H35.3133', 'H35.3134', 'H35.3113', 'H35.3114', 'H35.3123']. The drug mentioned is \"pqr309.\" \n\nThe eligibility criteria for this trial are as follows:\nInclusion Criteria:\n- The patient must have a histologically or cytologically confirmed diagnosis of advanced solid tumor for which no therapy of proven efficacy is available.\n- The patient must be at least 18 years old.\n- There must be evidence of tumor progression with measurable or evaluable disease.\n- Male patients must be using adequate contraceptive measures.\n- The patient must have an Eastern Cooperative Oncology Group (ECOG) Performance Score of 0-1.\n- The patient must have signed informed consent.\n\nExclusion Criteria:\n- The patient must not be receiving concomitant anticancer therapy such as chemotherapy, radiotherapy, hormonal therapy, immunotherapy, biological response modifiers, or signal transduction inhibitors.\n- The patient must not have a history of myocardial infraction or coronary artery bypass within the last 3 years.\n- The patient must not have severe/unstable angina, coronary/peripheral arterial bypass, symptomatic congestive heart failure NYHA Class 3 or 4, or hypertension with a blood pressure higher than 150/100mmHg.\n- The patient must not have pre-diagnosed diabetes mellitus.\n- The patient must not have a fasting glucose level higher than 7.0 mmol/L or HbA1c higher than 6%.\n\nThis sample provides specific details about the phase, disease, ICDCodes, drug, and eligibility criteria for a clinical trial.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The diseases being studied are \"relapsed multiple myeloma\" and \"end-stage renal disease.\" The ICDCodes associated with these diseases are \"['G35', 'M15.3', 'M67.49', 'M89.09', 'M89.59', 'M94.29', 'Q78.6']\" and \"['N18.6', 'I12.0', 'I13.11', 'I13.2']\" respectively. The drug being tested is \"carfilzomib.\" The eligibility criteria for this trial include having relapsed multiple myeloma, evaluable disease, prior treatment for multiple myeloma, end-stage renal disease on hemodialysis or CrCl \u2265 75 mL/min, ECOG performance status 0-2, adequate organ and bone marrow function, and certain exclusion criteria such as not having IgM multiple myeloma, POEMS syndrome, Waldenstr\u00f6m Macroglobulinemia, and others.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is \"infections, bacterial.\" The ICDCodes associated with this disease are ['A49.9', 'A04.9', 'A04.8', 'A49.8']. The drugs being used in the trial are 'gsk1322322', 'ee/ne', 'gsk1322322 placebo', and 'ee/ne placebo'. \n\nThe eligibility criteria for this trial include being a healthy non-smoking female between the ages of 18 and 45. The female subjects must either have a documented tubal ligation or hysterectomy without oophorectomy, or be of childbearing age with a non-drug eluting intrauterine device (IUD) in place. They must also be willing to use EE/NE in combination with an appropriate contraceptive method. Other criteria include specific body weight and body mass index ranges, normal liver function, and a QT interval corrected for heart rate below a certain threshold. \n\nThe exclusion criteria include pregnancy, history of certain medical conditions, liver disease, untreated or unstable thyroid disorder or diabetes, recent urinary tract, bladder, or vaginal infection, certain laboratory test results, and history of certain infections or drug/alcohol use. Other exclusion criteria include previous participation in a clinical trial within a certain time period, exposure to multiple new chemical entities, and inability to refrain from certain medications or substances. \n\nAdditionally, there are specific exclusion criteria related to ECG readings, such as abnormal heart rate, PR interval, QRS duration, QTcB interval, evidence of previous myocardial infraction, conduction abnormalities, and significant arrhythmias.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The diseases being studied are stage IA pancreatic cancer, stage IB pancreatic cancer, stage IIA pancreatic cancer, and stage IIB pancreatic cancer. The corresponding ICDCodes for these diseases are C25.3. The drug being investigated is metformin hydrochloride. \n\nThe eligibility criteria for this trial include the following inclusion criteria:\n- Patients must have histologically or cytologically confirmed resectable pancreatic carcinoma, excluding patients with pancreatic neuroendocrine tumors.\n- Patients must not have received prior chemotherapy or radiation therapy.\n- Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or lower.\n- Patients must have surgical resection of the pancreas planned, with enrollment at least 7 days before the surgery. Patients with surgery scheduled more than 15 days in advance will not be excluded.\n- Hemoglobin (Hg)A1C must be below 7%.\n- Total bilirubin must be less than 1.5 times the institutional upper limit of normal.\n- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) must be 2.5 times the institutional upper limit of normal or lower.\n- Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) must be 2.5 times the institutional upper limit of normal or lower.\n- Serum creatinine must be within the normal institutional limits.\n- Alkaline phosphatase must be less than 1.5 times the institutional upper limit of normal.\n- Subjects must have the ability to understand and provide written informed consent.\n\nThe exclusion criteria for this trial include:\n- History of metformin use in the previous 3 months.\n- Treatment with neoadjuvant chemotherapy or radiation therapy.\n- History of allergic reactions attributed to metformin.\n- Patients with uncontrolled intercurrent illness, including ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.\n- Metabolic acidosis, acute or chronic, including ketoacidosis.\n- Metastatic disease.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 1. The disease being studied is \"healthy,\" which suggests that the trial is focused on individuals who are not currently affected by any specific disease. The ICDCodes associated with this disease are \"Z76.3\" and \"Z76.2,\" which are codes used to classify health encounters and reasons for healthcare visits.\n\nThe drugs being tested in this trial are \"pf-06282999\" and \"placebo.\" It appears that there are multiple instances of each drug listed, possibly indicating different dosages or treatment groups.\n\nThe eligibility criteria for this trial are provided under \"Inclusion Criteria\" and \"Exclusion Criteria.\" Inclusion criteria state that the trial is open to healthy men or women (non-childbearing potential) between the ages of 18-40 years, with a specific BMI range and minimum body weight requirement.\n\nExclusion criteria list various conditions or factors that would disqualify individuals from participating in the trial. These include recent tobacco or nicotine use, frequent headaches or migraines, excessive caffeine consumption, recent cold/flu symptoms, history of recurrent or chronic infections, previous treatment with LPS (lipopolysaccharide), and known allergies or hypersensitivity to endotoxin.\n\nOverall, this sample provides a snapshot of a Phase 1 clinical trial focused on healthy individuals, with specific eligibility criteria and drugs being tested.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease mentioned is sickle cell disease, and the corresponding ICDCodes are ['D57.1', 'D57.20', 'D57.212', 'D57.219', 'D57.211', 'D57.213', 'D57.218']. The drug mentioned is hydroxyurea. \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include pediatric patients with documented sickle cell anemia, aged between 1.00 and 9.99 years, weighing at least 10.0 kg at the time of enrollment, and having a parent or guardian willing to provide written informed consent. The patient must also be willing to comply with all study-related treatments, evaluations, and follow-up.\n\nExclusion criteria include having a known medical condition that makes participation ill-advised (such as acute or chronic infectious disease, HIV, or malignancy), acute or chronic severe malnutrition, pre-existing severe hematological toxicity, recent blood transfusion, and recent use of hydroxyurea.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 1, and the disease is schizophrenia. The ICDCodes associated with schizophrenia are ['F20.0', 'F20.1', 'F20.2', 'F20.3', 'F20.5', 'F20.89', 'F20.9']. The drugs being tested in this trial are sep-363856, amisulpride, and placebo. The eligibility criteria include various requirements such as age, health status, blood pressure, heart rate, contraception methods, ECG results, language fluency, handedness, weight, smoking status, and more. There are also exclusion criteria listed, which include factors such as substance dependence, pregnancy, certain medical conditions, history of certain disorders, and more.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is categorized as \"phase 1\" and is focused on the disease \"head and neck squamous cell carcinoma.\" The corresponding ICD-10 codes for this disease are listed as \"C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8.\" The drug being studied in this trial is \"sativex.\" \n\nThe sample also includes the eligibility criteria for participants in the trial. The inclusion criteria state that participants must be willing and able to provide informed consent, be 18 years or older, have been diagnosed with Stage III or Stage IV HNSCC, and be scheduled to undergo radiotherapy of the head and/or neck with or without concomitant chemotherapy. Other criteria include the ability to comply with study requirements, communicate with the investigator, and have acceptable haematological and biochemical function. \n\nThe exclusion criteria state that subjects undergoing chemotherapy only, subjects with cancer other than HNSCC as the primary tumor, and subjects who have undergone reconstructive oral surgery for HNSCC within the last eight weeks are not eligible to participate. Other exclusion criteria include having RTOG Grade 4 oral mucositis, requiring hospital admission or extended hospitalization for the treatment of oral mucositis, and having certain oral conditions that may affect the absorption of Sativex\u00ae. \n\nAdditional exclusion criteria include having certain medical conditions or disorders that may significantly alter the absorption, distribution, metabolism, or excretion of drugs, having evidence of liver disease or liver injury, recent changes in medication, history of drug abuse, hypersensitivity to cannabinoids or the investigational medicinal product, and positive results for hepatitis B, hepatitis C, or HIV. \n\nOther exclusion criteria include current or recent use of cannabis or cannabinoid-based medications, history or family history of schizophrenia or other severe psychiatric disorders, history of epilepsy, significant cardiac disease, pregnancy or planning pregnancy, recent use of an investigational medicinal product, and any other significant disease or disorder that may put the subject at risk or influence the study results. \n\nThe sample also mentions that subjects must not have any abnormalities that would prevent safe participation in the study, must be willing to abstain from blood donation during the study, and must not have any planned travel outside the country of residence during the study. Finally, subjects who have previously been enrolled in this study are also excluded.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease mentioned is \"advanced solid tumors\" and its corresponding ICDCodes are ['K74.02', 'G47.22', 'H35.3133', 'H35.3134', 'H35.3113', 'H35.3114', 'H35.3123']. The drugs being used in the trial are \"lurbinectedin (pm01183)\" and \"cisplatin\". The eligibility criteria for this trial include various factors such as age, performance status, life expectancy, previous treatments, and medical conditions. The sample also includes exclusion criteria, which specify conditions or treatments that would disqualify a patient from participating in the trial.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is migraine. The ICDCodes associated with the disease are G43.B1, G43.D1, G43.B0, G43.D0, G43.A1, G43.411, and G43.419. The drugs being tested in this trial are pf-05180999, placebo, 120 mg mr pf-05180999, 360 mg mr pf-05180999, 10 mg cetirizine, and placebo. The eligibility criteria for this trial include being a healthy male between the ages of 18 and 55 years, having no history of clinically-relevant atopic or dermatological disease, and having a positive reaction to intradermal injection of histamine. The exclusion criteria include having screening laboratory test results outside the acceptable range, having a history of hepatic disorder or hepatitis B/C, intolerance to intradermal histamine injection, and having dark skin (only for Part B of the trial).",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The trial is a combination of phase 1 and phase 2.\n- Diseases: The trial is focused on diabetic macular edema.\n- ICD Codes: The ICD-10 codes associated with the disease are ['E10.311', 'E10.319', 'E11.311', 'E11.319', 'E13.311', 'E13.319', 'E10.3513'].\n- Drugs: The drugs being studied are ranibizumab.\n- Criteria: The eligibility criteria for participants in the trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". The criteria include factors such as age, visual acuity, previous treatments, medical history, and willingness to comply with study requirements.\n\nOverall, this sample provides information about a clinical trial focusing on diabetic macular edema, the phase of the trial, the drugs being studied, and the eligibility criteria for participants.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in either phase 1 or phase 2. The disease being studied is pain. The ICD-10 codes associated with this disease are 'N50.82', 'R07.2', 'R07.82', 'R10.13', 'R10.33', 'R14.1', and 'R52'. The drugs being used in the trial are clonidine and ropivacaine. The eligibility criteria for participants are listed, including requirements such as undergoing foot or ankle surgery with a planned popliteal nerve block for postoperative pain relief, being 19 years of age or older, and being classified as American Society of Anesthesiology (ASA) class 1, 2, or 3. There are also exclusion criteria, such as not meeting the ASA classification, having allergies or intolerance to certain medications, having a history of continuous opioid use, having a pre-existing neurologic deficit in the lower extremity, having a clinically significant coagulopathy, or not following the UAB Department of Anesthesiology Algorithm for the Preoperative Management of an Angiotensin Converting Enzyme Inhibitor (ACEI) or an Angiotensin Receptor Blocker (ARB).",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The phase of the trial, which in this case is a combination of phase 1 and phase 2.\n- Diseases: The specific disease being targeted in the trial, which in this case is \"carcinoma, hepatocellular.\"\n- ICD Codes: The ICD-10 codes associated with the disease, which are listed as \"C22.0\", \"C4A.9\", \"C7B.1\", \"C4A.0\", \"C4A.31\", \"C4A.51\", and \"C4A.8\".\n- Drugs: The drugs being used in the trial, which include \"tepotinib 300 mg\", \"tepotinib 500 mg\", \"tepotinib 1000 mg\", \"tepotinib\", and \"sorafenib\".\n- Criteria: The eligibility criteria for participants in the trial, which are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". These criteria include factors such as confirmed diagnosis of hepatocellular carcinoma, specific disease progression or treatment history, MET status, liver function, age, performance status, and willingness to comply with trial procedures.\n\nOverall, this sample record provides information about a clinical trial targeting hepatocellular carcinoma, using a combination of phase 1 and phase 2, with specific eligibility criteria for participants and a list of drugs being used in the trial.",
    "The sample from the table represents a clinical trial for the treatment of estrogen receptor positive breast cancer. The trial is in phase 1/phase 2. The diseases being studied are limited to estrogen receptor positive breast cancer. The corresponding ICD-10 codes for these diseases are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The drugs being tested in the trial are azd5363, placebo, and fulvestrant. \n\nThe eligibility criteria for the trial include being a post-menopausal woman with a life expectancy of at least 3 months. The participant must have histological confirmation of estrogen receptor positive breast cancer and either metastatic or locally advanced disease that cannot be surgically removed. The participant must also have measurable or non-measurable disease and adequate bone marrow, renal, and hepatic function. The Eastern Cooperative Oncology Group (ECOG) performance status must be less than or equal to 2. The participant must have experienced progressive disease while receiving an aromatase inhibitor for metastatic breast cancer or relapsed with metastatic disease while receiving an aromatase inhibitor in the adjuvant setting. The participant can have up to 3 prior lines of endocrine therapy for advanced breast cancer and up to 1 line of chemotherapy for advanced breast cancer. The participant must be willing to donate an archival tumor sample and a baseline blood sample. They must also be suitable for further endocrine therapy.\n\nThe exclusion criteria for the trial include previous treatment with fulvestrant or PI3K/mTOR/Akt inhibitor therapy, treatment with chemotherapy, immunotherapy, targeted therapy, biologic therapy, or tumor embolization within 21 days of study drug administration, palliative radiotherapy within 7 days of study drug administration, clinically significant abnormalities in glucose metabolism, rapidly progressive visceral disease not suitable for further endocrine therapy, known brain or leptomeningeal metastases, any co-existing medical condition that would prevent trial entry (including significant cardiac disease), and concomitant medication that is unsuitable for combination with the trial medication.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is Type 2 Diabetes Mellitus. The ICDCodes associated with this disease are E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, and E11.44. The drugs being tested in this trial are canagliflozin 100 mg, canagliflozin 50 mg, canagliflozin 300 mg, and a placebo. The eligibility criteria for participants include being diagnosed with Type 2 Diabetes Mellitus, being on a stable regimen of metformin immediate release (IR) monotherapy, being able to swallow whole tablets, not having pancreatic autoimmunity, and agreeing to perform fasting fingerstick glucose self-monitoring during the study. Exclusion criteria include a history of Type 1 diabetes mellitus, maturity onset diabetes of the young (MODY), any secondary form of diabetes, current clinically significant medical illness, abnormal blood pressure, and pregnancy for females.",
    "The sample in the table is for a phase 1 clinical trial. The disease being studied is diabetes mellitus, type 2. The corresponding ICD-10 codes for this disease are E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, and E11.44. The drugs being tested in the trial are canagliflozin, 100 mg and canagliflozin, 300 mg, as well as a placebo. The eligibility criteria for participants in the trial include having a diagnosis of type 2 diabetes for at least 3 months and being on either metformin monotherapy or combination therapy of metformin and a DPP-4 inhibitor for at least 12 weeks prior to screening. Other criteria include specific ranges for HbA1c, fasting plasma glucose, and fasting fingerstick glucose levels. There are also exclusion criteria, such as a history of diabetic ketoacidosis, type 1 diabetes, or pancreas-related conditions, as well as other medical conditions and previous negative experiences with magnetic resonance imaging procedures.",
    "The sample from the table represents a clinical trial with a phase 1/phase 2 designation. The trial focuses on two diseases, namely chronic lymphocytic leukemia and mantle cell lymphoma. The corresponding ICD-10 codes for these diseases are provided as well. The trial involves the use of two drugs, ublituximab and ibrutinib. The eligibility criteria for participants are outlined, including requirements such as confirmed mantle cell lymphoma, refractory or relapsed after prior treatment, and an Eastern Cooperative Oncology Group (ECOG) score of 0 to 2. The exclusion criteria specify conditions such as recent major surgery, chemotherapy, or immunotherapy, as well as the presence of hepatitis B, hepatitis C, or HIV infection. Additionally, recent autologous hematologic stem cell transplant and certain types of lymphoma are also exclusion criteria.",
    "The sample from the table represents a clinical trial for a drug called \"pralatrexate injection\" in patients with peripheral T-cell lymphoma. The trial is in phase 1/phase 2. The eligibility criteria for inclusion in the trial include being a Japanese patient at least 20 years of age, having a histological diagnosis of peripheral T-cell lymphoma, being relapsed or refractory with a treatment history of at least one regimen, having a measurable enlarged lymph node or extranodal mass lesion, and being expected to survive for at least 3 months. Other criteria include having an ECOG performance status of 0-2, having adequate hemopoietic efficacy, liver and kidney function, and providing written consent.\n\nExclusion criteria for the trial include recent use of chemotherapy agents or high doses of systemic adrenocorticosteroids, recent radiation therapy or other study drugs, history of allogeneic or autologous hematopoietic stem cell transplantation, presence of cerebral metastasis or central nervous system lesion, active multiple primary cancer or history of other malignant neoplasms within the past 5 years, severe cardiovascular disease, positive results for HBs antigen, HCV antibody, HIV antibody, or CMV antigen, presence of infectious disease requiring intravenous treatment, and presence of interstitial pneumonia or pulmonary fibrosis or insufficient pulmonary function.\n\nOverall, the sample provides information about the phase, diseases, ICDCodes, drugs, and eligibility criteria for a clinical trial in peripheral T-cell lymphoma.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1. The disease mentioned is \"carcinoma, non-small-cell lung.\" The ICDCodes associated with this disease are \"D02.20,\" \"D02.21,\" and \"D02.22.\" The drug mentioned is \"lenalidomide.\" The eligibility criteria include various conditions such as having stage IIIB or stage IV NSCLC with measurable disease, having a complete or partial response to first-line chemotherapy, and having normal organ and marrow function. There are also specific requirements for age, performance status, and organ functions. Additionally, there are exclusion criteria such as not receiving any other anti-cancer therapy, not having untreated brain metastasis, and not having certain genetic mutations. Other exclusion criteria include having a history of allergic reactions to similar drugs, having uncontrolled illnesses, being pregnant or breastfeeding, and having certain viral infections.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 1 and focuses on the disease called Rett syndrome. The ICD-10 code associated with Rett syndrome is \"F84.2\". The drug being studied is glatiramer acetate, also known as Copaxone\u00ae. \n\nThe eligibility criteria for this trial are as follows:\n1. Females between the ages of 6 and 15.\n2. Written informed consent from parents or legal custodians.\n3. A diagnosis of Rett syndrome based on the 2010 RetSearch criteria.\n4. Evidence of a genetic mutation in the MECP2 gene.\n5. Presence of epileptiform activity on an EEG.\n6. Normal blood pressure and heart rate.\n7. An electrocardiogram (ECG) that does not prevent participation.\n8. No significant abnormalities in blood tests.\n9. Parents must understand and comply with the study requirements.\n\nThe exclusion criteria for this trial are as follows:\n1. Any medical problem or chronic illness that would contraindicate the use of the study medication.\n2. Severe respiratory dysfunction.\n3. Intractable seizures within the last 6 months.\n4. Known hypersensitivity to glatiramer or mannitol.\n5. Participation in another clinical study.\n6. Parents who are unable to communicate effectively with the investigator and staff or comply with study procedures.\n7. Parents who are unwilling to sign the consent form.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 1 and focuses on the treatment of multiple myeloma, a type of cancer. The trial involves the use of drugs such as palbociclib, dexamethasone, and lenalidomide. The eligibility criteria for participants include having confirmed multiple myeloma, relapsed or refractory disease, and having received prior treatment with bortezomib. Participants must also have measurable disease and meet certain laboratory parameters. There are also exclusion criteria, such as having certain medical conditions or infections, being pregnant or lactating, and having a history of thromboembolic events. The sample includes detailed inclusion and exclusion criteria, as well as other requirements for participation in the trial.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a trial that is in both phase 1 and phase 2. The trial is focused on the disease called Prader-Willi syndrome. The corresponding ICD-10 code for this disease is Q87.11. The trial involves the use of two drugs, namely dccr and placebo. The record also includes the eligibility criteria for participants in the trial. The inclusion criteria specify that the trial is open to children, adolescents, and young adults with genetically confirmed Prader-Willi syndrome, aged between 10 and 22 years. Participants should be generally healthy based on medical history, physical examination, vital sign assessments, ECG, and clinical laboratory assessments. Their BMI should exceed the 95th percentile for their age according to CDC BMI charts, and their fasting glucose should be less than or equal to 126 mg/dL, while HbA1c should be less than or equal to 6.5%. The exclusion criteria state that participants should not have received any investigational drugs within the month prior to the screening visit, and they should not anticipate needing prohibited medications. They should also not have a history of allergic reactions or intolerance to certain medications, and they should not anticipate any disruptive changes in their care. Additionally, participants should not have congestive heart failure or compromised cardiac reserve, and they should not have any other clinically significant diseases that would interfere with the assessment of the investigational drug, as determined by the investigator.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is categorized as \"phase 1\" and focuses on the disease \"acute coronary syndrome.\" The corresponding ICD-10 code for this disease is \"I24.0.\" The trial involves the administration of several drugs, including \"clopidogrel,\" \"aspirin,\" \"apd791,\" and a \"placebo.\" \n\nThe eligibility criteria for participants in this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" Inclusion criteria include being a healthy adult between 20 and 45 years old, able to give written consent, weighing between 50 and 85 kg, and meeting certain requirements for women regarding pregnancy and contraception. Men are also required to meet specific contraception requirements. Other criteria include having normal vital signs, voluntarily deciding to participate, and being able to provide blood samples during the study period.\n\nExclusion criteria include having a recent history of gastric, duodenal, or esophageal ulcers, gastrointestinal diseases or surgeries that affect drug absorption, blood coagulation disorders or hemorrhagic diseases, dysfunctional uterine bleeding, epilepsy or convulsions, internal organ transplant, planned surgeries or medical procedures during the trial period, recent clinically significant new diseases, hypersensitivity reactions to drugs or gelatin, history of drug abuse or positive drug screening, recent alcohol abuse or positive nicotine test, recent blood donation or transfusion, recent use of other clinical trial drugs or contraindicated medications, positive reactions to certain serum tests, abnormal liver or kidney function, physical or mental conditions that may hinder trial completion, and being deemed inappropriate based on laboratory test results.\n\nOverall, this sample provides specific details about the phase, disease, drugs, and eligibility criteria for participants in a clinical trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is \"healthy.\" The ICDCodes associated with this disease are \"Z76.3\" and \"Z76.2.\" The drugs being tested in this phase are \"placebo to bi 1026706,\" \"pregabalin,\" \"bi 1026706,\" and \"celecoxib.\" \n\nThe eligibility criteria for this trial are as follows:\n\nInclusion criteria:\n1. The trial is open to healthy males, as determined by the investigator's assessment, which includes a complete medical history, physical examination, vital signs (blood pressure, pulse rate), 12-lead electrocardiogram, and clinical laboratory tests.\n2. Participants must be between the ages of 18 and 55 years.\n3. Participants must have a BMI (Body Mass Index) between 18.5 and 29.9 kg/m2.\n4. Participants must provide signed and dated written informed consent before being admitted to the study, following Good Clinical Practice (GCP) guidelines and local legislation.\n\nExclusion criteria:\n1. Any abnormal findings in the medical examination, including blood pressure, pulse rate, or electrocardiogram, that are deemed clinically relevant by the investigator.\n2. Repeated measurements of systolic blood pressure greater than 140 mm Hg or diastolic blood pressure greater than 90 mm Hg.\n3. Any laboratory values outside the reference range that the investigator considers clinically relevant.\n4. Any evidence of a concomitant disease that is deemed clinically relevant by the investigator.\n5. Presence of gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological, or hormonal disorders.\n6. Previous gastrointestinal tract surgery that could affect the absorption or metabolism of the study drug(s).\n7. Presence of central nervous system diseases (such as epilepsy), other neurological disorders, or psychiatric disorders.\n\nThis sample provides a snapshot of the information stored in the table, including the trial phase, disease, ICDCodes, drugs, and the specific eligibility criteria for participants.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease mentioned is \"adenocarcinoma of the pancreas,\" and the corresponding ICDCodes are ['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']. The drugs being used in the trial are 'mk-1775' and 'gemcitabine'. The eligibility criteria for this trial include various conditions such as confirmed diagnosis of adenocarcinoma of the pancreas, unresectable disease, specific performance status, adequate organ function, and written informed consent. There are also exclusion criteria mentioned, such as the presence of serious uncontrolled systemic disorders, previous chemotherapy or radiation therapy for pancreatic cancer, recent use of investigational agents, and the use of certain medications that interact with CYP3A4 enzymes.",
    "The sample from the table is a clinical trial for a drug called ldk378. The trial is in phase 1/phase 2 and is focused on treating non-small cell lung cancer (NSCLC) patients who carry an ALK rearrangement. The eligibility criteria for inclusion in the trial include having a confirmed diagnosis of NSCLC with ALK rearrangement, being 18 years or older, and having stage IIIB or IV NSCLC with progressive disease after crizotinib treatment. Exclusion criteria include hypersensitivity to ldk378, symptomatic central nervous system metastases, history of carcinomatous meningitis, presence or history of another malignant disease within the past 3 years, and clinically significant, uncontrolled heart disease.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The diseases being studied include recurrent colon cancer, recurrent rectal cancer, stage IVA colon cancer, stage IVA rectal cancer, stage IVB colon cancer, and stage IVB rectal cancer. The corresponding icd-10 codes for these diseases are also provided. The drugs being used in the trial are mek inhibitor mek162, leucovorin calcium, fluorouracil, and oxaliplatin. The eligibility criteria for the trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\" and include factors such as confirmed diagnosis of colon or rectal cancer, specific laboratory values, cardiac function, ability to take oral medications, and absence of certain medical conditions or treatments.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is multiple myeloma. The ICDCodes associated with this disease are C90.01, C90.02, and C90.00. The drugs being used in the trial are melphalan and filgrastim (g-csf). \n\nThe eligibility criteria for this trial include:\n1. Patients must meet the criteria for symptomatic myeloma.\n2. Patients must be at high or intermediate risk of disease progression, as defined by specific criteria such as ISS stage 2 or 3 disease, abnormal metaphase cytogenetics, or presence of FISH abnormalities aside from hyperdiploidy.\n3. Patients must have received at least 2 cycles of systemic treatment of any kind in the preceding 12 months.\n4. Patients must be between the ages of 18 and 75 at the time of enrollment.\n5. Patients must have a Karnofsky performance status of at least 70.\n6. Patients must have a cardiac function with a left ventricular ejection fraction (LVEF) greater than 40%.\n7. Patients must have normal liver function, with bilirubin levels less than 2 times the upper limit of normal, and ALT and AST levels less than 2.5 times the upper limit of normal.\n8. Patients must have a renal function with a creatinine clearance of at least 30mL/min.\n9. Patients must have pulmonary function with DLCO, FEV1, and FVC greater than 50% of predicted values (after correction for hemoglobin).\n\nThe exclusion criteria for this trial include:\n1. Patients with a diagnosis of plasma cell leukemia.\n2. Patients with myeloma who have had any disease progression prior to enrollment.\n3. Patients with truly non-secretory myeloma, except for patients with light chain disease.\n4. Pregnant or breastfeeding patients.\n5. Patients with uncontrolled viral, fungal, or bacterial infections, unless there is evidence of response to medication. Eligibility of HIV-infected patients will be determined on a case-by-case basis.\n6. Patients who have undergone prior allograft or autologous transplant.\n7. Patients who have had a prior solid organ transplant.\n8. Patients who have received prior radiation to more than 20% of bone marrow-containing areas.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied include acute biphenotypic leukemia, de novo myelodysplastic syndrome, previously treated myelodysplastic syndrome, recurrent adult acute myeloid leukemia, untreated adult acute myeloid leukemia, and secondary acute myeloid leukemia. The corresponding ICDCodes for these diseases are also provided.\n\nThe drugs being used in the trial are cladribine, cytarabine, and mitoxantrone hydrochloride. The eligibility criteria for the trial are listed, including specific requirements for patients with newly diagnosed disease and those with relapsed/refractory disease. Other criteria include the use of hydroxyurea prior to study registration, previous chemotherapy regimens, and the need to be off any active systemic therapy for at least 14 days prior to study registration.\n\nExclusion criteria are also listed, such as the presence of myeloid blast crisis of chronic myeloid leukemia, concomitant illness associated with a likely survival of less than 1 year, and active systemic infections. Other exclusion criteria include known hypersensitivity to any study drug, pregnancy or lactation, and treatment with any other investigational agent.",
    "The sample from the table represents a phase 1 clinical trial for the treatment of chronic myelogenous leukemia (CML). The trial involves the use of drugs such as zileuton (zyflo\u00ae) and dasatinib (sprycel\u00ae). The eligibility criteria for participants include being over 18 years old, having an ECOG performance status of 2 or lower, and meeting certain laboratory test requirements. Inclusion criteria also specify that patients must have known inadequate response or resistance to TKIs (tyrosine kinase inhibitors) as a first-line therapy. Exclusion criteria include intolerance to dasatinib, active malignancy within the past 5 years (except for nonmetastatic treated skin cancer or stage 0 cervical carcinoma), HIV-positive status, active uncontrolled infections, and certain medical conditions that may increase the risk of toxicity. The sample also lists prohibited treatments and therapies, as well as other exclusion criteria such as being a prisoner or involuntarily incarcerated.",
    "The sample from the table represents a clinical trial for the treatment of depression. The trial is divided into two phases, phase 1 and phase 2. The disease being studied is depression, and it is identified by the ICD-10 codes F32.A, F53.0, P91.4, Z13.31, and Z13.32. The drugs being tested are diazoxide and placebo.\n\nThe eligibility criteria for participants include being between 18 and 65 years old, women of childbearing potential must have a negative pregnancy test and use two effective methods of contraception. Participants must also be capable of understanding the tests and examinations required and must provide informed consent. They must fulfill the DSM-IV criteria for major depressive disorder (MDD) without psychotic features and be experiencing a current major depressive episode of at least four weeks duration. Additionally, participants must have a minimum score of 20 on the MADRS (Montgomery-\u00c5sberg Depression Rating Scale) at screening and baseline.\n\nExclusion criteria include having current or past psychotic features, a diagnosis of schizophrenia or any other psychotic disorder, a history of drug or alcohol dependency or abuse within the past three months, a head injury resulting in loss of consciousness exceeding five minutes, a diagnosis of borderline or antisocial personality disorder, pregnancy or nursing, serious unstable medical illnesses, hyperthyroidism or clinical hypothyroidism, unexplained seizures, abnormal laboratory tests, diabetes, specific blood pressure measurements, recent treatment with certain medications, deep brain stimulation, current serious suicidal or homicidal risk, positive HIV test, and contraindications to MRI.\n\nThe study does not permit structured psychotherapy during the trial. Treatment resistance is defined as having previously failed to respond to two adequate antidepressant trials, which will be determined using the clinician-administered modified Antidepressant Treatment History Form (ATHF).",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease being studied is \"hepatic impairment,\" and the corresponding ICDCodes are ['Z73.82', 'G31.84', 'M10.38', 'M10.30', 'M10.311', 'M10.312', 'M10.319']. The drug being tested is \"mek162.\" \n\nThe eligibility criteria for this trial include requirements such as written informed consent, a minimum body weight of 45 kg, and a body mass index (BMI) between 18 and 35. For subjects with normal hepatic function, certain liver function tests must be within normal limits, along with other criteria related to blood counts and renal function. \n\nThere are also exclusion criteria, which include factors such as pregnancy or nursing, cardiovascular diseases, retinal vein occlusion, history of Gilbert's syndrome, immunocompromised status, and various other medical conditions or treatments that could affect the absorption or metabolism of drugs or jeopardize the subject's participation in the study. \n\nAdditional exclusion criteria are specified for subjects with normal hepatic function or elevated serum bilirubin levels. These criteria include liver disease or injury, impaired renal function, positive Hepatitis B or Hepatitis C test results, symptoms or history of encephalopathy, severe ascites, abnormal international normalized ratio (INR), evidence of progressive liver disease, history of surgical portosystemic shunt with complications, and recent active bleeding.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is \"super-refractory status epilepticus.\" The ICDCodes associated with this disease are \"G40.803,\" \"G40.804,\" \"G40.823,\" \"G40.824,\" \"G40.833,\" \"G40.834,\" and \"G40.911.\" The drug being tested is \"sage-547.\" \n\nThe eligibility criteria for this trial include subjects who are 2 years of age or older and have been diagnosed with super-refractory status epilepticus confirmed by an EEG. They should also be under concomitant therapy with a continuous IV AED (third-line agent) for at least 24 hours. The criteria for defining super-refractory status epilepticus are also mentioned, including failure to respond to first-line and second-line agents and the presence of breakthrough seizures after initiation of the continuous IV AED/third-line agent. \n\nThere are also exclusion criteria listed, such as subjects with SRSE due to anoxic/hypoxic encephalopathy or children with an encephalopathy due to an underlying progressive neurological disorder. Subjects with clinically significant ECG abnormalities or other medical or surgical conditions that may compromise vital organ systems are also excluded. Subjects who are receiving a continuous IV AED for seizure suppression or burst-suppression that will require more than 24 hours to wean are also excluded.",
    "The sample is a record from a table that contains information about clinical trials. The phase of the trial is specified as \"phase 1/phase 2\". The disease mentioned in this record is \"squamous cell carcinoma of the head and neck\". The corresponding ICD-10 codes for this disease are ['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']. The drugs being studied in this trial are 'cetuximab' and 'methotrexate'. The eligibility criteria for participants in this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". The criteria include factors such as having a confirmed diagnosis of SCCHN, having measurable lesions, not having received prior systemic treatment, meeting certain organ function and laboratory parameters, and not having certain medical conditions or taking certain medications.",
    "The sample from the table is a clinical trial for the treatment of advanced, progressive, recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. The trial is in phase 1/phase 2 and involves the drugs pazopanib and fosbretabulin. The eligibility criteria for participants include having measurable disease, a World Health Organisation performance status of 0 or 1, and a life expectancy of at least 12 weeks. Other criteria include specific ranges for hemoglobin, neutrophil count, platelet count, and various other blood and urine measurements. Exclusion criteria include recent radiotherapy, surgery, or tumor embolization, ongoing toxic manifestations of previous treatments, and certain cardiovascular conditions. Participants must also not be pregnant or lactating and must agree to use contraception during and after the trial. Other exclusion criteria include certain medical conditions, history of certain cardiovascular events, and hypersensitivity to pazopanib or its excipients.",
    "The sample from the table represents a phase 1 clinical trial for the treatment of B-cell lymphoma. The trial includes patients with relapsed or refractory B-cell lymphoma, as well as untreated patients with mantle cell lymphoma. The eligibility criteria include signing an informed consent form, eligibility for autologous stem cell transplantation, measurable disease, prior therapy with one or two lines of treatment for B-cell lymphoma, age between 18 and 70, Eastern Cooperative Oncology Group (ECOG) performance status 0-2, specific hematology values, ability to receive full doses of the specified chemotherapy, life expectancy of at least 90 days, practicing effective birth control, and having a negative pregnancy test. The exclusion criteria include previous treatment with a BTK inhibitor, progression or refractory status while on treatment with a PI3K inhibitor, inability to tolerate high dose ara-C / platin compound, history of stroke or intracranial hemorrhage within 6 months, major surgery within 4 weeks, known bleeding diathesis, therapeutic anticoagulation with Vitamin K antagonists, treatment with a strong cytochrome P450 3A4/5 (CYP3A4/5) inhibitor, life-threatening illness or serious medical condition, central nervous system or meningeal involvement by lymphoma, contraindication to any drug in the regimen, known history of HIV or active Hepatitis C Virus (HCV) or active Hepatitis B Virus infection (HBV), left ventricular ejection fraction (LVEF) less than 45%, clinically significant cardiovascular disease, specific biochemical values, pre-existing Grade 2 neuropathy, prior history of malignancies other than lymphoma, use of any anti-cancer drug therapy within 28 days prior to the trial, pregnancy or breastfeeding, medical history of hepatic chronic disease, and sinusoidal obstruction syndrome (Veno-Occlusive Disease).",
    "The sample is a record from a table that contains information about a clinical trial. The phase of the trial is Phase 1/Phase 2. The disease being studied is multiple myeloma. The corresponding ICD-10 codes for the disease are C90.01, C90.02, and C90.00. The drug being used in the trial is carfilzomib. The eligibility criteria for participants in the trial are listed, including age requirements, consent, contraception requirements for female participants, and previous treatment history. The sample also includes specific criteria for measurable disease, performance status, life expectancy, and various laboratory values. The exclusion criteria are also listed, including pregnancy or lactation, certain medical conditions, allergies, and prior malignancies.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease mentioned is \"leukemia, myeloid, acute.\" The ICDCodes associated with this disease are ['C92.A1', 'C92.A2', 'C92.61', 'C92.62', 'C92.A0', 'C92.60']. The drugs being used in the trial are 'busulfan', 'fludarabine phosphate', 'cyclophosphamide', and 'tocilizumab'. The eligibility criteria for this trial include various conditions such as AML without complete remission, relapse after obtaining a CR, presence of estramedullary disease, availability of an HLA-haploidentical donor, Karnofsky performance status, and adequate organ function. There are also exclusion criteria listed, such as a high circulating blast count, known HIV or active hepatitis B or C infection, hypersensitivity to study agents, recent use of investigational drugs or intensive chemotherapy, pregnancy or breastfeeding, and uncontrolled intercurrent illness.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is bronchiectasis. The ICDCodes associated with this disease are \"J47.9\", \"Q33.4\", \"J47.1\", and \"J47.0\". The drugs being tested in this trial are \"gsk2793660 solution\", \"gsk2793660 capsule\", \"placebo solution\", and \"placebo capsule\". The eligibility criteria for participants in this trial include being healthy, aged between 18 and 55, and meeting specific medical and laboratory requirements. There are also criteria related to gender, body weight, blood pressure, liver function, and previous medical history. Additionally, there are exclusion criteria that disqualify individuals with certain medical conditions or sensitivities, as well as those who have recently participated in other clinical trials or have been exposed to multiple new chemical entities.",
    "The sample provided is a schema definition of a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. The table has the following columns: phase, diseases, icdcodes, drugs, and criteria.\n\nIn the sample, the phase is \"phase 1\" and the diseases listed include \"adenocarcinoma of the lung\", \"large cell lung cancer\", \"squamous cell lung cancer\", \"stage iia non-small cell lung cancer\", \"stage iib non-small cell lung cancer\", and \"stage iiia non-small cell lung cancer\", and \"stage iiib non-small cell lung cancer\". The corresponding ICDCodes for these diseases are also provided.\n\nThe drugs mentioned in the sample are \"paclitaxel\" and \"carboplatin\". The eligibility criteria for the clinical trial are listed under the \"criteria\" column. The inclusion criteria include histologically-proven unresectable or inoperable lung cancer of specific histologic types, specific tumor stage, specific laboratory values, and other requirements related to treatment planning and performance scale score. The exclusion criteria include previous treatments, specific medical conditions, and pregnancy or lactation.\n\nOverall, the sample provides information about the phase, diseases, ICDCodes, drugs, and eligibility criteria for a clinical trial related to lung cancer.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this specific sample, the phase of the trial is Phase 1. The diseases being studied include her2-positive breast cancer, male breast cancer, recurrent breast cancer, stage iiia breast cancer, stage iiib breast cancer, stage iiic breast cancer, and stage iv breast cancer. The corresponding ICDCodes for these diseases are also provided.\n\nThe drugs being used in the trial are ganetespib and paclitaxel. The eligibility criteria for participants in this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". The inclusion criteria include factors such as confirmed diagnosis of breast cancer, age of at least 18 years, specific performance status, life expectancy, prior treatment history, and various laboratory values. The exclusion criteria include factors such as recent anti-tumor therapy, major surgery, poor venous access, specific medication history, cardiac dysfunction, brain metastases, and history of other malignancies.\n\nOverall, this sample provides detailed information about the phase, diseases, drugs, and eligibility criteria for a specific clinical trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease mentioned is \"cutaneous t-cell lymphoma,\" and its corresponding ICDCodes are listed as \"['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']\". The drugs involved in the trial are \"romidepsin\" and \"poly iclc\". The eligibility criteria for this trial include having a prior biopsy confirming MF stage IIA-IVA, having failed at least one standard therapy, having specific skin lesion requirements, and meeting certain organ and marrow function criteria. Other criteria include age, performance status, life expectancy, and the need for contraception for women of child-bearing potential. The sample also mentions exclusion criteria, such as recent chemotherapy or radiotherapy, concurrent use of other investigational agents, and certain medical conditions.",
    "The sample is a phase 1 clinical trial for prostate cancer. The disease being studied is prostate cancer, and the corresponding ICD-10 codes are provided. The drug being tested is AZD2014. The eligibility criteria for participants are listed, including age, performance status, clinical diagnosis, suitability for radical prostatectomy, contraceptive method, bone marrow reserve or organ function, and normal chest radiograph or CT thorax. The exclusion criteria are also listed, including contraindications to AZD2014, recent medical procedures or surgeries, previous treatments, use of certain medications, evidence of severe or uncontrolled systemic disease, abnormal ECHO or MUGA, prolonged QTc interval, diabetes type, unsuitability or non-compliance with study procedures, and inability to provide informed consent.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are metastatic melanoma and brain metastases. The ICDCodes associated with these diseases are C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, and C43.4. The drugs being used in the trial are nab-paclitaxel, temozolomide, and bevacizumab. The eligibility criteria for participants include having histologically or cytologically confirmed malignant melanoma with clinical evidence of metastatic disease to the brain, newly developed inoperable brain metastases without associated hemorrhage or midline shift, and inoperable or metastatic extra cranial stage III or IV disease. There are additional criteria related to diagnostic imaging, prior therapy, age, peripheral neuropathy, pregnancy test, contraception, performance status, estimated life expectancy, and organ function. The exclusion criteria include prior surgical resection for brain metastases, history of allergic reactions to certain compounds, uncontrolled intercurrent illness, history of myocardial infraction or stroke, history of abdominal fistula or abscess, serious non-healed wounds or fractures, history of hepatitis B, C or HIV, uncontrolled hypertension or chronic renal disease, known hypersensitivity to human albumin, recent surgery or chemotherapy, evidence of other concurrent active malignancy, pregnancy or nursing, and not receiving any other investigational agent.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is atrial fibrillation. The ICDCodes associated with this disease are ['I48.0', 'I48.21', 'I48.91', 'I48.11', 'I48.19', 'I48.20']. The drugs being tested in this trial are 'opc-108459' and 'placebo'. The eligibility criteria for participants in this trial include being Japanese, aged between 20 to 85 years, diagnosed with recent or new onset of paroxysmal or persistent atrial fibrillation, and meeting certain treatment guidelines or having a low risk of thromboembolic potential. There are also exclusion criteria listed, such as having certain heart conditions, a history of certain cardiac events, or recent diagnoses of other cardiovascular conditions.",
    "The sample from the table represents a phase 1 clinical trial. The disease being studied is an unspecified adult solid tumor that is specific to the protocol. The ICD-10 codes associated with the disease are 'H01.009', 'H02.209', 'H02.009', 'H02.109', 'H04.209', 'H05.409', and 'H10.509'. The drugs being used in the trial are cyclophosphamide and fludarabine phosphate. \n\nThe eligibility criteria for the trial include having stage IV or locally advanced cancers for which no alternative therapies with proven survival advantage are available. Patients must have at least one lesion that can be biopsied, either cutaneous or palpable metastatic site or a deeper site accessible by image-guided biopsy. Patients must also be NY-ESO-1 positive by immunohistochemistry and HLA-A*0201 (HLA-A2.1) positive by molecular subtyping. \n\nOther criteria include having a life expectancy greater than 3 months, having at least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST), having an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and meeting certain blood count and liver function requirements. Patients must also be willing and able to accept two leukapheresis procedures and provide written informed consent.\n\nExclusion criteria for the trial include known hypersensitivity to any of the agents used in the study, receiving systemic treatment for cancer within one month prior to the study, having a history of chronic inflammatory or autoimmune disease, and having certain gastrointestinal conditions or current acute colitis. Other exclusion criteria include having certain immune deficiency states, dementia or altered mental status, active brain metastases, pregnancy or breastfeeding, and certain cardiac or pulmonary abnormalities. Evidence of diverticulitis at baseline is also an exclusion criterion.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The diseases being studied are \"malignant neoplasm\" and \"solid tumors.\" The ICDCodes associated with these diseases are \"C05.2,\" \"C10.0,\" \"C16.0,\" \"C16.4,\" \"C17.0,\" \"C17.1,\" and \"C17.2.\" The drugs being used in the trial are \"chloroquine,\" \"carboplatin,\" and \"gemcitabine.\" \n\nThe eligibility criteria for this trial include:\n- Histologically confirmed diagnosis of a metastatic or unresectable malignancy, where standard curative measures are not available or no longer effective, and carboplatin/gemcitabine is considered a reasonable treatment option.\n- Age greater than 18 years.\n- Performance status less than or equal to 2 (Karnofsky score >60%).\n- Life expectancy of more than 3 months.\n- Adequate lab results.\n- Measurable disease.\n\nThe exclusion criteria for this trial include:\n- Current treatment with any other investigational agents.\n- Patients with untreated brain metastases.\n- History of allergic reaction to compounds similar to chloroquine or other agents used in the study.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are metastatic melanoma, stage III melanoma, and stage IV melanoma. The corresponding ICDCodes for these diseases are C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, and C43.4.\n\nThe drugs being investigated in this trial are indoximod, ipilimumab, nivolumab, and pembrolizumab. \n\nThe eligibility criteria for this trial include:\n- Patients must have unresectable Stage III or Stage IV melanoma.\n- Patients must have measurable disease, with specific size requirements for lesions.\n- Patients should not have received any systemic treatment in the previous 28 days.\n- Patients must be at least 18 years old.\n- Patients' ECOG performance status should be \u22642 (Karnofsky \u226560%).\n- Patients with brain metastases are eligible if their tumors have been treated and they are neurologically stable for at least 1 month off steroids.\n\nThe exclusion criteria for this trial include:\n- Patients who have received molecular targeted therapy or radiotherapy within 4 weeks prior to the study or have not recovered from adverse events caused by previous treatments.\n- Patients who have previously received immune checkpoint inhibition or indoximod.\n- Patients with any other cancer, unless they have been disease-free for at least 5 years.\n- Patients with laboratory evidence of pancreatitis.\n- Patients with autoimmune disease.\n- Patients who chronically use immune-suppressive drugs, such as systemic corticosteroids.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The diseases being studied include relapsed or refractory acute myeloid leukemia (AML), untreated AML, other IDH1-mutated positive hematologic malignancies, and myelodysplastic syndromes. The ICDCodes associated with these diseases are ['D46.9', 'D46.C', 'D46.Z']. The drug being tested in this trial is AG-120. \n\nThe eligibility criteria for this trial include being at least 18 years old, having documented IDH1 R132 gene-mutated advanced hematologic malignancy, being amenable to bone marrow biopsies and other sampling procedures, having an ECOG PS (Eastern Cooperative Oncology Group Performance Status) of 0 to 2, having a platelet count of at least 20,000/\u00b5L, having adequate hepatic and renal function, being recovered from previous cancer treatments, and having a negative pregnancy test for female subjects of reproductive potential.\n\nThe exclusion criteria for this trial include recent hematopoietic stem cell transplant, recent systemic anticancer therapy or radiotherapy, recent use of investigational agents, pregnancy or breastfeeding, active severe infection or unexplained fever, certain heart conditions, recent myocardial infraction or unstable angina, known ventricular arrhythmias, prolonged QT interval or other factors increasing the risk of arrhythmic events, certain medications known to prolong the QT interval, infection with HIV or active hepatitis B or C, suspected or known central nervous system leukemia, and immediately life-threatening complications of leukemia.\n\nThis sample provides specific details about the trial phase, diseases being studied, associated ICDCodes, the drug being tested, and the eligibility and exclusion criteria for potential participants.",
    "The sample from the table represents a clinical trial for phase 1 of a drug study. The trial focuses on breast cancer patients with stage IV, HER2 negative breast cancer. The eligibility criteria include providing written informed consent, being at least 18 years old, having an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, and having failed two lines of systemic therapy for breast cancer. Additional criteria include a life expectancy of 6 months or more, normal liver and kidney function, adequate blood counts, normal thyroid function, and a negative pregnancy test for pre- or perimenopausal subjects with an intact uterus.\n\nThe exclusion criteria include clinically significant gastrointestinal abnormalities, uncontrolled infection, corrected QT interval (QTc) > 480 msecs, recent cardiovascular conditions, poorly controlled hypertension, recent cerebrovascular accident or deep venous thrombosis, recent major surgery or trauma, active bleeding or bleeding diathesis, endobronchial lesions or lesions infiltrating major pulmonary vessels, recent hemoptysis, serious pre-existing medical or psychiatric conditions, previous treatment with sunitinib or crizotinib, history of other malignancy within the last 5 years (except for certain types), concurrent use of specific medications, history of receiving any investigational treatment within 28 days, current severe, uncontrolled systemic disease, and pregnancy or lactation.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are metastatic pancreatic adenocarcinoma and metastatic pancreatic cancer. The ICDCodes associated with these diseases are C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31 for the first disease, and C25.3 for the second disease. The drugs being used in the trial are nab-paclitaxel, gemcitabine, and indoximod. The eligibility criteria for this trial include having a definitive histologically or cytologically confirmed metastatic adenocarcinoma of the pancreas, with the initial diagnosis of metastatic disease occurring within the past 8 weeks. Patients must have one or more measurable metastatic tumors, be at least 18 years old, and have a Karnofsky performance status of 70 or higher. Patients should not have received any previous radiotherapy, surgery, chemotherapy, or investigational therapy for the treatment of metastatic disease. Prior treatment with gemcitabine and/or nab-paclitaxel in the adjuvant setting is allowed if at least 6 months have passed since the last dose and there are no lingering toxicities. Patients should not have received any other immunomodulatory therapies for this or any other cancer. There are also exclusion criteria, such as not receiving any other investigational agents for metastatic disease, not having known brain metastases, and not having only locally advanced disease. Other exclusion criteria include having a history of malignancy in the last 3 years (except for in situ cancer or basal or squamous cell skin cancer), having any active autoimmune disease, and having undergone major surgery within 4 weeks prior to the start of treatment in this study.",
    "The sample from the table represents a phase 1 clinical trial for patients with cancer. The eligibility criteria include being at least 18 years old, having a confirmed diagnosis of cancer, and receiving stable or increasing doses of morphine for 1-2 weeks prior to the trial. Patients must also have inadequate pain control even with the use of morphine and have an ECOG Performance Status of 0-2. They should be able to swallow and tolerate oral tablets, and females of childbearing potential must have a negative pregnancy test. Various laboratory values must also meet certain criteria. The exclusion criteria include having active central nervous system metastases, concurrent use of certain medications, recent treatment with investigational agents, rapidly escalating pain requiring hospitalization or intravenous opioid therapy, concurrent participation in another clinical trial with investigational agents, and concurrent use of strong CYP3A4 inhibitors. Other contraindications include allergic reactions to certain medications, opiate-induced uncontrolled constipation or bowel obstruction, living alone, being pregnant or breastfeeding, and having a diagnosis of epilepsy or currently taking anti-epileptic drugs.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The trial is a combination of phase 1 and phase 2.\n- Diseases: The trial is focused on Alzheimer's disease.\n- ICD Codes: The ICD-10 codes associated with Alzheimer's disease are G30.8, G30.9, G30.0, and G30.1.\n- Drugs: The drugs being tested in the trial are iti-007 and placebo. The drugs are administered in alternating sequences.\n- Criteria: The eligibility criteria for the trial are divided into two parts. Part 1 includes healthy geriatric volunteers with a minimum MMSE score of 26, a BMI between 19.0 and 40.0 kg/m2, and a minimum body weight of 50 kg. Part 2 includes geriatric patients with a clinical diagnosis of dementia, a MMSE score of less than 26, a BMI between 19.0 and 40.0 kg/m2, and a minimum body weight of 50 kg. The exclusion criteria include recent clinically significant illness, history of cancer within the last 5 years, history of Hepatitis B or C infection with elevated ALT, AST, or bilirubin levels, and individuals considered to be an imminent danger to themselves or others.",
    "The sample from the table is for a clinical trial with a combination of phase 1 and phase 2. The trial is focused on treating glioblastoma, specifically adult brain glioblastoma and glioblastoma multiforme. The diseases are identified using their respective ICD-10 codes. The drug being tested in the trial is bevacizumab. \n\nThe eligibility criteria for the trial include being 18 years or older, having histologically confirmed GBM or WHO Grade IV variants, and having evidence of tumor recurrence or progression. Patients who have undergone resection of recurrent or progressive tumor must meet certain conditions, while those who have not had resection must have measurable disease. Other criteria include specific imaging requirements, recovery from prior therapy toxicity, specific time intervals from prior treatments, HLA-A2 positivity, and adequate organ function.\n\nThere are also exclusion criteria, such as prior use of certain chemotherapy or investigational agents, specific characteristics of the contrast-enhancing tumor, requirement of high-dose corticosteroid therapy, recent surgical procedures or radiation therapy, active infections, history of certain cancers, significant cardiovascular disease, immunosuppressive or autoimmune diseases, and other conditions that make the patient unsuitable for the study.\n\nAdditionally, there are requirements related to pregnancy testing and contraception for female patients, as well as the need for informed consent from the patient or legally authorized representative.\n\nOverall, the sample provides detailed information about the phase, diseases, drugs, and eligibility criteria for the clinical trial.",
    "The sample from the table is for a clinical trial in the field of oncology. The trial is in phase 1/phase 2 and focuses on the treatment of chronic myeloid leukemia. The trial includes patients who have been diagnosed with Philadelphia chromosome (Ph) positive chronic myelogenous leukemia in either chronic phase or accelerated phase. The eligibility criteria include having failed or demonstrated intolerance to at least 2 prior treatments with tyrosine kinase inhibitors (TKIs). The failure of TKI treatment can be primary (no response) or secondary resistance (loss of response). Intolerance to TKI therapy can be due to nonhematologic toxicity, hematologic toxicity, or any unacceptable toxicity. Patients must have completed all previous anticancer therapy and have adequate hepatic and renal function. The trial also has exclusion criteria, such as uncontrolled cardiac conditions, recent myocardial infraction, concurrent illnesses that would affect the study, recent stem cell transplant, and active viral infections. The sample does not mention the duration or other details of the trial.",
    "The sample from the table represents a Phase 1 clinical trial for the treatment of schizophrenia. The trial focuses on participants who meet the criteria for schizophrenia as defined by the Diagnostic and Statistical Manual of Mental Disorders (DSM-V). The participants must also be on a stable dose of second-generation antipsychotics (SGA) for at least 2 months.\n\nThe eligibility criteria for the trial include the participant's ability to understand and comply with the protocol requirements, signing a written informed consent form, and meeting specific symptom criteria related to schizophrenia. The participants must also have cognitive impairment, be between the ages of 18 and 55, weigh at least 60 kg, and have a body mass index (BMI) between 18 and 32 kg/m^2.\n\nBoth male and female participants must agree to use adequate contraception if sexually active with a partner of childbearing potential. The participants must also have normal clinical laboratory evaluations and meet certain exclusion criteria, such as not having received any investigational compound within the past 30 days and not having a history of drug or alcohol abuse.\n\nThe sample also lists various exclusion criteria, including contraindications for magnetic resonance imaging (MRI), hypersensitivity to the study drug, positive urine drug results for drugs of abuse, and a history of certain diseases or surgical interventions that may impact the study.\n\nOverall, the sample provides detailed information about the phase, diseases, icd-10 codes, drugs, and eligibility criteria for the clinical trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 1. The diseases being studied are diabetes, metabolism and nutrition disorder, and obesity. The corresponding ICDCodes for these diseases are provided as well. The drugs being tested in this trial are semaglutide and placebo. \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include being male or female above the age of 18, having a HbA1c (glycosylated haemoglobin A1c) level below 6.5%, and having a BMI (body mass index) between 30-45 kg/m^2. \n\nExclusion criteria include being pregnant, breastfeeding, or intending to become pregnant for females, having any disorder that may jeopardize the subject's safety or compliance with the protocol, being diagnosed with type 1 or type 2 diabetes mellitus, anticipating a change in lifestyle during the trial, using medications that could interfere with trial results, having a significant history of alcoholism or drug/chemical abuse, and smoking or using nicotine products in the last 3 months.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are lupus erythematosus and graft-versus-host disease. The ICDCodes associated with these diseases are D89.810, D89.811, D89.813, and D89.812. The drugs being used in the trial include cyclophosphamide, fludarabine, tacrolimus, mycophenolate mofetil, and rabbit antithymocyte globulin. The eligibility criteria for this trial include specific criteria for inclusion, such as meeting certain classification criteria for lupus erythematosus, involvement of specific organ systems, lack of response to corticosteroids, and eligibility for transplantation according to the BMT Policy Manual. The exclusion criteria include age restrictions, pregnancy risk, and patients who are preterminal or moribund.",
    "The sample provided is a record from a table that contains information about clinical trials. The phase of the trial is \"early phase 1\". The diseases being studied in this trial are \"non-hodgkin lymphoma\", \"hodgkin lymphoma\", \"kaposi sarcoma\", \"gastric cancer\", \"nasopharyngeal cancer\", \"ebv\", and \"castleman disease\". The corresponding ICD-10 codes for these diseases are provided as well. The drug being tested in this trial is \"nelfinavir\". The eligibility criteria for participants in this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". These criteria include factors such as age, biopsy results, previous treatments, performance status, and various medical conditions.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase is Phase 1, and the diseases listed are ovarian cancer, ovarian carcinoma, recurrent ovarian cancer, and recurrent ovarian carcinoma. The ICDCodes associated with these diseases are also provided. The drug mentioned in this sample is docetaxel. The eligibility criteria are listed under \"Inclusion Criteria\" and \"Exclusion Criteria,\" which include factors such as disease relapse timeframe, measurable disease, life expectancy, performance status, age, and various medical conditions.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is \"early phase 1\" and the disease being studied is \"social anxiety disorder\". The ICDCodes associated with this disease are \"F20.81, F21, F34.0, F34.1, F42.3, F45.0, F51.5\". The drugs being used in the trial are \"ketamine\" and \"saline\". The eligibility criteria for participants in this trial include being an adult between the ages of 18 and 65 years, meeting DSM IV criteria for Social Anxiety Disorder, and having a LSAS score greater than 60 with or without co-morbid MDD. Exclusion criteria include a positive pregnancy test, history of substance abuse disorder within the last 6 months, history of pervasive developmental disorder or psychotic disorder, and medical comorbidity that significantly increases the risks associated with ketamine infusion (e.g. untreated hypertension, significant cardiovascular disease).",
    "The sample from the table is for a phase 1 clinical trial. The disease being studied is graft versus host disease. The corresponding ICD-10 codes for the disease are D89.810, D89.811, D89.813, and D89.812. The drug being tested is lde225. \n\nThe eligibility criteria for this trial include:\n- Patients must provide written informed consent.\n- Patients must be 18 years or older.\n- Patients must have undergone allogeneic hematopoietic cell transplantation (HCT) after myeloablative or reduced intensity conditioning regimens.\n- Participants must be at least 100 days after HCT.\n- Patients must have steroid refractory classic cutaneous, myofascial, or sclerodermatous cGVHD (chronic graft versus host disease) with persistent signs and symptoms despite the use of prednisone or equivalent corticosteroids.\n- Patients must have a stable dose of corticosteroids for 4 weeks prior to enrollment.\n- No addition or subtraction of other immunosuppressive medications for 4 weeks prior to enrollment.\n- Patients must have an ECOG performance status of \u2264 3.\n- Patients must meet certain criteria for hepatic function, bone marrow function, and other laboratory values.\n- Patients must be able to swallow and retain oral medication.\n\nExclusion criteria for this trial include:\n- Patients who have had major surgery within 4 weeks of starting the study medication.\n- Patients with concurrent uncontrolled medical conditions that may interfere with their participation in the study.\n- Patients unable to take oral drugs or with malabsorption syndromes.\n- Patients who have previously been treated with systemic LDE225 or other Hh pathway inhibitors.\n- Patients with certain neuromuscular disorders or on concomitant treatment with drugs that can cause rhabdomyolysis.\n- Patients who are planning on embarking on a new strenuous exercise regimen after starting the study treatment.\n- Patients who have participated in an experimental drug study within 4 weeks or 5 half-lives of initiating treatment with LDE225.\n- Patients receiving other anti-neoplastic therapy concurrently or within 2 weeks of starting treatment with LDE225.\n- Patients receiving treatment with medications known to be strong inhibitors or inducers of certain enzymes.\n- Patients with certain cardiac conditions or impaired cardiac function.\n- Pregnant or nursing women.\n- Patients who are not willing to use highly effective contraception during the study and for a certain duration after the final dose of study treatment.\n- Patients who are unwilling or unable to comply with the protocol.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1 and is focused on ovarian cancer. The trial is looking at the effectiveness of a combination of drugs called omp-54f28, paclitaxel, and carboplatin. The eligibility criteria for participants include being at least 18 years old, having histologically documented ovarian, primary peritoneal, or fallopian tube cancer, and having recurrent platinum-sensitive disease. Other criteria include having a performance status of 0 or 1, resolving any acute treatment-related toxicity from prior therapy, and having adequate hematologic and end-organ function. Participants must also have evaluable or measurable disease and agree to use two effective forms of contraception if they are of childbearing potential. There are also exclusion criteria, such as having non-epithelial ovarian carcinoma, prior treatment with paclitaxel and carboplatin for recurrent platinum-sensitive ovarian cancer, and recent treatment with any anti-cancer therapy. Other exclusion criteria include having certain medical conditions, being pregnant or breastfeeding, having HIV infection, and having significant bone or gastrointestinal diseases.",
    "The sample from the table is for a clinical trial with a phase 1/phase 2 designation. The trial focuses on the treatment of leukemia. The specific diseases included in the trial are not mentioned. However, the ICD-10 codes associated with the diseases are provided. The drugs being tested in the trial are brentuximab vedotin and 5-azacytidine. The eligibility criteria for the trial are listed, including requirements such as confirmation of AML diagnosis, CD30 expression in AML blasts, age 18 or older, specific performance status score, and baseline laboratory data within certain ranges. Inclusion and exclusion criteria are also provided, outlining factors that would make a patient eligible or ineligible for the trial.",
    "The sample provided is a record from a table that contains information about clinical trials. The phase of the trial is a combination of phase 1 and phase 2. The disease being studied in this sample is Parkinson's disease. The corresponding ICD-10 code for Parkinson's disease is G20. The drugs being used in the trial are \"levodopa and carbidopa sc solution\" and \"oral levodopa and carbidopa\". The eligibility criteria for participants in this trial are listed under both inclusion and exclusion criteria. Inclusion criteria include being a male or female Parkinson's disease patient between the ages of 30 and 80, having a PD diagnosis consistent with the UK PD Society Brain Bank criteria, stable doses of anti-PD drugs for at least 30 days, well-defined morning \"OFF\" and a good response to LD, MMSE score greater than 26, and no clinically significant medical, psychiatric, or laboratory abnormalities. Exclusion criteria include having atypical or secondary Parkinsonism, acute psychosis or hallucinations, being treated with neuroleptics, having a history of melanoma or significant skin disorders, prior neurosurgical procedure for PD, history of drug abuse or alcoholism, clinically significant ECG abnormalities, renal or liver dysfunction, and having participated in another clinical study within 30 days.",
    "The sample from the table is for a clinical trial that is in phase 1/phase 2. The trial is focused on studying the effects of different drugs on myocardial reperfusion injury. The diseases being studied are specifically related to myocardial reperfusion injury, and the corresponding ICD-10 codes are provided. The drugs being tested in the trial are milrinone, esmolol, and saline infusion. \n\nThe eligibility criteria for the trial are as follows:\n- Participants must be men and women who are 18 years of age or older.\n- They must present within 12 hours after the onset of chest pain.\n- They must have ST-segment elevation of more than 0.1 mV in two contiguous leads.\n- The clinical decision must be made to treat them with PCI (percutaneous coronary intervention).\n\nThe exclusion criteria for the trial are as follows:\n- Patients with cardiac arrest, ventricular fibrillation, cardiogenic shock, or previous acute myocardial infraction will not be included.\n- Patients with occlusion of the left main will be excluded.\n- Patients with a baseline heart rate less than 50 beats/min and systolic blood pressure less than 90 mmHg will be excluded.\n- Pregnant patients will be excluded.\n- Patients who have any disorder associated with immunologic dysfunction (e.g., cancer, lymphoma, a positive serologic test for HIV or hepatitis) within the past 6 months will be excluded.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is multiple myeloma. The ICDCodes associated with this disease are C90.01, C90.02, and C90.00. The drugs being used in the trial are plitidepsin, bortezomib, and dexamethasone. \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" Inclusion criteria include being at least 18 years old, having undergone a prior autologous transplantation, and having received at least one previous treatment line of induction, chemotherapy, chemotherapy and transplantation, or previous treatment with bortezomib or another proteasome drug. \n\nExclusion criteria include previous treatment with plitidepsin, having an active or metastatic primary malignancy other than multiple myeloma, having serious concomitant systemic disorders, a history of hypersensitivity reactions to bortezomib, polyoxyl 35 castor oil, or mannitol, neuropathy, being pregnant or lactating, having HIV infection, having active hepatitis B or C virus infection, treatment with any Investigational Medicinal Product (IMP) in the 30 days before inclusion in the study, plasma cell leukemia at the time of study entry, and having a contraindication for the use of steroids.",
    "The sample provided is a record from a table that contains information about clinical trials. The record belongs to a trial in phase 1 and focuses on the disease \"chronic lymphocytic leukemia.\" The corresponding ICD-10 codes for this disease are \"C91.11,\" \"C91.12,\" and \"C91.10.\" The trial involves the drug combination of \"tgr-1202 + obinutuzumab + chlorambucil.\" The eligibility criteria for this trial include having confirmed CLL, an ECOG score of 0 to 2, and the ability to swallow oral medication. The exclusion criteria include having known infections of hepatitis B, hepatitis C, or HIV, having primary central nervous system lymphoma or intracranial involvement, and having undergone a hematologic stem cell transplant within a certain timeframe.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The diseases being studied are \"multiple myeloma in relapse,\" \"refractory multiple myeloma,\" and \"multiple myeloma.\" The corresponding ICDCodes for these diseases are \"C90.02,\" \"D46.4,\" \"D46.1,\" \"D46.A,\" \"D46.0,\" \"D46.20,\" \"D46.21,\" \"D46.22,\" \"C90.01,\" \"C90.02,\" and \"C90.00.\" The drugs being used in the trial are \"pomalidomide,\" \"marizomib,\" and \"low-dose dexamethasone.\" The eligibility criteria for participants include age, ability to understand and sign an informed consent form, adherence to the study schedule, documented diagnosis of multiple myeloma, previous treatment with lenalidomide and bortezomib, disease progression, performance status score, compliance with program requirements, contraception use, and other medical conditions that may affect participation. Exclusion criteria include certain medical conditions, previous therapy with specific drugs, history of allergic reactions, and other factors that may pose risks to participants.",
    "The sample provided is a schema definition of a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. The table has several columns, including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of the diseases being studied, \"icdcodes\" which contains the corresponding ICD-10 codes for the diseases, \"drugs\" which lists the names of the drugs being tested, and \"criteria\" which provides the eligibility criteria for participants.\n\nThe sample data in the table includes information for different parts of the trial, such as Part 1, Part II, Part IIIa, and Part IIIb. Each part has its own set of key inclusion and exclusion criteria for both healthy volunteers and participants with systemic lupus erythematosus (SLE).\n\nFor example, in Part 1, the key inclusion criteria for healthy volunteers include being in good health, having a body mass index (BMI) between 18 and 30 kg/m2, and a body weight of at least 45 kg. The key exclusion criteria for healthy volunteers include a history of certain infections, severe allergic reactions, significant cardiovascular or other major diseases, recent immunization/vaccination, recent blood donation, and vigorous exercise within 48 hours prior to Day -1.\n\nIn Part II, the key inclusion criteria for SLE participants include having definite SLE for at least 6 months or positive anti-dsDNA antibody, presence of active lupus skin disease, and meeting certain BMI and body weight requirements. The key exclusion criteria for SLE participants include active neuropsychiatric SLE, recent serious infections, symptoms of bacterial or viral infection, severe allergic reactions, and certain skin conditions.\n\nSimilar inclusion and exclusion criteria are provided for Part IIIa and Part IIIb, with specific requirements for healthy volunteers and SLE participants.\n\nIt is important to note that there may be additional protocol-defined inclusion and exclusion criteria that apply, which are not specified in the provided sample.",
    "The sample from the table represents a phase 1 clinical trial. The diseases being studied include adult b acute lymphoblastic leukemia, chronic lymphocytic leukemia, cutaneous b-cell non-Hodgkin lymphoma, and various other types of lymphomas and leukemias. The diseases are identified by their corresponding ICD-10 codes. The drug being tested in the trial is ibrutinib. The eligibility criteria for the trial include having a confirmed diagnosis of HIV infection and a B-cell non-Hodgkin lymphoma or B-cell lymphoproliferative disease. Other criteria include specific laboratory values, performance status, and the use of stable antiretroviral therapy. The sample also includes exclusion criteria, such as prior exposure to ibrutinib and certain medical conditions. Additionally, the sample mentions the need for",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2 and is focused on the treatment of metastatic pancreatic cancer. The disease is identified by the ICD-10 code C25.3. The drug being studied is paclitaxel bound albumin. \n\nThe eligibility criteria for participants in this trial include being male or female between the ages of 18 and 75, having a confirmed diagnosis of pancreatic ductal adenocarcinoma, providing written informed consent, having measurable metastatic disease that has not been previously treated with chemotherapy, having an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1, not having received previous abdominal radiotherapy on target lesions (except for analgesic radiation therapy), not having heart failure, angina, or myocardial infraction within the past 12 months, and having adequate organ function in terms of hematologic, hepatic, and renal parameters.\n\nThe exclusion criteria for this trial include being 76 years of age or older, having endocrine or acinar pancreatic carcinoma, having received previous radiotherapy for measurable lesions, having central nervous system metastasis, having other concomitant cancer or a history of cancer outside of carcinoma in situ of the cervix or basal or squamous cell of the skin, already being enrolled in another clinical trial with experimental drugs, having a current active infection, having serious pre-existing medical conditions or serious concomitant systemic disorders that would compromise the patient's safety or ability to complete the study, being pregnant or lactating, being unable to undergo medical tests for geographical, social, or psychological reasons, and having a known deficiency of dihydropyrimidine dehydrogenase (DPD).",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase is Phase 1, and the diseases listed are acute myeloid leukemia, relapsed acute myeloid leukemia, and refractory acute myeloid leukemia. The corresponding ICDCodes for these diseases are also provided. The drugs being studied in this trial are ficlatuzumab and cytarabine. The eligibility criteria for participants in this trial include specific requirements related to the type and stage of AML, age, prior treatment history, cardiac function, liver and renal function, and other factors. There are also exclusion criteria that specify conditions or circumstances that would disqualify a participant from the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease mentioned is \"head and neck cancer,\" and the corresponding ICDCodes are ['C76.0', 'C47.0', 'C49.0', 'C77.0', 'D17.0', 'D21.0', 'D36.11']. The drug mentioned is \"docetaxel.\" \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" Inclusion criteria include having recurrent or second primary squamous cell head and neck cancer, a defined area of recurrence on imaging, previous head and neck radiation (RT) to at least 50 Gy, a performance status score of 0-1, a time interval from previous RT of at least 9 months, a volume of disease appropriate for protocol treatment, a minimum estimated survival of at least 3 months, being 18 years or older, and having adequate labs.\n\nExclusion criteria include having primary tumors of the salivary gland, unavailable original pathology report and radiation therapy records, prior spinal cord dose exceeding 45 Gy, surgery or chemotherapy within the past 4 weeks, and prior invasive malignancy (except non-melanomatous skin cancer) unless disease-free for a minimum of 3 years (noninvasive cancers are permitted).",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1. The disease being studied is autism, and its corresponding icd-10 code is Z13.41. The drugs being tested are dmxb-a 150 mg and dmxb-a 75 mg. The eligibility criteria for this trial include being between the ages of 18 and 50, meeting the DSM-5 criteria for Autism Spectrum Disorder (Levels 1 or 2) as defined by the Autism Diagnostic Observation Schedule, being a non-smoker, and being in good health. The exclusion criteria include having an estimated verbal and nonverbal IQ below 70, abusing other substances, not being sufficiently fluent in English for testing purposes, having a history of severe head injury, and having Fragile X Syndrome or Rett Syndrome.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 1, the disease is chronic hepatitis B, the ICDCodes are B18.0, B18.1, B18.2, B18.8, and B18.9, the drugs are nvr 3-778, placebo for nvr 3-778, and pegasys. The eligibility criteria are described for both healthy volunteers and patients enrolling in Part II of the study. For healthy volunteers, they can be male or female between 18 and 65 years old with a BMI of 18-32kg/m2. They must be in good health and should not have any health condition that could interfere with the study drug's absorption, distribution, elimination, or the clinical and laboratory assessments. For patients enrolling in Part II, they can be male or female between 18 and 65 years old with a BMI of 18-35kg/m2. They must have HBeAg positive, chronic hepatitis B with no history of clinical decompensation, and should not have been treated for hepatitis B before.",
    "The sample from the table represents a clinical trial for wound infection treatment. The trial is in phase 1/phase 2. The disease being studied is wound infection. The ICD-10 codes associated with the disease are O86.00, O86.01, O86.02, O86.09, and O86.03. The drugs being tested in the trial are an E. coli phages cocktail, standard of care: silver sulfadiazine, and a P. aeruginosa phages cocktail. \n\nThe eligibility criteria for participants in the trial include being an adult patient treated for burn wounds in a burn unit, having a burn wound or graft harvesting area showing signs of infection according to SFETB criteria, having a microbiologically documented infection caused by Escherichia coli or Pseudomonas aeruginosa, and being treated with povidone-iodine. \n\nExclusion criteria for the trial include being pregnant or breastfeeding, having a condition requiring treatment that may interfere with analysis results, being currently involved in another interventional research protocol with ongoing therapeutic intervention, having participated in anti-infective drug trials in the previous month, being considered part of a vulnerable population, having treatment limitation or withdrawal during the study period, and having an allergy to Silver Sulfadiazine.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The diseases being studied are \"advanced intra-ocular retinoblastoma\" and \"retinoblastoma\". The ICDCodes associated with these diseases are \"S05.30XS\", \"S05.31XS\", \"S05.32XS\", \"S05.30XA\", \"S05.30XD\", \"S05.31XA\", and \"S05.31XD\". The drugs being used in the trial are \"melphalan\", \"carboplatin\", \"etoposide\", and \"vincristine\". The eligibility criteria for participants include age, previous treatment history, eye classification, renal function, hematological function, liver function, coagulation system, contraception use, and exclusion criteria such as evidence of extraocular retinoblastoma, previous treatment with chemotherapy or radiation therapy, and other medical conditions.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 1 and focuses on patients with pulmonary hypertension and cardiac MRI measurements below 40. The ICD-10 codes associated with these diseases are provided as well. The only drug mentioned in this sample is carvedilol. The eligibility criteria for this trial include being over 18 years old, having WHO category 1 pulmonary arterial hypertension, being in WHO functional class II-III, having a right ventricular ejection fraction (RVEF) below 40% as measured by cardiac MRI, and having a mean pulmonary artery pressure above 40 mm Hg. Patients must also be stable on PAH-specific therapy for the past 3 months. There are also exclusion criteria listed, such as having certain heart conditions, low blood pressure, recent hospitalization, allergies to carvedilol or other \u03b2 blockers, and having asthma.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2 and focuses on esophageal carcinoma. The ICD-10 codes associated with the disease are ['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']. The drugs being studied are pertuzumab and trastuzumab. The eligibility criteria for participants include having histologically proven adenocarcinoma of the intrathoracic esophagus or gastroesophageal junction, being HER2-positive, being surgically resectable, having specific tumor characteristics, meeting certain age and performance status requirements, and having adequate hematological, renal, and hepatic functions. There are also exclusion criteria, such as having certain types of tumors, a history of certain malignancies, being pregnant or planning to become pregnant, and having certain medical conditions.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1. The disease mentioned is \"diabetes mellitus, type 2\" and its corresponding ICDCodes are ['E11.65', 'E11.9', 'E11.21', 'E11.36', 'E11.41', 'E11.42', 'E11.44']. The drugs being tested in this trial are 'empagliflozin medium dose', 'empagliflozin high dose', and 'empagliflozin low dose'. The eligibility criteria for this trial are listed under inclusion and exclusion criteria, which include factors such as age, glycaemic control, insulin levels, BMI, and previous medical history.",
    "The sample from the table represents a clinical trial with a phase 1/phase 2 study design. The trial focuses on HIV infection and involves the evaluation of the drugs dipyridamole and placebo. The eligibility criteria for participants include being diagnosed with HIV-1 infection, being on antiretroviral therapy for at least 12 months, having a plasma HIV-1 RNA level below 50 copies/mL, and having a stable ART regimen for at least 8 weeks. Other criteria include providing informed consent, having no medical or mental health conditions that would prevent participation, and meeting specific laboratory values within 60 days prior to entry.\n\nExclusion criteria for the trial include pregnancy or breastfeeding, known allergies or hypersensitivity to the study drugs, history of cardiovascular disease, uncontrolled type II diabetes mellitus, and chronic inflammatory conditions. Other exclusions include a history of asthma requiring treatment, recent serious illness or hospitalization, use of certain medications within the past 60 days, recent vaccinations, participation in other HIV immunotherapy or therapeutic vaccination trials, active drug or alcohol use, and use of investigational therapies within 30 days prior to entry.\n\nFor the subset of participants undergoing rectal tissue analysis, additional criteria and exclusions apply. These include abstaining from certain sexual practices before and after rectal biopsy, absence of colorectal abnormalities or symptoms, and absence of active untreated gonorrhea or chlamydia infection.\n\nFor participants enrolled under Version 2.0, there are additional exclusions for spirometry testing, such as recent abdominal or cataract surgery, recent myocardial infraction or stroke, acute respiratory symptoms or fever, uncontrolled hypertension, and prior adverse reactions to albuterol.",
    "The sample provided is a schema definition of a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this specific sample, the phase of the trial is Phase 1. The diseases being studied are hepatic impairment, liver diseases, and digestive system diseases. The corresponding ICDCodes for these diseases are provided as well. The drug being tested is idn-6556. \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include being 18 years or older, providing written informed consent, having a BMI between 18.0 and 40.0 kg/m2, and having a body weight greater than 45 kg. Additionally, participants must be willing to use two reliable forms of contraception during the study period. \n\nThere are specific inclusion criteria for matched healthy volunteers, including being medically healthy, having a supine blood pressure of \u2264145/90 mmHg, and being demographically comparable to subjects with hepatic impairment in terms of body weight, age, and gender ratio. \n\nSubjects with hepatic impairment must have evidence of hepatic disease, meet certain criteria for Child-Pugh classification, and have a supine blood pressure of \u2264160/100 mmHg. \n\nExclusion criteria for all subjects include known HIV infection, clinically significant uncontrolled diseases, gastrointestinal disorders or surgeries that may interfere with drug absorption, recent febrile illness, ongoing drug abuse, history of malignancies (except for treated skin cancer), recent participation in another clinical trial, and pregnancy or breastfeeding for females. \n\nAdditional exclusion criteria for matched healthy volunteers include clinically significant liver disease or damage, low creatinine clearance, history of cardiac arrhythmias or prolonged QT interval, and excessive alcohol consumption. \n\nExclusion criteria for subjects with hepatic impairment include fluctuating or deteriorating hepatic function, history of liver transplant or certain procedures, history of cardiac arrhythmias or prolonged QT interval, and low creatinine clearance.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is categorized as phase 1. The disease being studied is neoplasms, and the corresponding ICD-10 codes for the diseases are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drugs being used in the trial are everolimus, exemestane, and bi 836845. The eligibility criteria for participants in the trial are listed, including requirements such as having locally advanced or metastatic breast cancer, being postmenopausal, having evidence of recurrence or progressive disease, and having certain tumor characteristics. There are also exclusion criteria, such as previous treatment with certain drugs, known hypersensitivity to certain medications, and presence of certain medical conditions.",
    "The sample from the table represents a clinical trial with different phases (phase I, phase II, phase III) and focuses on various diseases. The diseases mentioned in the sample are HIV-1 infection and hepatitis. The icd-10 codes associated with these diseases are also provided. The trial involves testing different drugs such as sofosbuvir, ribavirin, and ledipasvir/sofosbuvir. The eligibility criteria for participants are described in detail, including requirements related to HIV-1 infection, HCV infection, body mass index, electrocardiogram results, and willingness to provide informed consent. The criteria also include guidelines for contraception and reproductive potential for both men and women. The inclusion and exclusion criteria differ for different cohorts within the trial. Overall, the sample provides a comprehensive overview of the trial's schema and the criteria for participant selection.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2 and focuses on the treatment of ulcerative colitis. The trial involves the use of a drug called \"sb012\" and a placebo. The eligibility criteria for participants include being adults aged 18 to 75 with active ulcerative colitis. Other criteria include having a certain Mayo Score, body mass index, and negative pregnancy test for female subjects. There are also exclusion criteria, such as having certain medical conditions, recent use of specific medications, and prior participation in the trial.",
    "The sample provided is for a phase 1 clinical trial. The trial is focused on healthy individuals. The diseases listed in this sample are 'healthy', which means the trial is not targeting any specific disease. The icd-10 codes provided are \"['Z76.3', 'Z76.2']\", which are codes related to healthcare encounters for other specified examinations and investigations. The drugs being tested in this trial are 'palbociclib alone' and 'palbociclib plus itraconazole'. The eligibility criteria for this trial include being a healthy male or female between the ages of 18 and 55, having a body mass index within a specific range, and having a total body weight of more than 50 kg. Other criteria include providing informed consent, being willing to comply with the study procedures, and not having any significant medical conditions or drug-related issues. Additionally, pregnant or breastfeeding females, females of childbearing potential, and males with pregnant partners or who are of childbearing potential must use effective contraception during the study and for 90 days after the last dose of the investigational product.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is renal cell carcinoma. The ICDCodes associated with this disease are ['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']. The drugs being used in the trial are axitinib and mk-3475. The eligibility criteria for this trial include specific requirements such as confirmed advanced RCC with predominantly clear-cell subtype, measurable lesions as defined by RECIST version 1.1, Eastern Cooperative Oncology Group performance status of 0 or 1, and controlled hypertension. There are also exclusion criteria listed, such as prior treatment with systemic therapy for advanced RCC, prior treatment with agents targeting T-cell co-stimulation or checkpoint pathways, and various medical conditions within specific timeframes.",
    "The sample from the table represents a clinical trial with a combination of phase 1 and phase 2. The trial focuses on diseases related to end-stage renal disease, kidney failure, delayed graft function, and ischemic reperfusion injury. The diseases are identified using ICD-10 codes. The trial involves the use of two drugs, namely c1 esterase inhibitor and placebo. The eligibility criteria for participants include being between 18-70 years old, being a recipient of a specific type of donor allograft, having received meningococcal vaccination before the transplant, and providing written consent. The criteria also include a risk index based on factors such as donor age, cold ischemia time, recipient race, and donor death due to a cerebrovascular accident. There are also exclusion criteria, such as having a prothrombotic disorder, history of thrombosis or hypercoagulable state, and contraindications to treatment with C1INH. Other exclusion criteria include abnormal coagulation function, active presence of malignancies, and positive PCR results for hepatitis B, hepatitis C, or HIV. Additionally, recipients of preemptive kidney transplantation, multi-organ transplants, and certain types of kidney allografts are excluded from the trial. Pregnant or lactating female subjects are also excluded.",
    "The sample is a record from a table that contains information about clinical trials. It includes the phase of the trial (phase I, phase II, or phase III), a list of diseases, a list of corresponding ICD-10 codes for the diseases, a list of drug names, and eligibility criteria for participants. \n\nIn this specific sample, the phase of the trial is phase 1. The diseases being studied are HIV infection, recurrent non-small cell lung carcinoma, stage IIIA non-small cell lung cancer, stage IIIB non-small cell lung cancer, and stage IV non-small cell lung cancer. The corresponding ICD-10 codes for these diseases are provided. The drug being tested is erlotinib hydrochloride. \n\nThe eligibility criteria for participants include having known HIV infection and histologically confirmed non-small cell lung cancer that is metastatic or unresectable. Participants may have received prior lines of chemotherapy, except for erlotinib or other EGFR-targeted therapy. The criteria also specify different eligibility requirements based on the participants' prior therapy and EGFR mutation status. Other criteria include specific time intervals since prior treatments, molecular characterization of the cancer, measurable disease, serologic documentation of HIV infection, performance status, certain blood counts and levels, and other medical considerations. \n\nThe exclusion criteria include prior treatment with erlotinib or other EGFR-targeted agents, recent chemotherapy or radiotherapy, receiving other investigational agents, active brain metastases or epidural disease, history of allergic reactions to similar compounds, certain laboratory test results, uncontrolled intercurrent illness, chronic diarrhea, certain medications, significant cornea abnormalities, pregnancy or breastfeeding, and specific biomarkers predictive of resistance to erlotinib therapy.",
    "The sample from the table represents a clinical trial in phase 1 for the treatment of osteoporosis. The trial is conducted in China and is specifically focused on individuals of Chinese ancestry. The eligibility criteria include having certain liver enzyme levels within the normal range, being in good overall health, and meeting specific age and weight requirements. Female participants must either be unable to bear children or agree to use contraception during the study. The sample also lists exclusion criteria, such as a history of certain medical conditions, positive test results for certain infections, abnormal calcium levels, and recent participation in other clinical trials. The sample provides detailed information about the inclusion and exclusion criteria, ensuring that the participants are suitable for the study.",
    "The sample is a record from a table that contains information about clinical trials. In this particular record, the trial is in phase 1 and is focused on treating advanced cancer. The ICD-10 codes associated with the disease are \"K74.02\", \"G47.22\", \"H35.3133\", \"H35.3134\", \"H35.3113\", \"H35.3114\", and \"H35.3123\". The drug being tested is chlorogenic acid. The eligibility criteria for participants include having advanced cancer with no effective treatment, a Karnofsky performance status of at least 70, adequate organ function, and providing informed consent. The exclusion criteria include being allergic to chlorogenic acid and having persistent toxicities from previous treatments of at least grade 2.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is categorized as \"phase 1\" and focuses on the disease \"chronic constipation.\" The corresponding ICD-10 code for this disease is \"K59.04.\" The trial involves the use of two drugs, namely \"rm-131\" and \"placebo.\" The eligibility criteria for participants are listed, including requirements such as providing written informed consent, meeting the Rome III criteria for functional constipation, having a stable medication regimen, and having a body mass index (BMI) between 18 and 40 kg/m2. Female participants must have negative pregnancy tests and use appropriate birth control methods. The exclusion criteria specify conditions that would disqualify individuals from participating in the trial, such as secondary constipation, structural or metabolic diseases affecting the gastrointestinal system, recent surgery, acute or chronic illnesses, and abnormalities in physical examination or laboratory tests. Other factors, such as recent alcohol or substance abuse, participation in other clinical studies involving investigational medications, and any other reasons that could affect the interpretation of the study, are also considered.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease being studied is pancreatic cancer. The icd-10 code associated with this disease is C25.3. The drugs being used in the trial are enzalutamide, gemcitabine, and nab-paclitaxel. The eligibility criteria for participants include having histologically or cytologically confirmed metastatic or unresectable pancreatic adenocarcinoma, measurable disease according to RECIST criteria, an ECOG performance status of less than 2, a life expectancy of greater than 3 months, normal organ and marrow function, and meeting certain requirements regarding prior treatment and contraception. The exclusion criteria include prior treatment with certain chemotherapy agents, receiving other investigational agents within 4 weeks of starting the study, untreated brain or leptomeningeal metastases, history of allergic reactions to certain compounds, recent major surgery, uncontrolled intercurrent illness, history of HIV infection or hepatitis B or C, history of seizures or transient ischemic attack, pregnancy or breastfeeding, chronic treatment with immunosuppressant drugs, other active malignancy requiring treatment, significant medical conditions or psychiatric illness that would prevent participation, uncontrolled infection, and concomitant medications that lower seizure threshold.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is cancer. The ICDCodes associated with the disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drug being used in the trial is pazopanib. \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" Inclusion criteria include subjects providing written informed consent, being 18 years or older, having an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, and having adequate organ system function. Exclusion criteria include poorly controlled hypertension, a corrected QT interval (QTc) greater than 480msecs, a history of certain cardiovascular conditions within the past 6 months, clinically significant gastrointestinal abnormalities, history of cerebrovascular accident or untreated deep venous thrombosis within the past 6 months, recent major surgery or trauma, evidence of active bleeding or bleeding diathesis, known endobronchial lesions or lesions infiltrating major pulmonary vessels, recent hemoptysis, any serious pre-existing medical or psychiatric condition, inability or unwillingness to discontinue use of prohibited medications, concurrent use of substances that may interfere with the pharmacokinetics of pazopanib, and women of childbearing potential without adequate contraception, pregnant, or breastfeeding women.",
    "The sample from the table is for a phase 1 clinical trial. The disease being studied is leukemia, specifically acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). The ICD-10 codes associated with these diseases are C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, and C91.01. The drugs being tested in this trial are omacetaxine and decitabine. \n\nThe inclusion criteria for this trial are as follows:\n1. Patients must have previously untreated AML with at least 20% blasts or high-risk MDS. Prior therapy with certain medications is allowed, but no prior chemotherapy except for emergency use.\n2. Patients must be at least 70 years old.\n3. Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or lower.\n4. Patients must have adequate liver and kidney function.\n5. Patients must be willing and able to provide written consent before starting therapy.\n6. Men of childbearing potential must agree to use contraception during the study.\n\nThe exclusion criteria for this trial are as follows:\n1. Patients with severe heart disease, active ischemia, uncontrolled cardiac conditions, uncontrolled hypertension, uncontrolled diabetes, or congestive heart failure.\n2. Patients who have had a heart attack in the previous 12 weeks.\n3. Patients with active and uncontrolled disease or infection.\n4. Patients with acute promyelocytic leukemia (APL).",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The diseases being studied are leukemia, acute myeloid leukemia, acute lymphocytic leukemia, and acute leukemias. The corresponding ICDCodes for these diseases are also provided. The drug being tested in this trial is \"epz-5676\". The eligibility criteria for participants in this trial are listed, including age requirements, specific diagnosis criteria, therapeutic options, performance level, prior therapy history, renal and hepatic function requirements, cardiac function requirements, and exclusion criteria.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 1, and the disease being studied is Alzheimer's disease. The ICDCodes associated with this disease are G30.8, G30.9, G30.0, and G30.1. The drugs being tested in this trial are \"s-equol\" and \"placebo\". The eligibility criteria for this trial include having very mild or mild Alzheimer's disease, having a study partner, and speaking English as the primary language. The exclusion criteria include not having a viable study partner, reporting serious medical risks such as type 1 diabetes or cancer, and using any type of estrogen replacement therapy.",
    "The sample from the table represents a clinical trial study. It includes information about the phase of the trial (phase I, II, or III), a list of diseases being studied, the corresponding ICD-10 codes for those diseases, the drugs being used in the trial, and the eligibility criteria for participants.\n\nIn this specific sample, the phase of the trial is phase 1. The diseases being studied include adult glioblastoma, endometrial clear cell adenocarcinoma, endometrial serous adenocarcinoma, ovarian clear cell cystadenocarcinoma, ovarian endometrioid adenocarcinoma, ovarian mucinous cystadenocarcinoma, ovarian serous cystadenocarcinoma, recurrent fallopian tube carcinoma, recurrent ovarian carcinoma, recurrent primary peritoneal carcinoma, recurrent uterine corpus cancer, solid neoplasm, stage iiia fallopian tube cancer ajcc v7, stage iiia ovarian cancer ajcc v6 and v7, stage iiia primary peritoneal cancer ajcc v7, stage iiib fallopian tube cancer ajcc v7, stage iiib ovarian cancer ajcc v6 and v7, stage iiib primary peritoneal cancer ajcc v7, stage iiic fallopian tube cancer ajcc v7, stage iiic ovarian cancer ajcc v6 and v7, stage iiic primary peritoneal cancer ajcc v7, stage iv fallopian tube cancer ajcc v6 and v7, stage iv ovarian cancer ajcc v6 and v7, and stage iv primary peritoneal cancer ajcc v7. The corresponding ICD-10 codes for these diseases are also provided.\n\nThe drug being used in the trial is sapanisertib. The eligibility criteria for participants include having a confirmed diagnosis of recurrent glioblastoma or an advanced solid tumor, having measurable or evaluable disease, meeting specific prior therapy requirements, having recovered from previous therapy toxicity, having a certain performance status, meeting certain blood count and liver function requirements, and meeting various other criteria related to medical history, contraception, and concurrent illnesses.\n\nAdditionally, there are exclusion criteria listed, which include factors such as concurrent use of other investigational agents, history of allergic reactions to similar compounds, prior treatment with certain inhibitors, presence of certain medical conditions or diseases, and use of certain medications.\n\nOverall, this sample provides a snapshot of the information contained in the table, describing the phase, diseases, drugs, and eligibility criteria for participants in the clinical trial study.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The diseases being studied include breast neoplasms, lung neoplasms, cancer of the liver, lymphoma, and cancer of the kidney. The corresponding ICDCodes for these diseases are also provided. The drugs being used in the trial are metformin xr, delayed metformin, and sirolimus. The eligibility criteria for participants in this trial include having a confirmed solid tumor that is metastatic or unresectable, having an ECOG performance status of 0 or 1, being at least 18 years old, using adequate contraception if applicable, and having adequate hematologic, renal, and hepatic function. There are also additional criteria related to prior treatment with mTOR inhibitors, measurable or non-measurable disease, and the use of substrates, inhibitors, or inducers of CYP3A4. The exclusion criteria include having grade 3 toxicities with an mTOR inhibitor, specific glucose and triglyceride levels, recent chemotherapy, immunotherapy, or radiotherapy, and various other medical and lifestyle factors.",
    "The sample from the table is for a phase 1 clinical trial. The disease being studied is an unspecified adult solid tumor that is specific to the protocol. The ICD-10 codes associated with the disease are H01.009, H02.209, H02.009, H02.109, H04.209, H05.409, and H10.509. The drugs being used in the trial are a vegfr/pdgfr dual kinase inhibitor called x-82 and docetaxel. The eligibility criteria for the trial include having a confirmed metastatic or unresectable solid malignancy, no available therapies that will provide clinical benefit, measurable disease, a life expectancy of greater than 12 weeks, an ECOG performance status of 0 or 1, and meeting various laboratory and medical criteria. There are also exclusion criteria, such as recent chemotherapy or major surgery, history of allergic reactions to similar compounds, poorly controlled hypertension, and various other medical conditions. The sample also includes information on the eligibility of patients taking certain medications and the exclusion of patients with brain metastases or prior malignancies, except for specific cases.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 1 trial and the disease being studied is atrial fibrillation. The ICD-10 codes associated with this disease are ['I48.0', 'I48.21', 'I48.91', 'I48.11', 'I48.19', 'I48.20']. The drugs being tested in this trial are 'bms-919373', 'sotalol', and a placebo for 'bms-919373'. The eligibility criteria for this trial include being between the ages of 18 and 85, having a dual-chamber permanent pacemaker, and being a woman who is not of childbearing potential. The exclusion criteria include having a history of permanent or persistent atrial fibrillation, a history of transient ischemic attack or stroke in the last 12 months, clinically significant ventricular arrhythmia, complete heart block, planned surgery or intervention during the study period, and a history of atrial fibrillation.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied in this trial include breast cancer, cervical cancer, renal cancer, melanoma, and bladder cancer. The ICDCodes associated with these diseases are also provided. The drugs being used in the trial are aldesleukin, fludarabine, and cyclophosphamide.\n\nThe eligibility criteria for participants in this trial are listed in a numbered format. These criteria include having metastatic or locally advanced refractory/recurrent cancer that expresses MAGE-A3, having previously received prior first-line standard therapy, being HLA-A A serotype group (HLA-A*01) positive, being between the ages of 18 and 70, having a good understanding of the trial and willingness to sign the informed consent document, having a clinical performance status of Eastern Cooperative Oncology Group (ECOG) 0 or 1, practicing birth control, and meeting certain serology, hematology, and chemistry requirements.\n\nThere are also exclusion criteria listed, which include being pregnant or breastfeeding, having active systemic infections or major medical illnesses, having primary immunodeficiency, receiving concurrent opportunistic infections or systemic steroid therapy, having a history of severe immediate hypersensitivity reaction to any of the agents used in the study, having a history of cardiac events or a documented left ventricular ejection fraction (LVEF) of less than or equal to 45%, having central nervous system (CNS) metastases or symptomatic CNS involvement, presenting with lesions that may harbor an occult infectious source, having a documented forced expiratory volume 1 (FEV1) less than or equal to 60% predicted, and receiving any other investigational agents.\n\nOverall, this sample provides detailed information about the phase, diseases, drugs, and eligibility criteria for a clinical trial.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is categorized as phase 1. The disease being studied is pancreatic neoplasms, and the corresponding ICD-10 code is C25.3. The drugs being used in the trial are ly2157299 and gemcitabine. \n\nThe sample also includes the eligibility criteria for participants in the trial. Inclusion criteria include having a histological or cytological diagnosis of locally advanced or metastatic adenocarcinoma of the pancreas, having measurable or non-measurable disease, giving written informed consent, having adequate organ function, having a performance status of less than or equal to 1 on the Eastern Cooperative Oncology Group (ECOG), being reliable and willing to follow study procedures, and meeting certain requirements for prior radiation therapy and contraceptive use.\n\nExclusion criteria include being currently enrolled in or recently discontinued from another clinical trial, having moderate or severe cardiac disease, testing positive for HIV, hepatitis B, or hepatitis C, having symptomatic central nervous system malignancy or metastasis, being unable to swallow tablets or capsules, being pregnant or breastfeeding, having serious preexisting medical conditions, having previous or concurrent malignancy (with some exceptions), having endocrine pancreatic tumors or ampullary cancer, having current hematological malignancies, having previously completed or withdrawn from this study or any other study investigating LY2157299, having known allergies to LY2157299 or gemcitabine, and being assessed as inadequate for the study by the investigator.",
    "The sample from the table represents a phase 1 clinical trial for advanced or metastatic breast cancer. The trial is focused on women who have not received any prior therapy for advanced disease and are postmenopausal. The eligibility criteria include having received a maximum of two lines of chemotherapy for metastatic or recurrent breast cancer in the dose-escalation phase, having a confirmed diagnosis of estrogen-receptor positive and/or progesterone receptor positive breast cancer, and having HER2-negative breast cancer. Patients must have measurable disease or at least one predominantly lytic bone lesion. \n\nThere are also exclusion criteria, which include patients who have received any CDK4/6 or PI3K inhibitor, patients with active cardiac disease or a history of cardiac dysfunction, and patients currently receiving medications that are known strong inducers or inhibitors of CYP3A4, have a known risk to prolong the QT interval or induce Torsades de Points, or have a narrow therapeutic window and are predominantly metabolized through CYP3A4. Additionally, certain scores on anxiety and depression mood questionnaires may also exclude patients from the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is pancreatic cancer. The ICDCodes associated with this disease are ['C25.3']. The drugs being used in the trial are byl719, gemcitabine, and (nab)-paclitaxel. The eligibility criteria for this trial include various inclusion and exclusion criteria. Some of the inclusion criteria include the ability to swallow oral medication, a histologically documented diagnosis of pancreatic adenocarcinoma, and an Eastern Cooperative Oncology Group (ECOG) performance status of \u2264 2. Some of the exclusion criteria include prior sensitivity or intolerance to PI3K inhibitors, central nervous system (CNS) involvement unless certain conditions are met, prior treatment with cytotoxic chemotherapy for pancreatic cancer, and recent radiotherapy or major surgery. There are also additional criteria related to cardiac function, diabetes, gastrointestinal function, liver disease, lung function, medication use, compliance, and other medical conditions. Additionally, participants must not be pregnant or nursing and must use highly effective contraception during the study and for 12 weeks after the final dose of study treatment.",
    "The sample from the table represents a clinical trial for lung cancer patients in phase 1/phase 2. The trial is specifically targeting patients with advanced (non-operable or metastatic) biopsy-proven stage IV or recurrent lung cancer. The patients must have a documented somatic activating mutation in EGFR, such as Exon 19 deletion or L858R. They should also have experienced radiographic progression during treatment with erlotinib, and prior chemotherapy regimens are allowed.\n\nThe inclusion criteria also state that patients must have received erlotinib or other EGFR TK treatment for at least 2 weeks prior to enrollment. They should have a measurable indicator lesion that has not been previously irradiated. Additionally, patients must have undergone a biopsy after developing acquired resistance to erlotinib, with adequate tissue to determine EGFR T790M and tumor histology.\n\nOther eligibility criteria include a Karnofsky Performance Status (KPS) of at least 70%, age over 18 years old, and adequate organ function. Organ function is determined by criteria such as AST, ALT, and Alk phos levels being within 3.0 times the upper limit of normal, total bilirubin being within 2.0 times the upper limit of normal, and creatinine levels being below 2.0 times the upper limit of normal or a creatinine clearance of at least 60ml/min. The patient's ANC should be at least 1,000 cells/mm\u00b3, platelet count should be at least 100,000/mm\u00b3, and hemoglobin should be at least 9.0g/dL.\n\nOn the other hand, there are exclusion criteria that would disqualify patients from participating in the trial. These include concurrent therapy with a potent CYP3A4 inducer or inhibitor, symptomatic brain metastasis requiring escalating doses of steroids, any systemic therapy (chemotherapy or experimental drugs) within 3 weeks of starting treatment on the protocol (except for erlotinib or other EGFR TKI), and any radiation within 2 weeks prior to starting treatment on the protocol.\n\nOther exclusion criteria include patients with grade 2 or greater diarrhea despite maximal medical management, inadequate recovery from prior treatment toxicities, pregnancy or lactation, prior treatment with JAK inhibitor, previous or current malignancies at other sites within the last 2 years (with some exceptions), clinically significant cardiac disease, chronic or current active infections requiring systemic antibiotics, antifungals, or antiviral therapy, and known human immunodeficiency virus infection or hepatitis B or C virus viremia.\n\nIn summary, the sample represents a clinical trial for lung cancer patients in phase 1/phase 2, targeting those with specific genetic mutations and treatment history. The trial has various eligibility and exclusion criteria to ensure the safety and suitability of participants.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease mentioned is \"non hodgkin lymphoma.\" The corresponding ICDCodes for this disease are ['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']. The drug being tested in this trial is \"copanlisib (bay80-6946)\". \n\nThe eligibility criteria for this trial include:\n- Histologically confirmed diagnosis of various types of NHL or advanced and/or refractory solid tumors with specific genetic alterations.\n- The tumor must be accessible for biopsy.\n- Patients must be 18 years or older.\n- NHL patients must have at least one measurable lesion, while solid tumor patients must have at least one measurable lesion according to specific criteria.\n- Patients must have an Eastern Cooperative Oncology Group performance status of 2 or less.\n- Patients must have a life expectancy of at least 3 months.\n- Adequate bone marrow, liver, and renal functions are required.\n- Left ventricular ejection fraction must be equal to or greater than the lower limit of normal for the institution.\n\nThere are also exclusion criteria, which include:\n- Previous or concurrent cancer that is different from NHL or the solid tumor being studied, except for specific exceptions.\n- Lymphomatous involvement of the brain or leptomeningeal involvement, or CNS metastases in solid tumor patients.\n- Any unstable illness or medical condition that could jeopardize patient safety or compliance.\n- Current diagnosis of type 1 or type 2 diabetes mellitus with specific HbA1c or fasting blood glucose levels.\n\nThis sample provides a detailed description of the trial phase, disease, ICDCodes, drug, and the eligibility and exclusion criteria for potential participants.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is psoriasis. The ICDCodes associated with psoriasis are 'L40.0', 'L40.4', 'L40.8', 'L40.9', 'L40.1', and 'L40.50'. The drugs being tested in this trial are 'msb0010841' and 'placebo'. \n\nThe eligibility criteria for this trial are listed under both inclusion and exclusion criteria. Inclusion criteria include having chronic plaque psoriasis for at least 6 months, having at least 10% of the body surface area affected by plaques, having a Psoriasis Area and Severity Index (PASI) score of 12 or higher, and having a Static Physician's Global Assessment (sPGA) score of 3 or higher at the screening and baseline visits. \n\nExclusion criteria include having any condition or medical history that could pose a risk or contraindication for participation in the trial, having non-plaque psoriasis or drug-induced psoriasis, having received biological treatments or systemic immunosuppressants within a specified timeframe, using certain medications as defined in the protocol, having used certain topical corticosteroid treatments within a specified timeframe, and having received previous treatment with agents targeting interleukin (IL)-17, IL-12, and/or IL-23. \n\nIt is also mentioned that there may be other protocol-defined inclusion and exclusion criteria that could apply.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is chronic lymphocytic leukemia. The ICDCodes associated with this disease are C91.11, C91.12, and C91.10. The drugs being used in the trial are ipi-145, fludarabine, cyclophosphamide, and rituximab. The eligibility criteria for participants in this trial include having a confirmed diagnosis of CLL, no prior therapy for CLL, being between the ages of 18 and 65 with an ECOG performance status of \u22641. There are also exclusion criteria listed, such as not receiving any other study agents, having known CNS involvement, and having uncontrolled intercurrent illnesses. Other exclusion criteria include being pregnant, having a history of a different malignancy (with some exceptions), being HIV-positive, having inadequate hepatic or renal function, having a baseline QTcF >480 ms, and having a history of active tuberculosis or venous thromboembolic events. Additional exclusion criteria include a history of alcohol abuse, chronic hepatitis, or other chronic liver disease, taking certain foods or medications that may interact with the study treatment, and being unable to receive prophylactic treatment for pneumocystis.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is pancreatic cancer. The icd-10 code associated with this disease is C25.3. The drug being used in the trial is a combination of tolfenamic acid, gemcitabine, and radiation. \n\nThe eligibility criteria for this trial include the following:\n- Patients must have locally advanced (potentially resectable) pancreatic adenocarcinoma requiring neoadjuvant radiation or locally advanced (nonresectable) or metastatic pancreatic adenocarcinoma requiring definitive or palliative radiation therapy.\n- Patients may have measurable or non-measurable disease.\n- Patients must be at least 18 years old and have an ECOG performance status of 0 or 1.\n- Patients must have a life expectancy of at least 12 weeks.\n- Patients should not be receiving concurrent radiotherapy, chemotherapy, or immunotherapy.\n- A minimum of 4 weeks must have passed since the completion of any prior chemotherapy or immunotherapy.\n- Patients must meet certain blood count and liver function requirements.\n- Patients on warfarin must have maintained a stable INR on a stable dose for at least 4 weeks prior to treatment.\n\nThe primary exclusion criteria for this trial include:\n- Patients who have received prior radiation for their current malignancy at the location of interest.\n- Patients who have not recovered from adverse events caused by previously administered chemotherapeutic agents, except for alopecia and neuropathy.\n- Patients who have used tolfenamic acid concurrent with or within 8 weeks prior to the diagnosis of pancreatic cancer.\n- Patients who have used non-steroidal anti-inflammatory agents (NSAIDs), including aspirin, within 4 weeks prior to the start of active treatment, except for tolfenamic acid.\n- Patients with a history of hypersensitivity reactions to ibuprofen, aspirin, or other NSAIDs.\n- Patients with a history of recurrent peptic ulcer/hemorrhage or gastrointestinal bleeding/perforation related to previous NSAID use.\n- Patients with New York Heart Association Functional Classification of 3 or 4.\n- Patients with known autoimmune disease that could preclude the use of radiation.\n- Patients with a history or evidence of CNS disease, HIV positivity, active systemic infection requiring parenteral antibiotic therapy, or receiving systemic steroid therapy.\n- Patients with a history of other malignancies within the last 5 years, except for non-melanoma skin cancer or cervical cancer in situ that has been successfully treated.",
    "The sample from the table represents a clinical trial for a specific phase of treatment (Phase 1) for various diseases. The diseases listed include different stages of",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 1 trial and the disease being studied is gastrointestinal stromal tumor (GIST). The ICD-10 codes associated with this disease are C49.A0, C49.A1, C49.A2, C49.A5, C49.A3, C49.A4, and C49.A9. The drugs being investigated in this trial are sunitinib and regorafenib. \n\nThe eligibility criteria for this trial include being at least 18 years old, having confirmed metastatic and/or unresectable GIST, demonstrating prior failure to at least imatinib, sunitinib, and regorafenib, having measurable disease per modified RECIST 1.1, having an ECOG performance status of 0 or 1, having adequate organ and marrow function, being able to swallow oral medication, and being willing to use effective birth control during the study and for at least 3 months after completion of the study drug. \n\nExclusion criteria for this trial include recent use of approved tyrosine kinase inhibitors or investigational agents, intolerance to sunitinib and/or regorafenib, recent radiotherapy or major surgery, presence of symptomatic or uncontrolled brain or central nervous system metastases, known or suspected allergy to the investigational agent or any agent given in association with the trial, history of a different malignancy (except for certain exceptions), clinically significant cardiac arrhythmias or heart failure, hypertension despite optimal medical management, recent arterial or venous thrombotic or embolic events, bleeding diathesis, ongoing infection, seizure disorder requiring medication, non-healing wound, ulcer, or bone fracture, persistent proteinuria, HIV-positive individuals on antiretroviral therapy, active hepatitis B or C, interstitial lung disease with ongoing symptoms, uncontrolled intercurrent illness, pregnancy or lactation, presence of any condition that may hinder compliance with the study protocol, and recent use of strong CYP3A4 inhibitors.",
    "The sample provided is for a clinical trial study. The trial is in phase 1/phase 2 and focuses on the treatment of scleroderma and systemic sclerosis. The diseases are represented by the names \"scleroderma\" and \"systemic sclerosis\" and their corresponding ICD-10 codes are ['L94.1', 'L94.0'] and ['M34.0', 'M34.89', 'M34.9', 'M34.82', 'M34.83', 'M34.81', 'M34.2'] respectively. The drug being tested in the trial is \"divalproex sodium\". \n\nThe eligibility criteria for participants in the trial are as follows:\n- Participants must be 18 years of age or older.\n- Participants must have a diagnosis of scleroderma as defined by the American College of Rheumatology (ACR).\n- Participants must have at least one digital manifestation occurring within the past 6 months, such as digital swelling/edema, digital ulcer, calcinosis cutis, or restricted digital range of motion.\n- Female participants of childbearing potential must use an oral contraceptive pill or equivalent birth control method during the study.\n\nThe exclusion criteria for participants in the trial are as follows:\n- Participants must not be under 18 years old.\n- Participants must not be using high dose steroids (>10 mg/day) or have an unstable steroid dose in the past 4 weeks.\n- Participants must not have started an investigational drug or disease-modifying agent within the past 6 months, including systemic corticosteroids, methotrexate, cyclosporine, azathioprine, cyclophosphamide, bosentan, mycophenolate mofetil, thalidomide, or colchicine.\n- Participants must not be taking a medication with a significant drug-drug interaction with divalproex sodium, such as clomipramine and lamotrigine.\n- Participants must not have another connective tissue disease or condition that could affect rest pain and hand function, such as systemic lupus erythematosus, rheumatoid arthritis, or osteoarthritis.\n- Participants must not have uncontrolled diabetes, chronic kidney disease, or chronic hepatitis.\n- Participants must not have certain laboratory abnormalities at baseline, such as anemia, thrombocytopenia, abnormal INR, low estimated GFR, high serum creatinine, hyperbilirubinemia, or elevated AST or ALT.\n- Participants must not be pregnant or breastfeeding.\n- Participants must not have a history of severe depression, suicidal ideation, epilepsy, bipolar disorder, or schizophrenia.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is categorized as \"phase 1\" and focuses on high-grade glioma, which includes diseases such as anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic oligoastrocytoma, glioblastoma, and gliosarcoma. The corresponding ICD-10 codes for these diseases are also provided.\n\nThe trial involves the use of the drug temozolomide. The eligibility criteria for participants include having a confirmed diagnosis of high-grade glioma, having received prior radiation therapy and standard temozolomide, and being at least three months from the end of chemoradiotherapy or showing signs of disease progression through biopsy or imaging. Other criteria include having recovered from previous therapy, having an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 or better, and meeting certain blood count and liver function requirements.\n\nParticipants must also be aware of the nature of their disease and provide informed consent. Women of reproductive potential must use effective birth control during the study and for up to 6 months after treatment. Exclusion criteria include allergies to temozolomide or other specified medications, HIV positivity with active treatment, certain medical conditions or illnesses that may interfere with protocol adherence, and simultaneous participation in other therapeutic clinical trials. Pregnant and nursing women are also excluded from the study.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase is \"Phase 1\" and the diseases listed include various types of lymphomas, leukemias, and other related conditions. The ICDCodes column contains the corresponding ICD-10 codes for each disease. The drugs mentioned are \"6,8-bis(benzylthio)octanoic acid\" and \"bendamustine hydrochloride\". The eligibility criteria are divided into inclusion and exclusion criteria, which outline the requirements for patients to participate in the clinical trial. These criteria include factors such as confirmed diagnosis, measurable disease, performance status, expected survival, contraceptive use, liver and kidney function, absence of active infections, mental competence, and willingness to sign the informed consent form. The exclusion criteria include conditions such as cerebral metastases, active second malignancies, recent treatment with other therapies, serious medical illnesses, bleeding disorders, pregnancy or lactation, and certain heart conditions.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 1, and the disease mentioned is \"drug-drug interaction.\" The ICDCodes associated with this disease are \"Z71.51,\" \"E06.4,\" \"E23.1,\" \"E66.1,\" \"G25.1,\" \"G25.4,\" and \"G25.61.\" The drugs mentioned in this sample are \"avp-786,\" \"paroxetine,\" and \"duloxetine.\" The eligibility criteria for this trial include being a healthy adult male or female between the ages of 18 and 50, having a BMI between 18 and 30 kg/m2, and not having a history of significant disease, substance abuse, alcohol abuse within the past 3 years, or use of tobacco or certain medications within specific timeframes.",
    "The sample from the table is for a Phase 1 clinical trial for the treatment of lupus nephritis. The trial is evaluating the effectiveness of the drugs ixazomib and placebo. The eligibility criteria for participants include being capable of understanding and complying with the protocol requirements, having a diagnosis of systemic lupus erythematosus (SLE) and lupus nephritis, and having had an inadequate response to previous immunosuppressive treatments. Other criteria include age between 18 and 75, specific kidney biopsy results, and certain laboratory test values. Exclusion criteria include participation in other clinical studies, certain medical conditions, and use of specific medications. The sample also includes information on contraception requirements for participants of childbearing potential and additional criteria for re-enrollment of participants who discontinued the study.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is acute myeloid leukemia (AML). The ICDCodes associated with this disease are C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, and C91.01. The drug being tested in this trial is gilteritinib. \n\nThe eligibility criteria for this trial include the subject being diagnosed with primary or secondary AML according to the World Health Organization (WHO) criteria. The subject should either be refractory to prior induction chemotherapy or have relapsed after achieving remission with prior therapy. The subject should have an Eastern Cooperative Oncology Group (ECOG) performance status of \u2264 2. The interval between prior treatment and study drug administration should be at least 14 days for antineoplastic agents, except for hydroxyurea. For other investigational products or drugs used for immunosuppressive therapy post-hematopoietic stem cell transplantation (HSCT), the interval should be at least 5 half-lives or 14 days if the half-life is unknown.\n\nThere are also exclusion criteria, such as the subject being diagnosed with acute promyelocytic leukemia (APL) or BCR-ABL-positive leukemia. The subject should not have active malignant tumors other than AML or myelodysplastic syndrome (MDS). Persistent non-hematological toxicities of \u2265 Grade 2 due to prior AML treatment are also exclusion criteria. Subjects who have received HSCT within 2 months or have persistent and clinically significant graft-versus-host disease requiring treatment are excluded. Other exclusion criteria include clinically active central nervous system leukemia, disseminated intravascular coagulation (DIC), recent major surgery or radiation therapy, congestive heart failure, certain concomitant drug treatments, active uncontrollable infection, and known HIV or hepatitis B/C infection.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease being studied is \"healthy,\" which seems to indicate that the trial is focused on individuals without any specific medical conditions. The ICDCodes associated with this disease are \"Z76.3\" and \"Z76.2.\" \n\nThe drugs being tested in this trial are \"telmisartan/amlodipine,\" \"telmisartan/amlodipine/hctz,\" and \"telmisartan/hctz.\" These drugs are likely being evaluated for their effectiveness or safety in treating the specified disease.\n\nThe eligibility criteria for this trial are listed under \"Inclusion criteria\" and \"Exclusion criteria.\" Inclusion criteria specify the requirements for individuals to be eligible for participation in the trial, such as being a healthy Japanese male between the ages of 20 and 35, within a certain weight range, and having a specific body mass index. Exclusion criteria outline factors that would disqualify individuals from participating, such as any abnormal findings in medical examinations or clinical relevance.\n\nOverall, this sample provides a snapshot of a clinical trial focused on testing the effectiveness or safety of certain drugs in healthy individuals within a specific demographic.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is multiple myeloma, and the corresponding ICDCodes are C90.01, C90.02, and C90.00. The drugs being used in the trial are selinexor, liposomal doxorubicin, and dexamethasone. \n\nThe eligibility criteria for this trial include:\n- Patients must have relapsed and refractory multiple myeloma, having received at least 2 prior therapies, including lenalidomide and a proteasome inhibitor. The disease must be refractory to the most recent therapy.\n- Patients must have previously received or be ineligible for (or refused) autologous stem cell transplant.\n- Patients must have measurable myeloma paraprotein levels in serum or urine, or by free light chain.\n- Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, with ECOG 2 allowed if due to bone disease.\n- Patients must have a certain level of left ventricular ejection fraction (LVEF) as indicated by an echocardiogram or multigated acquisition (MUGA) scan.\n- Patients must have adequate hematological, hepatic, and renal function.\n- Female patients of child-bearing potential must agree to use dual methods of contraception, and male patients must use an effective barrier method of contraception if sexually active with a female of child-bearing potential.\n- There are also various exclusion criteria, such as pregnancy or lactation, recent radiation or chemotherapy, certain heart conditions, prior cumulative exposure to doxorubicin, uncontrolled infections, HIV seropositivity, active hepatitis A, B, or C infection, and other underlying conditions or medical conditions that could interfere with treatment.\n\nIt is important to note that this is just a sample record, and there may be additional records in the table with different phases, diseases, drugs, and eligibility criteria.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is gastroparesis, and its corresponding ICDCodes is \"K31.84\". The drugs being tested are \"tc-6499\" and \"placebo\". \n\nThe eligibility criteria for this trial include having a diagnosis of gastroparesis or symptoms consistent with gastroparesis for at least 6 months, confirmation of gastroparesis using the GEBT (Gastric Emptying Breath Test), having type 1 or type 2 diabetes with a Hemoglobin A1c level of \u2264 10%, fasting blood glucose level (finger stick) of \u2264 275 mg/dL prior to each GEBT, a body mass index (BMI) of \u2264 40, willingness to stay in a clinical research facility for the required treatment and study procedures, willingness to use a double barrier method of birth control (except for post-menopausal females), ability to understand the study procedures and provide written informed consent.\n\nThe exclusion criteria for this trial include a history of abdominal surgery including gastric banding procedure, chronic parenteral feeding or feeding through a gastrostomy or jejunostomy tube, persistent daily vomiting, a history of eating disorder, recent history of poor control of diabetes, acute severe gastroenteritis, use of gastric electric stimulator, use of opiates, anticholinergic medications, GLP-1 mimetics or amylin analogs, use of medications potentially influencing upper gastrointestinal motility or appetite, allergies or intolerance to egg, wheat, milk, or algae, being pregnant or lactating, presence of a clinically significant medical condition at any time during the study, presence of clinically significant abnormalities in laboratory findings, physical exam findings, or vital signs, and participation in an investigational drug study within 30 days of screening.",
    "The sample provided is a schema definition of a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. The table has the following columns: phase, diseases, icdcodes, drugs, and criteria.\n\nIn the sample, the phase is \"phase 1\" and the diseases listed are \"recurrent colorectal carcinoma\", \"solid neoplasm\", \"stage iiia colorectal cancer ajcc v7\", \"stage iiib colorectal cancer ajcc v7\", \"stage iiic colorectal cancer ajcc v7\", \"stage iva colorectal cancer ajcc v7\", and \"stage ivb colorectal cancer ajcc v7\". The corresponding ICDCodes for these diseases are also provided.\n\nThe drugs mentioned in the sample are \"cyclosporine\" and \"selumetinib\". The eligibility criteria for the trial are listed under the \"criteria\" column and include various requirements such as specific diagnoses, performance status, blood counts, organ function, and other medical conditions.\n\nOverall, the sample provides a snapshot of a clinical trial with information about the trial phase, diseases being studied, associated ICDCodes, drugs being used, and the eligibility criteria for participants.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease mentioned is glioblastoma multiforme. The ICDCodes associated with this disease are ['L51.0', 'L51.8', 'L51.9']. The drug mentioned is nvx-108. \n\nThe eligibility criteria for this trial include:\n1. The patient must have a histologically-confirmed newly-diagnosed glioblastoma multiforme.\n2. The patient should not have received any prior treatment for glioblastoma apart from surgical resection.\n3. The patient should be planned for 60 Gray of focal radiation administered in 30 fractions, concurrently with temozolomide chemotherapy.\n4. The patient should have manageable risks associated with potential radiation necrosis in the radiation field, based on the size of the field and proximity to eloquent brain regions.\n5. The patient should be aged between 18-70 years.\n6. The patient should have an ECOG performance status of 0-2.\n7. The patient should have a life expectancy of at least 3 months.\n8. If the patient is receiving glucocorticoid therapy, the dose must be stable over at least 7 days prior to study enrollment.\n9. Archived tumor tissue should be available for central review.\n10. The patient should be able to undergo gadolinium-enhanced MRI (Gd-MRI) scans.\n11. A baseline MRI should have been performed within 14 days before starting study treatment, while on a stable glucocorticoid dose for at least 5 days before and during the imaging study.\n12. The patient should have adequate hematologic, renal, and hepatic function.\n13. Patients who are women of childbearing potential or men (unless vasectomized) must agree to use a highly-effective method of birth control during the study and for 4 months after completing study therapy.\n14. The patient should have the ability to understand and be willing to sign a written informed consent document.\n\nThe exclusion criteria for this trial include various conditions such as the presence of leptomeningeal disease or multifocal glioblastoma that cannot be encompassed within a feasible and safe radiation field, intracranial bleeding, recent myocardial infraction, active major infection requiring treatment, history of other malignancies, known infection with HIV or hepatitis B or C virus, and inability to comply with study procedures, among others.",
    "The sample provided is a record from a table that contains information about clinical trials. The table has several columns, including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of the diseases being studied, \"icdcodes\" which contains the corresponding ICD-10 codes for the diseases, \"drugs\" which lists the names of the drugs being used in the trial, and \"criteria\" which provides the eligibility criteria for participants.\n\nIn this specific sample, the phase of the trial is phase 1. The disease being studied is multiple myeloma. The corresponding ICD-10 codes for multiple myeloma are listed as \"C90.01\", \"C90.02\", and \"C90.00\". The drug being used in the trial is \"acy-1215 in combination with pomalidomide and dexamethasone\". The eligibility criteria for participants are listed in a detailed format, including requirements such as age, previous treatments received, performance status, and various medical conditions or laboratory abnormalities that would exclude a patient from participating in the trial.\n\nOverall, this sample provides specific information about a clinical trial for multiple myeloma, including the phase, disease, drugs, and eligibility criteria.",
    "The sample from the table represents a clinical trial for the treatment of non-small cell lung cancer (NSCLC) in different phases (phase 1 and phase 2). The trial focuses on patients with specific mutations in the EGFR gene, namely del ex19, L858R, G719X, or L861Q. The eligibility criteria include a confirmed diagnosis of NSCLC, a life expectancy of at least 12 weeks, and previous treatment with EGFR tyrosine-kinase inhibitors (EGFR-TKIs) for phase 1 patients. Phase 2 patients should have progressive disease after previous treatment with EGFR-TKIs and the presence of the EGFR-T790M mutation. The sample also includes exclusion criteria such as previous treatment-related toxicity, interstitial lung disease, recent treatment with reversible EGFR-TKIs, and previous treatment with certain EGFR-TKIs. Additionally, it excludes patients with planned surgical procedures, unhealed wounds, or symptomatic central nervous system lesions.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is \"dry eye,\" and the corresponding ICDCodes associated with this disease are \"H04.121,\" \"H04.122,\" \"H04.123,\" \"H04.129,\" \"H35.3111,\" \"H35.3112,\" and \"H35.3121.\" The drugs being tested in this trial are \"dnase\" and \"vehicle.\" \n\nThe eligibility criteria for this trial are as follows:\nInclusion Criteria:\n- The participant must be 18 years of age or older.\n- They must be capable of giving informed consent.\n- The participant must have documented Dry Eye Disease for at least 6 months.\n- Schirmer I (a test for tear production) must be less than 10.\n- Corneal/conjunctival (Rose Bengal) staining must be equal to or greater than 1.\n- Ocular symptoms must be considered annoying or activity limiting, with an OSDI (Ocular Surface Disease Index) score of at least 13 (mild).\n- Women must be post-menopausal for at least 1 year or surgically sterilized. If not, a negative urine pregnancy test is required within 14 days of receiving the first dose of the test medication (placebo/study drug), along with evidence of contraceptive use throughout the study.\n\nExclusion Criteria:\n- The participant must not be allergic to Deoxyribonuclease eye drops or any similar products or excipients of Deoxyribonuclease eye drops 0.1%.\n- They must not be receiving or have received any experimental systemic medication within the past 30 days.\n- Active ocular infection or ocular allergies are not allowed.\n- Any history of eyelid surgery or ocular surgery within the past 3 months is an exclusion criterion.\n- The presence of a corneal epithelial defect larger than 1 mm2 in either eye is not allowed.\n- The use of topical cyclosporine or corticosteroids within 2 weeks of enrollment is an exclusion criterion.\n- Participants with active drug/alcohol dependence or a history of abuse are not eligible for the trial.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1 and focuses on the treatment of leukemia. The trial includes patients with B cell CLL/SLL who are 85 years old or younger and have active disease that meets specific criteria. These criteria include having failed at least one line of standard treatment and requiring treatment within 2 years of the completion of the last treatment regimen. Patients with del17p by FISH (high-risk) who do not have the option of an allogeneic stem cell transplant are also eligible. The sample also lists the drugs used in the trial, which are fludarabine, cyclophosphamide, rituximab, and bendamustine. The eligibility criteria for the trial are provided, including requirements for hepatic and renal function, cardiac function, and birth control. The sample also includes exclusion criteria, such as a low percentage of ROR1 expression by CLL cells, pregnancy or lactation in females, allergies to bovine or murine products, and certain medical conditions or treatments.",
    "The sample from the table represents a clinical trial for the treatment of graft versus host disease (GVHD) in patients who are steroid dependent or refractory. The trial is in phase 1/phase 2. The disease being studied is GVHD, and the corresponding ICD-10 codes are D89.810, D89.811, D89.813, and D89.812. The drug being tested is ibrutinib. \n\nThe inclusion criteria for the trial include being steroid dependent or refractory classic chronic GVHD, having received no more than 3 previous treatments for cGVHD, currently receiving baseline systemic glucocorticoid therapy, being at least 18 years old, and having a Karnofsky performance status of at least 60.\n\nThe exclusion criteria include having known or suspected active acute GVHD, currently being treated with sirolimus and either cyclosporine or tacrolimus, having a history of treatment with a tyrosine kinase inhibitor, purine analogs, or other cancer chemotherapy in the 4 weeks prior to starting the study drug, having currently active, clinically significant cardiovascular disease, having uncontrolled infections not responsive to antibiotics, antiviral medicines, or antifungal medicines, having a recent infection requiring systemic treatment completed within 14 days before the first dose of the study drug, having progressive underlying malignant disease including post-transplant lymphoproliferative disease, having a history of other malignancy (excluding the underlying malignancy that was the indication for transplant), concomitant use of warfarin or other Vitamin K antagonists, having known bleeding disorders or hemophilia, having a history of stroke or intracranial hemorrhage within 6 months prior to enrollment, having a known history of human immunodeficiency virus (HIV) or active with hepatitis C virus (HCV) or hepatitis B virus (HBV), and concurrent use of a strong cytochrome P450(CYP) 3A inhibitor.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular record, the phase of the trial is Phase 1. The disease being studied is recurrent ovarian cancer. The ICDCodes associated with this disease are G47.13, J01.41, K11.22, K12.0, N96, F33.8, and G03.2. The drug being used in the trial is lde225. The eligibility criteria for this trial include specific requirements for the type of ovarian cancer, previous treatments received, measurable disease, organ function, age, and other factors. There are also exclusion criteria listed, which specify conditions or circumstances that would disqualify a patient from participating in the trial.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1 and is focused on treating colorectal cancer patients who have the KRAS and NRAS wild-type mutation. The trial is testing the combination of regorafenib and panitumumab as a treatment. The sample includes the eligibility criteria for the trial, which includes requirements such as having a histological diagnosis of un-resectable or metastatic colorectal cancer, showing signs of progression after previous treatment, being 18 years or older, having an ECOG Performance Status of 0-1, and being able to understand and sign the informed consent form. The sample also includes exclusion criteria, such as having any known mutation in specific KRAS or NRAS codons, prior use of regorafenib, and having certain medical conditions or receiving certain treatments.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 1. The diseases being studied are chronic lymphocytic leukemia and small lymphocytic lymphoma. The corresponding ICDCodes for these diseases are C91.11, C91.12, C91.10, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, and S33.131S. The drugs being used in the trial are lenalidomide, ibrutinib, and rituximab.\n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include having previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma that requires treatment, no prior systemic treatment within 4 weeks of enrollment, no corticosteroids within 2 weeks prior to study entry, presence of measurable disease, no concomitant anti-cancer therapies, ECOG status less than or equal to 2, eligibility for patients with HIV infection or treated CLL or SLL in CNS, non-pregnant and non-nursing, life expectancy greater than 60 days, adequate bone marrow, kidney, and liver function, and no major surgery within 28 days or minor surgery within 5 days of starting treatment.\n\nExclusion criteria include a history of Richter's transformation, prior allogeneic transplant, radioimmunotherapy within 1 year of enrollment, prior Bruton's tyrosine kinase inhibitor or lenalidomide, history of allergic reactions to compounds similar to ibrutinib, lenalidomide, or rituximab, active or uncontrolled autoimmune hemolytic anemia or ITP, transfusion-dependent thrombocytopenia or bleeding disorders, active hepatitis B or C infections, history of known Human Anti-Chimeric Antibody positivity, history of erythema multiforme, toxic epidermal necrolysis, or Stevens-Johnson syndrome, history of uncontrolled seizures, autoimmune disorder that requires active immunosuppression, stroke or intracranial hemorrhage within the last 6 months, history of congestive heart failure, myocardial infraction, unstable angina, uncontrolled arrhythmia, or any Class 3 or 4 heart disease in the last 6 months, no prior malignancy except if treated with curative intent with no active disease for more than 3 years, adequately treated non-melanoma skin cancer or cervical cancer in situ, and using warfarin or similar Vitamin K antagonists, unable to swallow capsules, or disease significantly affecting gastrointestinal function or inhibiting small intestine absorption.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1. The disease mentioned is glioblastoma multiforme (gbm). The icd-10 codes associated with this disease are \"L51.0\", \"L51.8\", and \"L51.9\". The drug being used in the trial is \"mibefradil with radiation\". The eligibility criteria for participants include having a histologically proven progressive or recurrent glioblastoma multiforme, measurable contrast-enhancing progressive or recurrent GBM, prior history of standard dose focal radiation therapy, and meeting certain clinical laboratory requirements. There are also exclusion criteria listed, such as having concurrent malignancy, exclusive radionecrosis after initial GBM therapy, and certain medical conditions that would jeopardize the subject's ability to receive treatment safely.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The diseases being studied are squamous cell carcinoma of the head and neck (SCCHN) and metastatic colorectal cancer. The ICDCodes associated with these diseases are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drugs being used in the trial are inc280 and cetuximab. The eligibility criteria for this trial include being male or female aged 18 years or older, having metastatic colorectal cancer or head and neck squamous cell carcinoma, being c-MET positive, having at least one previous line of treatment for the metastatic disease, having measurable disease as per RECIST v1.1, and having an ECOG performance status of 2 or lower. The exclusion criteria include prior treatment with c-MET/HGF inhibitors, history of severe reactions to cetuximab and/or panitumumab, history of acute or chronic pancreatitis, active bleeding within 4 weeks prior to screening visit, symptomatic brain metastases, feeding tube dependence, and inadequate hematologic, renal, and hepatic function.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 1 and focuses on the treatment of pain. The associated ICD-10 codes for the disease are ['N50.82', 'R07.2', 'R07.82', 'R10.13', 'R10.33', 'R14.1', 'R52']. The drugs being studied are 'omnitram', 'tramadol', and 'placebo'. The eligibility criteria for participants are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". The inclusion criteria include being a healthy male between the ages of 21 and 55, having normal vital signs, providing informed consent, and being able to comply with study procedures. Additional criteria include having adequate hematologic, liver, and renal function, as well as negative tests for substances of abuse and certain serology tests. The exclusion criteria include having a current illness, a history of seizures or liver disease, recent alcohol or drug use, allergies to certain drugs, and the use of specific medications that may interfere with the study. Other exclusion criteria include having unstable acute or chronic diseases, a history of alcohol or drug abuse, recent use of other investigational agents, and any concurrent disease or condition that may impair the subject's ability to complete the trial.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is categorized as a combination of phase 1 and phase 2. The trial is focused on studying the effects of the drugs \"per977,\" \"placebo,\" and \"enoxaparin\" on a group of individuals with the disease \"healthy.\" The eligibility criteria for participants in this trial include being adults between the ages of 18 and 65, having normal laboratory values and electrocardiogram results, having a body mass index (BMI) between 18 and 27 kg/m2, and agreeing to use contraception for male participants and two forms of contraception for female participants. Female participants must also have a negative pregnancy test and agree to use contraception for at least one complete menstrual cycle or 28 days after the study. Participants must understand and agree to comply with the study requirements and provide voluntary consent. Exclusion criteria include having a history or current evidence of significant disease, abnormal liver or renal function tests, a prolonged QTcF interval, a history of unexplained syncope, hypersensitivity to certain medications, a history of major bleeding or recent surgical procedures, a history of gastrointestinal bleeding or peptic ulcers, a history of clotting disorders or abnormal bleeding, and various other conditions that may interfere with the study protocol.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The diseases being studied are related to safety, tolerability, pharmacokinetics, and pharmacodynamics. The ICDCodes associated with these diseases are \"Z71.85\", \"Y38.4X1S\", \"Y38.9X1S\", \"Y38.4X1A\", \"Y38.4X1D\", \"Y38.5X1S\", and \"Y38.6X1S\". The drugs being tested are \"mln3126\" and \"mln3126 matched placebo\". The eligibility criteria for participants are listed, including age requirements, health status, weight, BMI, and contraception use for sexually active participants. The exclusion criteria are also provided, which include restrictions on previous drug use, medical conditions, allergies, substance abuse, pregnancy or lactation, and abnormal test results.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1 and focuses on the disease hepatocellular carcinoma. The ICD-10 codes associated with this disease are ['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']. The drug being studied is oral pentamidine. The sample also includes the eligibility criteria for participants in the trial, including age, diagnosis, treatment suitability, and various medical conditions that would exclude someone from participating.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1. The disease mentioned is \"advanced solid tumors,\" and the corresponding ICDCodes are ['K74.02', 'G47.22', 'H35.3133', 'H35.3134', 'H35.3113', 'H35.3114', 'H35.3123']. The drug mentioned is \"veliparib (abt-888)\". The eligibility criteria for this trial include histologically or cytologically confirmed malignant solid tumor, Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, life expectancy of greater than 12 weeks, adequate organ and marrow function, and measurable or non-measurable disease. The exclusion criteria include recent major surgery or radiation, recent chemotherapy or hormone therapy (except for specific cases), recent use of investigational agents or anti-cancer Chinese medicine/herbal remedies, and the presence of toxicities from prior surgeries, radiation, or chemotherapy.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1. The diseases being studied are diabetes and diabetes mellitus, type 2. The ICDCodes associated with these diseases are E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65 for the first disease, and E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44 for the second disease. The drugs being used in the trial are semaglutide and placebo. The eligibility criteria for the trial include age between 18-64 years, being diagnosed with type 2 diabetes, being treated with diet and exercise and/or metformin monotherapy, having a specific BMI range, and having a specific HbA1c range. There are also exclusion criteria, such as being pregnant or breastfeeding, having certain diseases or medical conditions, using medications that could interfere with the trial, having a history of substance abuse, being a smoker, and not being able or willing to refrain from smoking during the inpatient period.",
    "The sample from the table represents a phase 1 clinical trial for the treatment of various diseases, including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS), and mixed phenotype acute leukemia (MPAL). The trial involves the use of drugs such as selinexor, fludarabine, cytarabine, and methotrexate/hydrocortisone/cytarabine. \n\nThe eligibility criteria for participants include having a diagnosis of AML, MDS, ALL, or MPAL with relapsed or refractory disease after chemotherapy or relapse after hematopoietic stem cell transplantation (HSCT). Inclusion criteria also specify the minimum percentage of leukemic blasts in the bone marrow or increasing levels of minimal residual disease (MRD) for AML or ALL patients. Adequate organ function, age criteria, ability to swallow tablets, and performance status are also considered for eligibility.\n\nExclusion criteria include a history of cerebellar toxicity, pregnancy or breastfeeding, certain diseases such as Down syndrome or acute promyelocytic leukemia, use of investigational agents within 30 days, significant concurrent diseases or psychiatric disorders, unstable cardiovascular function, uncontrolled infection, HIV infection, malabsorption syndrome, and prior treatment with selinexor.",
    "The sample from the table is for a Phase 1 clinical trial. The diseases being studied are advanced solid tumors and relapsed/refractory lymphoma. The corresponding ICD-10 codes for these diseases are \"K74.02\", \"G47.22\", \"H35.3133\", \"H35.3134\", \"H35.3113\", \"H35.3114\", and \"H35.3123\". The drug being tested in the trial is alisertib. \n\nThe eligibility criteria for participants in the trial include being 18 years of age or older, having metastatic and/or advanced solid tumors or lymphomas for which standard curative or life-prolonging treatment does not exist or is no longer effective or tolerable, having an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2, and meeting certain requirements for female and male participants regarding contraception or abstinence. \n\nOther criteria include giving voluntary written consent, having suitable venous access for blood sampling, being able to swallow tablets, having a stable liver function if a stent has been placed for biliary obstruction, and having recovered from the reversible effects of prior antineoplastic therapy. \n\nExclusion criteria include being of North/East Asian ethnicity, having recurrent nausea and/or vomiting or gastrointestinal abnormalities that could interfere with the absorption or tolerance of the drug, requiring treatment with certain enzyme-inducing medications, having inadequate bone marrow or organ function, being lactating or pregnant, having serious medical or psychiatric illnesses that could interfere with treatment, having received anticancer therapy or investigational products within the past 3 weeks, and having certain medical conditions or infections. \n\nOther exclusion criteria include having symptomatic brain metastasis, having certain cardiovascular conditions or sleep apnea, having a history of hepatitis C or suspected active hepatitis B infection, and having certain medication usage or conditions related to cytochrome P450 enzymes.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is gout. The ICDCodes associated with gout are listed as \"M10.9\", \"M10.08\", \"M10.00\", \"M10.011\", \"M10.012\", \"M10.019\", and \"M10.021\". The drug being tested is called rdea3170. \n\nThe eligibility criteria for this trial are then listed, including inclusion and exclusion criteria. Inclusion criteria state that the subject must have a body weight of at least 50 kg and a body mass index (BMI) between 18 and 40 kg/m2. They must also have renal impairment, as determined at screening, with specific creatinine clearance levels. Additionally, the subject's serum urate level must be between 4.5 mg/dL and 10 mg/dL.\n\nExclusion criteria include a history or clinical manifestations of various disorders, such as metabolic, hematological, pulmonary, cardiovascular, gastrointestinal, neurologic, hepatic, renal, urological, or psychiatric disorders. Other exclusion criteria include a history or suspicion of kidney stones, asthma, recent major surgery, blood donation or significant blood loss within a certain timeframe.",
    "The sample from the table is for a phase 1 clinical trial. The diseases being studied are \"cd20 positive,\" \"recurrent diffuse large b-cell lymphoma,\" and \"refractory diffuse large b-cell lymphoma.\" The corresponding ICD-10 codes for these diseases are \"S33.110S,\" \"S33.111S,\" \"S33.120S,\" \"S33.121S,\" \"S33.130S,\" \"S33.131S,\" and \"S33.140S.\" The drugs being used in the trial are \"carboplatin,\" \"etoposide,\" \"ibrutinib,\" and \"ifosfamide.\" The eligibility criteria for the trial include having a confirmed diagnosis of CD20 positive relapsed or refractory DLBCL, having undergone previous treatment with an anthracycline and rituximab-containing regimen, and meeting certain imaging criteria. There are also various other criteria related to performance status, blood counts, liver function, kidney function, contraception, and ability to understand and consent to the trial. The exclusion criteria include recent chemotherapy or radiotherapy, receiving other investigational agents, having brain metastases, known allergies to similar compounds, and various other medical conditions or situations that may limit compliance with the study requirements.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1. The diseases being studied include estrogen receptor positive, progesterone receptor positive, recurrent breast carcinoma, stage IIIB breast cancer, stage IIIC breast cancer, and stage IV breast cancer. The ICDCodes associated with these diseases are also provided. The drugs being used in the trial are alisertib and fulvestrant. The eligibility criteria for participants are listed, including requirements related to the type and stage of the disease, blood counts, liver function, kidney function, performance status, and prior treatments. Exclusion criteria are also mentioned, such as the presence of other active malignancies, certain medical conditions, and prior treatments with specific drugs.",
    "The sample from the table is for a clinical trial that is in phase 1/phase 2. The trial is focused on the disease of obesity, which is identified by the ICD-10 codes ['E66.8', 'E66.9', 'E66.1', 'O99.214', 'O99.215', 'O99.210', 'O99.211']. The drugs being tested in the trial are 'pp1420' and 'placebo'. \n\nThe eligibility criteria for participants in the trial are as follows:\n- Participants must be healthy males, as determined by a medical evaluation including history, physical examination, vital signs, laboratory tests, and 12-lead ECG.\n- Participants must be between 18 and 50 years of age.\n- Participants must have a body weight of 70 kg and a body mass index (BMI) within the range of 25 - 35 kg/m2.\n- Participants must be capable of giving written informed consent and willing to comply with the requirements and restrictions listed in the consent form.\n- Participants must be willing and able to comply with the protocol for the duration of the study.\n\nThere are also exclusion criteria for participants in the trial, which include:\n- Participants who are considered unsuitable for the study based on medical evaluation, physical examination, or screening investigations.\n- Participants who test positive for drugs or alcohol in a pre-study screening.\n- Participants who test positive for Hepatitis B surface antigen or Hepatitis C antibody within 3 months of screening.\n- Participants who test positive for HIV antibody.\n- Participants with a history of migraine.\n- Participants with a history or evidence of abnormal eating behavior.\n- Participants with a history of excessive alcohol consumption.\n- Participants with urinary cotinine levels indicative of smoking or a history of regular tobacco or nicotine use.\n- Participants with QTc (a measure of heart rate) greater than 450 msec at screening.\n- Participants with blood pressure or heart rate outside the specified ranges.\n- Participants who have participated in another clinical trial and received an investigational product within a certain time period prior to the current study.\n- Participants who have been exposed to more than four new chemical entities within 12 months prior to the study.\n- Participants who have used prescription or non-prescription drugs, including vitamins, herbal and dietary supplements, within a certain time period prior to the study.\n- Participants with a history of sensitivity or allergy to any of the study medications or their components.\n- Participants who would donate blood in excess of 500 mL within 3 months before or after the study.\n- Participants who are unwilling to abstain from certain substances (caffeine, illicit drugs, alcohol, smoking) during specific time periods related to the study.\n- Participants who are unwilling or unable to use a condom during sexual activity throughout the study.\n- Participants who are vegans or have milk or wheat intolerance or allergy.\n- Participants who are unwilling or unable to follow the procedures outlined in the protocol.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease being studied is \"healthy,\" which seems to indicate that the trial is focused on healthy individuals rather than specific diseases. The ICDCodes associated with this disease are \"Z76.3\" and \"Z76.2.\" The drugs being tested in this trial are \"palbociclib alone,\" \"palbociclib plus modafinil,\" and \"palbociclib plus pioglitazone.\" \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" Inclusion criteria include being a healthy male or female between the ages of 18 and 55, having a specific BMI range and body weight, providing informed consent, and being willing to comply with the study procedures. Exclusion criteria include having a history of certain medical conditions, drug addiction, positive drug or alcohol tests, being pregnant or breastfeeding, and not using effective contraception for the duration of the study.\n\nOverall, this sample provides information about the phase, diseases, ICDCodes, drugs, and eligibility criteria for a clinical trial focused on healthy individuals.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are \"progressive solid malignancies,\" \"refractory solid malignancies,\" and \"cancer.\" The ICDCodes associated with these diseases are provided as well. The drugs being used in the trial are \"cyclophosphamide pill\" and \"imiquimod topical cream.\" The eligibility criteria for participants are listed, including requirements such as providing informed consent, having specific TAPAs expression, having measurable or evaluable disease, not having active infections or certain medical conditions, and meeting certain laboratory values and performance status. There are also exclusion criteria listed, which specify conditions that would disqualify a participant from the trial.",
    "The sample from the table is for a phase 1 clinical trial. The disease being studied is leukemia, specifically advanced chronic myeloid leukemia (CML) or refractory chronic phase CML. The trial also includes patients with Philadelphia chromosome-positive acute leukemia. The trial is investigating the effectiveness of two drugs, mek-162 and nilotinib. The eligibility criteria for the trial include age (18 years or older), specific disease criteria for CML-AP, CML-BP, and Philadelphia-chromosome acute leukemias, prior treatment failure with tyrosine kinase inhibitors, and specific response criteria for imatinib, dasatinib, nilotinib, bosutinib, and ponatinib. Other eligibility criteria include cytogenetic BCR-Abl variants, organ function, cardiac function, and the use of effective contraception for men and women of childbearing potential. The exclusion criteria include impaired cardiac function, history of Gilbert's syndrome, uncontrolled arterial hypertension, prior therapy with a MEK-inhibitor, history of retinal vein occlusion or degenerative disease, recent treatment with ipilimumab or other immunotherapy, positive serology for HIV or active hepatitis B or C infection, neuromuscular disorders associated with elevated CK, planned strenuous exercise regimen, current treatment with strong CYP3A4 inhibitors or medications that prolong the QT interval, impaired gastrointestinal function or active GI disease, another active primary malignant disease, history of significant bleeding disorder, recent major surgery, pregnancy or nursing, non-compliance with medical regimens, and inability to grant consent.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are \"catheter-related bloodstream infection (crbsi) nos,\" \"bloodstream infection due to central venous catheter,\" and \"bloodstream infection due to hickman catheter.\" The corresponding ICDCodes for these diseases are \"T80.211S,\" \"T80.211A,\" and \"T80.211D.\" \n\nThe drugs being used in the trial are \"ethanol,\" \"heparin lock,\" and \"normal saline.\" \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" The inclusion criteria include being newly started on Home Parenteral Nutrition with an anticipated duration of more than 3 months, not previously being on Home Parenteral Nutrition, providing consent, having non-medicare insurance or medicare insurance with a supplementary insurance, having single lumen Hickman\u00ae catheters, and no known alcohol addiction. \n\nThe exclusion criteria include failure to provide consent, having medicare insurance without any supplemental private insurance, having a catheter type other than a single lumen Hickman\u00ae, being on Home Parenteral Nutrition for less than three months, being pregnant, having previous proven addiction and dependence to alcohol, lacking capacity to provide consent, and not being managed by the Home Parenteral Nutrition team at the investigator's institution.",
    "The sample from the table represents a clinical trial with a phase 1/phase 2 study design. The trial focuses on two diseases, diffuse large B-cell lymphoma (DLBCL) and Kaposi sarcoma (KS). The diseases are identified by their respective International Classification of Diseases, Tenth Revision (ICD-10) codes. The trial involves the use of a drug called abc294640.\n\nThe eligibility criteria for the trial are as follows:\n1. Patients must have a confirmed diagnosis of DLBCL or KS that is refractory to standard therapy or has relapsed after standard therapy.\n2. Patients with DLBCL must not be eligible for hematopoietic stem cell transplantation or have failed the transplantation.\n3. Patients must have tumor progression after receiving standard/approved chemotherapy or be ineligible for standard therapy.\n4. Patients must have one or more measurable tumors on PET-CT scan (for DLBCL) or CT scan/clinical examination of the skin (for KS).\n5. Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 3 or lower.\n6. Patients must have a life expectancy of at least 3 months.\n7. Patients must be 18 years or older.\n8. Patients must provide signed, written informed consent approved by the Institutional Review Board (IRB).\n9. Female patients must have a negative pregnancy test.\n10. Patients must have acceptable liver function, acceptable hematologic status, and no clinically significant abnormalities in urinalysis or PT/PTT levels.\n11. Patients of child-producing potential must be willing to use effective contraceptive methods during the study.\n\nThe exclusion criteria for the trial are as follows:\n1. Patients with severe cardiac disease, recent myocardial infraction, unstable arrhythmia, or evidence of ischemia on ECG.\n2. Pregnant or nursing women.\n3. Patients with active, life-threatening bacterial or fungal infections.\n4. Patients who have received radiation therapy, surgery, chemotherapy, or investigational therapy within one month prior to study entry.\n5. Patients unwilling or unable to comply with study procedures.\n6. Patients with serious nonmalignant diseases that could compromise the study objectives.\n7. Patients currently receiving any other investigational agent.\n8. Patients receiving drugs that interact with specific enzymes or substrates and cannot be stopped before starting treatment with abc294640.\n9. Patients currently taking Coumadin or Coumadin derivatives.\n10. Patients who have received antineoplastic therapy within one month of starting treatment with abc294640 or have not adequately recovered from previous therapy's side effects.\n11. Patients currently participating in any other clinical trial of an investigational product.\n12. Patients with an allergy to radiographic contrast.\n\nThis description provides an overview of the sample data and the criteria for eligibility and exclusion in the clinical trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease being studied is diabetes mellitus. The icd-10 codes associated with this disease are P70.2, O24.92, Z83.3, E10.65, E10.9, E11.65, and E11.9. The drugs being used in the trial are liraglutide and lixisenatide. The eligibility criteria for this trial include obtaining informed consent, being between the ages of 18 and 65, and having a diagnosis of type 2 diabetes mellitus. The exclusion criteria include contraindications to GLP-1 mimetics, the use of GLP-1 mimetics or DPP-IV inhibitors, and clinically relevant dysglycemia indicated by an HbA1C level of 10% or higher.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase is Phase 1, and the diseases listed include mucinous adenocarcinoma of the colon, mucinous adenocarcinoma of the rectum, recurrent colon cancer, recurrent rectal cancer, signet ring adenocarcinoma of the colon, signet ring adenocarcinoma of the rectum, stage IIIC colon cancer, stage IIIC rectal cancer, stage IVA colon cancer, and stage IVA rectal cancer. The ICDCodes associated with these diseases are also provided. The drugs mentioned in this sample are 6,8-bis(benzylthio)octanoic acid and fluorouracil. Lastly, the eligibility criteria for this trial are listed, including requirements such as confirmed metastatic colorectal adenocarcinoma, specific treatment history, performance status, and various medical parameters.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 1 and the disease being studied is \"healthy\" (which likely refers to a control group of individuals without any specific disease). The associated ICD-10 codes for this disease are \"Z76.3\" and \"Z76.2\". The drugs being tested in this trial are \"pf-06372865 (65mg)\", \"pf-06372865 (15mg)\", \"pregabalin\", and \"placebo\". \n\nThe sample also includes the eligibility criteria for participants in the trial. The inclusion criteria state that the trial is seeking healthy male subjects between the ages of 18 and 55 years, with no clinically relevant abnormalities identified through medical history, physical examination, ECG, or laboratory tests. The subjects must have a BMI between 17.5 and 30.5 kg/m2 and a total body weight of more than 50 kg (110 lbs). They must also provide informed consent and be willing to comply with all study procedures.\n\nThe exclusion criteria state that individuals with clinically significant diseases or conditions affecting drug absorption are not eligible for the trial. Additionally, those with a positive urine drug screen are excluded.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1. The disease being studied is cancer. The ICDCodes associated with the disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drugs being used in the trial are afuresertib and paclitaxel. The eligibility criteria for participants include providing signed written informed consent, being 18 years or older with a performance status score of 0 or 1, being able to swallow and retain orally administered study treatment, having adequate organ system functions, having histologically confirmed stomach or gastroesophageal cancer with HER2-negative status, having metastatic or locally advanced unresectable disease, having received first-line platinum/fluoropyrimidine doublet regimen for advanced gastric cancer and exhibiting progressive disease, and having at least one measurable disease. The exclusion criteria include a history of another malignancy, prior PI3K-AKT-mTOR pathway targeted therapy, unresolved toxicity from prior chemotherapy, uncontrolled brain metastases or spinal cord compression, current use of warfarin for therapeutic anticoagulation, presence of an active gastrointestinal disease, history of myocardial infraction or other coronary conditions, pregnancy or lactation, serious pre-existing medical or psychiatric disorders, contraindications to the doses of paclitaxel, history of reduction in standard of care paclitaxel dose for peripheral neuropathy, known HIV infection or active hepatitis B or C, and hypersensitivity reactions to drugs similar to afuresertib and taxanes.",
    "The sample provided is for a phase 1 clinical trial. The disease being studied is muscular atrophy, spinal. The corresponding ICD-10 codes for this disease are G12.9, G12.1, and G12.0. The drugs being tested in the trial are ro6885247 and a placebo. \n\nThe eligibility criteria for the trial include:\n- Participants must be males or females aged 2 to 55 years, or below 7 months old.\n- Patients aged 7 months or below must have a confirmed diagnosis of 5q-autosomal recessive SMA (Types 1 to 3) and clinical symptoms attributable to type 1 SMA with 2 SMN2 copies.\n- Participants must be able and willing to provide informed consent and comply with the study protocol. If the patient is unable to consent, a legally authorized representative must be able to consent on their behalf, and the patient must assent if possible.\n- Female patients of childbearing potential and male patients with a female partner of childbearing potential must agree to use the required contraceptive methods as defined in the protocol.\n- For patients aged 7 months or below, they must have a gestational age of 37 to 42 weeks and not be considered small for gestational age at birth.\n\nThe exclusion criteria for the trial include:\n- Participants who have participated in any investigational drug or device study within 90 days prior to screening.\n- Participants who have participated in a SMN2-targeting antisense oligonucleotide study within 12 months prior to screening.\n- Participants who have participated in a gene therapy study at any time.\n- For patients aged 2-55 years, those who have been hospitalized for a pulmonary event within the last 2 months or have a planned hospitalization at the time of screening.\n- Patients who have had surgery for scoliosis within the last 6 months from screening or have a planned surgery within 6 months from screening.\n- Patients with unstable gastrointestinal, renal, hepatic, endocrine, or cardiovascular system disease.\n- Patients with clinically relevant ECG abnormalities at screening or baseline, or a personal or family history of congenital long QT syndrome.\n- Patients with clinically significant abnormalities in laboratory test results at screening.\n- Patients with any concomitant disease or condition that could interfere with the study or pose an unacceptable risk to the subject.\n- Use of prohibited medications as per protocol within 90 days prior to randomization, except for patients using inhaled corticosteroids.\n- Recently initiated treatment (within <6 months prior to randomization) with oral salbutamol or another beta2-adrenergic agonist taken orally is not allowed. However, patients who have been on oral salbutamol (or another beta2-adrenergic agonist) for at least 6 months before randomization are allowed. Use of inhaled beta2-adrenergic agonists is allowed.\n- For patients aged 7 months or below, patients requiring invasive ventilation or tracheostomy, or presence of non-SMA related morbidities.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is dry eye disease. The icd-10 codes associated with this disease are H04.121, H04.122, H04.123, H04.129, H35.3111, H35.3112, and H35.3121. The drugs being used in the trial are \"p-321 ophthalmic solution\" and \"p-321 ophthalmic solution placebo\". \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include providing written informed consent, being between 18 and 80 years of age, having specific scores for corneal fluorescein staining and conjunctival lissamine staining, having a Schirmer score of less than 10mm/5min, being able to follow instructions and attend study visits, having a negative pregnancy test for females of childbearing potential, and having a history of dry eye disease supported by clinical diagnosis or self-reported complaints. \n\nExclusion criteria include having anterior segment eye disease other than primary dry eye, having an identifiable or suspected secondary dry eye, having current punctal plugs or punctal occlusion, having a history of glaucoma or elevated intraocular pressure, recent use of contact lenses or lid scrubs, known hypersensitivity to the study drug or its components, having a significant chronic illness that could interfere with the study, recent use of any investigational product or device, and inability to comply with study requirements or complete the study.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1. The diseases being studied include chronic lymphocytic leukemia, indolent non-Hodgkin lymphoma, follicular lymphoma, small lymphocytic lymphoma, lymphoplasmacytic lymphoma (with or without Waldenstrom macroglobulinemia), and marginal zone lymphoma. The corresponding ICDCodes for these diseases are also provided. The drug being tested in this trial is idelalisib. \n\nThe eligibility criteria for this trial include being diagnosed with mature B-cell malignancies of indolent non-Hodgkin lymphoma or chronic lymphocytic leukemia according to the World Health Organization classification. The participant must have been born in Japan and not have lived outside of Japan for more than one year in the five years prior to Day 1. They must also be able to trace their maternal and paternal ancestry as Japanese. Additionally, the participant must have previously received at least one regimen for indolent non-Hodgkin lymphoma or chronic lymphocytic leukemia and currently require treatment. Other criteria include discontinuation of all therapy for at least four weeks prior to Day 1, having an Eastern Cooperative Oncology Group performance status of 0 or 1, and meeting certain baseline laboratory data requirements. Female participants of childbearing potential must have a negative serum pregnancy test, and both males and females engaging in heterosexual intercourse must agree to use specified methods of contraception. The investigator must also determine that the potential benefits of participating in the trial outweigh the risks for the individual's disease. \n\nThere are also exclusion criteria, such as known histological transformation to an aggressive histology, presence of myelodysplastic syndrome, history of central nervous system involvement in the diseases, life expectancy less than 120 days, and history of certain nonlymphoid malignancies. Other exclusion criteria include specific liver, lung, and bowel conditions, pregnancy or breastfeeding, prior transplantation, concurrent participation in another therapeutic clinical trial, and any clinically significant illness, medical condition, or abnormality that could affect safety or assessment of study results.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is divided into different phases, and this particular record is from phase 1/phase 2. The trial is focused on the treatment of classical Hodgkin lymphoma. The ICD-10 codes associated with this disease are provided. The drugs being used in the trial include brentuximab vedotin, etoposide, soludomerin, cisplatin, and ara c. The record also includes the eligibility criteria for patients to participate in the trial, such as age restrictions, performance status, organ function, and absence of prior malignant diseases. Inclusion and exclusion criteria are listed, including factors like medical history, pregnancy or breastfeeding status, and concurrent medical conditions.",
    "The sample from the table represents a clinical trial for the treatment of ovarian carcinoma. The trial is a combination of phase 1 and phase 2. The diseases being studied are ovarian carcinoma, fallopian tube carcinoma, and primary peritoneal carcinoma. The corresponding ICD-10 codes for these diseases are ['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']. The drug being tested in the trial is paclitaxel. \n\nThe eligibility criteria for the trial include: \n1. Confirmation of histologically or cytologically confirmed ovarian carcinoma, fallopian tube carcinoma, or primary peritoneal carcinoma.\n2. Recurrent ovarian cancer with any number of prior therapies.\n3. Age of 18 years or older.\n4. Life expectancy of at least 12 weeks.\n5. Measurable disease according to the revised RECIST criteria version 1.1.\n6. ECOG score of 0-1.\n7. Adequate bone marrow, liver, and renal functions.\n8. Ability to operate the NovoTTF-100L(O) System independently or with the help of a caregiver.\n9. No concurrent anti-tumor therapy, except for weekly paclitaxel and NovoTTF Therapy as per protocol.\n10. At least 4 weeks since major surgery.\n\nThe exclusion criteria for the trial include:\n1. Meningeal carcinomatosis or known brain metastases that have not been treated, require steroid treatment, or are symptomatic.\n2. Any other malignancy requiring anti-tumor treatment in the past three years, except for resected non-melanomatous skin cancer, breast carcinoma in situ, adequately treated stage I breast cancer, or in situ cervical cancer.\n3. Chemotherapy or radiotherapy within 4 weeks prior to treatment start.\n4. Significant comorbidity that is expected to affect the patient's prognosis or ability to receive the combined therapy.\n5. Implantable electronic medical devices including pacemaker, implantable automatic defibrillator, etc.\n6. Known history of sensitivity to taxanes or drugs containing Cremophor.\n7. Grade 2 or greater peripheral neuropathy.\n8. Known allergies to medical adhesives or hydrogel.\n9. Pregnant or breastfeeding.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is \"advanced cancer.\" The ICDCodes associated with this disease are \"K74.02,\" \"G47.22,\" \"H35.3133,\" \"H35.3134,\" \"H35.3113,\" \"H35.3114,\" and \"H35.3123.\" The drug being tested is \"chlorogenic acid.\" \n\nThe eligibility criteria for this trial include:\n1. Patients must have confirmed advanced cancer without effective treatment or with treatment failure.\n2. Patients must be between 18 and 65 years old with a Karnofsky Performance Status (KPS) of at least 70.\n3. Patients must have at least one tumor lesion that can be accurately measured by CT or MRI, with specific size requirements.\n4. Patients must have a life expectancy of at least three months at the time of enrollment.\n5. Patients must meet specific laboratory criteria related to organ function and blood counts.\n6. Female patients must have a negative pregnancy test, and patients of reproductive age must not have pregnancy planning in the next 12 months.\n7. Patients must volunteer for the Phase 1 trial and sign the informed consent without protest.\n\nThe exclusion criteria for this trial include various factors such as previous large area radiotherapy, serious complications, brain metastases, recent chemotherapy or other drug therapies, recent surgery or biopsy, recent radiotherapy, past toxicities from therapies, history of drug abuse or alcoholism, smoking habits, uncontrollable psychopathology, pregnancy or breastfeeding, previous or ongoing participation in another clinical trial, known active hepatitis B/hepatitis C or positive HIV/syphilis antibody, need for long-term treatment with corticosteroids or immunosuppressive drugs, allergies to the investigational drug, and any other reasons deemed ineligible by the investigator.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 1 and involves two groups of participants: those with diabetes and those who are healthy. The diseases column lists the names of the diseases, while the icdcodes column contains the corresponding ICD-10 codes for each disease. In this case, the icdcodes for diabetes are 'E23.2', 'N25.1', 'P70.2', 'O24.92', 'Z83.3', 'Z86.32', and 'E10.65', and the icdcodes for healthy are 'Z76.3' and 'Z76.2'. The drugs column lists the names of the drugs being tested, which are semaglutide and omeprazole. The criteria column provides the eligibility criteria for participants in the trial, including inclusion and exclusion criteria. The inclusion criteria specify that participants must be between the ages of 18 and 75, have a body mass index (BMI) between 18.5 and 29.9, and be in good general health based on various medical assessments. The exclusion criteria include factors such as pregnancy or intent to become pregnant, certain medical conditions like Crohn's disease or hypertension, and recent blood donations or excessive blood draws.",
    "The sample provided is a record from a table that contains information about clinical trials. The table has several columns, including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of the diseases being studied, \"icdcodes\" which contains the corresponding ICD-10 codes for the diseases, \"drugs\" which lists the names of the drugs being tested, and \"criteria\" which includes the eligibility criteria for the trial.\n\nIn this particular sample, the phase of the trial is phase 1. The diseases being studied are \"pleural effusion, malignant\" and \"breast cancer\". The corresponding ICD-10 codes for these diseases are \"C79.81\", \"D24.1\", \"D24.2\", \"D24.9\", \"D49.3\", \"C44.501\", and \"D48.60\". The drug being tested is \"bevacizumab\". The eligibility criteria for the trial are listed, including criteria related to the patient's medical history, age, gender, performance status, expected life span, biological functions, cardiac function, birth control methods, social security system, and informed consent. The exclusion criteria are also provided, which include factors such as pregnancy, certain types of pleural effusion, co-morbidities, contraindications to the drug, and previous malignancies.\n\nOverall, this sample provides specific details about the phase, diseases, drugs, and eligibility criteria for a clinical trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease mentioned is \"allogeneic hematopoietic stem cell transplantation\" and its corresponding ICDCodes is \"M31.11\". The drug mentioned is \"mln9708\". \n\nThe sample also includes detailed inclusion and exclusion criteria for the trial. The inclusion criteria specify the requirements for patients to be eligible for the trial, such as having a history of a hematological malignancy or bone marrow failure syndrome, being aged 18 or older, having received or planning to receive an allograft from a suitable donor, and meeting certain medical conditions like bilirubin levels, creatinine clearance, and performance status. It also includes criteria for female patients of childbearing potential to practice contraception and for male patients to practice effective barrier contraception.\n\nThe exclusion criteria outline the conditions under which patients would not be eligible for the trial, such as having peripheral neuropathy, allergy or intolerance to the drug, certain gastrointestinal diseases or procedures, receiving specific types of allografts or conditioning regimens, experiencing disease relapse or progression, or having certain medical conditions like uncontrolled cardiovascular conditions or active GVHD.\n\nOverall, this sample provides a snapshot of the information stored in the table, including the trial phase, disease, ICDCodes, drug, and detailed eligibility criteria for patients.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are glioblastoma, glioma, and brain tumor. The ICDCodes associated with these diseases are C71.7, C71.9, C79.31, D33.0, D33.1, D33.2, and D49.6. The drug being used in the trial is carboplatin. \n\nThe eligibility criteria for this trial include being over 18 years old, having recurrent glioma that has not responded to standard therapy, being eligible for carboplatin-based chemotherapy, having a contrast-enhanced tumor less than 35 mm in diameter, having no risk of cerebral herniation, being able to tolerate pre/post procedure steroid treatment, being affiliated with social security in France, being able and willing to give signed and informed consent, having normal biological status, having a hemoglobin level of at least 10 g/dl, having platelets of at least 100000/mm3, having neutrophils of at least 1500/mm3, having normal creatine clearance of at least 60ml/mn, having ASAT levels less than 3 times the normal range, having ALAT levels less than 3 times the normal range, having a normal bilirubin level less than 1.5 times the normal range, having alkaline phosphatase levels less than 3 times the normal range, having an INR less than 1.5, and having a prothrombin level of at least 70%.\n\nThe exclusion criteria for this trial include being allergic to iodine, gadolinium, or xylocain, having contraindications to echographic contrast agent (microbubbles), having severe renal insufficiency, having hepatic insufficiency, receiving possible toxic treatment for CNS, having a previously infected surgical field, having uncontrolled epilepsy, having MRI contraindications, having hemostasis troubles such as thrombopenia less than 75,000, TP less than 60%, INR greater than 1.5, or ongoing anti-platelet or anticoagulant therapy, having active phlebitis or active pulmonary embolism, being pregnant or currently breastfeeding, and being under judicial protection.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is chronic myeloid leukemia. The ICDCodes associated with this disease are C92.11, C92.12, C92.21, C92.22, C92.10, and C92.20. The drugs being used in the trial are nilotinib and ruxolitinib. The eligibility criteria for this trial include specific requirements for patients' medical conditions, organ function, laboratory values, and other factors. Exclusion criteria are also listed, which specify conditions or circumstances that would disqualify a patient from participating in the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease being studied is \"healthy,\" and the corresponding ICDCodes are \"Z76.3\" and \"Z76.2.\" The drugs being used in the trial are \"matching placebo,\" \"bi 1181181 healthy elderly,\" and \"bi 1181181 healthy young.\" \n\nThe eligibility criteria for this trial are as follows:\nInclusion criteria:\n1. The subjects must be healthy males or females, determined by the investigator based on a complete medical history, physical examination, vital signs, ECG, and laboratory tests.\n2. For young healthy volunteers, the age range is 18 to 50 years, and for elderly healthy volunteers, the age range is 65 to 80 years.\n3. The subjects must have a BMI between 18.5 and 29.9 kg/m2.\n4. Prior to participating in the study, the subjects must provide written informed consent in accordance with GCP and local legislation.\n\nExclusion criteria:\n1. Any abnormal findings in the medical examination, such as abnormal blood pressure, pulse rate, or ECG, that are considered clinically relevant by the investigator.\n2. Any laboratory values outside the reference range that are deemed clinically relevant by the investigator.\n3. Any evidence of concomitant diseases that are considered clinically relevant by the investigator.\n4. The presence of gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological, or hormonal disorders.\n5. Previous gastrointestinal surgery, except for appendectomy, that could affect the trial medication's kinetics.\n6. Any central nervous system diseases (such as epilepsy), other neurological disorders, or psychiatric disorders.\n\nThis sample provides a specific example of the data stored in the table, including the trial phase, disease, ICDCodes, drugs, and the eligibility criteria for participants.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 1, and the diseases listed are acute myeloid leukemia (AML), acute myelocytic leukemia, acute myelogenous leukemia, acute granulocytic leukemia, and acute non-lymphocytic leukemia. The corresponding ICDCodes for these diseases are also provided. The drugs mentioned in this sample are lenalidomide and cytarabine. The eligibility criteria for this trial include various requirements such as age, remission status, liver function, renal function, performance status, diagnosis of high-risk AML, cardiac function, and more. There are also exclusion criteria listed, which include specific diagnoses, prior use of certain medications, uncontrolled illnesses, HIV-positive status, active hepatitis B or C, hypersensitivity to certain drugs, significant cardiac disease, and other medical conditions that may pose excessive risk. Pregnant women are also excluded from this study.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase is \"Phase 1\" and the diseases listed include various childhood brain tumors such as choroid plexus tumor, ependymoblastoma, meningioma, and astrocytoma. The ICDCodes associated with these diseases are also provided. The drug mentioned in this sample is \"palbociclib isethionate\". The eligibility criteria for this trial include requirements such as patients having retinoblastoma protein (Rb1) positive recurrent, progressive, or refractory central nervous system tumors, having measurable disease on MRI scan, and meeting certain organ function criteria. There are also specific requirements related to prior treatments, corticosteroid use, growth factors, performance scale, blood counts, and other medical factors.",
    "The sample provided is a record from a table that contains information about clinical trials. The phase of the trial is \"phase 1/phase 2\". The disease being studied is \"idiopathic pulmonary fibrosis\". The corresponding ICD-10 code for this disease is \"J84.112\". The drugs being tested in the trial are \"inhaled td139\" and \"placebo\". The eligibility criteria for participants in the trial are listed, including age range, lung function requirements, oxygen saturation levels, diagnosis criteria, ability to undergo bronchoalveolar lavage, and negative test results for HIV, hepatitis B, and hepatitis C. The exclusion criteria are also listed, which include conditions that make the patient at risk for bronchoscopy, active smoking, certain comorbidities, specific CT scan patterns, evidence of organ dysfunction, poorly controlled diabetes, recent use of immunosuppressants or other specific medications, history of malignancy or asthma, and recent participation in other clinical studies.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is categorized as \"phase 1\" and focuses on the disease \"asthma.\" The corresponding ICD-10 codes for asthma are listed as ['J45.998', 'J82.83', 'J45.909', 'J45.991', 'J45.20', 'J45.30', 'J45.40']. The drugs being studied in this trial are 'ot329 (combination of fluticasone propionate and salmeterol xinafoate)', 'advair diskus (combination of fluticasone propionate and salmeterol xinafoate)', and 'placebo'. \n\nThe eligibility criteria for participants in this trial are as follows:\n1. Participants must be males or females aged 18 or older, either not capable of bearing children or willing to use effective birth control methods.\n2. Participants must have a documented clinical history of asthma at least 12 weeks prior to screening.\n3. Participants must have a pre-bronchodilator FEV1 (forced expiratory volume in one second) between >40% and <85% of the predicted value during screening and on the first day of treatment.\n4. Participants must be non-smokers and have not used tobacco products in the past year, with less than 10 pack-years of historical use.\n5. Participants must show >15% reversibility of FEV1 within 30 minutes after inhaling 360 mcg of albuterol.\n6. Participants must be able to discontinue their current asthma medications (inhaled corticosteroids and long-acting beta agonists) during the trial.\n7. Participants must be able to replace their current short-acting beta agonists (SABAs) with salbutamol/albuterol inhaler for the duration of the trial.\n8. Participants must be able to continue certain medications without significant dosage adjustments and withhold them for specified time intervals before each clinic visit.\n9. Participants must discontinue certain medications for specified time intervals before the trial.\n10. Participants must provide written informed consent to participate in the study.\n\nThe exclusion criteria for participants in this trial are as follows:\n11. Pregnant or breastfeeding females.\n12. Participants with a history of life-threatening asthma in the past 10 years, including episodes requiring intubation, hypercapnoea, respiratory arrest, hypoxic seizures, asthma-related syncopal episodes, or hospitalizations within the past year or during the run-in period.\n13. Participants with clinically significant diseases or abnormalities that could put them at risk or affect the study analyses.\n14. Participants with hypersensitivity to sympathomimetic drugs or inhaled, intranasal, or systemic corticosteroid therapy.\n15. Participants on medications that could affect asthma or interact with sympathomimetic amines.\n16. Participants with recent respiratory or sinus infections.\n17. Participants with factors that may limit compliance with the study protocol or scheduled clinic visits.\n18. Participants who have used any investigational drug in a clinical trial within 1 month prior to receiving the first dose of the study medication.\n19. Participants who may have difficulty communicating reliably or cooperating with the study requirements.\n20. Participants with a milk protein allergy.",
    "The sample from the table is for a Phase 1 clinical trial. The disease being studied is pulmonary disease, chronic obstructive. The ICD-10 codes associated with this disease are J44.9, J44.1, and J44.0. The drugs being tested in the trial are gsk2256294 and placebo. The eligibility criteria for participants include being between 18 and 65 years old, having a screening echocardiogram without significant abnormalities, being in good health, having a body weight of at least 60 kilograms and a body mass index between 19 and 35 kilograms per square meter. Female participants must be of non-reproductive potential or use highly effective contraception methods. Male participants with female partners of childbearing potential must also use contraception. Participants must be capable of giving informed consent. Exclusion criteria include having sickle cell trait, a history of pulmonary hypertension, abnormal liver function, prolonged QTc interval, and certain medication use. Other criteria for exclusion include regular alcohol consumption, smoking or tobacco use, allergies to study medications, certain infections, and recent participation in other clinical trials or exposure to multiple new chemical entities.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is \"early phase 1\" and the disease is \"tobacco use disorder\". The ICDCodes associated with this disease are \"Z72.0\" and \"P04.2\". The drugs being studied are \"levomilnacipran\" and \"placebo\". The eligibility criteria for this trial include being between 25 and 55 years old, smoking a minimum number of cigarettes per day, and indicating motivation to quit smoking. The exclusion criteria include having medical or psychiatric conditions that could interfere with the study, using medication that could interfere with the study or interact with levomilnacipran, and being pregnant or breastfeeding. The investigators will also consider other reasons why someone may not be eligible to participate.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is categorized into different phases, with this particular record belonging to phase 1. The diseases being studied in this trial include pulmonary hypertension, chronic obstructive pulmonary disease (COPD), and idiopathic pulmonary fibrosis. The corresponding ICD-10 codes for these diseases are also listed.\n\nThe drugs being investigated in this trial are inhaled nitric oxide at different dosages. The eligibility criteria for participants in this trial are outlined, including specific inclusion and exclusion criteria. Inclusion criteria include having a confirmed diagnosis of COPD, pulmonary hypertension determined by specific measurements, being a current or former smoker, and meeting certain age and lung function requirements. Exclusion criteria include having a diagnosis of asthma or other non-COPD respiratory disease, recent exacerbations requiring hospitalization or systemic oral corticosteroid therapy, left ventricular dysfunction, renal impairment, known allergy to contrast media, and other medical or psychiatric conditions that would make the subject unsuitable for the study.\n\nOverall, this sample provides a snapshot of the phase 1 trial, including the diseases being studied, the drugs being tested, and the eligibility criteria for participants.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The diseases being studied are pancreatic neoplasms and cholestasis. The corresponding ICDCodes for these diseases are C25.3 and K71.0, respectively. The drugs being used in the trial are nab-paclitaxel and gemcitabine. The eligibility criteria for this sample include specific requirements for subjects to be included in the trial, such as having a confirmed diagnosis of locally advanced unresectable or metastatic pancreatic adenocarcinoma, having cholestatic hyperbilirubinemia due to bile duct obstruction, and not having received prior therapy for metastatic disease. The criteria also include various blood counts, blood chemistry levels, coagulation studies, and other medical parameters that need to be within acceptable ranges. Additionally, there are criteria related to pregnancy and contraception for female subjects, as well as exclusion criteria for subjects with certain medical conditions or infections.",
    "The sample provided is a record from a table that contains information about clinical trials. The record belongs to a trial in phase 1 and focuses on two diseases: chronic lymphocytic leukemia/small lymphocytic lymphoma and mantle cell lymphoma. The diseases are associated with specific ICD-10 codes. The trial involves the use of two drugs: tgr-1202 and ibrutinib. The eligibility criteria for participants are listed, including the requirement of a confirmed diagnosis of one of the mentioned diseases, adequate organ system function, a specific performance status, ability to swallow oral medication, and willingness to comply with the trial procedures. The exclusion criteria are also provided, which include recent cancer therapy, certain types of stem cell transplants, active infections, central nervous system involvement by lymphoma, and various medical conditions that could affect participation. Other factors such as specific medications, medical history, and pregnancy/lactation status are also considered.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1 and focuses on the treatment of lymphoma. The trial includes patients who have been diagnosed with mantle cell lymphoma and have previously received at least 2 lines of therapy. The eligibility criteria include having measurable disease, a performance status of 2 or less, and meeting certain laboratory values. The trial also has specific criteria for female patients of childbearing potential and male patients. The exclusion criteria include various medical conditions, pregnancy or breastfeeding, recent use of certain therapies, and certain medical history or conditions.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is allergic rhinitis. The ICDCodes associated with this disease are \"J30.89\", \"J30.9\", \"J30.2\", \"J30.1\", \"J30.5\", and \"J30.81\". The drugs being used in the trial are \"hollisterstier\" and \"normal saline\". The eligibility criteria for this trial include having allergic rhinitis to house dust mite (Df, Dp), cat, or dog, and having a skin prick test reaction of more than 3mm for Df, Dp, cat, or dog, or a serum specific IgE level of more than class 3. There are also exclusion criteria listed, such as having uncontrolled or severe asthma, low lung function, pregnancy or lactation, and various other medical conditions or medication usage. Additionally, vulnerable volunteers are not eligible for this trial.",
    "The sample is a phase 1 clinical trial for patients with recurrent ovarian epithelial cancer, recurrent fallopian tube carcinoma, or recurrent primary peritoneal carcinoma. The trial is focused on evaluating the effectiveness of gemcitabine hydrochloride as a treatment option. The eligibility criteria include having measurable or detectable disease, specific timeframes for disease recurrence, certain performance status and life expectancy, and various blood count and organ function requirements. Patients with certain mutations or overexpression of the p53 gene are also eligible. The sample also includes exclusion criteria such as uncontrolled illness, other active malignancies, pregnancy, brain metastases, recent radiotherapy, and certain medical conditions or medications.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 1, and the disease mentioned is HIV-1 infection. The ICDCodes associated with the disease are \"B20\", \"Z71.7\", \"O98.72\", \"Z21\", \"O98.73\", \"R75\", and \"Z11.4\". The drugs mentioned are bictegravir and placebo. The eligibility criteria include specific requirements for participants, such as not having received any anti-HIV treatment within 12 weeks of screening, having a certain range of HIV-1 RNA copies in plasma, and a CD4+ cell count above 200 cells/mm^3. There are also exclusion criteria, such as not being able to start HIV-1 therapy during the study period, not participating in another study of investigational or approved ART agents, and having certain conditions like positive hepatitis C antibody or chronic hepatitis B virus infection.",
    "The sample provided is a schema definition of a table that contains information about different phases of a clinical trial, diseases, ICDCodes, drugs, and eligibility criteria. The table has three cohorts: Cohort A for Soft Tissue Sarcoma, Cohort B for Myxoid Liposarcoma, and Cohort C for Retroperitoneum Sarcoma.\n\nFor each cohort, there are inclusion and exclusion criteria listed. The inclusion criteria specify the requirements for patients to be eligible for the trial, such as age, specific disease diagnosis, tumor characteristics, disease progression, performance status, organ function, and other medical conditions. The exclusion criteria list the factors that would disqualify patients from participating in the trial, such as previous treatments, certain medical conditions, infections, pregnancy, and participation in other clinical trials.\n\nThe sample also includes additional details about the specific histological subtypes that can be included, the need for measurable disease according to RECIST criteria, the requirement for normal cardiac function, and the performance of HBV and HCV serologies before inclusion.\n\nOverall, the sample provides a comprehensive overview of the different cohorts, their specific inclusion and exclusion criteria, and the necessary medical conditions for patients to participate in the clinical trial.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is focused on the treatment of malignant melanoma, a type of cancer. The phase of the trial is a combination of phase 1 and phase 2. The diseases column specifies the disease being studied, which in this case is malignant melanoma. The icdcodes column contains a list of ICD-10 codes associated with the disease. The drugs column lists the drug being used in the trial, which is ipilimumab. The criteria column provides the eligibility criteria for participants in the trial, including requirements such as confirmed diagnosis of unresectable or metastatic malignant melanoma, specific stage of melanoma, performance status, age, and various health parameters. The exclusion criteria are also listed, which include factors such as autoimmune diseases, active brain metastasis, uncontrolled infectious diseases, pregnancy, breastfeeding, and other medical or psychiatric conditions that may make the administration of the study drug hazardous.",
    "The sample provided is a schema definition of a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. The table has the following columns: phase, diseases, icdcodes, drugs, and criteria. \n\nIn the sample, the phase is \"phase 1\" and the diseases listed are \"carcinoma, squamous cell of head and neck\", \"squamous cell carcinoma of the head and neck\", and \"squamous cell carcinoma, head and neck\". The corresponding ICDCodes for these diseases are [\"C22.0\", \"C4A.9\", \"C7B.1\", \"C4A.0\", \"C4A.31\", \"C4A.51\", \"C4A.8\"] and [\"C22.0\", \"C4A.9\", \"C7B.1\", \"C4A.0\", \"C4A.31\", \"C4A.51\", \"C4A.8\"] respectively. The drugs mentioned are \"ficlatuzumab\" and \"cetuximab\". \n\nThe eligibility criteria for the trial are also provided, including inclusion and exclusion criteria. The inclusion criteria specify the requirements for patients to be enrolled in the study, such as having histologically confirmed HNSCC, being recurrent/metastatic, and meeting certain laboratory values. The exclusion criteria list the conditions that would prevent patients from participating in the study, such as severe allergic reactions, uncontrolled CNS metastases, and significant cardiovascular or dermatological diseases. Additionally, there are criteria related to pregnancy and breastfeeding for female participants.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. \n\nIn this specific sample, the phase of the trial is Phase 1. The disease being studied is pancreatic cancer. The icd-10 code associated with this disease is C25.3. The drugs being used in the trial are nab-paclitaxel and gemcitabine. \n\nThe eligibility criteria for this trial include the following:\n- Patients must have histologically or cytologically confirmed locally advanced adenocarcinoma of the pancreas that is considered unresectable or borderline resectable.\n- Prior systemic chemotherapy is allowed, and it is expected that most patients enrolled will have received approximately 2 months of systemic therapy.\n- Patients must be at least 18 years old and have an ECOG performance status of 1 or lower.\n- Normal bone marrow and organ function is required, including specific criteria for absolute neutrophil count, platelets, hemoglobin, total bilirubin, AST/ALT, and serum creatinine.\n- Women of childbearing potential and men must agree to use adequate contraception during the study.\n- Patients must be able to understand and sign an informed consent document.\n\nThe exclusion criteria for this trial include the following:\n- Patients with distant metastatic disease or known brain metastases are not eligible.\n- Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields is not allowed.\n- Patients currently receiving any other investigational agents are excluded.\n- Major surgery within 4 weeks prior to the first study drug administration is not allowed.\n- Patients with a history of allergic reactions to compounds similar to gemcitabine or nab-paclitaxel or other agents used in the study are excluded.\n- Uncontrolled intercurrent illness, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements are exclusion criteria.\n- Pregnant and/or breastfeeding patients are not eligible, and a negative pregnancy test is required within 14 days of study entry.\n- Patients with known HIV-positivity on combination antiretroviral therapy are excluded due to potential pharmacokinetic interactions and increased risk of infections when treated with marrow-suppressive therapy.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is Hepatitis B. The ICDCodes associated with this disease are B18.0, B18.1, B19.10, B19.11, B17.0, B16.0, and B16.1. The drugs being used in the trial are antiviral therapy (tenofovir or entecavir), birinapant, and placebo (for birinapant). \n\nThe eligibility criteria for this trial include having a documented history of chronic Hepatitis B infection and currently being treated with tenofovir or entecavir for at least 3 months. Other criteria include having a measurable titer of HBsAg, HBV DNA level below a certain threshold, specific liver function and renal function requirements, and not meeting certain exclusion criteria such as participation in other studies, having certain infections or liver disorders, or being pregnant or breastfeeding.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is hepatocellular cancer. The ICDCodes associated with this disease are \"P59.20\" and \"P59.29\". The drug being tested is sorafenib. The eligibility criteria for this trial include various factors such as confirmed diagnosis of HCC, specific liver cancer stages, absence of cirrhosis, presence of measurable tumor lesions, consultation with an interventional radiologist, and adequate hematologic, hepatic, and renal function. The sample also includes exclusion criteria, such as allergies to sorafenib, malabsorption conditions, brain metastases, concurrent chemotherapy or herbal therapy, pregnancy or nursing, prior radiation therapy to the liver, and other medical conditions that may compromise patient safety or ability to complete the study.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is multiple myeloma. The ICDCodes associated with this disease are C90.01, C90.02, and C90.00. The drugs being used in the trial are mk-3475, pomalidomide, and dexamethasone. \n\nThe eligibility criteria for this trial include:\n1. Confirmed diagnosis of relapsed and/or refractory multiple myeloma.\n2. Having received two lines of prior therapy, including an IMiD (lenalidomide or thalidomide) and a proteasome inhibitor (bortezomib and/or carfilzomib).\n3. Measureable disease as defined by the protocol.\n4. Willingness and ability to provide written informed consent/assent for the trial.\n5. Being over 18 years of age.\n6. Having a performance status of 2 on the ECOG Performance Scale.\n7. Demonstrating adequate organ function.\n8. Female subjects of childbearing potential should have a negative serum pregnancy test.\n9. Male subjects should agree to use contraception.\n\nThe exclusion criteria for this trial include:\n1. Currently participating in or having participated in another investigational study within 4 weeks of the first dose of treatment.\n2. Having immunodeficiency (HIV) or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.\n3. Having received a prior monoclonal antibody within 4 weeks prior to study Day 1 or not having recovered from adverse events due to agents administered more than 4 weeks earlier.\n4. Having received prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or not having recovered from adverse events due to a previously administered agent.\n5. Having a known additional malignancy that is progressing or requires active treatment, except for certain types of skin cancer or situ cervical cancer that has undergone potentially curative therapy.\n6. Having known active central nervous system disease and/or carcinomatous meningitis.\n7. Having an active autoimmune disease requiring systemic treatment within the past 3 months or a history of clinically severe autoimmune disease.\n8. Having evidence of interstitial lung disease or active, non-infectious pneumonitis.\n9. Having an active infection requiring systemic therapy.\n10. Having a history or current evidence of any condition, therapy, or lab abnormality that might confound the results of the trial or interfere with the subject's participation.\n11. Having known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n12. Being pregnant or breastfeeding, or expecting to conceive or father children during study participation.\n13. Having received prior therapy with certain antibodies as per the protocol.\n14. Having known active Hepatitis B or Hepatitis C.\n15. Having a known history of Human Immunodeficiency Virus (HIV).\n16. Having received a live vaccine within 30 days prior to the first dose of trial treatment.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 1, and the disease is \"infection, human immunodeficiency virus\" with the ICDCodes \"Z21\". The drugs being studied are \"gsk2838232\", \"placebo\", and \"ritonavir\". The eligibility criteria include age requirements, health evaluations, specific laboratory parameters, creatinine clearance, body weight and BMI ranges, and gender-specific conditions for female participants. There are also exclusion criteria related to liver disease, asthma, cardiac history, medication use, alcohol consumption, smoking, allergies, hepatitis, cardiac troponin levels, HIV status, blood donation, previous clinical trial participation, exposure to new chemical entities, abnormal cardiac findings, and abnormal ECG results.",
    "The sample provided is for a phase 1 clinical trial. The disease being studied is respiratory syncytial virus (RSV). The ICD-10 codes associated with this disease are J12.1, J20.5, J21.0, Z29.11, and B97.4. The drugs being tested in this trial are placebo, medi8897 10 mg, medi8897 25 mg, and medi8897 50 mg. \n\nThe eligibility criteria for this trial include healthy infants who were born between 32 weeks 0 days and 34 weeks 6 days gestational age and are entering their first RSV season at the time of screening. \n\nThe exclusion criteria include infants with gestational age less than 32 weeks 0 days or greater than 34 weeks 6 days, infants who meet the criteria to receive commercial palivizumab according to AAP or other local guidelines, infants with any fever or lower respiratory illness within 7 days prior to randomization, infants with acute illness at the time of randomization, infants with active RSV infection (unless they have tested negative for RSV), and infants who have received palivizumab or any RSV vaccine, including maternal RSV vaccination.",
    "The sample provided is a record from a table that contains information about clinical trials. The table has several columns, including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of diseases being studied, \"icdcodes\" which contains the corresponding ICD-10 codes for the diseases, \"drugs\" which lists the names of drugs being used in the trial, and \"criteria\" which includes the eligibility criteria for participating in the trial.\n\nIn this specific sample, the phase of the trial is described as \"phase 1/phase 2\". The disease being studied is \"liver cancer\" and the corresponding ICD-10 codes are provided as \"['D13.4', 'Z85.05', 'C22.8', 'C78.7', 'C22.9', 'D37.6']\". The drug being used in the trial is \"bleomycin phc 15 e. (united states pharmacopeia - usp)\". \n\nThe eligibility criteria for this trial include various conditions such as having primary liver tumors (hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and other primary tumors not larger than 7 cm), disease progression after treatment with TACE, RFA, or percutaneous alcohol ablation, relatively good \"performance status\" and Child-Pugh score < 8, and more. The criteria also mention different patient groups and their suitability for standard treatment procedures or electrochemotherapy (ETC) as the only therapeutic option.\n\nAdditionally, the exclusion criteria are listed, which include conditions such as secondary primary tumors (except for specific cases), visceral, bone or diffuse metastases, life-threatening infections or organ failures, significant respiratory function reduction, and various other factors.\n\nOverall, this sample provides specific details about the phase, diseases, drugs, and eligibility criteria for a clinical trial focused on liver cancer.",
    "The sample from the table represents a clinical trial for the treatment of hepatocellular cancer (HCC) in its advanced stage. The trial is in Phase 1 and involves the use of two drugs, trametinib and sorafenib. The eligibility criteria for participants include having a radiographic or histological diagnosis of HCC, a Child Pugh score of 5 or 6, measurable disease, an Eastern Cooperative Oncology Group (ECOG) performance status of \u22641, normal organ and marrow function, and the ability to swallow and retain orally administered medication. Female participants of child-bearing potential must agree to use dual methods of contraception, and male participants must use an effective barrier method of contraception. Participants must also be able to understand and sign a written informed consent document. Exclusion criteria include recent radiation therapy or major surgery, prior treatment-related toxicities above Grade 1, previous use of sorafenib or other systemic therapies for HCC, and the presence of certain medical disorders or conditions that could interfere with participant safety or compliance. Other exclusion criteria include a history of cardiovascular risk, HIV positivity, retinal vein occlusion, symptomatic or untreated brain or spinal cord metastases, interstitial lung disease or pneumonitis, pregnancy or lactation, and underlying conditions that would interfere with oral medication absorption. The sample also specifies that participants with a history of another active malignancy in the last 3 years are generally not eligible, except for those who have been disease-free for 3 years or have a history of completely resected nonmelanoma skin cancer. Additionally, participants with controlled infections or on prophylactic antibiotics are permitted in the study, while those with uncontrolled infections requiring parenteral antibiotics, antivirals, or antifungals within one week prior to the first dose are excluded. Other exclusion criteria include known hypersensitivity reactions to related drugs or excipients, concurrent therapy with approved or investigational anticancer therapy, and concomitant use of strong Cytochrome P450 3A4 (CYP3A4) inducers.",
    "The sample from the table represents a clinical trial for the treatment of non-small cell lung cancer. The trial is in phase 1 and focuses on patients with ALK-positive advanced NSCLC. The eligibility criteria include having an ECOG performance status of 2 or lower, measurable disease as per RECIST v1.1, and the availability of a tumor sample. For patients who have not received any ALK inhibitor therapy, a representative tumor sample must be submitted. For patients who have progressed on an ALK inhibitor, a new tumor biopsy is required unless a biopsy after progression on the most recent ALK inhibitor is available. The exclusion criteria include not having received at least one line of therapy for ALK-positive NSCLC, prior therapy with certain ALK inhibitors, intolerance to ceritinib (except for nausea, vomiting, and diarrhea under fasted conditions), unstable symptomatic central nervous system metastases, abnormal laboratory values, gastrointestinal impairment, current treatment with certain medications, history of pancreatitis or increased amylase/lipase due to pancreatic disease, impaired cardiac function or uncontrolled cardiac disease, and certain cardiac abnormalities. Other protocol-defined inclusion/exclusion criteria may also apply.",
    "The sample provided is a record from a table that contains information about clinical trials. The table has several columns, including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of the diseases being studied, \"icdcodes\" which contains the corresponding ICD-10 codes for the diseases, \"drugs\" which lists the names of the drugs being tested, and \"criteria\" which provides the eligibility criteria for participants in the trial.\n\nIn this particular sample, the phase of the trial is described as \"phase 1/phase 2\". The diseases being studied are \"acute myelogenous leukemia\" and \"myelodysplastic syndrome\". The corresponding ICD-10 codes for these diseases are provided as well. The drug being tested is \"bvd-523\". The eligibility criteria for participants are listed, including specific diagnoses, prior therapy requirements, performance status, predicted life expectancy, and adequate organ function. There are also exclusion criteria listed, such as the presence of other malignancies, certain medical conditions, recent cancer-directed therapy, and concurrent use of certain drugs.\n\nOverall, this sample provides information about a clinical trial that is investigating the use of the drug \"bvd-523\" in patients with acute myelogenous leukemia and myelodysplastic syndrome, and it outlines the criteria that potential participants must meet to be eligible for the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is \"respiratory syncytial virus infections.\" The ICDCodes associated with this disease are \"R09.2,\" \"A15.7,\" \"A15.8,\" \"A15.9,\" \"J98.9,\" \"R06.03,\" and \"J12.1.\" The drugs being used in the trial are \"ak0529\" and \"placebo.\" \n\nThe eligibility criteria for this trial include being a healthy male or a healthy non-childbearing potential female, aged 18 to 55 years, with a body mass index (BMI) between 18.0 and 31.0 kg/m2. The total body weight must be between 50 kg and 100 kg. Participants must be willing to communicate and participate in the entire study, provide written informed consent, and use an adequate method of contraception. They must also have certain laboratory values within the reference range, normal ECG measurements, and be free from hepatitis B, hepatitis C, and HIV infections.\n\nExclusion criteria include male subjects with pregnant partners or partners planning to become pregnant during the study, a history of significant medical conditions or current infections, abnormal ECG findings, family history or clinical conditions that prolong the QTc interval, symptomatic cardiac arrhythmias or bradycardia, electrolyte disturbances, conditions affecting drug absorption, history of post-antibiotic colitis, drug or alcohol abuse in the past 2 years, excessive alcohol consumption, tobacco use within 90 days of screening, recent participation in other clinical research studies, and certain affiliations with the study site or sponsor employees.\n\nIt is important to note that there may be additional inclusion/exclusion criteria defined by the study protocol.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 1, the disease is non-small cell lung cancer, the ICDCodes are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2, and the drug is ceritinib. The eligibility criteria for this trial include specific requirements for inclusion and exclusion. For inclusion, the patient must have a confirmed diagnosis of stage IIIB or IV ALK-positive NSCLC, may have received one prior treatment regimen with crizotinib, and must have a WHO performance status of 0-2. Exclusion criteria include prior treatment with an ALK inhibitor other than crizotinib, history of carcinomatous meningitis, presence or history of a malignant disease other than an ALK-positive advanced tumor within the past 3 years, clinically significant uncontrolled heart disease or recent cardiac event, history of interstitial lung disease or pneumonitis, other severe medical conditions, and current treatment with certain anticoagulants.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The diseases being studied include various types of adult acute myeloid leukemia, recurrent adult acute myeloid leukemia, and secondary acute myeloid leukemia. The ICDCodes associated with these diseases are also provided. The drugs being used in the trial are mitoxantrone hydrochloride, etoposide, cytarabine, and selinexor. The eligibility criteria for participants include age restrictions, previous treatment history, co-morbid medical illness, performance status, laboratory values, cardiac function, contraception requirements, ability to understand and provide informed consent, and exclusion criteria such as recent chemotherapy or radiotherapy, active CNS malignancy, major surgery, uncontrolled infection, gastrointestinal issues, history of seizures or movement disorders, visual impairments, uncontrolled intercurrent illness, serious medical or psychiatric illness, pregnancy or breastfeeding, advanced malignant solid tumors, being significantly below ideal body weight, and inability to swallow capsules or tablets.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 1, the disease is \"carcinoma, non-small-cell lung,\" the ICDCodes are ['D02.20', 'D02.21', 'D02.22'], and the drugs are 'nintedanib' and 'docetaxel'. The eligibility criteria are listed under inclusion and exclusion criteria, which include age requirements, specific cancer subtype, prior treatments, performance status, and other factors. The sample also mentions that additional exclusion criteria may apply.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1 and focuses on bladder cancer, transitional cell carcinoma, renal pelvis cancer, ureter cancer, and urethra cancer. The corresponding ICD-10 codes for these diseases are provided. The drugs being studied in the trial are enzalutamide, cisplatin, and gemcitabine. The sample also includes the eligibility criteria for the trial, including requirements for disease confirmation, disease stage, previous treatments, performance status, organ function, and more. Additionally, there are exclusion criteria listed, such as previous chemotherapy treatment, recent major surgery, certain medical conditions, and allergies to study drugs.",
    "The sample provided is a record from a table that contains information about clinical trials. The phase of the trial is indicated as \"phase 1/phase 2\". The disease being studied in this particular trial is \"mucositis\". The corresponding ICD-10 codes for this disease are \"J34.81\", \"K92.81\", \"K12.30\", \"K12.39\", \"K12.33\", \"N76.81\", and \"K12.31\". The drugs being tested in this trial are \"curcumin-mtd\", \"mouthwash-standard pharmacy preparation\", and \"curcumin\". \n\nThe eligibility criteria for participants in this trial are as follows:\n- Participants must have grade 2 or higher oral mucositis related to chemotherapy for cancer.\n- Participants must be able to understand and willing to review and sign a written informed consent document.\n- Participants must be 18 years of age or older.\n- Female participants of child-bearing potential and male participants must be willing to use adequate contraception prior to study entry, during the study, and for 30 days after the last dose.\n\nThe exclusion criteria for this trial are as follows:\n- Participants currently using therapeutic doses of anticoagulants such as warfarin or antiplatelet agents (prophylactic doses and agents are acceptable).\n- Participants with biliary tract obstruction or cholelithiasis.\n- Participants with a history of gastric or duodenal ulcers or hyperacidity syndromes.\n- Participants with AST or ALT levels greater than 2 times the upper limit of normal (ULN).\n- Participants with a total bilirubin level equal to or greater than 2 times the ULN.\n- Participants with an INR (International Normalized Ratio) greater than 1.5.\n- Participants with a previous stem cell transplant (allogeneic or autologous).\n- Participants with preexisting oral disease, such as active oral infection, trauma to the oral mucosa, or oral ulceration prior to chemotherapy.\n- Participants with a known allergy or hypersensitivity to curcumin, yellow food coloring, or other members of the Zingiberaceae (ginger) family.\n- Participants who are pregnant or breastfeeding.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 1 trial and the disease being studied is \"advanced solid tumors\". The ICD-10 codes associated with these tumors are \"K74.02\", \"G47.22\", \"H35.3133\", \"H35.3134\", \"H35.3113\", \"H35.3114\", and \"H35.3123\". The drug being tested in this trial is \"tas-102\". The record also includes the eligibility criteria for participants in the trial, including requirements for informed consent, specific tumor types, hepatic function, performance status, ability to take medications orally, organ function, and birth control for women of childbearing potential. The record also lists certain exclusions, such as certain medical conditions, recent treatments, previous use of TAS-102, unresolved toxicity from prior therapies, and pregnancy or lactation in females.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1 and is focused on the treatment of recurrent ovarian cancer. The ICD-10 codes associated with the disease are G47.13, J01.41, K11.22, K12.0, N96, F33.8, and G03.2. The drug being tested is a combination of nuc-1031 and carboplatin. The eligibility criteria for participants include having a confirmed diagnosis of relapsed epithelial ovarian, fallopian tube, or primary peritoneal cancer, relapse within 24 months of completing a platinum-containing regimen, being at least 18 years old, having an ECOG performance status of 0, 1, or 2, having measurable or evaluable disease, and meeting certain requirements for bone marrow, liver, and renal function. Participants must also be postmenopausal, surgically sterile, or agree to use contraception. There are also exclusion criteria, such as a history of allergic reactions to previous gemcitabine or carboplatin treatment, symptomatic CNS or leptomeningeal metastases, recent treatment with Nuc-1031, and other medical conditions that may interfere with participation in the study.",
    "The sample is a clinical trial for phase 1/phase 2 of a drug study. The trial is focused on the disease leukemia, specifically acute myeloid leukemia (AML). The trial is for patients who are newly diagnosed with AML and are considered inappropriate for intensive remission induction therapy. Patients who are not eligible for stem cell transplantation are also included. However, patients with acute promyelocytic leukemia, current myelodysplastic syndrome only subjects, unstable angina or uncontrolled congestive heart failure, any other malignancy (excluding specific types), and respiratory disease requiring continuous supplemental oxygen are excluded from the trial. The sample also mentions that there may be other protocol-defined inclusion/exclusion criteria that could apply.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is acute myeloid leukemia. The ICDCodes associated with this disease are C92.A1, C92.A2, C92.61, C92.62, C92.A0, and C92.60. The drugs being used in the trial are gmi-1271, mitoxantrone, etoposide, cytarabine, and idarubicin. The eligibility criteria for inclusion in the trial include specific age requirements, prior treatment history, blast count, ECOG performance status, and organ function. There are also exclusion criteria listed, such as specific types of leukemia, CNS involvement, prior use of certain medications, and certain medical conditions.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1 and focuses on treating t-cell lymphoma, specifically relapsed and refractory t-cell lymphoma. The trial uses the drug ibrutinib. The eligibility criteria for participants include having confirmed relapsed or refractory T-cell lymphoma, having undergone at least 1 previous systemic therapy, being at least 18 years old, and being able to adhere to the study visit schedule and other protocol requirements. Other criteria include discontinuing previous therapies and having certain laboratory test results within specified ranges. There are also exclusion criteria, such as having a curative option for the lymphoid malignancy, recent infection, bleeding disorders, and certain medical conditions that could compromise safety.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The diseases being studied are myelodysplastic syndrome and acute myeloid leukemia. The corresponding ICDCodes for these diseases are 'D46.9', 'D46.C', 'D46.Z' for myelodysplastic syndrome and 'C92.A1', 'C92.A2', 'C92.61', 'C92.62', 'C92.A0', 'C92.60' for acute myeloid leukemia. The drugs being used in the trial are lenalidomide and velcade. The eligibility criteria for participants include having a diagnosis of recurrent, persistent, or progressive AML or MDS, having undergone an allogeneic SCT, being 18 years or older, adhering to the study schedule and protocol requirements, being off immunosuppressive medications (except prednisone) for at least 2 weeks prior to study entry, having an ECOG performance status of 0-2, and meeting certain organ function criteria. There are also exclusion criteria listed, such as having certain medical conditions or laboratory abnormalities, recent major surgery, peripheral neuropathy or active herpes infection, and being pregnant or breastfeeding.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease mentioned is epithelial ovarian cancer. The ICDCodes associated with this disease are H18.523, H18.521, H18.522, and H18.529. The drugs being used in the trial are metformin, carboplatin, and paclitaxel. The eligibility criteria for this trial include patients with advanced stage epithelial ovarian carcinoma, patients eligible for neo-adjuvant or palliative carboplatin/paclitaxel chemotherapy, patients with an Eastern Cooperative Oncology Group-performance status (ECOG-PS) of 0-2, patients aged 18 years or older, and patients meeting specific laboratory requirements. The exclusion criteria include patients currently or recently participating in another investigational study, recent use of metformin, presence of symptomatic central nervous system (CNS) metastasis, pre-existing peripheral neuropathy of grade 2 or higher, pregnant or lactating females, women of childbearing potential not using effective contraception, known hypersensitivity to any study drugs or excipients, serious active infection requiring intravenous antibiotics, unstable medical conditions, and evidence of any other medical conditions or findings that may interfere with treatment or place the patient at high risk.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are \"diabetic macular edema\" and \"age-related macular degeneration\". The corresponding ICDCodes for these diseases are provided as well.\n\nThe drug being tested in this trial is \"mtp-131\". The eligibility criteria for participants are listed, including age requirements, pregnancy testing for women of childbearing potential, and the specific criteria for the DME Treatment Group and AMD Treatment Group.\n\nThe exclusion criteria are also listed, which include factors such as the inability to self-administer eye drops, use of medications toxic to the eye, and medical conditions that may interfere with study participation.\n\nOverall, this sample provides a snapshot of the information stored in the table, including the phase, diseases, ICDCodes, drugs, and eligibility criteria for a clinical trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is \"healthy,\" which seems to indicate that the trial is focused on testing a drug or treatment on individuals who are considered healthy. The ICDCodes associated with this disease are \"Z76.3\" and \"Z76.2.\" The drug being used in this trial is a placebo.\n\nThe eligibility criteria for participants in this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" Inclusion criteria include being healthy based on physical examination, medical history, ECG, and laboratory criteria, as well as having negative HIV test results. Female participants of childbearing potential must also have negative pregnancy tests. Participants must also be assessed as being at low risk for HIV infection.\n\nExclusion criteria include having certain infections or diseases such as chronic active hepatitis B or active hepatitis C, syphilis, chlamydia, gonorrhea, or trichomonas. Participants with a history of certain infections or diseases in the 12 months prior to enrollment are also excluded. Other exclusion criteria include having significant medical conditions, recent major surgery, thyroid disease, heart conditions, abnormal ECG findings, history of adverse reactions to vaccines or vaccine products, neomycin, streptomycin, or egg products.\n\nOverall, this sample provides information about the phase, disease, ICDCodes, drug, and eligibility criteria for participants in a clinical trial.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are liver metastasis and colorectal cancer. The ICDCodes associated with these diseases are provided as well. The drug being tested in this trial is decitabine. The eligibility criteria for participants are listed under both inclusion and exclusion criteria. Inclusion criteria include having a histological documentation of colorectal adenocarcinoma stage IV with unresectable liver metastases, meeting certain performance status and laboratory value requirements, and having progressive disease following standard palliative chemotherapy. Exclusion criteria include not having prior radiotherapy to target liver lesions, no previous history of gastric or hepatobiliary surgery, no concurrent liver disease or serious medical condition, no use of other investigational drugs, no pre-existing neuropathy above grade 1, no previous or concurrent malignancies except for certain treated cases, not being pregnant or breastfeeding, and not being a candidate for resection of all colorectal cancer metastases with curative intent.",
    "The sample in the table represents a clinical trial for the treatment of gastric carcinoma, specifically for patients in phase 1/phase 2 of the trial. The trial aims to evaluate the effectiveness of the drug combination oxaliplatin+s-1. The eligibility criteria for participants include having histologically confirmed gastric carcinoma at clinical stage III, having undergone radical resection, being able to read and understand the informed consent document, and being between the ages of 18 and 75. Other criteria include the availability of at least 0.5 g tumor sample, having an ECOG score of \u22641, having a life expectancy of at least 12 weeks, and being able to comply with study-related procedures. Adequate bone marrow, liver, renal, and heart function are also required. Exclusion criteria include being unable to provide informed consent, being pregnant or breastfeeding, having disease progression prior to treatment, being a transplant recipient, having HIV or other active uncontrolled infection, having unstable or severe intercurrent medical conditions, having an allergic constitution, or needing treatment with immunosuppressants or corticosteroids for any systemic disease.",
    "The sample is a phase 1 clinical trial for the treatment of hepatocellular carcinoma, a type of liver cancer. The trial is investigating the effectiveness of two drugs, cc-122 and sorafenib. The eligibility criteria for participants include being 18 years or older, having a confirmed diagnosis of hepatocellular carcinoma, and having unresectable stage B or C cancer. Participants must also have measurable lesions, satisfactory archival tumor biopsy tissue, and a life expectancy of more than 12 weeks. Other criteria include specific laboratory parameters, such as adequate hematologic and hepatic function, and a Child-Pugh score of less than 7. Subjects must also adhere to the study visit schedule and other protocol requirements. Pregnancy prevention measures are required for female participants of childbearing potential, and male participants must use barrier contraception. The exclusion criteria include previous systemic therapy for hepatocellular carcinoma, recent surgery, receipt of investigational drugs or therapies, and certain medical conditions that may affect participation in the study.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in either phase I, phase II, or phase III. The disease being studied is seizures. The ICD-10 codes associated with this disease are 'G40.89', 'R56.1', 'F44.5', 'G40.501', 'G40.509', 'G40.111', and 'G40.119'. The drug being tested is cannabidiol oral solution. The sample also includes the eligibility criteria for participants in the trial. The inclusion criteria specify that participants must have a treatment-resistant seizure disorder, be able to understand the study requirements, and have signed an informed consent form. The exclusion criteria state that participants or their caregivers should not have commitments that would interfere with attending study visits, should not have a history of using medications outside the study parameters, and should not have any conditions that could compromise safety or the analysis of results.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 1 trial and focuses on the disease \"head and neck cancer.\" The corresponding ICD-10 codes for this disease are ['C76.0', 'C47.0', 'C49.0', 'C77.0', 'D17.0', 'D21.0', 'D36.11']. The trial involves the drugs \"metformin\" and \"cisplatin\". \n\nThe eligibility criteria for this trial are as follows:\n\nInclusion Criteria:\n- The patient must have locally advanced squamous cell cancer of the head and neck, specifically stage III or IV disease (T1-2, N2a-3 or T3-4).\n- The patient must have measurable disease.\n- The patient must not have received prior chemotherapy or radiation for head and neck squamous cell cancer.\n- The patient must have a life expectancy of greater than 3 months.\n- The patient must have adequate lab results.\n\nExclusion Criteria:\n- The patient must not have known metastatic disease.\n- The patient must not have nasopharyngeal carcinoma.\n- The patient must not have a history of allergic reactions attributed to metformin or other agents used in the study.\n- The patient must not have a known diagnosis of diabetes requiring insulin for control.\n- The patient must not have received metformin within the last 4 weeks.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease mentioned is \"hematologic neoplasms\" and its corresponding ICDCodes are ['E70.338', 'E70.339', 'P09.3', 'O28.0', 'P61.8', 'P61.9', 'T45.8X1A']. The drugs being tested in this trial are 'ibrutinib' and 'nivolumab'. The eligibility criteria for this trial include specific requirements for Eastern Cooperative Oncology Group (ECOG) performance status, bone marrow, liver, and renal function, as well as histologically confirmed B-cell non-Hodgkin lymphoma (B-NHL), Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL), and relapsed refractory disease. There are also specific criteria for different cohorts within the trial, such as B-cell follicular lymphoma, diffuse large B-cell lymphoma (DLBCL), and Richter syndrome. The exclusion criteria include prior therapy or surgery, previous use of certain inhibitors or antibodies, cardiovascular diseases, history of stroke or intracranial hemorrhage, and certain medical conditions like HIV, Hepatitis B, or Hepatitis C.",
    "The sample is from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 1, the disease is schizophrenia, the icd-10 codes associated with schizophrenia are F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, and F20.9. The drugs being tested are pf-04958242 and placebo. The eligibility criteria include being psychiatrically stable, having a BMI between 17.5 and 30.5 kg/m2, and a total body weight over 55 kg. The sample also includes key inclusion and exclusion criteria related to suicide attempts, seizures, head injuries, and medication usage.",
    "The sample provided is a record from a table that contains information about clinical trials. The trial is in phase 1 and is focused on the treatment of B-cell chronic lymphocytic leukemia. The trial includes the use of drugs such as chlorambucil, obinutuzumab, placebo, and tocilizumab. The eligibility criteria for participants are listed, including requirements such as having documented CD20+ B-CLL, a certain Cumulative Illness Rating Scale (CIRS) score, and previously untreated CLL. Exclusion criteria are also listed, such as previous CLL treatment, abnormal laboratory test values, and history of certain medical conditions. The sample provides detailed information about the inclusion and exclusion criteria for potential participants in the clinical trial.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 1, and the disease mentioned is osteoarthritis of the knee. The ICDCodes associated with this disease are ['M17.9', 'M17.0', 'M17.10', 'M17.11', 'M17.12', 'M17.2', 'M17.30']. The drugs being tested in this trial are 'neo6860' and 'placebo'. The eligibility criteria for participants are listed, including age, body mass index (BMI), body weight, general health requirements, and consent. Exclusion criteria are also mentioned, such as contraception requirements, restrictions on blood/plasma/platelet donation, alcohol consumption limits, recent medication use, abnormal vital signs, positive drug/alcohol tests, and various medical conditions. The final decision on participation is at the discretion of the investigator.",
    "The sample from the table represents a phase 1 clinical trial for prostate cancer. The eligibility criteria for patients to participate in the trial include having histologically or cytologically confirmed prostate cancer with a Gleason score available or interpretable. Patients must also have prostate cancer deemed to be castration-resistant and show progression of measurable or evaluable disease within a specific timeframe. Other criteria include having had X-rays, scans, or physical examinations completed within a certain timeframe, being surgically or medically castrated, and having certain blood counts and liver function within normal limits. Patients must also meet certain requirements for birth control if they are of childbearing potential. Exclusion criteria include recent radiotherapy, history of seizures or other conditions predisposing to seizure, current use of metformin or certain other medications, and certain prior therapies for metastatic castration-resistant prostate cancer. Patients with brain metastases, known allergies to similar compounds, uncontrolled intercurrent illnesses, or certain psychiatric or HIV-related conditions are also excluded from the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is chronic hepatitis C. The icd-10 codes associated with this disease are B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, and K71.4. The drugs being tested in this trial are \"al-335 matching placebo\" and \"al-335\". \n\nThe eligibility criteria for this trial include providing written consent, being able to understand and comply with the protocol requirements, being in good health, and meeting certain age and body mass index (BMI) requirements. For female participants, there are additional criteria related to reproductive status. Male participants must be surgically sterile or practicing specific forms of birth control. \n\nThere are also exclusion criteria, such as having certain medical illnesses or disorders, testing positive for certain infections, having abnormal ECG findings, recent participation in other clinical trials, and abnormal laboratory results. Additional exclusion criteria are specific to subjects with chronic hepatitis C, such as a history of hepatic decompensation, previous treatment for CHC, and certain liver-related measurements exceeding certain thresholds.\n\nOverall, this sample provides a snapshot of the information stored in the table, including the phase, diseases, icd-10 codes, drugs, and eligibility and exclusion criteria for a specific clinical trial.",
    "The sample from the table is for a phase 1 clinical trial for the treatment of melanoma. The trial is investigating the use of pembrolizumab and high dose interferon alfa-2b (hdi) as a neoadjuvant therapy. The eligibility criteria for participants include being at least 18 years old, having melanoma in certain stages, having measurable disease, providing tumor tissue from a biopsy, having an ECOG performance status of 0 or 1, and having adequate organ function. Exclusion criteria include currently participating in another investigational study, having immunodeficiency or receiving immunosuppressive therapy, recent chemotherapy or radiation therapy, progressing or active additional malignancy, active autoimmune disease, interstitial lung disease or pneumonitis, active infection requiring systemic therapy, and various other conditions or disorders that may interfere with the trial. Participants who are pregnant, breastfeeding, or planning to conceive or father children during the trial period are also excluded. Prior treatment with certain antibodies or drugs targeting T-cell co-stimulation or checkpoint pathways is not allowed, except for interferon alfa. History of HIV or active Hepatitis B or C is also exclusionary. Finally, receiving a live vaccine within 30 days prior to the trial treatment is not allowed.",
    "The sample provided is a schema definition of a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. The phase column indicates the phase of the trial, which can be phase I, phase II, or phase III. The diseases column contains a list of disease names, while the icdcodes column contains a list of corresponding ICD-10 codes for those diseases. The drugs column contains a list of drug names. The criteria column provides the eligibility criteria for the trial.\n\nIn the sample, the phase is listed as phase 1/phase 2. The diseases listed include adenocarcinoma of the esophagus, adenocarcinoma of the gastroesophageal junction, diffuse adenocarcinoma of the stomach, gastrointestinal cancer, intestinal adenocarcinoma of the stomach, mixed adenocarcinoma of the stomach, stage iiia esophageal cancer, stage iiia gastric cancer, stage iiib esophageal cancer, stage iiib gastric cancer, stage iiic esophageal cancer, stage iiic gastric cancer, stage iv esophageal cancer, and stage iv gastric cancer. The corresponding ICDCodes are provided for each disease.\n\nThe drugs listed in the sample are c-met inhibitor amg 337, oxaliplatin, leucovorin calcium, and fluorouracil. The eligibility criteria are also provided, including requirements such as a minimum life expectancy of 12 weeks, specific performance status, and various medical conditions that would exclude a patient from participating in the trial.\n\nAdditionally, the sample includes specific criteria for phase I and phase II trials, such as the need for measurable disease, histologically or cytologically confirmed adenocarcinoma, and specific requirements for previous treatments or MET expression status.\n\nOverall, the sample provides a comprehensive overview of the table's schema and the information it contains.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2 and focuses on the treatment of systemic scleroderma, a disease affecting the skin and other organs. The trial involves the use of two drugs: c-82 topical gel (1% concentration) and a placebo. The eligibility criteria for participants include meeting specific criteria for systemic sclerosis, having a disease duration of less than 36 months, having certain skin scores and assessments, and being on a stable dose of immunosuppressive medication. Participants must also agree to use contraception during and after the treatment period. There are several exclusion criteria, such as recent participation in another clinical trial, use of high-dose steroids or certain topical treatments, and certain medical conditions or infections. The sample also includes additional criteria for exclusion related to pregnancy, nursing, gastrointestinal and pulmonary conditions, cardiac disease, liver function, and other medical or psychosocial problems.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2 and focuses on the treatment of heart failure. The trial includes patients who have been on oral furosemide or a therapeutic equivalent for at least 90 days before the study. The inclusion criteria specify that participants must have a history of chronic heart failure with moderate symptoms of chronic fluid overload. The exclusion criteria include recent acute decompensated heart failure, contraindication to furosemide, low blood pressure, high temperature or infection, abnormal levels of sodium or potassium, current or planned treatment with certain medications or therapies, history of gastric or intestinal surgery, need for urinary catheterization, impaired renal function, recent administration of radiographic contrast agent, recent major surgery, recent participation in another trial or use of investigational drugs or devices, inability to follow instructions or comply with procedures, and any other surgical or medical condition that may interfere with participation or affect the study outcome.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is ovarian cancer, and the associated ICDCodes are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drugs being used in the trial are niraparib and bevacizumab. \n\nThe eligibility criteria for this trial include:\n- Patients must have recurrent platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer.\n- The histology of the cancer must be high-grade serious or high-grade endometrioid.\n- Patients must consent to perform a HRD test, and if they have known BRCA status, they must submit tissue for the test.\n- Patients must have received platinum-containing therapy for primary disease, with no limits on the number of platinum-based therapies.\n- Patients may have received up to one non-platinum-based therapy in the recurrent setting.\n- Patients who have been treated with bevacizumab just prior to the trial must not have progressed under or within 3 months after bevacizumab.\n- Patients may have participated in a PARP inhibitor trial as first-line maintenance therapy and have not progressed within 3 months after PARP/placebo.\n- Patients must be at least 18 years old and have histologically confirmed ovarian, fallopian tube, or peritoneal cancers.\n- Patients must give informed consent and may have undergone primary or interval debulking surgery.\n- Patients may have received bevacizumab but no other prior use of anti-angiogenic therapy.\n- Patients may have received a PARP inhibitor as first-line maintenance therapy.\n- Patients must have measurable disease according to RECIST or assessable disease according to the GCIG criteria.\n- Patients must have an ECOG performance status of 0-2 and adequate organ function.\n- Patients must be able to take oral medications and have a life expectancy of at least 12 weeks.\n- Patients must fulfill all inclusion criteria and be deemed fit by the investigator to receive niraparib and/or bevacizumab.\n- Women of childbearing potential must use adequate birth control for the duration of the study.\n\nThe exclusion criteria for this trial include:\n- Patients with ovarian sarcomas, small cell carcinoma with neuroendocrine differentiation, non-epithelial cancers, or cancer types not mentioned in the inclusion criteria.\n- Patients receiving concurrent cancer therapy or treatment with an investigational agent or participation in another clinical trial.\n- Patients with major injuries or surgery within the past 21 days prior to the start of study treatment with incomplete wound healing or planned surgery during the on-treatment study period.\n- Patients with a previous diagnosis, detection, or treatment of invasive cancer (other than ovarian cancer) within 2 years prior to randomization.\n- Patients with active infections, serious underlying medical illness, abnormal laboratory findings, or psychiatric illness/social situations that would make them inappropriate for the study.\n- Patients with gastrointestinal disorders or abnormalities that would interfere with absorption of the study drug.\n- Patients with a history of bowel obstruction, abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess.\n- Patients with known contraindications to PARP inhibitors or VEGF directed therapy.\n- Patients with known uncontrolled hypersensitivity to the investigational drugs.\n- Patients with a history of major thromboembolic events, cerebral vascular accidents, transient ischemic attacks, or subarachnoid hemorrhage within the past 3 months.\n- Patients with a history of clinically significant hemorrhage in the past 3 months.\n- Patients with uncontrolled and/or symptomatic CNS metastasis or leptomeningeal carcinomatosis.\n- Patients with significant cardiovascular diseases, pregnancy, breastfeeding, radiographic evidence of cavitation or necrotic tumors with invasion of adjacent major blood vessels, active or chronic hepatitis C and/or B infection, persistence of clinically relevant therapy-related toxicity from previous chemotherapy, proteinuria, known history of MDS, known persistent hematological toxicity, or known Grade 3 thrombocytopenia or anemia with the last chemotherapy regimen.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is focused on the treatment of metastatic melanoma, a type of skin cancer that has spread to other parts of the body. The trial is in phase 1/phase 2, which means it is still in the early stages of testing. The diseases column specifies the disease being studied, which in this case is metastatic melanoma. The icdcodes column contains a list of ICD-10 codes associated with the disease. The drugs column lists the names of the drugs being used in the trial, including vemurafenib, lymphodepleting chemotherapy, til infusion, and interleukin-2. The criteria column provides the eligibility criteria for participants in the trial. This includes requirements such as having confirmed unresectable stage III or stage IV metastatic melanoma, having a certain type of genetic mutation (BRAF mutation), and having a certain performance status. There are also exclusion criteria, which specify conditions or factors that would disqualify someone from participating in the trial. These include having other malignancies, having cerebral metastasis, and having certain medical or psychiatric comorbidities. The sample also includes additional details about the trial, such as the need for informed consent and the timeline for prior treatments.",
    "The sample provided is a schema definition of a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. The table has several columns including \"phase\" which represents the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of diseases, \"icdcodes\" which lists the corresponding ICD-10 codes for the diseases, \"drugs\" which lists the names of drugs, and \"criteria\" which represents the eligibility criteria for the trial.\n\nThe sample data in the table includes information for two cohorts: Renally Impaired Subjects (Cohort 1) and Healthy Subjects (Cohort 2). For each cohort, there are specific inclusion and exclusion criteria listed.\n\nFor Renally Impaired Subjects (Cohort 1), the inclusion criteria include being between 18 and 70 years of age, having severe renal impairment, having stable clinical laboratory test results, having a body weight of at least 50 kilograms, and being capable of giving informed consent. The exclusion criteria include having abnormal liver function, prolonged QT interval, abnormal blood pressure or heart rate, active cardiovascular disease, conduction abnormalities, significant arrhythmia, active infection, fluctuating or deteriorating renal function, history of certain medical conditions, and use of prohibited medications, among others.\n\nFor Healthy Subjects (Cohort 2), the inclusion criteria include being between 18 and 70 years of age, being healthy as determined by medical evaluation, having a creatinine clearance within a certain range, and being capable of giving informed consent. The exclusion criteria include abnormal liver function, prolonged QT interval, abnormal blood pressure or heart rate, previous myocardial infraction, conduction abnormalities, significant arrhythmia, active infection, fluctuating or deteriorating renal function, pre-existing conditions that interfere with gastrointestinal anatomy or function, history of certain medical conditions, use of prohibited medications, regular alcohol consumption, regular use of tobacco or nicotine-containing products, and positive tests for certain diseases, among others.\n\nOverall, the sample provides detailed information about the eligibility criteria for the clinical trial, including specific requirements for different cohorts of subjects.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1. The disease being studied is \"healthy,\" which indicates that the trial is focused on individuals without any specific disease. The ICDCodes associated with this disease are \"Z76.3\" and \"Z76.2.\" The drugs being tested in this trial are \"placebo\" and \"myk-461.\" \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" Inclusion criteria include having a normal body mass index (BMI), normal left ventricular ejection fraction (LVEF), normal electrocardiogram (ECG), and being a female who is not breastfeeding and is either permanently sterilized or postmenopausal. Exclusion criteria include having any structural abnormalities on echocardiography and testing positive for HIV or being seropositive for HCV or HBV.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1. The disease mentioned is \"stomach neoplasms\" and its corresponding ICDCodes are ['D13.1', 'C16.9', 'C16.1', 'C16.2', 'D37.1', 'C16.8', 'C16.5']. The drugs being tested in this trial are 'ramucirumab', 'capecitabine', 'cisplatin', 's-1', and 'oxaliplatin'. The eligibility criteria for participants are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". These criteria include factors such as confirmed diagnosis, prior treatment history, organ function, performance status, and various medical conditions.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is Alzheimer's disease. The ICDCodes associated with this disease are G30.8, G30.9, G30.0, and G30.1. The drugs being tested in this phase are \"jnj-54861911, 10 mg\", \"jnj-54861911, 50 mg\", and \"placebo\". \n\nThe eligibility criteria for participants in this trial are as follows:\n\nInclusion Criteria:\n- Participants must have had sufficient education or work experience to exclude mental retardation based on Diagnostic and Statistical Manual of Mental Disorders 4th edition, Text Revision (DSM-IV-TR). They must also be able to read and write and have adequate hearing and visual acuity to complete the required psychometric tests.\n- Participants must have a Clinical Dementia Rating Scale- Japanese version (CDR-J) score of '0', indicating that they are rated as normal.\n- Participants must have evidence of amyloid deposition as demonstrated by low Cerebrospinal Fluid (CSF) Amyloid (A)-beta 1-42 levels at Screening.\n- Participants must have a body mass index between 18 and 35 kilogram per square meter, inclusive, at Screening.\n- Participants must be otherwise healthy for their age group or medically stable with or without medication, based on physical examination, medical history, vital signs, and 12-lead electrocardiogram (ECG) performed at Screening or at Baseline.\n\nExclusion Criteria:\n- Participants must not have evidence of any brain disease other than potential very early signs of Alzheimer's disease (AD) or typical age-related changes, or any other abnormality that could explain a possible cognitive deficit.\n- Participants must not have been diagnosed with dementia due to AD, due to other diseases, or with AD and contribution of other disorders (mixed dementia).\n- Participants must not have evidence of familial autosomal dominant AD.\n- Participants must not have any contra-indications for Magnetic Resonance Imaging (MRI), such as prostheses, implants, claustrophobia, pacemakers, and others.\n- Participants must not have a clinically significant abnormal physical or neurological examination, vital signs, or 12-lead ECG at Screening or Baseline, which, in the opinion of the investigator, is not appropriate and reasonable for the population under study.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease being studied is \"prostatic neoplasms.\" The ICDCodes associated with this disease are \"B38.81,\" \"N42.31,\" \"Z87.430,\" \"N40.0,\" and \"N40.1.\" The drug being tested is \"bay 1841788(odm-201).\" The eligibility criteria for this trial include being a Japanese male aged 20 years or older, having histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features, having metastatic castration-resistant prostate cancer, having an Eastern Cooperative Oncology Group performance status of 0-1, having a life expectancy of at least 3 months, meeting certain blood count requirements, and meeting certain screening values for liver and kidney function. The sample also includes exclusion criteria such as having known brain metastases, requiring medical intervention for symptomatic local-regional disease, having unresolved acute toxicities from prior treatments, and having a history of other malignancies within the previous 5 years, among others.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is \"long qt syndrome.\" The ICDCodes associated with this disease are \"I45.81.\" The drugs being used in the trial are \"gs-6615,\" \"placebo to match gs-6615,\" \"placebo to match dofetilide,\" and \"dofetilide.\" \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" Inclusion criteria include being in good health based on medical history and physical examination, having a BMI between 18 and 30 kg/m^2, and having a normal or clinically insignificant abnormality in the 12-lead electrocardiogram (ECG). \n\nExclusion criteria include a history of certain medical conditions such as meningitis, epilepsy, seizures, migraines, and head injuries, as well as the presence of serious or active medical or psychiatric illnesses that could interfere with treatment or compliance with the protocol. Additional exclusion criteria are related to cardiovascular health, including specific findings on the screening ECG, history of cardiovascular disease, and symptoms such as syncope, palpitations, or unexplained dizziness.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is categorized into different phases, such as phase I, phase II, or phase III. The specific sample is from a phase 1 trial. \n\nThe trial focuses on the treatment of Crohn's Disease, a type of inflammatory bowel disease. The diseases column lists \"Crohn disease\" as the specific disease being studied. The icdcodes column contains a list of ICD-10 codes associated with Crohn's Disease. In this case, the codes are \"K50.90\", \"K50.913\", \"K50.914\", \"K50.911\", \"K50.912\", \"K50.918\", and \"K50.919\".\n\nThe drugs column lists the drugs being used in the trial, which are \"ged-0301\" and \"placebo\". \n\nThe criteria column provides the eligibility criteria for participants in the trial. It includes various conditions that potential participants must meet, such as being at least 18 years old, having a diagnosis of Crohn's Disease for at least 3 months, having specific disease activity scores, and having failed or experienced intolerance to certain medications.\n\nThe exclusion criteria are also listed, which outline conditions or factors that would prevent someone from participating in the trial. These include having certain types of colitis, recent surgeries, positive stool tests for pathogens, history of certain cancers, recent use of specific medications, and various medical conditions that could interfere with the study.\n\nOverall, this sample provides a detailed description of the trial, including the phase, specific disease being studied, drugs used, and eligibility criteria for participants.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is \"early phase 1\" and the disease being studied is \"pain\". The ICDCodes associated with this disease are \"N50.82\", \"R07.2\", \"R07.82\", \"R10.13\", \"R10.33\", \"R14.1\", and \"R52\". The drugs being used in the trial are \"exparel\", \"ropivacaine cocktail (pic)\", and \"bupivacaine\". The eligibility criteria for this trial include age (\u2265 40 years old) and being scheduled for primary total knee arthroplasty. There are also exclusion criteria listed, such as being opiate tolerant, having certain neuromuscular deficits, allergies or intolerance to specific drugs, hepatic or renal disease, and other factors that may affect the patient's ability to participate or comply with the trial requirements.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1. The disease mentioned is \"cardiovascular disease,\" and the corresponding ICDCodes are ['A52.00', 'A52.09', 'A50.54', 'Z01.810', 'Q87.418', 'Z13.6', 'R94.30']. The drugs being studied are \"aspirin\" and \"durlaza\u2122\". The eligibility criteria for this trial include specific inclusion and exclusion criteria. Inclusion criteria involve being a male or non-lactating, non-pregnant female with a history of Type 2 Diabetes and at least one of the following: Coronary Artery Disease, Peripheral Vascular Disease, or Ischemic Stroke, along with at least 2 cardiovascular disease risk factors. Exclusion criteria include sensitivity to aspirin or any NSAID, evidence of uncontrolled or unstable cardio- or cerebrovascular disorder, presence of uncontrolled or chronic medical illness, GI disorder or surgery leading to impaired drug absorption, clinically significant abnormal baseline ECG, history of hepatitis, malignancy within the past five years, or HIV, and history of alcohol or drug abuse.",
    "The sample is a phase 1 trial for the treatment of leukemia, myeloid and myelodysplastic syndromes. The trial focuses on the drug lenalidomide. The eligibility criteria for participants include being at least 18 years old, having undergone an allogeneic transplant, and having high-risk AML or MDS. Additional criteria include having a documented complete remission, a certain performance status, specific blood counts, and normal liver and kidney function. Participants must also be registered in the Revlimid REMS\u00ae program and comply with its requirements. Females of child-bearing potential must adhere to pregnancy testing requirements. Exclusion criteria include certain types of AML or MDS, inability to give informed consent, active infections, hypersensitivity to lenalidomide, acute GVHD, inability to swallow the lenalidomide capsule, and pregnancy or nursing for female participants.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is multiple myeloma, and the corresponding ICDCodes are C90.01, C90.02, and C90.00. The drug being used in the trial is vlx1570 and dexamethasone. \n\nThe eligibility criteria for this trial include:\n1. Diagnosis of relapsed or relapsed and refractory multiple myeloma following at least 2 prior therapies, including an immunomodulatory drug and a proteasome inhibitor.\n2. Measurable disease as defined by specific criteria related to serum and urine protein levels.\n3. Adequate kidney function.\n4. Age of 18 years or older.\n5. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.\n6. Females of child-bearing potential must have a negative pregnancy test, and both males and females of child-bearing potential must be willing to use effective contraception during chemotherapy treatment and for at least 6 months afterward.\n7. Adequate blood counts and liver function.\n8. Patient must have or be willing to have a central venous catheter for drug administration.\n\nThe exclusion criteria for this trial include:\n1. Any concurrent treatment that would compromise the study, ongoing corticosteroid use exceeding a certain dose, or persisting effects of previous or ongoing treatment that may interfere with study treatment or assessment of adverse events.\n2. Any cytotoxic or biologic therapy within 2 weeks prior to starting therapy.\n3. Pregnant or breastfeeding females.\n4. Uncontrolled hypertension or diabetes.\n5. Known active hepatitis B or C infection or HIV infection.\n6. Significant cardiovascular disease or history of certain cardiac conditions.\n7. QTc interval exceeding certain thresholds or history of risk factors for torsade de points.\n8. Use of concomitant medications that prolong the QT/QTc interval.\n9. Uncontrolled intercurrent illness or psychiatric illness/social situations that may compromise compliance or put the patient at risk.\n10. Active infection requiring systemic treatment within one week prior to the first dose.\n11. Major surgery within 1 month prior to enrollment.\n12. Use of any investigational agent within the last 28 days.\n13. History of other malignancy, except for certain exceptions.\n14. Known intolerance to steroids or H1/H2-antagonists.\n15. Serum calcium level above the upper limit of normal range.\n16. Diagnosed with plasma cell leukemia, POEMS syndrome, or amyloidosis.\n17. History of central nervous system (CNS) myeloma or other CNS malignancy.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is idiopathic Parkinson's disease. The ICDCodes associated with this disease are E20.0, I95.0, L50.1, D61.3, G24.2, G24.4, and G60.3. The drugs being tested in this trial are pf-06649751, trimethobenzamide hydrochloride, and a placebo. The eligibility criteria for this trial include being L-DOPA-responsive, being in Hoehn & Yahr Stage II-III, experiencing motor fluctuations, having a stable daily dose of L-DOPA of at least 300 mg, and being a non-childbearing potential female or a male subject. The exclusion criteria include a history of troublesome dyskinesias and a history of surgical intervention for Parkinson's disease.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1 and focuses on the disease \"hypercholesterolemia\". The corresponding ICD-10 codes for this disease are \"E78.01\", \"E78.00\", and \"Z83.42\". The trial involves the use of drugs such as \"cat-2054\", \"placebo\", \"cat-2054-c\", and \"atorvastatin\". The eligibility criteria for participants include providing written informed consent, being in good health, and meeting specific requirements based on gender and reproductive status. Other criteria include specific LDL-C levels, body mass index (BMI), and body weight. The exclusion criteria include recent use of drugs or supplements, presence of significant diseases or abnormalities, and recent participation in other studies or use of investigational drugs.",
    "The sample is a record from a table that contains information about clinical trials. The phase of the trial is a combination of phase 1 and phase 2. The disease being studied is seasonal allergic rhinitis. The corresponding ICD-10 code for this disease is J30.2. The drugs being tested in the trial are nasapaque nasal solution and placebo saline nasal solution. The eligibility criteria for participants include being 18 years of age or older, having a history of allergic rhinitis, and having a positive response to the Allergen BioCube. The exclusion criteria include not having a significant illness such as moderate to severe allergic asthmatic reactions, not having compromised lung function, not using any disallowed medications, and not having participated in an investigational study in the last 30 days.",
    "The sample from the table represents a clinical trial for the treatment of metastatic melanoma. The trial is a combination of phase 1 and phase 2. The disease being studied is metastatic melanoma, and the corresponding ICD-10 codes for the disease are ['C43.0', 'C43.31', 'D03.9', 'C43.51', 'C43.9', 'D03.0', 'C43.4']. The drugs being used in the trial are cyclophosphamide, fludarabine, interleukin-2, and peginterferon alfa-2b. \n\nThe eligibility criteria for participants in the trial include having histologically confirmed unresectable stage III or stage IV metastatic melanoma with available metastasis for surgical resection and residual measurable disease after resection. Other criteria include having an ECOG performance status of 0-1, a life expectancy of at least 3 months, no significant toxicity from prior treatments, and adequate renal, hepatic, and hematologic function. Women of childbearing potential and men in a sexual relationship with a woman of childbearing potential must be using effective contraception during treatment and for at least 6 months after completion of treatment. Participants must also be able to comprehend the information given and willing to sign informed consent.\n\nThe exclusion criteria for the trial include having other malignancies, unless followed for at least 5 years with no sign of disease, except for squamous cell carcinoma or adequately treated carcinoma in situ colli uteri. Patients with cerebral metastasis are excluded, unless the metastases have been surgically removed or treated with stereotactic radiosurgery and have been stable for at least 28 days after treatment. Patients with ocular melanoma, severe allergies or a history of anaphylaxis, serious medical or psychiatric comorbidity, creatinine clearance less than 70 ml/min, acute or chronic infection with HIV, hepatitis, tuberculosis, severe and active autoimmune disease, pregnancy or nursing, need for immunosuppressive treatment, concomitant treatment with other experimental drugs, uncontrolled hypercalcemia, or less than four weeks since prior systemic antineoplastic treatment are also excluded from the trial.",
    "The sample from the table is for a clinical trial with a phase 1/phase 2 combination. The trial is focused on breast cancer, specifically HER-2 negative breast cancer that is either stage III disease not amenable to curative therapy or stage IV. The trial includes patients with measurable disease of at least 2 cm by conventional measurement or at least 1 cm on spiral CT. Prior chemotherapy for metastatic disease is allowed, with no limitations on the number of prior chemotherapies. Prior taxanes (except Nab-Paclitaxel) are allowed if it has been at least 6 months since the last taxane treatment. Patients should have received at least one line of chemotherapy in either the advanced or adjuvant setting and hormonal therapy if appropriate. The trial also requires patients to have an ECOG Performance status of at least 2 and be able to swallow and retain oral medicines. Various laboratory values need to be within specified ranges, including absolute neutrophil count, platelets, hemoglobin, bilirubin, AST/ALT, serum creatinine, INR, fasting plasma glucose, HBA1c, and potassium, calcium, and magnesium levels. Bisphosphonates and denosumab for bony metastatic disease are allowed, and radiation to bony metastases is allowed at least 14 days before starting study treatment. Patients with previously treated brain metastases who are free of CNS symptoms and more than 3 months from treatment are eligible. Women of childbearing potential and their partners must use contraception prior to study entry and for 90 days after treatment. Exclusion criteria include other medical or psychiatric disorders placing the subject at undue risk for treatment complications, pregnancy or nursing, previous treatment with Nab-Paclitaxel (except in the adjuvant or neoadjuvant setting), inflammatory breast cancer, known hypersensitivity to Nab-Paclitaxel or BYL719, concurrent malignancy or malignancy within 3 years (except for certain types), diabetes mellitus or steroid-induced diabetes mellitus, impaired gastrointestinal function or disease altering the absorption of study drugs, classification into Child-Pugh class C, known history of HIV infection, active and uncontrolled infection, symptomatic/untreated CNS disease, Grade 2 or higher peripheral neuropathy, active or history of cardiac disease, QTcF > 480 msec on the screening ECG, recent major surgery or not recovered from major side effects, recent use of systemic corticosteroids or not fully recovered from side effects, use of drugs known to be inhibitors or inducers of CYP3A, use of warfarin or other coumarin-derived anticoagulant, previous treatment with a PI3K inhibitor (with exceptions), and participation in a clinical trial within 30 days prior to enrollment.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2 and is focused on the disease \"atopic dermatitis\". The corresponding ICD-10 codes for this disease are \"L20.89\" and \"L20.9\". The drug being tested is \"am1030-cream or placebo\". The eligibility criteria for participants include being between 18 and 65 years old, having a body mass index between 18.0 and 35.0 kg/m2, having atopic dermatitis with mild to severe disease activity, and having AD lesions on the trunk and/or limbs that can be treated topically. The exclusion criteria include having scars, moles, tattoos, sunburn, or other blemishes in the test areas, recent systemic or topical treatment with certain medications, and recent treatment with antihistamines or SSRIs. Participants who have received phototherapy within the past 4 weeks are also excluded.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease being studied is B-cell chronic lymphocytic leukemia. The ICDCodes associated with this disease are C91.11, C91.12, and C91.10. The drugs being used in the trial are ibrutinib, erythromycin, and voriconazole. The eligibility criteria for participants include having confirmed chronic lymphocytic leukemia/small lymphocytic lymphoma, marginal zone lymphoma, mantle cell lymphoma, follicular lymphoma, or Waldenstrom's macroglobulinemia. Participants must also have relapsed or refractory disease after at least one prior line of systemic therapy. Other criteria include a performance status score of 0 or 1, specific hematology and biochemical values within certain limits, and not meeting certain exclusion criteria such as recent major surgery or a history of stroke.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease mentioned is \"non-small cell lung cancer,\" and the corresponding ICDCodes are provided as well. The drugs being tested in this trial are \"carboplatin,\" \"nab-paclitaxel,\" \"mk-3475 (phase i),\" and \"mk-3475 (phase ii).\" The eligibility criteria for this trial include various factors such as age, stage of cancer, performance status, measurable disease, availability of archival tissue, and willingness to undergo certain tests. There are also exclusion criteria listed, which include factors such as the presence of symptomatic CNS metastases, history of certain treatments, and certain medical conditions. Additionally, there are criteria related to pregnancy and contraception for female participants.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is chemotherapy-induced nausea and vomiting. The ICDCodes associated with this disease are 'D61.810'. The drug being tested is rolapitant. \n\nThe sample also includes the eligibility criteria for participants in this trial. The main inclusion criteria include being a healthy male or female aged 18 to 55 years, having a negative pregnancy test, using a non-hormonal method of birth control, having a specific body mass index (BMI) and weight, providing informed consent, and being in general good health. \n\nOn the other hand, the main exclusion criteria state that participants should not have been dosed with the test drug or blinded study drug in another investigational study within a certain timeframe, should not have a history of hypersensitivity to rolapitant IV or any of its excipients, should not have poor venous access or consider venipuncture intolerable, should not have a history of complications or anxiety associated with IV administration of medications, and should not be pregnant or lactating.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1 and focuses on the disease muscular dystrophy, specifically Duchenne muscular dystrophy. The trial uses the ICD-10 code \"G71.01\" to identify the disease. The drugs being tested in the trial are \"smt c1100\". The sample also includes the eligibility criteria for participants in the trial. Inclusion criteria include being a male with a genetic diagnosis of DMD, aged between 5 and 13 years, having a parent or legal guardian provide consent, and being willing to adhere to a balanced diet. Exclusion criteria include recent participation in another clinical trial, known hypersensitivity to the study drug, unwillingness to adhere to a balanced diet, and various medical conditions or factors that may increase the risk of participating in the study.",
    "The sample provided is a record from a table that contains information about clinical trials. The table has several columns, including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of diseases being studied, \"icdcodes\" which contains the corresponding ICD-10 codes for the diseases, \"drugs\" which lists the names of drugs being used in the trial, and \"criteria\" which provides the eligibility criteria for the trial.\n\nIn this specific sample, the phase of the trial is phase 1. The disease being studied is breast cancer. The corresponding ICD-10 codes for breast cancer are listed as ['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']. The drugs being used in the trial are fulvestrant and mln9708. The eligibility criteria for the trial are then provided, including criteria for inclusion and exclusion.\n\nThe inclusion criteria state that the trial is for female post-menopausal patients aged 18 or older who have either histologic documentation of metastatic or locally advanced breast cancer or a history of breast cancer with radiologic evidence of bone-only metastatic disease. Other criteria include being HER2-negative, having received previous treatment with fulvestrant, and meeting certain clinical laboratory data requirements.\n\nThe exclusion criteria list various factors that would disqualify a patient from participating in the trial, such as not having fully recovered from prior chemotherapy or endocrine therapy, recent major surgery or radiotherapy, central nervous system involvement, ongoing infections, uncontrolled cardiovascular conditions, and other serious medical or psychiatric illnesses.\n\nOverall, this sample provides a detailed description of the phase 1 trial for breast cancer, including the diseases being studied, the drugs being used, and the eligibility criteria for participation.",
    "The sample from the table is for a clinical trial with a phase 1/phase 2 trial phase. The trial focuses on melanoma, a type of skin cancer. The trial includes participants with stage IIA through IV melanoma, including those with cutaneous, uveal, mucosal, or unknown primary melanoma. The participants must be eligible for treatment with the drug ipilimumab based on clinician judgment within the standard of care.\n\nThe trial has three cohorts: advanced patients with unresectable stage III or IV melanoma, neoadjuvant therapy for primary melanoma with lymph node involvement or recurrence amenable to complete resection, and adjuvant therapy for resected stage IIA to IV melanoma.\n\nParticipants must have radiologically evident disease, confirmed by chest, abdominal, and pelvic CT scans, and a head CT scan or MRI PET/CT fusion scan. Biopsies of melanoma lesions are required before treatment and on day 22.\n\nParticipants with brain metastases are eligible if they have been treated and there has been no growth of the metastases. The most recent surgical resections or gamma-knife therapy for malignant melanoma must have been completed at least 1 week prior to registration.\n\nOther eligibility criteria include an ECOG performance status of 0 or 1, ability and willingness to give informed consent, adequate lab function tests, age 18 years or older, and at least two intact axillary and/or inguinal lymph node basins.\n\nExclusion criteria include recent use of certain medications or treatments, HIV positivity or active Hepatitis C virus, recent nitrosoureas therapy, current or recent use of checkpoint molecule blockade therapy, known allergies to the vaccine components, previous vaccination with the synthetic peptides included in the protocol, pregnancy or breastfeeding, medical contraindications or potential problems in complying with the protocol, Class III or IV heart disease, uncontrolled diabetes, prior autoimmune disorders requiring cytotoxic or immunosuppressive therapy, and other cancer diagnoses except for specific allowed cases.\n\nParticipants with addiction to alcohol or drugs or recent illicit IV drug use, body weight less than 110 pounds, and participants with certain medical conditions or treatments are also excluded from the trial.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is congestive heart failure. The ICDCodes associated with this disease are I50.20, I50.21, I50.22, I50.30, I50.31, I50.32, and I50.40. The drugs being used in the trial are mtp-131 and placebo. The eligibility criteria for participants in this trial include having chronic ischemic or non-ischemic cardiomyopathy, a left ventricular ejection fraction (LVEF) of 35% or less, a diagnosis of NYHA Class II or III heart failure, stable heart failure with no hospitalization in the previous 3 months, and treatment with appropriate pharmacologic therapy for heart failure. There are also exclusion criteria listed, such as certain dimensions of the left ventricle, recent cardiac procedures or surgeries, uncontrolled hypertension, and other medical conditions.",
    "The sample provided is a schema definition of a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. The table has several columns, including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of the diseases being studied, \"icdcodes\" which contains the corresponding ICD-10 codes for the diseases, \"drugs\" which lists the names of the drugs being used in the trial, and \"criteria\" which provides the eligibility criteria for the trial.\n\nThe sample data in the table includes information for a specific trial. The phase of the trial is \"phase 1\". The diseases being studied are \"advanced solid tumours\" and \"breast cancer\". The corresponding ICD-10 codes for the diseases are [\"C79.81\", \"D24.1\", \"D24.2\", \"D24.9\", \"D49.3\", \"C44.501\", \"D48.60\"]. The drug being used in the trial is \"palbociclib + taselisib / pictilisib\". The eligibility criteria for the trial are provided in a detailed format, including information about the types of patients that can participate, prior cancer treatments, disease assessment requirements, laboratory test values, and exclusion criteria.\n\nOverall, the sample provides a comprehensive description of a specific clinical trial, including the phase, diseases being studied, drugs being used, and the eligibility criteria for participation.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is \"early phase 1\", the disease is \"lymphoma\", the ICDCodes are \"S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S\", the drugs are \"pegfilgrastim\" and \"loratadine\", and the eligibility criteria are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". The inclusion criteria include having specific types of lymphoma, planned chemotherapy treatment, being at least 18 years old, having a certain performance status, and being able to provide informed consent. The exclusion criteria include having chronic bone pain, low creatinine clearance, allergies to certain medications, chronic daily usage of antihistamines, inability to swallow medications, and inability to complete the survey accurately.",
    "The sample from the table is for a clinical trial study. The phase of the trial is Phase 1/Phase 2. The disease being studied is non-small cell lung cancer. The corresponding ICD-10 codes for the disease are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The drugs being investigated are docetaxel and tak-117. \n\nThe eligibility criteria for participants in the trial include having a confirmed diagnosis of NSCLC, locally advanced or metastatic disease, failure of at least 1 prior chemotherapy regimen, adequate organ function, Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1, and meeting certain requirements for contraception for female participants. \n\nThere are also exclusion criteria, such as previous treatment with a PI3K or AKT inhibitor, recent cancer therapy or investigational therapy, poorly controlled diabetes mellitus, use of certain medications within a specific timeframe, and presence of certain medical conditions or illnesses. \n\nOverall, the sample provides information about the phase, disease, drugs, and eligibility criteria for participants in the clinical trial study.",
    "The sample provided is a schema definition of a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. The table has the following columns: phase, diseases, icdcodes, drugs, and criteria.\n\nIn the sample, the phase column has the value \"phase 1/phase 2\". The diseases column contains a list of disease names, including \"colon adenocarcinoma\", \"rectal adenocarcinoma\", \"recurrent colon carcinoma\", and others. The icdcodes column contains a list of ICDCodes corresponding to the diseases mentioned. The drugs column contains a list of drug names, including \"capecitabine\" and \"nintedanib\". The criteria column contains the eligibility criteria for the clinical trial.\n\nThe eligibility criteria include various conditions such as Eastern Cooperative Oncology Group (ECOG) performance status, hemoglobin levels, absolute neutrophil count, platelet count, creatinine levels, bilirubin levels, liver function, coagulation parameters, measurable disease, histological or cytological proof of adenocarcinoma, prior treatment history, ability to swallow oral medication, contraceptive methods for participants of child-bearing potential, and informed consent.\n\nThe exclusion criteria include prior treatment with nintedanib or regorafenib, recent major injuries or surgery, uncontrolled hypertension, abnormal urine protein/creatinine ratio, history of hemorrhagic or thrombotic events, unstable angina or cardiac arrhythmia, history of cerebrovascular or myocardial ischemia, known inherited predisposition to bleeding or thrombosis, active or chronic hepatitis B or C or HIV, untreated brain metastases, recent second primary malignancy, pregnancy or nursing, inability to follow protocol requirements, unsuitability for study drug, recent use of investigational agents, and specific history of intolerance to capecitabine based on the phase of the trial.\n\nOverall, the sample provides detailed information about the clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria for participants.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1 and focuses on the treatment of soft tissue sarcoma and bone tumors. The diseases are represented by their names and corresponding ICD-10 codes. The drugs being studied are trabectedin and olaparib. \n\nThe eligibility criteria for the trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include requirements such as written informed consent, documented histologically sarcomas that are not surgically resectable or metastatic, measurable disease, specific performance status, estimated life expectancy, age, and adequate organ function. \n\nExclusion criteria include factors such as involvement in the planning or conduct of the study, previous enrollment in the study, participation in another clinical study with an investigational product in the last month, persistent toxicities caused by previous anticancer therapies, dementia or altered mental status, severe or uncontrolled medical conditions, HIV infection, active infections, viral hepatitis, symptomatic metastatic brain or meningeal tumors, seizure disorders requiring medication, pregnancy or breastfeeding, bleeding diathesis, renal dialysis, inability to swallow oral medications, uncontrolled diabetes, chronic systemic treatment with corticosteroids or immunosuppressive agents, history of another malignancy within 5 years, recent anticancer chemotherapy or immunotherapy, recent radiotherapy, recent major surgery, prior exposure to the study drugs or their analogues, known hypersensitivity to the study drugs, substance abuse or medical/psychological/social conditions that may interfere with participation, history of noncompliance or inability/unwillingness to return for scheduled visits, corrected QT interval on ECG exceeding a certain threshold, use of strong CYP3A4 inhibitors/inducers, and presence of myelodysplastic syndrome or acute myeloid leukemia.",
    "The sample is from a table that contains information about clinical trials. In this particular sample, the phase of the trial is Phase 1. The disease being studied is chronic hepatitis B. The ICD-10 codes associated with this disease are B18.0, B18.1, B18.2, B18.8, and B18.9. The drugs being tested in this trial are nvr 3-778, placebo for nvr 3-778, and pegasys. The eligibility criteria for patients participating in this trial include being male or female between 18 and 65 years of age, having a BMI of 18-35kg/m2, being HBeAg positive, and having chronic hepatitis B with no history of clinical decompensation.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are non-small cell lung cancer, breast cancer (HER2 positive or triple negative), and pancreatic cancer (adenocarcinoma). The corresponding ICDCodes for these diseases are also provided.\n\nThe drugs being investigated in this trial are ibrutinib and durvalumab. The eligibility criteria for participants in this trial include:\n\n1. Pathological confirmation of the specified types of cancer.\n2. Relapsed or refractory disease (Stage III or IV) with a certain number of prior treatments.\n3. Presence of measurable lesions according to RECIST 1.1 criteria.\n4. Adequate hematologic function, including specific thresholds for ANC, platelet count, and HGB.\n5. Adequate hepatic and renal function, with specific limits for AST, ALT, bilirubin, creatinine, and creatinine clearance.\n6. PT/INR and PTT/aPTT values within certain limits.\n\nThe exclusion criteria for this trial include:\n\n1. Mixed small cell and non-small cell lung cancer histology.\n2. History of central nervous system (CNS) involvement, except for specific cases where CNS metastases have been adequately treated and are stable.\n3. Recent anti-tumor therapy within 21 days prior to the start of the trial.\n4. Prior treatment with ibrutinib or other BTK inhibitor anti-CD137 or CTLA-4 antibody, with exceptions for certain anti-PD1, anti-PD-L1, or anti-PD-L2 antibodies.\n5. History of allogeneic organ transplant.\n6. Treatment with a strong cytochrome P450 (CYP) 3A inhibitor.\n\nThis sample provides a snapshot of the information stored in the table, including the phase, diseases, ICDCodes, drugs, and eligibility criteria for a specific clinical trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is hypoglycemia. The ICDCodes associated with this disease are E16.1, E16.2, P70.3, P70.4, E16.0, E10.641, and E10.649. The drugs being tested in this trial are biod-961, lilly glucagon, and novo glucagon. The eligibility criteria for participants in this trial include having a Body Mass Index (BMI) between 18.5 and 25.0 kg/m2, providing informed consent, and not having type 1 or type 2 diabetes mellitus. There are also additional exclusion criteria, such as a history of certain diseases, regular alcohol consumption, significant cardiovascular or other medical conditions, and being pregnant or intending to become pregnant during the study.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this specific sample, the phase of the trial is Phase 1. The disease being studied is asthma, and the corresponding ICDCodes associated with asthma are ['J45.998', 'J82.83', 'J45.909', 'J45.991', 'J45.20', 'J45.30', 'J45.40']. The drugs being tested in this trial are 'fluticasone/formoterol bai', 'formoterol', 'fluticasone/formoterol pmdi without spacer', 'fluticasone/formoterol pmdi with spacer', and 'fluticasone/formoterol pmdi without spacer low dose'.\n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include being male or female aged 18 years or older, being healthy with no significant abnormal findings in medical history, physical examination, vital signs, laboratory tests, and ECG. Additionally, normal lung function (FEV1 >90% of predicted normal value) and satisfactory technique in using the study drug devices are required. The exclusion criteria include subjects who use any asthma medication or are regularly exposed to asthma medication, a history of drug or alcohol abuse, conditions that may interfere with drug absorption, distribution, metabolism, or excretion, a history of asthma, COPD, or other bronchial or lung diseases, and the use of steroid medication within 8 weeks prior to study screening.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is focused on the treatment of metastatic renal cell carcinoma, a type of kidney cancer. The phase of the trial is Phase 1. The diseases column lists the disease names, with only one disease mentioned in this sample. The icdcodes column contains a list of ICD-10 codes associated with the diseases, with multiple codes provided in this sample. The drugs column lists the names of drugs being used in the trial, with three drugs mentioned in this sample (pazopanib, sorafenib, and radium-223). The criteria column provides the eligibility criteria for participants in the trial, including age requirements, specific diagnosis requirements, performance status, organ and bone marrow function, recovery from prior treatments, understanding and compliance with the protocol, and contraceptive use. The exclusion criteria are also listed, which include restrictions on prior therapies, radiation therapy, brain metastases, spinal cord compression, and various medical conditions.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 1. The diseases being studied are \"polycythemia vera\" and \"essential thrombocythemia\". The corresponding ICDCodes for these diseases are \"D45\" and \"D47.3\" respectively. The drugs being used in the trial are \"rg7388\" and \"pegasys\". \n\nThe eligibility criteria for this trial include:\n- Patients must be JAK2V617F-positive for either polycythemia vera or essential thrombocythemia, as confirmed by WHO diagnostic criteria.\n- Patients must have high-risk essential thrombocythemia/polycythemia vera (age >60 or history of thrombosis) or low-risk disease with symptoms (recurrent headaches, paresthesias, pruritus).\n- Patients must have been previously treated with at least one other agent (hydroxyurea, interferon, anagrelide) and determined to be intolerant or resistant.\n- Patients must be at least 18 years of age.\n- Patients must have an Eastern Cooperative Oncology Group (ECOG) Performance status of 0-2.\n- Patients must have acceptable pre-study organ function, including total bilirubin, AST, ALT, and serum creatinine levels within specified limits.\n- Women of childbearing potential and males must agree to use adequate contraception during the study.\n- Patients must have the ability to understand and sign a written informed consent document.\n\nThe exclusion criteria for this trial include:\n- Patients who meet the criteria for post essential thrombocythemia/polycythemia vera myelofibrosis as defined by the International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT).\n- Patients with blast phase disease (more than 20% blasts in the marrow or peripheral blood).\n- Patients who have had acute thrombosis within 3 months of screening.\n- Patients with uncontrolled intercurrent illnesses such as hepatitis, HIV, ongoing or active infection, congestive heart failure, unstable angina pectoris, ventricular arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is \"early phase 1\" and the disease being studied is \"ovarian cancer\". The ICDCodes associated with this disease are \"C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2\". The drugs being tested in this trial are \"fermented wheat germ extract (fwge)\" and \"placebo\". The eligibility criteria for participants in this trial include being women with suspected epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, having an Eastern Cooperative Oncology Group (ECOG) Performance status of 0, 1, or 2, and having adequate bone marrow, renal, and hepatic function. Participants must also sign an informed consent and authorization form and women of childbearing potential must have a negative pregnancy test and practice effective birth control. The exclusion criteria include current use of FWGE, known allergies to wheat, rice, orange, or the sweetener Stevia, previous neoadjuvant chemotherapy for ovarian cancer, and various medical conditions that would impair participation in the trial.",
    "The sample provided is a record from a table that contains information about clinical trials. The table has several columns, including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of the diseases being studied, \"icdcodes\" which lists the corresponding ICD-10 codes for the diseases, \"drugs\" which lists the names of the drugs being tested, and \"criteria\" which provides the eligibility criteria for participants in the trial.\n\nIn this specific sample, the phase of the trial is phase 1, and the disease being studied is \"type 2 diabetes mellitus\". The corresponding ICD-10 codes for this disease are listed as \"['E11.65', 'E11.9', 'E11.21', 'E11.36', 'E11.41', 'E11.42', 'E11.44']\". The drugs being tested in this trial are \"sar425899\", \"placebo\", and \"metformin\". The eligibility criteria for participants are then provided, including specific criteria for healthy subjects and for patients with type 2 diabetes mellitus. The criteria include age ranges, body mass index (BMI) ranges, medical history, physical examination results, vital signs, electrocardiogram (ECG) parameters, laboratory parameters, and other factors. Exclusion criteria are also listed, which specify conditions or factors that would disqualify a participant from the trial.\n\nIt is important to note that the provided information is not exhaustive and may not include all considerations relevant to a patient's potential participation in a clinical trial.",
    "The sample from the table is for a clinical trial with a phase 1/phase 2 designation. The trial focuses on autism spectrum disorder (ASD) and includes the following information: \n\n- Diseases: The trial is specifically targeting individuals with a confirmed diagnosis of autism spectrum disorder.\n- ICD Codes: The ICD-10 code associated with the disease is \"Z16.12\".\n- Drugs: The trial involves the administration of three different drugs - \"8iu intranasal oxytocin\", \"24iu intranasal oxytocin\", and a placebo.\n- Criteria: The eligibility criteria for the trial are outlined in the sample. Inclusion criteria include being a male between the ages of 18 and 35, being in good general health, having no clinically significant abnormalities in physical examination, vital signs, and ECG, being able to communicate well and understand the study requirements, and providing written informed consent. Exclusion criteria include having certain nasal conditions, previous nasal disease or surgery, nasal congestion due to common colds, significant medical disorders, psychiatric co-morbidity requiring intervention, recent systemic illness or drug/alcohol abuse, abnormal laboratory values, low IQ, known allergies to study medication components, recent participation in other clinical trials, or any other reasons that make the subject unsuitable for enrollment.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase is \"early phase 1\" and the disease is \"depression\". The ICDCodes associated with the disease are ['F32.A', 'F53.0', 'P91.4', 'Z13.31', 'Z13.32']. The drugs being studied in this trial are \"ketamine\" and \"midazolam\". The eligibility criteria for inclusion in the trial include being at least 18 years old, having unipolar major depressive disorder (DSM-IV), and having a Hamilton Rating Scale for Depression (HRSD-24) score of at least 21. Patients must also have been referred for ETC (electroconvulsive therapy). For the randomized Phase 2, patients must have received at least five sessions of ETC in Phase 1, achieved a response criteria of at least a 60% decrease from baseline HRSD-24 score and a score of 16 or lower on two consecutive weekly ratings, have a nominated adult who can stay with them for 24 hours on out-patient treatment days, have a Mini-Mental State Examination (MMSE) score of at least 24, and be able to provide informed consent. The exclusion criteria include any condition that renders the patient medically unfit for ETC, active suicidal intention, dementia or intellectual disability, a history of bipolar affective disorder, current history of post-traumatic stress disorder, other Axis I diagnosis (DSM-IV), ETC in the six months prior to recruitment, alcohol dependence or substance misuse in the six months prior to recruitment, pregnancy or breastfeeding, residing in a nursing home, being a prisoner, diagnosis of terminal illness, and inability or refusal to provide valid informed consent.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The phase of the trial is Phase 1.\n- Diseases: The trial is focused on treating breast cancer, ovarian cancer, and advanced cancer.\n- ICD Codes: The ICD-10 codes associated with the diseases are provided.\n- Drugs: The drugs being used in the trial are carboplatin and olaparib.\n- Criteria: The eligibility criteria for participants in the trial are listed, including requirements such as having a histological or cytological proof of advanced cancer, being at least 18 years old, having a WHO performance status of 0, 1, or 2, and meeting certain safety laboratory values.\n\nThe record also includes exclusion criteria, which specify conditions that would disqualify a participant from the trial. These include recent treatment with investigational drugs, positive pregnancy test or breastfeeding for women, unreliable contraceptive methods, recent radiotherapy, and various medical conditions that could interfere with the study procedures or jeopardize safe treatment.\n\nOverall, this record provides information about the phase, diseases, drugs, and eligibility criteria for a clinical trial focused on treating breast cancer, ovarian cancer, and advanced cancer using carboplatin and olaparib.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease mentioned is \"her2 positive metastatic breast cancer.\" The ICDCodes associated with this disease are \"C79.81,\" \"D24.1,\" \"D24.2,\" \"D24.9,\" \"D49.3,\" \"C44.501,\" and \"D48.60.\" The drugs being studied in this trial are \"pyrotinib,\" \"lapatinib,\" and \"capecitabine.\"\n\nThe eligibility criteria for this trial include being aged between 18 and 70 years, having an ECOG performance status of 0 to 1, having a life expectancy of more than 12 weeks, having at least one measurable lesion according to RECIST 1.1, having histologically or cytologically confirmed HER2 positive advanced breast cancer that has failed prior therapies, and meeting certain laboratory value requirements.\n\nThe laboratory value requirements include ANC (Absolute Neutrophil Count) of at least 1.5 x 10^9/L, platelet count of at least 100 x 10^9/L, hemoglobin level of at least 9.0 g/dL, total bilirubin level less than or equal to 1.5 times the upper limit of normal (ULN), ALT (Alanine Aminotransferase) and AST (Aspartate Aminotransferase) levels less than or equal to 1.5 times the ULN, BUN (Blood Urea Nitrogen) and creatine clearance rate of at least 50 mL/min, left ventricular ejection fraction (LVEF) of at least 50%, and QTcF (corrected QT interval) less than 470 ms for females and less than 450 ms for males.\n\nThe exclusion criteria for this trial include having received previous therapy with lapatinib, neratinib, pyrotinib, or any other HER2 directed tyrosine kinase inhibitor, and having received previous therapy with capecitabine within the last 3 months.\n\nOverall, this sample provides specific details about the phase, disease, ICDCodes, drugs, and eligibility criteria for a clinical trial related to her2 positive metastatic breast cancer.",
    "The sample from the table is a clinical trial for patients with advanced non-small-cell lung carcinoma. The trial is in phase 1/phase 2. The diseases column specifies the disease being studied, which is \"carcinoma, non-small-cell lung\". The icdcodes column contains the ICD-10 codes associated with the disease, which are \"['D02.20', 'D02.21', 'D02.22']\". The drugs column lists the drugs being used in the trial, which are \"mk-3475\" and \"gemcitabine\". The criteria column provides the eligibility criteria for the trial, including requirements such as histologically proven NSCLC, prior systemic therapies, Eastern Cooperative Oncology Group (ECOG) performance status, negative pregnancy test for women of childbearing potential, ability to give informed consent, anticipated survival of at least 3 months, normal organ and marrow function, availability of archived tumor tissue, measurable disease, and completion of prior therapy with investigational agents. The exclusion criteria include prior therapy with specific antibodies and gemcitabine, complications from radiation, active autoimmune disease, ongoing steroid use, active other malignancy, and certain medical or psychiatric conditions that may preclude safe participation in the trial.",
    "The sample from the table represents a clinical trial with a phase 1/phase 2 trial design. The trial focuses on the treatment of melanoma, a type of skin cancer. The trial includes patients with different stages of melanoma, including stage IIB, IIC, III, and IV, as well as high-risk stage IIA melanoma. The diagnosis of melanoma must be confirmed through cytological or histological examination.\n\nThe trial involves the use of drugs such as montanide isa-51, polyiclc, and cyclophosphamide. The eligibility criteria for participants include having accessible metastases of melanoma for biopsy, specific radiological studies to rule out disease, and certain laboratory parameters within normal ranges. Participants must also have an ECOG performance status of 0 or 1 and be willing to give informed consent.\n\nThere are also exclusion criteria, which include recent use of certain medications or treatments, current or recent use of specific therapies, known allergies to components of the vaccine, pregnancy or breastfeeding, certain medical conditions or contraindications, and prior autoimmune disorders requiring cytotoxic or immunosuppressive therapy.\n\nThe sample provides detailed inclusion and exclusion criteria, as well as specific requirements for participants' medical history, laboratory parameters, and disease stage.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease mentioned is squamous cell carcinoma of the head and neck. The ICDCodes associated with this disease are C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, and C4A.8. The drug mentioned is lee011. \n\nThe eligibility criteria for this trial include:\n1. Recurrent and/or metastatic head and neck squamous cell carcinoma that cannot be treated with surgery, chemotherapy, or radiation.\n2. The tumors should be HPV negative.\n3. Previous treatment with anti-EGFR based therapy is allowed.\n4. The patient should have at least one measurable lesion as per RECIST 1.1 criteria.\n5. Progressive disease within 1 year after first-line platinum-based chemotherapy.\n6. The tumor should be easily accessible for a biopsy.\n7. The patient should have an ECOG performance status of 0-1 and be in stable medical condition.\n8. The expected survival of the patient should be at least 3 months.\n9. Paraffin-embedded tumor tissue should be available for immunohistochemistry.\n10. The patient should be over 18 years old and able to give written informed consent.\n11. Women of child-bearing age or sexually active female patients with reproductive potential should have a negative pregnancy test.\n12. The patient should be able to swallow ribociclib capsules/tablets.\n13. The patient should have adequate bone marrow and organ function.\n14. The patient should provide signed informed consent.\n \nThe exclusion criteria for this trial include:\n1. Non-squamous head and neck cancer.\n2. Nasopharynx cancer.\n3. Patients who have received any CDK4/6 inhibitor.\n4. Patients with known hypersensitivity to LEE011 (ribociclib) or combination drug.\n5. Patients concurrently using other anti-cancer therapy.\n6. Patients who have had major surgery within 14 days prior to starting the study drug or have not recovered from major side effects.\n7. Patients who have not had resolution of all acute toxic effects of prior anti-cancer therapy.\n8. Patients who have received radiotherapy or limited field radiation for palliation within a certain time frame.\n9. Patients with concurrent malignancy or malignancy within 3 years prior to starting the study drug.\n10. Patients with central nervous system (CNS) involvement, unless they meet specific criteria.\n11. Patients with impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of the study drugs.\n12. Patients with a known history of HIV infection.\n13. Patients with any other concurrent severe and/or uncontrolled medical condition.\n14. Patients with active cardiac disease or a history of cardiac dysfunction.\n15. Patients with certain cardiac parameters or conditions.\n16. Patients with a Child-Pugh score B or C.\n17. Patients currently receiving certain medications that are known strong inducers or inhibitors of CYP3A4/5 or have a known risk to prolong the QT interval or induce Torsades de Points.\n18. Patients currently receiving or have received systemic corticosteroids within a certain time frame.\n19. Patients currently receiving warfarin or other coumarin-derived anticoagulant.\n20. Patients who have participated in a prior investigational study within a certain time frame.\n21. Women of child-bearing potential who are not using highly effective methods of contraception.\n22. Sexually active males who are not using a condom during intercourse.\n23. Patients with a history of non-compliance to medical regimen or inability to grant consent.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 1. The diseases being studied are \"hormone-resistant prostate cancer,\" \"metastatic malignant neoplasm in the bone,\" and \"metastatic prostate carcinoma.\" The corresponding ICDCodes for these diseases are ['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5'], ['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2'], and ['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31'] respectively.\n\nThe drugs being used in this trial are 'fludeoxyglucose f-18' and 'fluorine f 18 sodium fluoride'. The eligibility criteria for participants in this trial include providing written informed consent, being diagnosed with mCRPC (metastatic castration-resistant prostate cancer) and painful bone metastases, and being able to remain still for the duration of the imaging procedure (approximately one hour). The exclusion criteria include having metallic implants.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 1 and is focused on studying the effects of certain drugs on a specific disease. In this case, the disease mentioned is \"healthy,\" which seems to indicate that the trial is targeting individuals who are in good health.\n\nThe table also includes additional details such as the ICD-10 codes associated with the diseases being studied, which in this case are \"Z76.3\" and \"Z76.2.\" The drugs being tested are \"nestorone\u00ae /testosterone gel\" and \"testosterone only gel.\"\n\nThe eligibility criteria for participants in this trial are listed, including requirements such as being a male volunteer in good health, aged between 18 and 50, having a BMI below 33, and not having a history of hormonal therapy use in the past six months. Other criteria include agreeing to use contraception, being able to comply with the study protocol, and not meeting any of the exclusion criteria.\n\nThe exclusion criteria are also provided, which outline conditions that would disqualify a participant from the trial. These include factors such as participating in another clinical trial involving an investigational drug within the last 30 days, having abnormal physical findings, elevated PSA levels, abnormal serum chemistry values, and various medical conditions or history that may affect the study or participant's health.\n\nOverall, this sample provides a snapshot of the phase 1 clinical trial, the specific disease being studied, the drugs being tested, and the eligibility and exclusion criteria for potential participants.",
    "The sample provided is for a phase 1 clinical trial. The disease being studied is plaque psoriasis, which is identified by the ICD-10 codes L40.0, L40.4, L40.8, L40.9, L40.1, and L40.50. The drugs being tested are dalazatide and a placebo. \n\nThe eligibility criteria for this trial include being an adult between the ages of 18-65, having active plaque psoriasis with at least 3% of the body surface area involved, having a sufficient number of psoriatic plaques of at least 2 cm X 2 cm with Target Lesion Investigator Global Assessment scores greater than 3 (excluding those on the face, scalp, groin, genitals, folds, palms, or soles), weighing between 50-100 kg, being non-childbearing or willing to use contraception, being evaluated for latent TB infection, being able to communicate and provide informed consent.\n\nExclusion criteria for this trial include having erythrodermic, predominantly guttate, exclusively palmar/plantar, or generalized pustular psoriasis, having drug-induced or aggravated psoriasis, using certain systemic medications or topical medications, undergoing UVA or UVB therapy within 4 weeks of baseline, having uncontrolled hypertension, uncontrolled diabetes, significant cardiovascular disease, asthma, reduced pulmonary capacity, or a history of seizure or other neurologic disorder, having pre-existing paresthesia or neuropathy, having abnormal neurological exam results, having clinically significant ECG abnormalities, having a history of cancer requiring systemic chemotherapy or radiation, having acute infection or clinically significant laboratory abnormalities, testing positive for hepatitis or HIV, having a history of treated or untreated TB, having a history of anaphylaxis, participating in another clinical trial within 90 days, having a history of alcohol abuse, testing positive for certain drugs, having inadequate venous access, testing positive for pregnancy or currently lactating (for female subjects), and being unable or unwilling to comply with study restrictions or follow-up appointments.\n\nOverall, this sample represents a phase 1 clinical trial for the treatment of plaque psoriasis with dalazatide and a placebo, with specific eligibility and exclusion criteria outlined.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1 and focuses on Parkinson's disease. The ICD-10 code for Parkinson's disease is \"G20\". The drug being studied is called \"irx4204\". The eligibility criteria for participants include being between 40-80 years old, having a clinical diagnosis of Parkinson's disease based on the UK Brain Bank Criteria, having a Hoehn and Yahr stage less than 3, and being on a stable dose of PD symptomatic therapy for at least 30 days prior to the screening visit. Participants must also be willing and able to provide informed consent. Female participants must either be post-menopausal for at least 2 years or surgically sterilized. If they are of childbearing potential, they must not be pregnant or breastfeeding at the screening and must be willing to use contraception. The exclusion criteria include having any form of parkinsonism other than idiopathic PD, experiencing motor fluctuations reflective of later stage PD, having evidence of dementia or significant cognitive dysfunction, having clinically significant abnormal laboratory values or unstable medical or psychiatric illness, having any disorder that may interfere with drug absorption, distribution, metabolism, or excretion, having evidence of clinically significant gastrointestinal, cardiovascular, hepatic, renal, hematological, neoplastic, endocrine, alternative neurological, immunodeficiency, pulmonary, or other disorder or disease, and being pregnant or breastfeeding.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 1 trial and the disease being studied is thrombosis. The ICD-10 codes associated with this disease are ['I81', 'K64.5', 'I51.3', 'I67.6', 'I74.11', 'I74.5', 'I74.8']. The drugs being tested in this trial are bms-986120, aspirin, and clopidogrel. The eligibility criteria for participants in this trial include being healthy with no significant medical history, having a body mass index (BMI) between 18 and 32 kg/m2, and being either a post-menopausal female or a male between the ages of 18 and 65. There are also exclusion criteria, such as evidence of organ dysfunction, conditions that could affect drug absorption, and other criteria defined by the protocol. For more information about participating in this clinical trial, individuals are directed to visit www.BMSStudyConnect.com.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The trial is a combination of phase 1 and phase 2.\n- Diseases: The trial is focused on muscular dystrophy, specifically Duchenne muscular dystrophy.\n- ICD Codes: The ICD-10 code associated with the disease is \"G71.01\".\n- Drugs: The trial involves the drugs \"edasalonexent\" and \"placebo\".\n- Criteria: The eligibility criteria for the trial are listed, including requirements for written consent, diagnosis of DMD, ability to walk independently, and adequate immunization. There are also exclusion criteria, such as recent use of corticosteroids or participation in other clinical trials. Additionally, there are specific criteria for patients who have already participated in a previous part of the trial.\n\nIt is mentioned that there are no entry criteria for Part C, and patients who complete Part B will automatically continue in Part C.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The diseases being studied are cancer, metastatic cancer, and solid tumors. The ICDCodes associated with these diseases are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drug being used in the trial is cripec\u00ae docetaxel. \n\nThe eligibility criteria for this trial are as follows:\n- The patient must be at least 18 years old.\n- The patient must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.\n- The patient must have an estimated life expectancy of at least 12 weeks.\n- The patient must be willing to give written informed consent and comply with the study requirements.\n\nFor Part 1 of the trial:\n- The patient must have a pathologically confirmed diagnosis of advanced, recurrent, and progressive solid tumors that are refractory to standard therapy or for which no standard therapy exists.\n- The patient must have measurable or evaluable disease according to RECIST 1.1.\n\nFor Part 2 of the trial:\n- The patient must have a pathologically confirmed diagnosis of advanced, recurrent, and progressive cancer with measurable disease according to RECIST 1.1 of a histological type that is refractory to standard therapy or for which no standard therapy exists.\n- Treatment with a taxane must be an appropriate treatment option.\n\nThere are also exclusion criteria listed, which include factors such as recent treatment with other investigational products, symptomatic brain metastases, unresolved toxicities from previous anticancer therapy, inadequate bone marrow function, abnormal liver function, and various medical conditions that may interfere with the treatment or place the patient at high risk for complications.\n\nOverall, this sample provides information about the phase, diseases, ICDCodes, drugs, and eligibility criteria for a specific clinical trial.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The phase of the trial is \"early phase 1\".\n- Diseases: The diseases being studied in this trial are \"head and neck cancer\", \"pancreatic cancer\", and \"depression\".\n- ICD-10 Codes: The ICD-10 codes associated with these diseases are \"C76.0\", \"C47.0\", \"C49.0\", \"C77.0\", \"D17.0\", \"D21.0\", \"D36.11\" for head and neck cancer, \"C25.3\" for pancreatic cancer, and \"F32.A\", \"F53.0\", \"P91.4\", \"Z13.31\", \"Z13.32\" for depression.\n- Drugs: The drug being tested in this trial is \"ketamine\".\n- Criteria: The eligibility criteria for participants in this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". The inclusion criteria include factors such as the ability to understand and sign a consent form, specific cancer stages, age, liver function, and fluency in English. The exclusion criteria include factors such as participation in other clinical trials, certain mental health conditions, use of specific medications, certain cancer diagnoses, history of allergic reactions to ketamine, and various cardiovascular conditions.\n\nOverall, this sample record provides information about the phase, diseases, ICD-10 codes, drug, and eligibility criteria for a clinical trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is ulcerative colitis. The ICDCodes associated with this disease are K51.80, K51.813, K51.814, K51.90, K51.913, K51.914, and K51.811. The drug being used in the trial is a herbal treatment called sa100. \n\nThe eligibility criteria for this trial include:\n1. Age between 13 and 75 years.\n2. Patients with mild, moderate, and severe ulcerative colitis (confirmed by biopsy).\n3. Mayo Scoring System Assessment of Ulcerative Colitis Activity score of 3 to 12 at screening.\n4. Patients who are refractory to, intolerant to, or unwilling to take 5-aminosalicylic acid (5-ASA).\n5. Patients aged between 13 and 17 years who are refractory or intolerant to 5-aminosalicyclic acid (5-ASA), corticosteroids, small molecule immunomodulators, and biologics or corticosteroid-dependent.\n6. Physician's Global Assessment (PGA) Mayo subscore of at least 1 at screening.\n7. Endoscopic evidence of active mucosal disease as assessed by flexible sigmoidoscopy with Mayo mucosal appearance subscore of at least 1 at screening.\n8. Female patients of child-bearing potential must have a negative serum pregnancy test at the screening visit and agree to use two medically reliable methods of contraception during the study period.\n9. Male patients must be willing to use acceptable contraceptive methods and assure that their female partners of child-bearing potential use acceptable contraceptive methods during the study period.\n10. Ability to adhere to the study visit schedule and other protocol requirements.\n11. Adequate cardiac, renal, and hepatic function as determined by the principal investigators.\n12. Written informed consent will be obtained before any study procedure is performed.\n\nThe exclusion criteria for this trial include:\n1. Nursing or pregnant patients.\n2. Patients who are in critical condition.\n3. Patients with Crohn's disease or indeterminate colitis.\n4. Known sensitivity to any ingredients in the study drug.\n5. A change in therapy within 2 weeks before the baseline visit.\n6. Use of immunomodulators (cyclosporine, mercaptopurine, azathioprine, etc.).\n7. Diagnosis of diabetes, heart failure, unstable angina, liver or kidney disease, or any other unstable medical condition.\n8. Any clinically meaningful laboratory abnormality that, in the judgment of the investigator, should preclude participation in the study.\n9. Impaired renal function (serum creatinine levels >2.0 mg/dL) at screening.\n10. Alanine transaminase (ALT) or aspartate transaminase (AST) laboratory values >1.5 times the upper limit of normal at screening.\n11. Diagnosis of Clostridium difficile, Salmonella, Shigella, Yersinia, Campylobacter, enteropathogenic E. coli in stool.\n12. Positive test for hepatitis C virus (HCV) antibody or hepatitis B surface antigen (HBsAg) at screening.\n13. Active malignancy (except basal cell carcinoma).\n14. Active alcohol or drug abuse.\n15. Tobacco smoking within 2 weeks before study entry.",
    "The sample from the table represents a clinical trial study with a focus on different phases of the trial (phase I, phase II, or phase III). The diseases being studied include adult acute lymphoblastic leukemia in complete remission, acute myeloid leukemia in remission, previously treated myelodysplastic syndrome, recurrent adult acute lymphoblastic leukemia, recurrent adult acute myeloid leukemia, recurrent childhood acute lymphoblastic leukemia, recurrent childhood acute myeloid leukemia, and childhood acute lymphoblastic leukemia in complete remission. The diseases are associated with specific ICD-10 codes. The study also involves the use of certain drugs such as cyclophosphamide, fludarabine phosphate, mycophenolate mofetil, and tacrolimus. The eligibility criteria for participants include specific disease categories, performance status, organ function, and other factors. The study also includes criteria for the eligibility of donors. There are also exclusion criteria for both patients and donors.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is \"early phase 1\" and the disease being studied is \"prostate cancer\". The ICDCodes associated with this disease are \"C61\", \"D29.1\", \"D40.0\", \"Z15.03\", \"Z80.42\", \"Z85.46\", and \"Z12.5\". The drug being investigated is \"pyruvate\". \n\nThe eligibility criteria for this trial include:\n- The subject must have biopsy-proven adenocarcinoma of the prostate with intermediate to high risk disease.\n- The subject must possess a Gleason 4 component to the tumor.\n- The subject can be enrolled either prior to radical prostatectomy or prior to 2 months of androgen deprivation therapy followed by definitive radiation therapy as their primary treatment for prostate cancer.\n- The subject must be able and willing to comply with study procedures and provide informed consent.\n- The subject must have at least 5 mm of tumor on biopsy.\n- The subject must have concordant MRI/1H MRSI findings from a MR staging exam at UCSF performed prior to the 13C MRSI exam performed in this study with IMP, or be willing to undergo MRI/1H MRSI in connection with the study exam.\n- The subject must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.\n- The subject must meet certain laboratory criteria such as ANC, hemoglobin, platelets, creatinine clearance, total bilirubin, AST, and ALT levels.\n- The subject must be willing to use contraception during and for 1 month after completion of the study.\n- For part 2 of the study, the subject must have plans to initiate castrating therapy.\n\nThe exclusion criteria for this trial include:\n- The subject has received, or is scheduled to receive, another IMP from 1 month before to 1 month after inclusion in this study.\n- The subject is currently or has previously undergone androgen deprivation therapy, except for previous use of a 5-\u03b1 reductase inhibitor that was discontinued at least one month prior to study entry.\n- The subject has poorly controlled hypertension.\n- The subject has a contraindication for or inability to tolerate MRI examination.\n- The subject has had a prostate biopsy within 12 weeks prior to study entry.\n- The subject has a BMI of less than 18.5 or greater than 32.\n- The subject has congestive heart failure or a New York Heart Association (NYHA) status of \u22652.\n- The subject has a history of clinically significant EKG abnormalities or ongoing acute or chronic pulmonary bronchospastic disease.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is non-alcoholic fatty liver disease (NAFLD). The ICDCodes associated with this disease are Z52.6, K71.8, K71.7, A06.4, C22.0, C22.3, and K70.0.\n\nThe drug being investigated in this trial is metformin. The eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include subjects between the ages of 18-80 who have been diagnosed with NAFLD based on alanine aminotransferase (ALT) levels greater than 1.5 times the upper limit of normal, along with other diagnostic evidence such as hepatic serology workup, ultrasound evidence, or histologically confirmed NAFLD within the past year. The upper limit of normal for ALT is defined as 35 U/L in males and 19 U/L in females.\n\nExclusion criteria include a prior history of diabetes, failure to meet criteria for HbA1C screening, evidence of hepatic disorders, use of insulin or oral hypoglycemic agents, eGFR (estimated glomerular filtration rate) less than 30, blood transfusion within the past 3 months, steroid use in the past 6 months, excessive alcohol use, acute or unstable congestive heart failure, age over 80 years old, lactic acidosis, inability to consent due to cognitive impairment, and pregnancy.\n\nOverall, this sample provides specific details about the phase, disease, ICDCodes, drug, and eligibility criteria for a clinical trial focused on non-alcoholic fatty liver disease and the use of metformin as a potential treatment.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 1 and involves two groups: individuals with Parkinson's disease and healthy individuals. The diseases column includes the names of the diseases, while the icdcodes column includes the corresponding ICD-10 codes for each disease. In this case, the ICD-10 code for Parkinson's disease is \"G20\" and for the healthy group, it includes \"Z76.3\" and \"Z76.2\" codes.\n\nThe drugs column lists the names of the drugs being studied, which are \"biib054\" and \"placebo\". The criteria column provides the eligibility criteria for participants in the trial. It includes key inclusion criteria such as practicing effective contraception, having a specific body mass index range, and being in good health based on medical history, physical examination, and ECG. There is also a specific inclusion criterion for cohort 7, which requires a diagnosis of idiopathic PD.\n\nThe key exclusion criteria include a history of cardiovascular disease, smoking more than 5 cigarettes per day, recent surgery, history or positive test result for hepatitis C, hepatitis B, or HIV, and being pregnant, breastfeeding, or attempting to conceive during the study.\n\nIt is important to note that there may be additional inclusion/exclusion criteria defined in the protocol for this trial.",
    "The sample from the table is for a phase 1 trial. The disease being studied is hypoglycemia, and the corresponding ICD-10 codes for the disease are E16.1, E16.2, P70.3, P70.4, E16.0, E10.641, and E10.649. The drugs being tested in this trial are glucagon (zp-glucagon) and glucagon (glucagen). The eligibility criteria for participants include being women or men between the ages of 18 and 60 with type-1 diabetes on daily insulin treatment for at least two years. Their total daily insulin dose should have been stable for the last three months with no more than a 20% variation, and their current glycated hemoglobin level should be between 6.5% and 10%. Exclusion criteria include a history of hypoglycemic coma or seizures, any severe hypoglycemic episodes requiring treatment within the past month, and any history of pheochromocytoma or insulinoma.",
    "The sample provided is for a phase 1 clinical trial for pancreatic cancer. The trial is specifically for patients with unresectable or metastatic pancreatic cancer who have not responded to previous standard chemotherapy treatments. The eligibility criteria include being 18 years or older, having an ECOG performance status of 0 or 1, and a life expectancy of at least 3 months. The patient must also have satisfactory organ and bone marrow function, meet blood coagulation parameters, and agree to use approved contraceptive methods if of reproductive potential. \n\nThere are also exclusion criteria, such as recent participation in another therapeutic investigational study, anticipated need for systemic chemotherapy, active invasive cancer other than pancreatic cancer, and HIV, HCV, or HBV infections. Patients with active autoimmune diseases requiring immunosuppressive therapy, ongoing or active infections, planned concurrent treatment with high dose corticosteroids, or requiring supplemental oxygen therapy are also excluded. \n\nAdditionally, patients who have received prior therapy with gene modified cells, experimental therapy with certain antibodies, have a history of allergy to murine proteins or study product excipients, clinically significant pericardial effusion, congestive heart failure, or other cardiovascular conditions that may preclude assessment or worsen as a result of expected toxicities for this study, as well as pregnant or breastfeeding women, are also excluded from the trial.",
    "The sample provided is a record from a table that contains information about clinical trials. The table has several columns, including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of the diseases being studied, \"icdcodes\" which contains the corresponding ICD-10 codes for the diseases, \"drugs\" which lists the names of the drugs being tested, and \"criteria\" which includes the eligibility criteria for the trial.\n\nIn this specific sample, the phase of the trial is listed as \"phase 1/phase 2\". The diseases being studied are \"clinical efficacy\" and \"safety\". The corresponding ICD-10 codes for these diseases are provided as \"['Z71.85', 'Y38.4X1S', 'Y38.9X1S', 'Y38.4X1A', 'Y38.4X1D', 'Y38.5X1S', 'Y38.6X1S']\". The drug being tested is \"adcetris-levact\". The eligibility criteria for the trial are then listed, including specific requirements for patients with advanced classical Hodgkin Lymphoma, age range, previous treatment history, organ function, contraception, informed consent, and affiliation with a health insurance system. The exclusion criteria are also provided, which include age restrictions, previous or concurrent malignancies, specific neurological conditions, use of other investigational agents, recent chemotherapy or treatment, recent major surgery, active infections, hypersensitivity to certain proteins, psychiatric or medical conditions that may interfere with the study, diabetes mellitus, cardiovascular conditions, and vulnerability of certain individuals.\n\nOverall, this sample provides a detailed description of the phase, diseases, drugs, and eligibility/exclusion criteria for a specific clinical trial.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 1, and the disease is non-small cell lung cancer. The ICDCodes associated with this disease are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The drugs being tested in this trial are inc280 single agent and erlotinib. The eligibility criteria for this trial include having locally advanced or metastatic NSCLC, having an EGFR mutation (L858R and/or ex19del), having cMET amplification by FISH (GCN \u2265 6), having acquired resistance to EGFR TKI (1st or 2nd generation), and having an ECOG performance status (PS) \u2264 1. The exclusion criteria include prior treatment with 3rd generation TKI and prior treatment with specific agents such as Crizotinib or any other cMET inhibitor or HGF-targeting inhibitor. Additionally, concomitant EGFR TKI and platinum-based chemotherapy as a first-line regimen, as well as platinum-based chemotherapy as first-line treatment, are also excluded.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is systemic lupus erythematosus. The ICDCodes associated with this disease are M32.9, M32.0, M32.11, M32.12, M32.13, M32.14, and M32.8. The drugs being tested in this trial are a matching placebo and cenerimod. The eligibility criteria for participants include being aged 18 to 65 years with established SLE, having active SLE symptoms, and a positive ANA or anti-dsDNA antibodies. Participants must also be receiving background SLE medications. Exclusion criteria include significant medical conditions or therapies, pregnancy or lactation, severe SLE disease, and other medical or surgical conditions that may put the participant at risk.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 1 and focuses on HIV infection. The ICD-10 code for HIV infection is \"Z21\". The drugs being studied in this trial are \"raltegravir 1200 mg\", \"tums\", and \"leader antacid\". The eligibility criteria for participants are listed, including being HIV positive, being on a stable raltegravir-containing antiretroviral regimen, being at least 18 years old, and having a Body Mass Index (BMI) of less than or equal to 32 kg/m^2. The exclusion criteria are also provided, which include having a history of certain medical conditions, surgeries, allergies, or drug use.",
    "The sample from the table represents a phase 1 clinical trial for major depressive disorder. The trial includes the following information:\n\n- Phase: Phase 1\n- Diseases: Major depressive disorder\n- ICD-10 Codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40\n- Drugs: jnj-42847922, diphenhydramine, placebo\n\nThe eligibility criteria for participants in this trial are as follows:\n\nInclusion Criteria:\n- Women must either be not of childbearing potential or practicing a highly effective method of birth control.\n- Participant's body mass index (BMI) must be between 18 and 30 kg/m2.\n- Participants must meet the diagnostic criteria for major depressive disorder (MDD) without psychotic features and have a confirmed diagnosis.\n- Participants must have an Inventory of Depressive Symptomatology- Clinician rated-30 (IDS-C30) total score of >= 30.\n- Participants must be either antidepressant naive or currently being treated with a maximum of two concurrent antidepressants.\n- Men who are sexually active with women of childbearing potential must use a barrier method of birth control.\n- Participants must be willing and able to adhere to the protocol's prohibitions and restrictions.\n\nExclusion Criteria:\n- Pregnant or breastfeeding women are excluded.\n- Participants with a history of malignancy within 5 years before screening, except for certain types of skin and cervical cancers, are excluded.\n- Participants with primary diagnoses of general anxiety disorder (GAD), panic disorder, obsessive-compulsive disorder (OCD), posttraumatic stress disorder (PTSD), anorexia nervosa, or bulimia nervosa are excluded, unless MDD is considered the primary diagnosis.\n- Participants with a current major depressive episode lasting more than 24 months despite adequate treatment are excluded.\n- Participants who have failed more than 2 treatments with a different pharmacological mode of action, despite adequate dose and duration, are excluded.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is multiple myeloma, and the associated ICDCodes are C90.01, C90.02, and C90.00. The drugs being used in the trial are mln9708, dexamethasone, bendamustine (multiple dose levels), and bendamustine (mtd). \n\nThe eligibility criteria for this trial include being 18 years or older, providing voluntary written consent, and meeting certain requirements for contraception for female patients. Male patients must also agree to contraception or abstinence. Patients must have confirmed symptomatic multiple myeloma that is non-responsive to or ineligible for autologous stem cell transplant, and have progressed after prior exposure to certain drugs. They must also meet specific parameters for measurable disease or lytic bone disease. Other criteria include performance status, previous transplantation, recovery from prior treatments, and meeting certain laboratory criteria.\n\nExclusion criteria include lactating or pregnant female patients, not fully recovering from prior chemotherapy, recent major surgery or radiotherapy, central nervous system involvement, active infections or cardiovascular conditions, ongoing use of certain medications, certain medical or psychiatric illnesses, allergies to study medications, gastrointestinal issues, poor prognosis for another malignancy, peripheral neuropathy, participation in other clinical trials, previous treatment with the study drug, and severe chronic obstructive pulmonary disease.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is prostate cancer. The icd-10 codes associated with this disease are 'C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', and 'Z12.5'. The drugs being used in the trial are 'burixafor hydrobromide', 'docetaxel', and 'g-csf'. \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include factors such as signing an informed consent document, being willing to adhere to the study protocol, being male and aged 18 years or above, having an Eastern Cooperative Group (ECOG) performance status of \u22642, having histologically confirmed adenocarcinoma of the prostate, and having metastatic prostate cancer to the bone as confirmed by positive bone scan imaging. \n\nExclusion criteria include factors such as known allergies or intolerance to docetaxel or dexamethasone, prior pelvic radiation that may affect bone marrow cellularity, ongoing systemic therapy for prostate cancer, prior radiopharmaceutical therapy within the past year, any condition that may compromise the well-being of the subject or prevent them from meeting study requirements, active infection or medical conditions contraindicating the use of corticosteroids, uncontrolled hypertension, severe hepatic impairment, history of pituitary or adrenal dysfunction, poorly controlled diabetes, and any psychological, familial, sociological, or geographical condition that could interfere with compliance with the study protocol and follow-up schedule.",
    "The sample provided is a record from a table that contains information about clinical trials. The trial is in phase 1 and is focused on the disease \"rheumatoid arthritis\". The ICD-10 codes associated with this disease are \"M06.9\", \"M05.9\", \"M06.08\", \"M06.00\", \"M06.011\", \"M06.012\", and \"M06.019\". The drugs being studied in this trial are \"t0001\" and \"enbrel\". \n\nThe eligibility criteria for this trial are as follows:\n- Participants must be between the ages of 18 and 45.\n- Participants must have been diagnosed with active rheumatoid arthritis.\n- Participants must not have used DMARDs therapy for at least 28 days prior to the trial.\n- If a participant has been using NSAIDs, the dosage must have been stable for at least 28 days prior to the trial.\n- The participant or their legal representative must be able to provide written informed consent.\n\nThe exclusion criteria for this trial are as follows:\n- Participants with acute or chronic infections, or a history of active tuberculosis, are excluded.\n- Participants with a history of diseases affecting the central nervous system, cardiovascular system, kidney, liver, digestive system, respiratory system, or metabolism system are excluded.\n- Participants at high risk of infection, with a current infectious disease, chronic infectious disease, or history of serious infectious disease, are excluded.\n- Participants with a positive 5 Unit doses tuberculin skin test (48-72 hour scleroma reading \u22655mm) are excluded.\n- Participants with current or previous malignancy are excluded.\n- Participants who lack understanding, communication, or collaboration, and cannot comply with the trial protocols, are excluded.\n- Female participants who are breastfeeding, pregnant, or of childbearing potential are excluded.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The diseases being studied are \"advanced relapsed tumors\" and \"refractory solid tumors\". The ICDCodes associated with these diseases are \"D46.4\", \"D46.1\", \"D46.A\", \"D46.0\", \"D46.20\", \"D46.21\", and \"D46.22\". The drugs being used in the trial are \"omp-131r10\" and \"folfiri\". The eligibility criteria for this sample include various requirements such as histologically confirmed advanced relapsed or refractory solid tumors, age over 18 years, ECOG performance status of 0 or 1, evaluable disease per RECIST 1.1, availability of FFPE tissue, a certain time frame since the last anti-cancer therapy, specific blood test results, and exclusion criteria such as receiving other therapeutic treatments, uncontrolled seizure disorder, history of allergic reactions to certain therapies, significant intercurrent illness, pregnancy or nursing, congestive heart failure, and clinically significant gastrointestinal disease.",
    "The sample from the table is for a phase 1 clinical trial. The disease being studied is ovarian cancer. The ICD-10 codes associated with the disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drugs being tested in the trial are veliparib, carboplatin, and paclitaxel. The eligibility criteria for participants include having histologically or cytologically confirmed epithelial ovarian, fallopian tube, or primary peritoneal carcinoma at stage IC - IV with either optimal or suboptimal residual disease. Participants must be newly diagnosed, chemotherapy-na\u00efve, and entered between 1 and 12 weeks after initial cytoreductive surgery. Other criteria include having an Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 1, adequate organ and marrow function, ability to swallow and retain oral medication, and no uncontrolled emesis. Women of childbearing potential must agree to use adequate contraception, and post-menopausal women must be amenorrheic for at least 12 months. There are also exclusion criteria, such as a history of another invasive cancer within the past 3 years, prior radiotherapy or chemotherapy for abdominal or pelvic tumors, and prior therapy with a Poly-(ADP-ribose)-Polymerase (PARP) inhibitor. Additionally, participants with certain uncontrolled conditions or medical conditions that place them at high risk for toxicities are excluded. Pregnant or lactating individuals are also excluded from the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is breast cancer. The icd-10 codes associated with the disease are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The drug being used in the trial is rosuvastatin. \n\nThe eligibility criteria for this trial include:\n- Women with ER+/PR+ HER2-negative breast cancer who are starting neoadjuvant endocrine therapy with curative intent or initiating endocrine therapy for the treatment of metastatic breast cancer with a biopsy accessible primary breast tumor.\n- Patients may start any FDA approved endocrine therapy (except tamoxifen) at week 4 of the trial.\n- Palbociclib can be started at week 4 if indicated.\n- Patients with metastatic disease currently on endocrine therapy must be willing to stop endocrine therapy for 2 weeks prior to starting the study and switch to a new endocrine therapy on the study.\n- An intact breast tumor must be present and measure at least 1cm at enrollment.\n- Patients must be post-menopausal at enrollment (age \u2265 60, age \u2264 60 and amenorrhea for \u226512 months in the absence of chemotherapy, tamoxifen, ovarian suppression, and FSH/estradiol in the post-menopausal range).\n- ECOG performance status must be \u2264 2.\n- Patients can be on other endocrine therapy if willing to change to a different endocrine therapy agent for the trial.\n- Patients must have at least one FDA approved endocrine therapy option with which they have not received prior treatment.\n- Life expectancy must be greater than 12 weeks.\n- Laboratory criteria include normal renal function, liver function, and blood counts.\n- Patients must be over 18 years of age.\n- Patients must have the ability to give informed consent and have a signed informed consent form prior to enrollment.\n\nThe exclusion criteria for this trial include:\n- Statin use in the last 6 months.\n- Patients who have been treated with all FDA approved endocrine therapies or have been treated with all FDA approved endocrine therapies except for tamoxifen (tamoxifen is excluded from the trial).\n- Active liver disease with elevated transaminases > 2x ULN.\n- Known hypersensitivity to rosuvastatin.\n- Any history of any other cancer, unless the patient has been in remission and off all other cancer therapy for at least 3 years (except non-melanoma skin cancer or carcinoma in-situ of the cervix).\n- Patients should have no significant psychiatric illness or medical illness that would preclude the ability to comply with the protocol.\n- Patients currently taking medications with known rosuvastatin interactions, including cyclosporine, gemfibrozil, lopinavir/ritonavir, atazanavir/ritonavir, coumarin anticoagulants, colchicine, fenofibrates, and niacin.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is macular edema. The ICDCodes associated with this disease are ['H59.033', 'H34.8130', 'H59.031', 'H59.032', 'H59.039', 'H34.8110', 'H34.8120']. The drug being used in the trial is dexamethasone phosphate ophthalmic. The eligibility criteria for participants include being between the ages of 18 and 90, having a diagnosis of macular edema secondary to specific conditions, having a mean CST (central subfield thickness) of at least 300\u00b5m on SD-OCT images taken at the baseline visit, and being able to comply with study instructions and attend all study visits. There are also exclusion criteria, but they are not provided in the sample.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1 and focuses on hematologic malignancies. The ICD-10 codes associated with these diseases are ['E70.338', 'E70.339', 'P09.3', 'O28.0', 'P61.8', 'P61.9', 'T45.8X1A']. The drug being studied is 'ap1903'. The eligibility criteria for participants include being 18 to 65 years old, having one of the specified hematological malignancies, being eligible for allogeneic stem cell transplantation, and lacking a suitable conventional donor. The sample also includes exclusion criteria such as having a matched donor, recent autologous transplantation, active CNS involvement by malignant cells, and certain medical conditions.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease being studied is renal cell cancer. The ICDCodes associated with this disease are C96.20, C96.29, and D47.09. The drugs being used in the trial are avelumab (msb0010718c) and axitinib (ag-013736). The eligibility criteria for participants in this trial include having histologically or cytologically confirmed advanced RCC with a clear cell component, having the primary tumor resected, and having availability of recent formalin-fixed, paraffin-embedded (FFPE) tumor tissue block from a de novo tumor biopsy during screening. There are also additional criteria related to age, performance status, and adequate bone marrow, renal, and liver functions. The exclusion criteria include prior systemic therapy directed at advanced RCC, prior immunotherapy with specific antibodies, and certain medical conditions within the previous 6 months. Vaccination within 4 weeks of the first dose of avelumab and while on the trial is also prohibited, except for inactivated vaccines.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is focused on the treatment of non-small-cell lung cancer. The phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are specified as non-small-cell lung cancer. The corresponding ICD-10 codes for the diseases are provided. The drugs being tested in the trial are gilteritinib and erlotinib. The eligibility criteria for participants are listed, including requirements such as having a confirmed diagnosis of metastatic or locally advanced non-small-cell lung cancer, having specific EGFR activating mutations, and having received prior treatment with an EGFR tyrosine kinase inhibitor. Additional criteria are specified for participants in phase 1b and phase 2. Exclusion criteria are also listed, which include factors such as ongoing toxicity from prior treatment, recent use of certain medications, active infections, uncontrolled hypertension, and various other medical conditions.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this specific sample, the phase of the trial is Phase 1. The disease being studied is multiple myeloma. The ICDCodes associated with this disease are C90.01, C90.02, and C90.00. The drugs being used in the trial are jnj-54767414 (daratumumab), bortezomib, and dexamethasone. \n\nThe eligibility criteria for participants in this trial include having symptomatic multiple myeloma according to the International Myeloma Working Group (IMWG) diagnostic criteria. Participants must have documented MM, with specific disease measurements such as serum M-protein levels, urine M-protein levels, and abnormal serum immunoglobulin kappa lambda free light chain ratio. They must have received at least 1 prior line of therapy for MM and have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1. Additionally, participants must have achieved a response (partial response [PR] or better) to at least 1 prior regimen.\n\nExclusion criteria for this trial include previous treatment with daratumumab or other anti-CD38 therapies, refractoriness to bortezomib or other proteasome inhibitors, intolerance to bortezomib, recent anti-myeloma treatment, history of malignancy (other than multiple myeloma) within 3 years, and concurrent medical conditions or diseases that may interfere with study procedures.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is small cell lung cancer, and the corresponding ICDCodes for this disease are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The drugs being tested in this trial are carboplatin, placebo, trilaciclib, and etoposide. \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" Inclusion criteria include being male or female aged 18 years or older, having a confirmed diagnosis of small cell lung cancer, having at least one unirradiated and measurable target lesion, having an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, and having adequate organ function. Exclusion criteria include having received prior chemotherapy for extensive-stage small cell lung cancer, having symptomatic brain metastases requiring immediate treatment, having uncontrolled ischemic heart disease or congestive heart failure, having a history of stroke or cerebrovascular accident within the past 6 months, having other uncontrolled serious chronic diseases or conditions that could affect compliance or follow-up, having concurrent radiotherapy or recent radiotherapy to the target lesion sites, and having received any investigational medication within the past 4 weeks.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is HIV. The ICDCodes associated with this disease are \"B20\", \"Z71.7\", \"O98.72\", \"Z21\", \"O98.73\", \"R75\", and \"Z11.4\". The drugs being used in the trial are efavirenz, tenofovir/emtricitabine, tenofovir/lamivudine, and lamivudine/zidovudine. \n\nThe eligibility criteria for this trial are as follows:\n\nInclusion Criteria:\n1. The participant must have provided a personally signed and dated informed consent document, indicating their understanding of the study.\n2. The participant must be a pregnant female infected with HIV-1 and currently stable on two nucleos/tide analogues (tenofovir/emtricitabine or tenofovir/lamivudine or zidovudine/lamivudine) and efavirenz 600mg once daily for more than 12 weeks. They must also be willing to take efavirenz 400 mg once daily at a gestational age of 28 weeks +/- 3 weeks.\n3. The participant must have an undetectable viral load (as determined by a local assay).\n4. The participant's CD4 count must be greater than 100 cells/mm3.\n5. The participant must be between the ages of 18 to 45 years, inclusive.\n\nExclusion Criteria:\n1. The participant's viral load must be greater than or equal to 50 copies/mL (or detectable by a local assay).\n2. The participant must not have evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG, or clinical laboratory determinations.\n3. The participant must not have a positive blood screen for chronic hepatitis C (if available locally) or hepatitis B.\n4. The participant must not have a current or recent (within 3 months) gastrointestinal disease.\n5. The participant must not have clinically relevant alcohol or drug use (positive urine drug screen) or a history of alcohol or drug use that is considered by the Investigator to be sufficient to hinder compliance with treatment, follow-up procedures, or evaluation of adverse events.\n6. The participant must not have been exposed to any investigational drug or placebo within 3 months prior to the first dose of the study drug.\n7. The participant must not have used any other drugs, including over-the-counter medications and herbal preparations, within two weeks prior to the first dose of the study drug, unless approved/prescribed by the Principal Investigator as known not to interact with the study drugs.",
    "The sample provided is a record from a table that contains information about clinical trials. The trial is in phase 1 and focuses on the disease \"type 1 diabetes mellitus.\" The associated ICD-10 codes for this disease are \"E10.65,\" \"E10.9,\" \"E10.21,\" \"E10.36,\" \"E10.41,\" \"E10.42,\" and \"E10.44.\" The drugs being studied in this trial are \"pramlintide acetate,\" \"placebo,\" \"lispro insulin u-100,\" and \"regular insulin u-100.\" \n\nThe eligibility criteria for this trial are as follows:\n- Participants must provide informed consent before any study-specific procedures.\n- Both males and females between the ages of 18 and 70 are eligible.\n- Participants must have a prior diagnosis of type 1 diabetes mellitus.\n- Body mass index (BMI) should be less than 30 kg/m2.\n- Participants should not be currently on treatment with pramlintide or have received it in the 6 months prior to enrollment.\n- Participants must be willing to consume all components of the standardized meals provided during the study.\n- Female participants of childbearing potential must have a negative serum pregnancy test and either be 1 year postmenopausal, surgically sterile, or using an acceptable method of contraception throughout the study.\n- Male participants must be surgically sterile or using an acceptable method of contraception throughout the study.\n\nThe exclusion criteria for this trial are as follows:\n- Participants who have experienced recurrent severe hypoglycemia requiring assistance within the 6 months before screening.\n- Participants with a history of hypoglycemia unawareness.\n- Participants with a confirmed diagnosis of gastroparesis.\n- Participants who have been treated, are currently being treated, or are expected to require or undergo treatment with certain medications, including oral antihyperglycemic agents, injectable antihyperglycemic agents that are not insulin, drugs that directly affect GI motility, drugs that slow the intestinal absorption of nutrients, and acetaminophen.\n- Participants with a history of gastric surgery.\n- Participants who have experienced diabetic ketoacidosis within the last 24 weeks.\n- Participants who have been hospitalized within the last 6 months for glycemic control.\n- Participants with any significant disease or disorder that may put them at risk or influence the results of the study.\n- Participants with any clinically relevant abnormal findings that may put them at risk or affect their ability to participate in the study.\n- Pregnant or breastfeeding participants.\n- Participants with positive test results for hepatitis C virus antibody, hepatitis B virus surface antigen, hepatitis B virus core antibody, or human immunodeficiency virus 1/2 antibody.\n- Participants with a history of alcohol or drug abuse.\n- Participants who have donated blood within 2 months before screening or plan to donate blood during the study.\n- Participants who have had major surgery or a blood transfusion within 2 months before screening.\n- Participants who have participated in any other clinical study with an investigational drug or new formulation of a marketed drug within the last 1 month prior to screening.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2, and the diseases being studied are gastrointestinal problems and autism spectrum disorders. The corresponding ICD-10 codes for these diseases are ['A21.3', 'A22.2', 'B46.2', 'K92.2', 'K92.81', 'K91.0', 'P54.3'] and ['Z16.12'], respectively. The drugs being tested in the trial are oral vancomycin, moviprep, and prilosec. \n\nThe eligibility criteria for participants in the trial are as follows:\nInclusion Criteria:\n1. Children ages 7-17 years\n2. Diagnosis of autism per Autism Diagnostic Interview-Revised (ADI-R)\n3. Moderate or Severe GI problems (on the GSRS, a single score of 4 (severe) on any item, or a score of 3 (moderate) on two items, or a score of 2 (mild) or more on any 4 items)\n4. No changes in medications, supplements, diet, therapies, or education in the last 3 months, and no intention to change them during the clinical trial\n5. General good physical health aside from gastrointestinal problems\n6. Cognitive ability to provide informed assent\n\nExclusion Criteria:\n1. Antibiotics in the last 6 months\n2. Probiotics in the last 3 months\n3. Single-gene disorder (Fragile X, etc.)\n4. Major brain malformation\n5. Tube feeding\n6. Severe gastrointestinal problems that require immediate treatment (life-threatening)\n7. Ulcerative Colitis, Crohn's Disease, diagnosed Celiac Disease, Eosinophilic Gastroenteritis, or similar conditions\n8. Severely underweight/malnourished\n9. Recent or scheduled surgeries\n10. Current participation in other clinical trials",
    "The sample from the table represents a clinical trial for the treatment of head and neck squamous cell carcinoma. The trial is in phase 1. The diseases column lists the disease name, which in this case is \"head and neck squamous cell carcinoma.\" The icdcodes column contains a list of icd-10 codes associated with the disease. The drugs column lists the drugs being used in the trial, which are \"cisplatin,\" \"docetaxel,\" and \"wee1 inhibitor azd1775.\" The criteria column provides the eligibility criteria for participating in the trial, including requirements such as providing informed consent, having a current diagnosis of the specified stage of the disease, and meeting certain medical criteria such as blood counts, liver function, and kidney function. The exclusion criteria are also listed, which include conditions or circumstances that could interfere with the study or compromise its objectives, prior treatment with certain medications, presence of certain medical conditions, and pregnancy or breastfeeding.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease mentioned is \"myelodysplastic syndromes.\" The ICDCodes associated with this disease are \"D46.9,\" \"D46.C,\" and \"D46.Z.\" The drugs being used in the trial are \"atezolizumab\" and \"azacitidine.\" The eligibility criteria for participants include a diagnosis of MDS, a performance status score of less than or equal to 2, adequate end-organ function, willingness to undergo bone marrow biopsies, and certain requirements for women of childbearing potential. The sample also includes specific inclusion and exclusion criteria for participants in different cohorts. Exclusion criteria include certain medical conditions, prior transplants, pregnancy or lactation, recent immunosuppressive therapy, and other specified therapies or medical conditions that may affect safe participation in the study.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is pregnancy. The ICDCodes associated with this disease are ['O00.00', 'O00.01', 'O00.101', 'O00.102', 'O00.109', 'O00.111', 'O00.112']. The drugs being used in this trial are 'menopur 150 international units' and 'endometrin 100 mg'. \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include age between 18-37, BMI between 19-34 kg/m2, FSH levels less than 10IU/mL, E2 levels less than 80 pg/mL, AMH levels more than 1.5 ng/mL or AFC up to 10, confirmation of two patent fallopian tubes, and a normal uterine cavity confirmed by HSG, SIS, or hysteroscopy.\n\nExclusion criteria include severe male factor (total count less than 10 million sperm), systemic diseases not limited to diabetes, pregnancy within 3 months, more than 1 prior cycle of gonadotropin treatment, ovarian cyst >15mm persisting for >1 month, endometrioma and/or endometriosis-stage III or IV, submucosal uterine fibroids, untreated endometrial polyps >1 cm, abnormal reproductive tract bleeding, intolerance or allergy to study drug, substance abuse, history of chemotherapy or radiotherapy (except for gestational conditions), and minors or adults not capable of consenting on their own.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is categorized as \"phase 1\" and the diseases being studied are \"glioblastoma multiforme\" and \"astrocytoma, grade iv\". The corresponding ICD-10 codes for these diseases are \"L51.0\", \"L51.8\", and \"L51.9\". The drugs being used in the trial are \"poly-iclc\" and \"temozolomide\". \n\nThe eligibility criteria for participants in the trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include being newly diagnosed with histologically confirmed glioblastoma multiforme, having undergone certain types of surgical procedures, consenting to genome sequencing and data sharing, being at least 18 years old, having a Karnofsky performance status of at least 60%, and meeting certain normal bone marrow and organ function requirements. \n\nExclusion criteria include having received prior immunotherapy (except non-immunologic therapy), inadequate tissue acquisition for neoantigen screening, no candidate neoantigen identified during screening, a history of other malignancy within the past 3 years (with some exceptions), currently receiving any other investigational agents, known allergies or serious adverse reactions to vaccines, uncontrolled intercurrent illness, history of pre-existing immunodeficiency disorder or autoimmune condition requiring immunosuppressive therapy, presence of clinically significant increased intracranial pressure or hemorrhage, and being pregnant or breastfeeding.\n\nOverall, this sample provides specific details about the phase, diseases, drugs, and eligibility criteria for participants in a clinical trial focused on glioblastoma multiforme and astrocytoma.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2 and focuses on small cell lung cancer (SCLC). The ICD-10 codes associated with SCLC are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The drugs being studied in the trial are trilaciclib, placebos, and topotecan. The sample also includes the eligibility criteria for the trial, including age, confirmed diagnosis of SCLC, progression after prior chemotherapy, presence of measurable target lesions, performance status, and adequate organ function. The exclusion criteria include symptomatic brain metastases, uncontrolled heart disease, recent stroke, other serious chronic diseases, concurrent or recent radiotherapy, recent use of investigational medication, and previous topotecan treatment for SCLC.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2 and is focused on the disease muscular dystrophy (DMD). The ICD-10 codes associated with this disease are 'H35.51', 'L60.3', 'G71.00', 'G71.02', 'G71.11', 'H35.52', and 'H18.513'. The drugs being studied are ro7239361 and placebo. The sample also includes the eligibility criteria for participants. Inclusion criteria include being diagnosed with DMD, being able to walk without assistance, being able to walk up 4 stairs in 8 seconds or less, weighing at least 15 kg, and taking corticosteroids for DMD. Exclusion criteria include having an ejection fraction less than 55% on an echocardiogram, having any behavior or mental issues that would affect the ability to complete study procedures, previously or currently taking medications like androgens or human growth hormone, using a ventilator during the day, being unable to have blood samples collected or receive an injection under the skin, receiving exon skipping therapies within 6 months prior to the study start, and receiving ataluren or any investigational drug within 5 half-lives prior to the study start.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease being studied is multiple myeloma. The ICDCodes associated with this disease are C90.01, C90.02, and C90.00. The drugs being used in the trial are daratumumab subcutaneous (sc) administration and recombinant human hyaluronidase [rhuph20]) sc administration. The eligibility criteria for participants include having a proven diagnosis of multiple myeloma according to the International Myeloma Working Group (IMWG) diagnostic criteria, measurable disease, a specific performance status score, and meeting certain laboratory values. There are also criteria related to birth control, prior treatment, and exclusion criteria such as previous use of daratumumab or other anti-CD38 therapies, recent anti-myeloma treatment, and history of certain malignancies.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease being studied is Type 1 Diabetes Mellitus. The ICDCodes associated with this disease are E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, and E10.44. The drugs being used in the trial are Biochaperone Insulin Lispro and Humalog\u00ae. The eligibility criteria for this trial include specific requirements for the duration of diabetes diagnosis, insulin treatment, total daily insulin dosage, body mass index (BMI), HbA1c levels, and fasting C-peptide levels. There are also exclusion criteria listed, which include hypersensitivity to trial products, type 2 diabetes mellitus, previous participation in the trial, recent use of investigational products, abnormal screening test results, gastrointestinal symptoms, gastric emptying issues, special diet requirements, and unwillingness to eat the provided food.",
    "The sample provided is a record from a clinical trial database. It contains information about a specific trial phase, diseases being studied, associated ICD-10 codes, drugs being tested, and eligibility criteria for participants.\n\nIn this particular sample, the trial is in Phase 1. The diseases being studied are malignant glioma, astrocytoma, and glioblastoma. The associated ICD-10 codes for these diseases are provided as well. The drug being tested in this trial is nivolumab.\n\nThe eligibility criteria for participants are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include age between 18-80 years, first or second recurrence of malignant glioma or astrocytoma, no prior exposure to Bevacizumab (another drug), a Karnofsky Performance Status (KPS) of at least 70%, completion of radiation therapy with a tumor dose of at least 45 Gray (Gy) at least 8 weeks prior to study entry, and meeting specific laboratory value requirements.\n\nThe laboratory value requirements include minimum values for white blood count, neutrophils, platelets, and hemoglobin, as well as maximum values for serum creatinine, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and bilirubin. Resting baseline O2 saturation by pulse oximetry must be at least 92% at rest.\n\nExclusion criteria include the presence of certain tumor characteristics, clinically significant increased intracranial pressure, uncontrolled seizures, pregnancy or breastfeeding, active infection, known immunosuppressive or autoimmune diseases, severe allergies or hypersensitivity to certain vaccines or monoclonal antibodies, previous radiation therapy or treatment with immune checkpoint inhibitors, unstable or severe intercurrent medical conditions, corticosteroid use exceeding 4 mg/day, and prior inguinal lymph node dissection.",
    "The sample from the table describes a clinical trial for patients with leukemia, specifically acute myeloid leukemia (AML). The trial is divided into different phases, such as phase I and phase II. The diseases column lists the specific diseases being studied, which in this case are leukemia and acute myeloid leukemia. The icdcodes column contains the corresponding ICD-10 codes for these diseases.\n\nThe drugs column lists the drugs being used in the trial, which are selinexor and sorafenib. The criteria column provides the eligibility criteria for patients to participate in the trial. These criteria include having specific genetic mutations, previous treatment history, age, performance status, and various health parameters such as liver and kidney function.\n\nThe inclusion criteria specify the requirements for patients to be eligible for each phase of the trial. The exclusion criteria list the conditions or situations that would disqualify a patient from participating in the trial. These include allergies to the drugs, concurrent medical conditions, recent surgeries, receiving other treatments for AML, and unstable cardiovascular function, among others.\n\nOverall, the sample provides detailed information about the phase, diseases, icd codes, drugs, and eligibility criteria for patients participating in the clinical trial for leukemia.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 1. The diseases being studied include \"castration levels of testosterone,\" \"castration-resistant prostate carcinoma,\" \"metastatic prostate carcinoma,\" \"recurrent prostate carcinoma,\" and \"stage IV prostate adenocarcinoma.\" The corresponding ICDCodes for these diseases are provided as well.\n\nThe drugs being investigated in this trial are \"enzalutamide\" and \"niclosamide.\" The eligibility criteria for participants in this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" \n\nThe inclusion criteria include requirements such as signing an informed consent document, adhering to study restrictions, having a certain performance status, having confirmed adenocarcinoma of the prostate, and meeting specific criteria for castration-resistant prostate cancer. \n\nThe exclusion criteria include factors such as allergies or intolerance to the drugs being studied, ongoing systemic therapy for prostate cancer, certain medical conditions that may compromise the well-being of the participant, and other factors that may interfere with compliance or benefit from chemotherapy.\n\nOverall, this sample provides a snapshot of the information stored in the table, including the phase, diseases, ICDCodes, drugs, and eligibility criteria for a specific clinical trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is cystic fibrosis, and the corresponding ICDCodes associated with this disease are E84.9, Z14.1, E84.0, E84.11, E84.8, E84.19, and P09.4. The drugs being tested in this trial are qr-010 and placebo. The eligibility criteria for participants are listed under inclusion and exclusion criteria, which include factors such as confirmed diagnosis of CF, specific CFTR gene mutations, body mass index, non-smoking status, lung function, and hepatic and renal function. Exclusion criteria include factors such as pregnancy, use of specific drugs, history of lung transplantation, and hemoptysis.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The trial is a combination of phase 1 and phase 2.\n- Diseases: The trial is focused on the treatment of condylomata acuminata, papillomavirus infections, and sexually transmitted diseases.\n- ICD Codes: The ICD-10 codes associated with the diseases are ['A64', 'A63.8'].\n- Drugs: The drugs being tested in the trial are ranpirnase and a vehicle (presumably a control substance).\n- Criteria: The eligibility criteria for participants in the trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". The criteria include specific requirements related to the diagnosis of external genital/perianal warts, willingness to follow study instructions, abstaining from sexual intercourse after applying the study product, and restrictions on previous treatments, allergies, and other medical conditions or medications.\n\nOverall, this sample provides a snapshot of a clinical trial that focuses on the treatment of specific diseases using certain drugs, with defined eligibility criteria for participants.",
    "The sample from the table represents a clinical trial with a phase 1/phase 2 trial phase. The trial focuses on the disease \"functional constipation\" and includes a list of associated ICD-10 codes. The trial involves testing various drugs, including \"yh12852 ir\" at different dosages, \"yh12852 dr1\" at different dosages, \"yh12852 dr2 8mg\", \"prucalopride 2mg\", and a placebo. \n\nThe eligibility criteria for participants in the trial are as follows:\n- Subjects must be willing and able to provide written informed consent.\n- BMI must be within the range of 18 to 25 kg/m2.\n\nThe exclusion criteria for participants are as follows:\n- History of positive serologic evidence for infectious diseases such as HBsAg, anti-HCV, anti-HIV.\n- Clinically significant lab/ECG abnormalities in the opinion of the investigator.\n- Women of childbearing potential (WOCBP) who are unwilling or unable to use an adequate contraceptive method to avoid pregnancy for the entire study. Acceptable contraceptive methods include intrauterine devices, physical barrier methods with chemical barrier methods, sterile partner, or practicing abstinence.\n- WOCBP who are willing to use hormonal methods or hormone-releasing devices for the entire study.\n- WOCBP who are pregnant or breastfeeding.\n- WOCBP with a positive pregnancy test prior to randomization.\n- Males who have not received a vasectomy must agree to use contraceptive methods and refrain from donating sperm throughout the study.\n- Presence of uncontrolled or severe medical illness.\n- Presence of a disease that requires surgery at any time during the study.",
    "The sample from the table represents a clinical trial for the treatment of various types of head and neck cancers. The trial is divided into three phases: phase I, phase II, and phase III. The diseases included in the trial are head and neck squamous cell carcinoma, recurrent nasal cavity and paranasal sinus squamous cell carcinoma, recurrent nasopharynx carcinoma, recurrent salivary gland carcinoma, squamous cell carcinoma metastatic in the neck with occult primary, stage III major salivary gland carcinoma, stage III nasal cavity and paranasal sinus squamous cell carcinoma, stage III nasopharyngeal carcinoma, stage IV nasopharyngeal carcinoma, stage IVA major salivary gland carcinoma, stage IVA nasal cavity and paranasal sinus squamous cell carcinoma, stage IVB major salivary gland carcinoma, stage IVB nasal cavity and paranasal sinus squamous cell carcinoma, stage IVC major salivary gland carcinoma, and stage IVC nasal cavity and paranasal sinus squamous cell carcinoma.\n\nThe diseases are associated with specific ICD-10 codes. The drugs being tested in the trial include vorinostat. The eligibility criteria for the trial include having biopsy-proven head and neck squamous cell carcinoma, evidence of disease progression, previous lines of systemic therapy, willingness to provide informed consent, and meeting certain organ function requirements. There are also exclusion criteria, such as participation in other clinical trials, immunodeficiency, prior use of certain medications, active infections, and certain medical conditions.\n\nOverall, the sample provides detailed information about the phase, diseases, drugs, and eligibility criteria for a clinical trial focused on head and neck cancers.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease being studied is \"healthy,\" which seems to refer to individuals without any specific disease. The ICDCodes associated with this disease are \"Z76.3\" and \"Z76.2.\" The drugs being tested in this trial are \"ixekizumab,\" \"boostrix\u00ae,\" and \"pneumovax\u00ae23.\" \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" Inclusion criteria state that the trial is open to healthy males and females without a compromised immune system, with a body mass index (BMI) between 18 and 32 kg/m\u00b2. Exclusion criteria include factors such as previous participation in an ixekizumab or interleukin-17 (IL-17) antagonist study, recent participation in a clinical trial involving an investigational product, known allergies or hypersensitivity to biologic therapy, past vaccination allergies or hypersensitivity, recent tetanus toxoid-containing vaccine, severe allergic reaction to Boostrix, latex allergy, recent immunization with pneumococcal vaccine, known hypogammaglobulinemia, history of Guillain-Barre Syndrome, active infectious disease, recent live vaccination, evidence of uncontrolled neuropsychiatric disorder, depressive symptoms, HIV infection, Hepatitis C or B, recent symptomatic herpes zoster, and lactating women.\n\nOverall, this sample provides information about a Phase 1 clinical trial that is studying the effects of ixekizumab, boostrix\u00ae, and pneumovax\u00ae23 on healthy individuals without compromised immune systems.",
    "The sample is a phase 1 clinical trial for rheumatoid arthritis. The trial is testing the effectiveness of a drug called meriva compared to a placebo. The eligibility criteria for participants include being diagnosed with rheumatoid arthritis according to the ACR 2010 criteria, being over 18 years old, having active disease as defined by specific disease activity scores, and being willing to sign an informed consent document. There are also exclusion criteria, such as current treatment with certain biologic agents, recent use of biologics, history of non-response to biologics, and use of certain medications within a specific time frame. Other exclusion criteria include certain medical conditions, recent surgery, history of malignancy or serious chronic infection, and certain reproductive factors for pre-menopausal women. The sample also includes criteria related to liver function, heart health, substance abuse, and ability to swallow medications.",
    "The sample from the table represents a phase 1 trial for the treatment of various diseases, including cutaneous T-cell non-Hodgkin lymphoma, recurrent mycosis fungoides and sezary syndrome, and different stages of mycosis fungoides and sezary syndrome. The diseases are associated with specific ICD-10 codes. The trial involves the use of drugs such as fludarabine, cyclophosphamide, mycophenolate mofetil, and tacrolimus. The eligibility criteria for participants include having failed previous therapies or being ineligible for standard therapy, having responsive skin disease without organ or lymph node involvement, having a related donor with specific HLA mismatches, and meeting certain organ function and performance status requirements. There are also exclusion criteria, such as having a poor performance status, being HIV positive, having active central nervous system involvement, and having certain psychiatric disorders. Additionally, patients who are pregnant or have a life expectancy of less than 6 months, among other conditions, are excluded from the trial.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is type 2 diabetes mellitus. The ICDCodes associated with this disease are E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, and E11.44. The drugs being tested in this trial are medi0382 and placebo. The eligibility criteria for participants include a diagnosis of T2DM, written informed consent, a body mass index (BMI) between 27 and 40 kg/m^2, suitable venous access, normal vital signs, non-lactating and non-childbearing potential for females, and the practice of two effective contraceptive measures for sexually active males. The exclusion criteria include any concurrent condition that may interfere with the evaluation of the investigational product, history or presence of gastrointestinal, renal, or hepatic disease, history of cancer within the last 10 years (excluding non-melanoma skin cancer), recent illness, medical/surgical procedure, or trauma, fasting glucose level of 200 mg/dL or higher, positive tests for Hepatitis B, Hepatitis C, or human immunodeficiency virus, previous use of a glucagon-like peptide 1 receptor agonist or systemic corticosteroids, prohibition of using medicinal products or herbal preparations for weight control or appetite, known or suspected history of alcohol or drug abuse within the past 3 years, and positive drug screen.",
    "The sample from the table represents a Phase 1 clinical trial. The trial is focused on healthy individuals, as indicated by the \"diseases\" field containing the value \"healthy\". The corresponding ICD-10 codes for this disease are \"Z76.3\" and \"Z76.2\". The drugs being tested in this trial are \"clonidine mbt 50\u00b5g\", \"clonidine mbt 100\u00b5g\", and \"catapres 100\u03bcg\". \n\nThe eligibility criteria for participants in this trial include being a healthy male or female aged 18-50 years with a body mass index (BMI) between 18 and 30. Participants should not have any clinically significant abnormal serum biochemistry, haematology, or urine examination values. They should also have negative results for urinary drugs of abuse, HIV, and Hepatitis B and C. Additionally, participants should not have any clinically significant abnormalities in their 12-lead electrocardiogram (ECG), blood pressure, or pulse. They should not have any allergies or sensitivities to clonidine or any of its excipients, as well as no allergies to milk or milk derivatives. Written informed consent is required from participants to participate in the study.\n\nThe main exclusion criteria for this trial include having a current or past medical condition that could significantly affect the response to clonidine, recent participation in a clinical study involving a new chemical entity or a marketed drug, oral cavity conditions that would affect buccal administration, Raynaud's disease or other peripheral vascular disease, regular medication use within 14 days that may impact the study's safety and objectives, evidence of dysfunction in renal, hepatic, central nervous system, respiratory, cardiovascular, or metabolic systems, symptomatic postural hypotension evident during screening, and a history or evidence of suicidal ideation and/or behavior as determined by the Columbia-Suicide Severity Rating Scale (C-SSRS).",
    "The sample is a record from a table that contains information about clinical trials. The phase of the trial is a combination of phase 1 and phase 2. The diseases being studied in this trial are \"basal cell nevus syndrome,\" \"skin neoplasm,\" and \"nodular basal cell carcinoma of skin.\" The corresponding ICD-10 codes for these diseases are \"D68.61,\" \"D69.41,\" \"D81.4,\" \"E24.1,\" \"E26.01,\" \"E26.81,\" and \"E34.0.\" The drug being tested in this trial is \"5-fu.\" The eligibility criteria for this trial include specific inclusion and exclusion criteria, such as having low-risk nodular basal cell carcinoma, willingness to undergo injection therapy followed by surgery, and not having known or suspected metastatic disease. Other criteria include not being pregnant or lactating, not having clinically active or uncontrolled skin disease, not being immunocompromised or receiving immunomodulating agents, and not having received psoralen plus Ultraviolet A or Ultraviolet B light therapy within the past 6 months. Additionally, participants should not have any serious or active medical or psychiatric illness, engage in recreational or therapeutic drug or alcohol use, or have taken any investigational product within 1 month of the first dose of ASN-002.",
    "The sample from the table is for a phase 1 clinical trial for rectal cancer. The eligibility criteria for patients to participate in the trial are as follows:\n\n- Patients must have histologically proven adenocarcinoma of the rectum with no evidence of distant metastases.\n- The tumor must be clinically Stage II (T3-4 N0) or stage III (N+).\n- Measurable disease is not required at baseline.\n- Patients must not have received pelvic radiation for rectal cancer or prior pelvic radiation for any other malignancy that would prevent them from receiving the required radiation treatments for this study.\n- Patients must not have an active concurrent invasive malignancy, except for certain low-risk conditions.\n- Patients must be over 18 years of age and have an ECOG performance status of 0-1.\n- Various blood counts and liver function tests must be within specified ranges.\n- Patients must be able to swallow and retain oral medication.\n- Left ventricular ejection fraction must be within normal range.\n- Patients must provide signed informed consent and be able to comply with study and/or follow-up procedures.\n- QTcF (corrected QT interval) must be less than 480 msec.\n- Patients with a history of diarrhea must be informed of potential study drug-induced diarrhea and its management.\n- There are also exclusion criteria, such as known hypersensitivity to the study drug, suspected or confirmed metastatic disease, impaired gastrointestinal function, recent major surgery, certain cardiac abnormalities, and other medical conditions that would preclude participation in the study.\n- Pregnant or nursing women are excluded, and women of child-bearing potential must use highly effective contraception during the study and for a certain period after the final dose of study treatment.\n- The use of certain herbal medications and consumption of certain fruits and juices are not allowed during the study.\n- Patients must not be concurrently using other anti-cancer therapy.\n\nThis sample provides an overview of the eligibility criteria for patients participating in the phase 1 clinical trial for rectal cancer, including disease stage, medical history, laboratory values, and other factors that determine eligibility.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 1. The diseases being studied are non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma (MPM). The ICDCodes associated with these diseases are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The drug being tested is vinorelbine. \n\nThe eligibility criteria for this trial include patients who are 18 years of age or older, have histologically documented locally advanced or recurrent non-small cell lung cancer or malignant pleural mesothelioma for which no standard treatment exists, have at least one measurable lesion according to RECIST v.1.1 for NSCLC and modified RECIST 1.1 for MPM, and have an ECOG performance status of 2 or lower. \n\nThe exclusion criteria include patients with an ECOG performance status higher than 2, significant or uncontrolled cardiovascular disease within 6 months of starting the study treatment, any neurological or psychiatric condition that interferes with the understanding of the study, uncontrolled infectious condition, and any other medical condition that would jeopardize the subject's participation.",
    "The sample provided is a schema definition of a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. The phase column indicates the phase of the trial, which can be phase I, phase II, or phase III. The diseases column lists the names of the diseases being studied, while the icdcodes column contains the corresponding ICD-10 codes for those diseases. The drugs column lists the names of the drugs being tested in the trial. The criteria column provides the eligibility criteria for participants in the trial.\n\nThe sample data in the table includes information for a trial involving psoriasis. The phase is listed as \"phase 1/phase 2\". The disease is specified as \"psoriasis\", and the corresponding ICDCodes are provided as \"['L40.0', 'L40.4', 'L40.8', 'L40.9', 'L40.1', 'L40.50']\". The drugs being tested in this trial are \"vtp-43742\", \"placebo 1\", and \"placebo 2\". The eligibility criteria are then listed for both healthy volunteers and psoriasis patients, including age requirements, body weight and mass index ranges, medical health conditions, contraception requirements for women of child-bearing potential, and consent to participate in the trial.\n\nAdditionally, the exclusion criteria are provided for both healthy volunteers and psoriasis patients, which include factors such as history of significant diseases, organ dysfunction, recent surgeries, positive test results for certain infections, history of alcoholism or drug abuse, hypersensitivity to drugs, gastrointestinal conditions, recent blood donations or transfusions, and pregnancy for women of child-bearing potential.\n\nOverall, the sample provides a comprehensive overview of the schema definition and includes specific information about a trial involving psoriasis.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 1, and the diseases listed are rhabdomyosarcoma, neuroblastoma, sarcoma, sarcoma, ewing, osteosarcoma, and desmoid. The ICDCodes associated with these diseases are C96.A, C46.9, C96.22, C46.0, C46.2, C92.31, and C92.32. The drug mentioned is doxorubicin hcl liposomal injection. The eligibility criteria include age requirements, confirmation of malignant tumors, relapse or failure to respond to frontline therapy, life expectancy, performance status, measurable target lesions, recovery from prior therapy, organ and marrow function, cardiac function, cumulative lifetime anthracycline dose, contraception requirements for females and males of child-bearing potential, negative pregnancy test, and the need for signed written informed consent. The exclusion criteria include receiving other investigational agents or anticancer therapies, active brain metastases, prior treatment with Doxil and progression, history of tumor progression within 30 days of anthracycline administration, allergic reactions to doxorubicin or Doxil, uncontrolled intercurrent illness, pregnancy or nursing, contraindication to MR-HIFU, and high anesthetic risk conditions.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied include anaplastic large cell lymphoma (ALK-negative and ALK-positive), hepatosplenic T-cell lymphoma, peripheral T-cell lymphoma (not otherwise specified), and various stages of angioimmunoblastic T-cell lymphoma and enteropathy-associated T-cell lymphoma. The ICDCodes associated with these diseases are also provided.\n\nThe drugs being used in the trial include cyclophosphamide, doxorubicin hydrochloride, etoposide, lenalidomide, prednisone, and vincristine sulfate.\n\nThe eligibility criteria for participants in the trial are listed, including requirements such as a confirmed diagnosis of certain types and stages of peripheral T-cell non-Hodgkin's lymphoma, pathology material for review, no prior therapy except for radiation or prednisone, expected survival duration of more than 3 months, certain blood counts and liver function within specified limits, and other medical and logistical considerations.\n\nThere are also exclusion criteria listed, such as pregnancy or breastfeeding, certain viral infections, recent major surgery, other types of peripheral T-cell lymphoma not specified in the inclusion criteria, contraindications to required medications or treatments, and other medical or psychiatric conditions that may interfere with the study.\n\nOverall, this sample provides a snapshot of the information contained in the table, including the specific diseases being studied, the drugs being used, and the criteria for eligibility and exclusion from the clinical trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is Type 1 Diabetes Mellitus. The ICDCodes associated with this disease are E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, and E10.44. The drugs being used in the trial are Biochaperone Insulin Lispro and Humalog\u00ae. \n\nThe eligibility criteria for this trial include having Type 1 diabetes for at least 12 months, a body mass index (BMI) between 18.5 and 28.5 kg/m^2, and using or having used a Roche CSII system (Accu-Chek\u00ae Spirit Combo/ Accu-Chek\u00ae Spirit) for at least 6 months before screening. Other criteria include having an HbA1c level of <= 9.0%, a total insulin dose of < 1.2 (I)U/kg/day, the ability to calculate insulin bolus manually or using a bolus calculator, and willingness to perform carbohydrate counting, self-monitoring of plasma glucose (SMPG) profiles, and use of Continuous Glucose Monitoring (CGM). Additionally, fasting C-peptide should be <= 0.30 nmol/L.\n\nThe exclusion criteria for this trial include known or suspected hypersensitivity to the investigational medicinal product(s) (IMP(s)) or related products, having Type 2 diabetes mellitus, previous participation in this trial, receipt of any investigational product in a clinical trial within 60 days before randomization in this trial, clinically significant abnormal haematology, biochemistry, urinalysis, or coagulation screening test, presence of clinically significant acute gastrointestinal symptoms, known slowing of gastric emptying and/or gastrointestinal surgery, unusual meal habits and special dietary requirements or unwillingness to eat the food provided in the trial, history of diabetic ketoacidosis (DKA) episodes requiring hospitalization within 6 months prior to screening, history of abscess at the infusion site within 6 months prior to screening, hypoglycemia unawareness as judged by the investigator, and history of severe hypoglycemic episodes requiring hospitalization within the last 6 months prior to screening.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a trial in Phase 1 and focuses on the disease \"type 2 diabetes mellitus\". The ICD-10 codes associated with this disease are \"E11.65\", \"E11.9\", \"E11.21\", \"E11.36\", \"E11.41\", \"E11.42\", and \"E11.44\". The trial involves the drugs \"biochaperone insulin lispro\" and \"humalog\u00ae\". \n\nThe eligibility criteria for this trial are as follows:\n- The participant must have had type 2 diabetes mellitus for at least 12 months.\n- The participant must have been treated with stable multiple daily insulin for at least 3 months, either through basal-bolus therapy or bolus insulin therapy.\n- The participant's current total daily insulin treatment should be less than 1.2 (I)U/kg/day.\n- The participant's body mass index (BMI) should be below or equal to 40.0 kg/m\u00b2.\n- The participant's HbA1c level should be less than or equal to 9.0% according to local laboratory analysis.\n\nThere are also exclusion criteria for this trial, which include:\n- Known or suspected hypersensitivity to the trial products or related products.\n- Type 1 diabetes mellitus.\n- Previous participation in this trial.\n- Receipt of any investigational product within 60 days prior to this trial.\n- Clinically significant abnormal screening tests for haematology, biochemistry, lipids, or urinalysis, as determined by the investigator.\n- Presence of clinically significant acute gastrointestinal symptoms, such as nausea, vomiting, heartburn, or diarrhea, as determined by the investigator.\n- Presence of renal impairment with an estimated glomerular filtration rate (eGFR) below 60 milliliters/minute/1.73m\u00b2.\n- Presence of late diabetic complications and/or acute coronary heart disease.\n- Known slowing of gastric emptying and/or gastrointestinal surgery that may affect gastrointestinal motility and food absorption, as determined by the investigator.\n- Unusual meal habits, special diet requirements, or unwillingness to eat the food provided in the trial.\n- Current treatment with corticosteroids.",
    "The sample from the table is for a phase 1 trial. The disease being studied is idiopathic Parkinson's disease. The corresponding ICD-10 code for this disease is G20. The drugs being tested in the trial are pf-06669571 and a placebo. The eligibility criteria for the trial include having a clinical diagnosis of idiopathic Parkinson's disease with at least 2 out of 3 cardinal characteristics (tremor, rigidity, and/or bradykinesia), being at Hoehn & Yahr Stage II-III, experiencing motor fluctuations such as end-of-dose wearing off or early morning akinesia, being able to recognize and verify improvement of symptoms after taking Parkinson's disease medication, and being able to recognize and assess the impact of drug-induced dyskinesias. The exclusion criteria include a history or clinical features consistent with an atypical parkinsonian syndrome, such as ataxia, dystonia, or clinically significant orthostatic hypotension.",
    "The sample is a phase 1 trial for diabetes, specifically type 1 diabetes mellitus. The trial is testing two drugs, faster-acting insulin aspart and insulin aspart. The eligibility criteria for participants include being between the ages of 18-64, having been diagnosed with type 1 diabetes mellitus at least a year prior to screening, and having a body mass index between 18.5-28.0 kg/m^2. Some exclusion criteria include being a smoker who is unable or unwilling to refrain from smoking during the trial, and having donated blood or plasma within the past month or more than 500 mL within the past 3 months.",
    "The sample is a record from a table that contains information about clinical trials. The phase of the trial is \"phase 1/phase 2\". The disease mentioned in this sample is \"non-hodgkin lymphoma\". The corresponding ICD-10 codes for this disease are \"['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']\". The drugs being tested in this trial are \"entospletinib\" and \"vincristine\". The eligibility criteria for participants in this trial include having measurable disease, a confirmed diagnosis of relapsed or refractory B-Cell NHL, and having received prior treatment for lymphoid malignancy. Other criteria include performance status, organ function, discontinuation of prior therapy, and willingness to comply with study procedures. There are also exclusion criteria, such as having certain medical conditions, ongoing infections, or prior treatment with a specific type of inhibitor.",
    "The sample is a record from a table that contains information about clinical trials. In this particular sample, the trial is in phase 1/phase 2. The disease being studied is Hodgkin lymphoma. The ICD-10 codes associated with this disease are 'S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', and 'S33.131S'. The drugs being tested in this trial are brentuximab vedotin and nivolumab. The eligibility criteria for participants include having relapsed or refractory Hodgkin lymphoma after standard frontline chemotherapy, having an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and not having been previously treated with brentuximab vedotin, immune-oncology agents, or received a stem cell transplant. Exclusion criteria include a history of cerebral vascular event, another invasive malignancy that has not been in remission for at least 3 years, and a history of progressive multifocal leukoencephalopathy (PML).",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 1. The diseases being studied are gastric cancer, gastroesophageal junction adenocarcinoma, non-small cell lung cancer, and hepatocellular carcinoma. The corresponding ICDCodes for these diseases are also provided.\n\nThe drugs being investigated in this trial are ramucirumab and medi4736. The eligibility criteria for participants in this trial include having measurable metastatic or locally advanced and unresectable disease, having confirmed histopathological evidence of the specified diseases, documented disease progression after a certain number of prior lines of systemic therapy, availability of tumor tissue for biomarker analysis, Eastern Cooperative Oncology Group Performance Status of 0 or 1, and adequate organ function.\n\nThe exclusion criteria for this trial include having known brain metastases, a history of prior cancers not included in the study, history of allogeneic organ transplant, active or prior documented autoimmune disease, HIV infection or AIDS-related illness, active hepatitis B or hepatitis C infection, chronic hepatitis B or hepatitis C infection for certain participants, history of lung diseases, previous systemic therapy targeting specific signaling pathways, and previous systemic therapy with ramucirumab.",
    "The sample provided is for a clinical trial study. The trial is in phase 1/phase 2 and focuses on the disease osteoarthritis. The associated ICD-10 codes for osteoarthritis are ['M15.4', 'M15.0', 'M16.9', 'M17.9', 'M19.011', 'M19.012', 'M19.019']. The drug being studied is hyaluronic acid. \n\nThe eligibility criteria for inclusion in the trial are as follows:\n- Patients must have symptomatic knee osteoarthritis, with Kellgren and Lawrence grade I, II, or III on plain radiographs.\n- Patients must have chondromalacia patella grade I-III on knee MRI, with or without a meniscal tear.\n- The knee must be stable and have a normal clinical examination.\n- Patients must provide written informed consent.\n\nThe exclusion criteria for the trial are as follows:\n- Patients with bilateral symptomatic knee osteoarthritis are not eligible.\n- Patients with local or systemic infection are not eligible.\n- Patients with active neoplasia or an immunosuppressive state are not eligible.\n- Pregnant or breastfeeding individuals are not eligible.\n- Patients with a body mass index (BMI) of 30 or higher are not eligible.\n- Patients with a pacemaker or lower extremity metal implant are not eligible.\n- Patients on anticoagulant treatment other than aspirin are not eligible.\n- Patients who have recently used oral (within the previous month) or intra-articular (within the previous 3 months) corticosteroids are not eligible.\n- Patients with concomitant inflammatory joint disease (such as crystal or connective tissue disease) are not eligible.\n- Patients with a valgus (>10\u00b0) or varus (>5\u00b0) deformity of the involved extremity are not eligible.\n- Patients with condylar or tibial plateau generalized bone marrow edema on MRI are not eligible.\n- Patients with significant symptomatic hip or spine disease are not eligible.\n- Patients with significant abnormalities in baseline lab tests are not eligible.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1 and is focused on pancreatic cancer. The ICD-10 code for pancreatic cancer is C25.3. The drug being tested in the trial is called GAX, which is a combination of gemcitabine, abraxane, and xeloda. The eligibility criteria for the trial include having histologically confirmed adenocarcinoma of the pancreas that has metastasized to a distant site, having a measurable lesion according to CT or MRI scans, and meeting certain health requirements such as liver, bone marrow, and renal function. Other criteria include being of childbearing potential and using contraception, having a certain level of pre-existing peripheral neuropathy, and being able to tolerate oral medications. Informed consent is also required. The exclusion criteria include ruling out neuroendocrine cancer, limiting prior chemotherapy use, and excluding patients with hypersensitivity to certain drugs. Other exclusion criteria include having serious medical or psychiatric illnesses, compromised immune systems, serious cardiovascular thromboembolic disease, non-healing wounds or fractures, bleeding diathesis, recent major surgery or trauma, use of certain drugs, and having had another malignancy within the past 2 years.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1 and focuses on the disease \"type 1 diabetes mellitus\". The icd-10 codes associated with this disease are \"E10.65\", \"E10.9\", \"E10.21\", \"E10.36\", \"E10.41\", \"E10.42\", and \"E10.44\". The drugs being studied are \"dapagliflozin 5mg\", \"dapagliflozin 10mg\", and \"placebo tablet\". The eligibility criteria for participants are listed, including requirements such as signed informed consent, a diagnosis of T1DM, specific insulin use and administration methods, gender and age restrictions, HbA1c levels, BMI range, and exclusion criteria related to other diseases, medication use, medical history, and laboratory test results.",
    "The sample provided is for a phase 1 clinical trial. The diseases being studied are pneumonia and pneumococcal infections. The corresponding ICD-10 codes for these diseases are A01.03, A02.22, A54.84, B01.2, B06.81, B77.81, and J12.0. The drugs being tested in this trial are cal02 low-dose, cal02 high-dose, and placebo. \n\nThe eligibility criteria for inclusion in the trial are as follows:\n- Adult male or female patients aged 18 to 80 years\n- Body weight between 40 and 140 kg\n- Severe pneumonia caused by Streptococcus pneumoniae managed in an ICU\n- CURB-65 score of 3 or higher in patients aged over 65, and CURB-65 score of 2 or higher in patients aged under 65\n- Streptococcus pneumoniae identification with the urine antigen test or any other proven documented identification method\n- Written informed consent provided by the patient, relatives, or designated trusted person according to local guidelines\n\nThe exclusion criteria for the trial are as follows:\n- Patients with hospital-acquired, health care-acquired, or ventilator-associated pneumonia\n- More than 12 hours since diagnosis of severe CAPP and more than 24 hours or 60 hours since antibiotic treatment IV or per os, respectively, unless documented not to be active against S. pneumoniae, will have elapsed at the time of IMP administration\n- APACHE II score greater than 30 points\n- SOFA score greater than 12 points\n- Inability to maintain a mean arterial pressure of 50 mm Hg or higher\n- Known hypersensitivity to liposomal formulations\n- Patients with severe neutropenia or lymphoma or current or anticipated chemotherapy\n- End-stage neuromuscular disorders\n- Patients who have long-term tracheostomy\n- Current or recent participation in an investigational study\n- Presence of other pneumococcal site infection\n- Patients with known acquired immune deficiency syndrome (AIDS) with CD4 count less than 200 cells/mL\n- Patients with known post-obstructive pneumonia (active primary lung cancer or another malignancy metastatic to the lungs)\n- Patients with cystic fibrosis, Pneumocystis jiroveci pneumonia, or active tuberculosis\n- Patients receiving immunosuppressant therapy\n- Patients with a known liver function deficiency\n- Splenectomized patients\n- Patients who have experienced an allergic reaction to eggs\n- Moribund clinical condition\n- Nursing and pregnant women\n- Women of childbearing potential not using effective contraception.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is \"early phase 1\" and the disease is \"diabetic retinopathy\". The ICDCodes associated with the disease are \"H35.23\", \"H35.20\", \"H35.21\", \"H35.22\", \"E10.3553\", \"E11.3553\", and \"E13.3553\". The drugs being studied are \"metformin\", \"lantus\", and \"novomix30\". The eligibility criteria for this trial include being aged 30-65, diagnosed with type 2 diabetes according to the WHO diagnostic criteria in 1999, having diabetes duration of 5 years or less, having a glycosylated hemoglobin (HbA1c) level higher than or equal to 7.0%, having a body mass index (BMI) between 20-35 kg/m2, having no diabetic retinopathy according to fluorescein fundus angiography (FFA), and having a birth control plan for women of childbearing age for 5 years. The exclusion criteria include being pregnant or lactating, testing positive for diabetes autoantibodies (GAD) antibodies, experiencing certain diabetic complications within the past half year, having abnormal liver or kidney function, having a history of hemoglobin diseases that can affect HbA1c determination, having a history of certain cardiovascular procedures or conditions, being a psychiatric patient, having severe eye conditions or surgeries, having other serious diseases that are deemed unfit for the trial by the researchers.",
    "The sample from the table represents a clinical trial for the treatment of lymphoma. The trial is in phase 1/phase 2. The diseases being studied are lymphoma. The icd-10 codes associated with the diseases are ['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']. The drugs being tested in the trial are lenalidomide, vorinostat, gemcitabine, busulfan, melphalan, rituximab, dexamethasone, caphosol, glutamine, pyridoxine, enoxaparin, and palifermin. The eligibility criteria for the trial include age between 15-65, patients with ABC DLBCL with primary refractory disease, relapse <12 months after initial therapy, secondary International Prognostic Index (IPI) >1, less than partial response to salvage treatment or exposure to >3 salvage regimens, adequate renal function, adequate hepatic function, adequate pulmonary function, adequate cardiac function, ECOG performance status <2, negative Beta HCG in women with child-bearing potential, registration into the mandatory Revlimid REMS program, and adherence to the scheduled pregnancy testing for females of reproductive potential. The exclusion criteria include grade >/= 3 non-hematologic toxicity from previous therapy, prior whole brain irradiation, active hepatitis B or hepatitis C, active infection requiring parenteral antibiotics, HIV infection without effective antiretroviral therapy, recent radiation therapy, history of arterial or venous thromboembolic events, and history of hypersensitivity to lenalidomide or thalidomide.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease being studied is myelofibrosis. The ICDCodes associated with this disease are D75.81, C94.41, C94.42, and C94.40. The drugs being used in the trial are ruxolitinib and vismodegib. \n\nThe eligibility criteria for this trial include:\n- The participant must have a confirmed diagnosis of primary MF, post-polycythemia vera MF, or post-essential thrombocythemia MF based on the 2008 revised World Health Organization criteria.\n- The participant must be classified as intermediate-1, intermediate-2, or high-risk according to the IWG-MRT Dynamic International Prognostic Scoring System.\n- The participant must have a life expectancy of at least 6 months.\n- The participant's peripheral blood blast count must be less than 10%.\n- The participant must have palpable splenomegaly greater than 5 centimeters below the left costal margin.\n- The participant's Eastern Cooperative Oncology Group performance status must be between 0 and 2.\n- The participant must have adequate hepatic and renal function.\n\nThe exclusion criteria for this trial include:\n- The participant must not have received prior treatment with a Hedgehog or Janus kinase pathway inhibitor.\n- The participant must not have received treatment with strong cytochrome P450 3A4 inhibitors/inducers within 28 days prior to Day 1.\n- The participant must not have received prior therapy for the treatment of intermediate- or high-risk MF, including chemotherapy, interferon, thalidomide, busulfan, lenalidomide, anagrelide, or androgens within 28 days prior to Day 1.\n- The participant must not have undergone prior splenectomy or splenic irradiation.\n- The participant must have adequate bone marrow reserve.\n- The participant must not have a history of platelet counts below 50,000/mccL or ANC below 500/mL, except during treatment for myeloproliferative neoplasm or treatment with cytotoxic therapy for any other reason.\n- The participant must not have a planned allogeneic bone marrow transplant during the study.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease mentioned is \"end stage renal disease,\" and the corresponding ICDCodes are ['N18.6', 'I12.0', 'I13.11', 'I13.2']. The drug mentioned is \"triferic.\" \n\nThe eligibility criteria for this trial include:\n1. The parents or legal guardians of the patient must understand the study requirements and have given consent for their child to participate.\n2. The patient must be under 18 years of age at the screening.\n3. The patient must have chronic kidney disease and receive in-center hemodialysis at least twice weekly for at least 1 month prior to screening.\n4. The patient must be receiving adequate hemodialysis, as assessed by a single pool Kt/V measurement >1.2.\n5. The patient must have a suitable vascular access for hemodialysis treatment (tunneled catheter, AV fistula, or AV graft).\n6. The patient must have a body mass of at least 11 lbs (5 kg).\n7. The patient must have sufficient iron levels, indicated by a TSAT >20% and a ferritin >100 micrograms/L at screening.\n8. The patient must have a whole blood Hgb concentration of at least 10.0 g/dL at screening.\n9. If the patient is receiving ESA (erythropoiesis-stimulating agents), the dose must have been stable for at least 3 weeks prior to baseline admission.\n10. The patient must have appropriate laboratory values for their disease state, as determined by the investigator.\n11. The patient must not have any significant abnormal findings on physical examination that would prevent participation in the study.\n12. If the patient is female, she must be pre-pubertal, have undergone surgical sterilization, or be practicing adequate birth control. Female patients aged 9 years and older, as well as those who have reached menarche before age 9 years, must have a negative serum pregnancy test during screening. The investigator is responsible for determining whether the patient has adequate birth control for study participation.\n\nThe exclusion criteria for this trial include:\n1. The patient is positive for human immunodeficiency virus (HIV) or hepatitis B based on their medical history.\n2. The patient has had an acute illness within 1 week of baseline admission (they may be screened again 2 weeks after the illness has resolved).\n3. The patient is currently receiving intravenous or oral antibiotics or antifungals for any infectious process. However, regular prophylactic antibiotics are allowed.\n4. The patient has evidence of an ongoing active inflammatory process, such as systemic lupus erythematosus or acute/chronic active hepatitis.\n5. The patient has participated in another investigational drug study within the 30 days prior to baseline admission.\n6. The patient has received IV or oral iron supplements within 2 weeks prior to baseline admission.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is categorized as \"phase 1\" and the disease being studied is a \"healthy volunteer.\" The corresponding ICD-10 code for this disease is \"Y99.2.\" The drugs being used in the trial are \"dsta4637s\" and \"placebo.\" \n\nThe eligibility criteria for participants in this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" Inclusion criteria include factors such as signing an informed consent form, being able to comply with the study protocol, having a body mass index (BMI) between 18 and 32 kg/m^2, being in good health based on medical history, ECG, and vital signs, and agreeing to abstain from drug use during the study period. \n\nExclusion criteria include having any diseases or conditions that contraindicate the use of the investigational drug, recent use of tobacco or electronic nicotine delivery systems, recent vaccination, pregnancy or lactation, positive pregnancy test, recent use of antibiotics or hospitalization, positive test results for hepatitis C, hepatitis B, or HIV, history of drug abuse, positive drug screen, history of drug hypersensitivity, recent blood transfusion or blood donation, abnormal ECG, recent exposure to biological therapy or investigational treatment, and history of hypersensitivity or allergy to rifampin or other rifamycin analogs.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is Type 2 Diabetes Mellitus. The ICDCodes associated with this disease are E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, and E11.44. The drugs being investigated in this trial are Metformin and HMS5552. \n\nThe eligibility criteria for this trial are as follows:\nInclusion Criteria:\n- The trial is open to both male and female subjects aged between 18 and 70 years.\n- The subjects must have a Body Mass Index (BMI) ranging from approximately 22 to 38kg/m2.\n- The HbA1c levels of the subjects must be between 7% and 12%.\n- The subjects must be capable of providing informed consent and complying with the study procedures.\n\nExclusion Criteria:\n- Subjects with fasting blood glucose levels below 110mg/dL or above 270mg/dL are not eligible.\n- Subjects with Type 1 Diabetes Mellitus or latent autoimmune diabetes in adults are excluded.\n- Individuals with a history or symptoms of clinically significant cardiovascular disease, particularly coronary artery disease, arrhythmias, atrial tachycardia, or congestive heart disease within one year of screening are not eligible.\n- Subjects with a history of liver disease or clinically significant renal disease are excluded.\n- Individuals with a known hypersensitivity to metformin hydrochloride are not eligible.\n- Subjects with a positive pregnancy test result are also excluded from the trial.",
    "The sample provided is for a phase 1 trial. The disease being studied is \"healthy,\" which seems to indicate that the trial is focused on individuals who are not currently suffering from any specific disease. The icd-10 codes associated with the disease are \"Z76.3\" and \"Z76.2.\" \n\nThe drugs being tested in this trial are \"ly3154207,\" \"placebo,\" and \"modafinil.\" \n\nThe eligibility criteria for participants include being overtly healthy males who are 18 years of age or older and have given consent. They should also be reliable and willing to make themselves available for the duration of the study and follow study procedures. Additionally, participants should have a regular sleep pattern, spending between 6.5 and 9 hours in bed each night. \n\nExclusion criteria include being shift workers who have shifted work within 14 days prior to screening or plan to do so during the study. Participants should not have a known sleep disorder or a history of a sleep disorder. They should not have traveled 2 time zones or more within 7 days prior to screening or plan to do so during the study. Regularly taking naps during the day or being hearing impaired are also grounds for exclusion from the trial.",
    "The sample provided is a record from a table that contains information about clinical trials. The phase of the trial is a combination of phase 1 and phase 2. The disease being studied is influenza, and its corresponding ICD-10 codes are ['J11.81', 'J11.82', 'J10.01', 'J10.81', 'J10.82', 'J11.08', 'J11.2']. The drugs being tested in this trial are oseltamivir, medi8852, and a placebo. The eligibility criteria for participants in this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include age between 18 and 65, symptomatic presumptive Influenza A infection, confirmation of infection through a positive rapid antigen test, ability to complete the follow-up period, and the use of contraception for sexually active females. Exclusion criteria include hospitalization, recent influenza antiviral therapy, immunoglobulin or blood product receipt, immunodeficiency, pneumonia, active bacterial infection, history of certain malignancies, and planned surgical procedures before the completion of the study.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2 and focuses on the treatment of postpartum hemorrhage. The trial is investigating the use of tranexamic acid and ethamsylate as drugs. The eligibility criteria for participants include being women undergoing elective caesarean section, having one or more risk factors for postpartum hemorrhage, being at least 18 years old, and having a gestational age of at least 35 weeks. Informed oral consent from the patient is also required. The exclusion criteria include a history of venous or arterial thrombosis, epilepsy or seizure history, any known cardiovascular, renal, or liver disease, autoimmune diseases, sickle cell disease, severe hemorrhagic disease, placenta previa, morbidly adherent placenta, abruptio placenta, eclampsia, hemolysis, elevated liver enzymes, and low platelet count syndrome, and administration of low molecular weight heparin or antiplatelets the week before delivery.",
    "The sample is a phase 1 clinical trial for patients with metastatic melanoma. The trial is evaluating the effectiveness of the drugs SGI-110 and ipilimumab. The eligibility criteria for participants include having unresectable Stage III or Stage IV melanoma with measurable lesions, being previously treated or untreated, having an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1, and having negative screening tests for HIV, Hepatitis B, and Hepatitis C. Other criteria include having a life expectancy greater than 16 weeks, not having any contraindications for ipilimumab, not having active brain metastases or leptomeningeal metastases, not having metastatic uveal melanoma, and not having active, known, or suspected autoimmune disease. Exclusion criteria include having a condition requiring systemic treatment with corticosteroids or other immunosuppressive medications, having symptomatic effusions due to pleural or pericardial metastases of melanoma, having prior treatment with certain antibodies, having had major surgery or radiation therapy within 21 days of starting treatment, and being unable to return for follow-up visits as required by the study. Additionally, prisoners or subjects who are involuntarily incarcerated, as well as subjects who are compulsorily detained for treatment of a psychiatric or physical illness, are also excluded from the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The diseases being studied include locally advanced solid tumors, metastatic solid tumors, and ovarian cancer. The ICDCodes associated with these diseases are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drug being tested is AZD1775. The eligibility criteria for this trial include various medical and demographic requirements such as prior radiation completion, ECOG PS score, laboratory values, contraceptive measures, life expectancy, age, and documented tumor type. The exclusion criteria include restrictions on prior treatment, investigational drug use, recent surgical procedures, toxicity from prior therapy, ability to swallow oral medications, CNS disease, drug interactions, cardiac diseases, QTc interval, pregnancy or lactation, active infections or other medical conditions, presence of other active invasive cancers, and factors that may hinder compliance with the protocol.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease being studied is chronic lymphocytic leukemia. The ICDCodes associated with this disease are C91.11, C91.12, and C91.10. The drugs being used in the trial are ibrutinib and obinutuzumab. The eligibility criteria for this trial include clinical and phenotypic verification of B cell CLL or SLL with measurable disease, prior therapy with single-agent ibrutinib, progressive disease on current ibrutinib therapy, ECOG performance status of 0-2, adequate hematologic, renal, and hepatic function. The exclusion criteria include known CNS lymphoma or leukemia, history of Richter's or prolymphocytic transformation, primary ibrutinib resistance, uncontrolled autoimmune hemolytic anemia or idiopathic thrombocytopenia purpura, recent CLL therapy, history of major surgery, history of prior malignancy (except for certain cases), currently active cardiovascular disease, active hepatitis B or C infection, history of HIV infection, inability to swallow capsules or gastrointestinal issues, history of stroke or intracranial hemorrhage, requirement for anticoagulation or strong CYP 3A inhibitor, pregnancy or breastfeeding, receiving another investigational therapy, and current infection requiring parenteral antibiotics.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is \"healthy.\" The ICDCodes associated with this disease are \"Z76.3\" and \"Z76.2.\" The drugs being tested in this phase are \"glpg1972 single ascending doses,\" \"placebo single dose,\" \"glpg1972 multiple ascending doses,\" and \"placebo multiple doses.\" \n\nThe eligibility criteria for this trial are as follows:\nInclusion Criteria:\n- Males between 18-50 years of age\n- Subjects must have a body mass index between 18-30 kg/m\u00b2\n- Subjects must be judged to be in good health based upon the results of a medical history, physical examination, vital signs, 12-lead electrocardiogram, and laboratory profile\n\nExclusion Criteria:\n- A subject with a known hypersensitivity to study drug ingredients or a significant allergic reaction to any drug\n- Concurrent participation or participation within 8 weeks prior to the initial study drug administration in a drug/device investigational research study\n- A subject with active drug or alcohol abuse within 2 years prior to the initial study drug administration\n- Current sexually active (and/or child wish) male; a contraception method should be used",
    "The sample from the table is a clinical trial for colorectal cancer patients in phase 1/phase 2. The eligibility criteria for participants include being aged between 20 and 75 years, having unresectable adenocarcinoma originating in the large intestine, having lesions that can be evaluated according to specific criteria, and being refractory to or failing previous chemotherapies for metastatic colorectal cancer. Participants must also be classified as KRAS/NRAS wild-type, able to take medications orally, and have satisfactory organ function. Other criteria include having an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and a life expectancy of at least 3 months. Exclusion criteria include previous treatment with certain drugs, recent radiotherapy or chemotherapy, brain metastasis, synchronous or metachronous cancers with a disease-free period of 5 years or more, and various other medical conditions. Participants who do not meet the eligibility criteria or are deemed ineligible by the investigator or subinvestigator are excluded from enrollment in the study.",
    "The sample from the table is for a Phase 1 clinical trial. The disease being studied is advanced solid tumors. The ICD-10 codes associated with these tumors are K74.02, G47.22, H35.3133, H35.3134, H35.3113, H35.3114, and H35.3123. The drug being tested is a combination of interferon-gamma and nivolumab. \n\nThe eligibility criteria for this trial include:\n1. Patients must have a histologically or cytologically confirmed metastatic solid tumor that has shown evidence of responding to anti-PD-1 therapy or the ability to up-regulate PD-L1. Various tumor types are listed, including RCC, UC, melanoma, NSCLC, small cell lung cancer, SCCHN, ovarian carcinoma, triple negative breast cancer, gastric cancer, MSI-high colon cancer, hepatocellular carcinoma, mesothelioma, gastrointestinal stromal tumors, endometrial carcinoma, liposarcomas, chondrosarcomas, and uterine sarcomas. Other solid tumor types may be enrolled at the discretion of the Principal Investigator.\n2. Patients must have received at least one line of systemic therapy in the metastatic setting, including prior immunotherapy with nivolumab or another PD-1 inhibitor.\n3. Patients must have measurable disease according to RECIST criteria v. 1.1.\n4. Patients must have a site of disease amenable to pretreatment and on-treatment core biopsies.\n5. Patients must be at least 18 years old and have an ECOG performance status of 0 or 1.\n6. Patients must have normal organ and marrow function.\n7. Patients must be able to understand and sign an informed consent and HIPAA consent document.\n\nThe exclusion criteria for this trial include:\n1. Patients who have received chemotherapy or radiotherapy within 2 weeks prior to entering the study.\n2. Patients with active or recent history of autoimmune disease or syndromes requiring systemic corticosteroids or immunosuppressive medications, except for certain syndromes.\n3. Patients who have received systemic treatment with corticosteroids or other immunosuppressive medications within 14 days prior to the first dose of the study drug.\n4. Patients who are receiving any other investigational agents.\n5. Patients with active or symptomatic central nervous system metastases or carcinomatous meningitis.\n6. Patients with a history of allergic reactions to similar compounds.\n7. Patients with uncontrolled intercurrent illness or medical conditions that could interfere with the study or increase the risk to the patient.\n8. Patients who are HIV positive or have a history of AIDS or AIDS-defining illness.\n9. Patients with current or history of hepatitis B or C virus, unless the disease has been treated and cleared.\n10. Patients with any medical condition that could interfere with the interpretation of the study or increase the risk of potential toxicity.\n11. Patients who have undergone major surgery within 4 weeks of starting the study drug.\n12. Pregnant or breastfeeding patients.\n13. Patients with a second invasive malignancy requiring active treatment.",
    "The sample from the table represents a clinical trial in Phase 1 for the treatment of schizophrenia. The trial includes participants who are between 18 and 60 years old and have been diagnosed with schizophrenia according to the Diagnostic & Statistical Manual of Mental Disorders, 5th Edition (DSM-V). The participants must be in good health and have acceptable clinical laboratory evaluations.\n\nIn terms of medication, the participants must be on a stable dose of a single second-generation antipsychotic (SGA) for at least 2 months prior to screening. The trial will assess the effectiveness of the drugs \"tak-058\" and \"ondansetron\" compared to their respective placebos.\n\nThe inclusion criteria also require participants to have a Positive and Negative Syndrome Scale (PANSS) total score of less than or equal to 85 and a P50 ratio greater than 0.5 at both screening assessments.\n\nOn the other hand, there are exclusion criteria that disqualify participants who have a history of treatment with clozapine or olanzapine, have taken any excluded medications or supplements, have gastrointestinal diseases that may affect drug absorption, or have significant medical histories that contraindicate the administration of TAK-058, ondansetron, or similar compounds.\n\nParticipants with substance abuse or dependence within the previous 12 months, unstable mood or anxiety disorders, current diagnosis of significant psychiatric illnesses other than schizophrenia, or clinically meaningful hearing loss are also excluded from the trial.\n\nOverall, this sample represents a Phase 1 clinical trial for the treatment of schizophrenia, with specific eligibility criteria and exclusion criteria for participant selection.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1 and focuses on the disease \"ulcerative colitis\". The ICD-10 codes associated with this disease are \"K51.80\", \"K51.813\", \"K51.814\", \"K51.90\", \"K51.913\", \"K51.914\", and \"K51.811\". The drugs being studied in this trial are \"ser-287\", \"placebo\", \"placebo pre-treat\", and \"vancomycin pre-treat\". The eligibility criteria for this trial include specific inclusion and exclusion criteria, such as the diagnosis of ulcerative colitis, certain health conditions, medication usage, and previous medical history.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease mentioned is pancreatic adenocarcinoma. The icd-10 codes associated with this disease are C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, and C4A.31. The drugs being used in the trial include chemotherapy, gemcitabine, irinotecan, leucovorin, 5-fluorouracil, and pembrolizumab. The eligibility criteria for patients to participate in this trial are listed, including having confirmed advanced or metastatic pancreatic adenocarcinoma, having failed or not tolerated first-line therapy, having measurable disease, and meeting certain laboratory result requirements. There are also exclusion criteria listed, such as not receiving concurrent therapy with any other investigational anticancer agent, not being on immunosuppressive therapy or having known HIV infection or active hepatitis B or C, and not having clinically significant cardiac disease.",
    "The sample is a phase 1 clinical trial for the treatment of triple negative breast neoplasms. The trial is investigating the effectiveness of several drugs, including nab-paclitaxel, anthracycline (doxorubicin), cyclophosphamide, carboplatin, and paclitaxel. The eligibility criteria for participants include having previously untreated, locally advanced TNBC, being able to provide tumor biopsies, having a performance status of 0 or 1, and having adequate organ function. Exclusion criteria include having metastatic breast cancer, receiving prior chemotherapy or radiation therapy within the past 12 months, participating in another study within 4 weeks of the trial, having certain medical conditions or infections, and being pregnant or breastfeeding. Participants must also not have any known hypersensitivity to the study drugs.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this specific sample, the phase of the trial is Phase 1. The disease mentioned is \"advanced solid tumors.\" The ICDCodes associated with this disease are \"K74.02,\" \"G47.22,\" \"H35.3133,\" \"H35.3134,\" \"H35.3113,\" \"H35.3114,\" and \"H35.3123.\" The drug mentioned is \"anlotinib and 14c-labeled anlotinib.\" \n\nThe eligibility criteria for this trial are as follows:\n\nInclusion Criteria:\n- The participant must have signed and dated informed consent.\n- The participant must have a histologically or cytologically confirmed diagnosis of advanced solid tumor, including RCC, NSCLC, STS, and CRC.\n- The participant must have failed the treatment of line 1 or 2.\n- The participant's ECOG PS (Eastern Cooperative Oncology Group Performance Status) must be 0-1, and their life expectancy should be more than 3 months.\n- The participant's main organs' function should be normal.\n\nExclusion Criteria:\n- The participant should not have had prior treatment with Anlotinib or be allergic to the drug or its formulation ingredients.\n- The participant should not have gastrointestinal tract, liver, or kidney diseases that affect drug absorption and metabolism.\n- The participant should not have CTCAE (Common Terminology Criteria for Adverse Events) Grade 1 or higher non-remission toxicity induced by any other previous treatments.\n- The participant should not have pleural effusion or ascites causing respiratory syndrome (CTCAE Grade 2 or higher dyspnea).\n- The participant should not have undergone major surgical treatment, open biopsy, or significant traumatic injury within 28 days prior to assignment.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2 and focuses on the disease \"appendicitis\". The ICD-10 codes associated with the disease are ['K36', 'K37', 'K35.80', 'K35.20', 'K35.21', 'K35.890', 'K35.891']. The drugs being studied are \"ropivacaine\" and \"normal saline\". \n\nThe eligibility criteria for participants are as follows:\n- Children and adolescents aged 7-18 years old\n- ASA Score I or II (American Society of Anesthesiologists classification) indicating a normal healthy patient or a patient with mild systemic disease\n- Patients scheduled for laparoscopic appendectomy surgery\n- Uncomplicated appendicitis, with no evidence of appendiceal perforation based on preoperative clinical and imaging assessment, and diagnosed as simple acute appendicitis by intraoperative laparoscopy\n- Patients who have provided a written informed assent, and caregivers who have provided a written informed consent\n\nThe exclusion criteria for participants are as follows:\n- ASA Score III, IV, or V indicating severe systemic disease or a moribund patient\n- Hemodynamically unstable patient\n- Evidence of appendiceal perforation based on preoperative clinical and imaging assessment, or diagnosed with perforated or gangrenous appendicitis during laparoscopic surgery\n- Postoperative admission in an intensive care unit with sedation or ventilatory assistance\n- Cognitive impairment or mental retardation\n- Progressive degenerative diseases of the CNS\n- Seizures or chronic therapy with antiepileptic drugs\n- Severe hepatic or renal impairment\n- Allergy to one of the specific drugs under study\n- Alcohol or drug addiction\n- Failure to successfully undergo a laparoscopic appendectomy\n- A significant communication problem including language barrier, precluding phone follow-up\n- Participation in a concomitant research study\n- Inability to assure complete follow-up\n- Failure to acquire informed consent and assent",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is oral mucositis, and the corresponding ICDCodes are K12.30, K12.39, K12.33, K12.31, and K12.32. The drugs being tested are melatonin oral gel 3% and placebo oral gel. The eligibility criteria for this trial include requirements such as patients being 18 years or older, providing written informed consent, having a life expectancy of at least 3 months, and being willing to comply with treatment and follow-up. Other criteria include specific histological diagnoses, treatment plans, performance status, and baseline organ function. The exclusion criteria list various conditions and circumstances that would make a patient ineligible for participation in the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are solid tumors, soft-tissue sarcoma, and breast cancer. The ICDCodes associated with these diseases are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The drugs being used in the trial include cyclophosphamide and jx-594 dose escalation, cyclophosphamide and jx-594, cyclophosphamide, and avelumab and jx-594 and cyclophosphamide. The eligibility criteria for the trial include specific histology requirements, metastatic or unresectable locally advanced disease, age over 18 years, specific ECOG scores, life expectancy of more than 3 months, measurable disease according to RECIST v1.1 criteria, a certain time since last treatment, and adequate hematological, renal, metabolic, and hepatic functions. There are also additional criteria related to pregnancy, drug interactions, informed consent, and social security compliance. The exclusion criteria include previous treatment with specific drugs, certain concomitant diseases/conditions, active central nervous system metastasis, recent participation in other studies, inability to comply with study procedures, known hypersensitivity to study drugs, use of certain medications, previous malignancies, active cardiovascular disease, and other specific medical conditions. Household contact exclusions and vaccination restrictions are also mentioned.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1 and focuses on endometrial cancer. The diseases associated with the trial include endometrial cancer, endometrial carcinoma, and neoplasms, endometrial. The corresponding ICD-10 codes for these diseases are N85.00, N85.01, N85.02, N99.85, C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, and C4A.31. The drugs being studied in the trial are mk-3475, paclitaxel (standard of care), and carboplatin (standard of care). The eligibility criteria for the trial include a diagnosis of FIGO grade 3 endometrioid cancer or other high-grade endometrial cancers, radiographically confirmed advanced stage endometrial adenocarcinoma, and specific requirements for bone marrow and organ function. There are also exclusion criteria, such as prior treatment for endometrial cancer, prior treatment with certain anti-cancer agents, and certain medical conditions.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 1 and focuses on the disease \"anemia.\" The ICD-10 codes associated with this disease are \"D53.2,\" \"D64.9,\" \"D46.4,\" \"D53.0,\" \"D53.9,\" \"D61.3,\" and \"D61.9.\" The drugs being studied are \"ag-519\" and \"placebo.\" \n\nThe sample also includes the eligibility criteria for participants in the trial. Inclusion criteria include being a healthy adult male or female, aged 18 to 60 years, with a specific body mass index range, good overall health, non-smokers, and willing to participate in the study. Exclusion criteria include recent participation in another clinical research study, being an employee or immediate family member of a study site or sponsor employee, history of drug or alcohol abuse, regular alcohol consumption above certain limits, current smokers, females of childbearing potential, and various other medical and psychological conditions that may interfere with participation.\n\nOverall, this sample provides information about the phase, diseases, ICD-10 codes, drugs, and eligibility criteria for a specific clinical trial.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2 and is focused on the treatment of lymphoma, specifically follicular lymphoma. The trial involves the use of drugs such as atezolizumab (mpdl3280a) [tecentriq], lenalidomide, and obinutuzumab. The eligibility criteria for participants include having an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2, having relapsed or refractory follicular lymphoma after previous treatment, and having a histologically documented CD20-positive lymphoma. Other criteria include having measurable lesions, availability of a tumor specimen for confirmation, and compliance with contraception requirements. Exclusion criteria include having grade 3b follicular lymphoma, a history of transformation to diffuse large B-cell lymphoma, and known CD20-negative status. Other exclusion criteria include prior stem-cell transplantation, previous resistance to lenalidomide, and certain medical conditions or infections. The sample also mentions criteria related to pregnancy and lactation.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 1 and focuses on the disease \"diabetes mellitus.\" The associated ICD-10 codes for this disease are \"P70.2,\" \"O24.92,\" \"Z83.3,\" \"E10.65,\" \"E10.9,\" \"E11.65,\" and \"E11.9.\" The trial involves two drugs: \"human biphasic insulin\" and \"human biphasic insulin, reference.\" \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" Inclusion criteria include obtaining informed consent, being a healthy male between the ages of 18 and 55, having a body mass index (BMI) between 18.5 and 28.0 kg/m^2, and having a fasting plasma glucose concentration of <= 100 mg/dL. \n\nExclusion criteria include hypersensitivity to investigational medicinal products (IMPs) or related products, previous participation in the trial, recent use of any medicinal product in clinical development, history or presence of cancer (except basal cell skin cancer or squamous cell skin cancer), and various other medical conditions or diseases. Other exclusion criteria include recent surgery or blood/plasma donation, increased risk of thrombosis, abnormal values in medical tests, abnormal blood pressure or pulse, abnormal electrocardiogram (ECG), positive screening tests for certain infections, history of severe allergies or anaphylactic reactions, likelihood of needing prohibited drugs during the study, recent medication use, history of alcoholism or drug abuse, positive alcohol or drug screen, smoking, mental incapacity or language barriers, and potential noncompliance or uncooperativeness.\n\nOverall, this sample provides specific details about the phase, diseases, ICDCodes, drugs, and eligibility criteria for a clinical trial focused on diabetes mellitus.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific record, the phase of the trial is Phase 1, and the disease mentioned is \"recurrent adult acute myeloid leukemia.\" The ICDCodes associated with this disease are \"G47.13, J01.41, K11.22, K12.0, N96, F33.8, G03.2.\" The drugs mentioned in this record are \"cytarabine, ibrutinib, idarubicin.\" The eligibility criteria for this trial are listed under \"INCLUSION CRITERIA\" and \"EXCLUSION CRITERIA.\" The inclusion criteria include factors such as previous diagnosis of acute myeloid leukemia, prior chemotherapy regimen, age, performance status, and various medical test results. The exclusion criteria include factors such as recent anticancer therapy, prior treatment with ibrutinib, certain medical conditions, and inability to comply with study requirements.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is \"neoplasms\". The icd-10 codes associated with this disease are \"C05.2\", \"C10.0\", \"C16.0\", \"C16.4\", \"C17.0\", \"C17.1\", and \"C17.2\". The drug being used in the trial is \"sorafenib\". The eligibility criteria for this trial include various requirements such as histological or cytological documentation of an incurable locally advanced or metastatic solid malignancy, evaluable disease by RECIST version 1.1 criteria, documented radiographic or clinical progressive disease, age \u2265 18 years, Eastern Cooperative Oncology Group (ECOG) performance status of \u2264 1, normal 12-lead ECG and left ventricular ejection fraction (LVEF), normal or regulated thyroid function, and adequate bone marrow, liver, and renal function. The exclusion criteria include various factors such as significant uncontrolled concomitant diseases, prior radiotherapy in specific areas, poorly controlled hypertension, seizure disorders requiring anticonvulsant therapy, major surgery within 4 weeks prior to day 1, known active infections, hypersensitivity to sorafenib, significant central nervous system or psychiatric disorders, drug or alcohol abuse, and other factors that might affect compliance with the protocol or interpretation of the study results. The sample also includes information about the timing of previous treatments, history of liver disease, presence of central nervous system metastases, and pregnancy or breastfeeding status. Additionally, it states that adequate barrier birth control measures must be used during the trial, and concomitant medication with drugs having proarrhythmic potential is not permitted.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in either phase 1 or phase 2. The disease being studied in this particular record is pruritus. The ICD-10 codes associated with this disease are L29.0, L29.1, L29.2, L29.8, L29.9, and L29.3. The drugs being used in the trial are botox and saline. \n\nThe eligibility criteria for participants in this trial are as follows:\n\nInclusion Criteria:\n1. Healthy volunteers between 18 and 50 years of age.\n2. Must be in general good health with no disease or physical conditions that would impair evaluation of itch and pain perception.\n3. No history of chronic itch or pain.\n4. Must abstain from the use of any systemic or topical anti-histamine, steroid, or pain relief medications from the week prior to the study till the completion of the study.\n5. Must abstain from the use of moisturizers on the arm.\n\nExclusion Criteria:\n1. Individuals under 18 or over 50 years of age.\n2. Inability to complete the required measures.\n3. The presence of an itchy skin disease.\n4. Diagnosis of diseased that would affect itch or pain perception (e.g. neuropathies).\n5. Currently enrolled in any investigational study in which the subject is receiving any type of drug, biological, or non-drug therapy.\n6. Use of oral, topical analgesics, or other medications known to interfere with itch or pain perception in the week prior to the study and throughout the study (e.g. antihistamines, anesthetics, opioids, neuroleptics, etc.).\n7. Use of emollients on the arms a week prior to the study and throughout the study.\n8. Use of anti-depressants, anti-psychotics, and illicit drugs.\n9. Known history of neuropathy, uremia, uncontrolled thyroid disease, and diabetes mellitus.\n10. Use of Botulinum toxin in the last year.\n11. Known allergies to Botox.\n12. Pregnant women. (Women of childbearing potential will undergo a human chorionic gonadotrophin (hCG) pregnancy test before Botox application).\n13. Hypersensitivity to any botulinum toxin preparation or to any of the components in the formulation.\n14. Infection at the injection site.\n15. Cardiovascular disease.\n16. Neuromuscular disorder (e.g., amyotrophic lateral sclerosis, myasthenia gravis, or Lambert-Eaton syndrome).\n17. Compromised respiratory function.\n18. Dysphagia.\n19. History of urinary tract infection.\n20. History of urinary retention.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is basal cell carcinoma. The icd-10 codes associated with this disease are C44.510, C44.91, C44.01, C44.311, C44.511, C44.81, and C44.41. The drug being used in the trial is vismodegib. \n\nThe eligibility criteria for this trial include being at least 18 years old, having a diagnosis of basal cell carcinoma with at least 4 nodular lesions of a certain size, being a non-surgical candidate or refusing surgery, and having normal hematopoietic capacity, hepatic and renal function. Male patients must use condoms during sexual intercourse with female partners of reproductive potential and agree not to donate sperm or blood during the study and for a certain period after discontinuation of vismodegib. \n\nExclusion criteria include being a woman of childbearing potential, having aggressive subtypes of basal cell carcinoma, having certain medical conditions or illnesses, having a life expectancy of less than one year, and being unable or unwilling to comply with study procedures.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1. The disease mentioned is \"malignant pleural mesothelioma,\" and its corresponding ICDCodes are ['C45.9', 'C45.0', 'C45.1', 'C45.2', 'C45.7']. The drug being tested is \"pemetrexed/cisplatin.\" \n\nThe eligibility criteria for this trial include various factors such as a confirmed diagnosis of malignant pleural mesothelioma, no plans for surgical resection, specific stage classification, no prior radiation therapy to certain areas, limited prior chemotherapy regimens, age of 18 years or older, a certain level of performance status, specific pulmonary function test results, and adequate hematologic, hepatic, and renal function.\n\nThere are also exclusion criteria, which include factors such as pregnancy or lactation, active infections requiring systemic treatment, concurrent active malignancy (except for skin cancer), serious unstable medical illness, idiopathic pulmonary fibrosis, NYHA heart failure class greater than 2, having only one kidney on the same side as the mesothelioma, and having an implanted pacemaker or defibrillator that cannot be moved.\n\nAdditionally, there are specific exclusion criteria for the MRI portion of the trial, such as having a metallic implant, unmanageable claustrophobia, or being at high risk for nephrogenic systemic fibrosis.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is categorized into different phases, with this particular sample being from phase 1. The trial focuses on a specific disease, which in this case is \"pulmonary disease, chronic obstructive.\" The disease is identified using ICD-10 codes, with the codes listed as \"J44.9,\" \"J44.1,\" and \"J44.0.\"\n\nThe table also includes a list of drugs being used in the trial, which in this case are \"bi 1026706,\" \"placebo,\" and \"placebo.\" Additionally, there is a section for eligibility criteria, which outlines the requirements for participants to be included or excluded from the trial.\n\nThe inclusion criteria include factors such as the need for signed informed consent, age range between 40 and 80 years, a documented diagnosis of COPD, specific lung function measurements, smoking history, stable respiratory medications, and the ability to perform pulmonary function tests.\n\nOn the other hand, the exclusion criteria specify conditions that would disqualify a patient from participating in the trial. These conditions include significant pulmonary diseases other than COPD, current asthma, abnormal laboratory results, recent myocardial infraction or apoplexy, cardiac arrhythmia, prolonged QT interval, active tuberculosis, bronchiectasis, recent respiratory infections or COPD exacerbations, previous thoracotomy, recent malignancy treatments, alcohol or drug abuse, use of non-permitted medications, recent use of investigational drugs, gastrointestinal surgery that could affect the trial medication, unsuitable veins for blood collection, inability to comply with the dietary regimen, previous participation in the same study, blood donation within a specific timeframe, pregnancy or breastfeeding, and male patients not agreeing to minimize the risk of their female partners becoming pregnant during and after the trial.\n\nFinally, the sample concludes by stating that patients who are deemed unsuitable for inclusion by the investigator, for any reason that may hinder their compliance with the study requirements, will also be excluded from the trial.",
    "The sample from the table represents a clinical trial for the treatment of acute myeloid leukemia (AML). The trial is divided into different phases, including phase I, phase II, and phase III. The diseases targeted in the trial include recurrent childhood AML, secondary AML, and therapy-related AML. The diseases are identified by their corresponding ICD-10 codes. The drugs being tested in the trial include cytarabine, fludarabine phosphate, and liposome-encapsulated daunorubicin-cytarabine.\n\nThe eligibility criteria for the trial are outlined, including the requirement for histologic verification of AML at the original diagnosis. Patients must meet specific criteria based on the phase of the trial they are being considered for, such as relapsed patients, refractory patients, or treatment-related AML patients. Other criteria include performance status, recovery from prior treatments, absence of certain toxicities, and specific laboratory values.\n\nThere are also exclusion criteria, such as patients who have received a certain dosage of daunorubicin equivalents, patients currently receiving another investigational drug, and patients with certain diagnoses or active infections. Female patients who are pregnant or lactating, as well as sexually active patients of reproductive potential, must meet additional requirements.\n\nOverall, the sample provides detailed information about the phase, diseases, drugs, and eligibility criteria for the clinical trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is atopic dermatitis. The ICDCodes associated with this disease are \"L20.89\" and \"L20.9\". The drugs being used in the trial are dupilumab, midazolam, omeprazole, warfarin, caffeine, and metoprolol. The eligibility criteria for this trial include being 18 years or older, having a diagnosis of chronic atopic dermatitis for at least 3 years, meeting certain severity scores and body surface area involvement, having a recent history of inadequate response to topical medications, and providing informed consent. There are also exclusion criteria listed, such as prior participation in a dupilumab clinical trial, recent use of certain treatments, contraindications to specific drugs, and various medical conditions or abnormalities. Additionally, there are criteria related to lifestyle factors, such as abstaining from certain foods and beverages, excessive caffeine consumption, history of substance abuse, and smoking. The sample also includes criteria related to lab abnormalities, infections, immunodeficiency, and pregnancy/birth control for female participants.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is Hepatitis B. The ICDCodes associated with this disease are B18.0, B18.1, B19.10, B19.11, B17.0, B16.0, and B16.1. The drugs being used in the trial are GSK3389404 and a matching placebo. \n\nThe eligibility criteria for participants in this trial include being capable of giving written informed consent, understanding and complying with the protocol requirements, being healthy with no evidence of certain disorders or cancer within the past 5 years, and meeting specific age, weight, and BMI criteria. Additional criteria include having certain blood test results within the normal reference range, not being pregnant or lactating, and using contraception if applicable. \n\nThe exclusion criteria include a history or clinical evidence of certain diseases or conditions, regular alcohol or tobacco use, sensitivity to the study drug, recent use of certain medications or substances, positive test results for hepatitis C, hepatitis B, or HIV, abnormal kidney function, and other factors that may affect participation in the study.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is categorized as \"phase 1\" and is focused on the disease \"Alzheimer's disease.\" The corresponding ICD-10 codes for this disease are listed as \"G30.8,\" \"G30.9,\" \"G30.0,\" and \"G30.1.\" The trial involves the use of two drugs, namely \"bpn14770\" and \"placebo.\" \n\nThe eligibility criteria for participants in this trial are as follows:\n- The subject must be a healthy male or female, with female subjects not being pregnant or breastfeeding.\n- The subject must be between 18 and 55 years of age.\n- The subject's body mass index (BMI) must be between 18 and 32 kg/m2, and they must weigh at least 50 kg (110 lbs).\n- Female subjects must be surgically sterile or at least 2 years postmenopausal, with menopausal status verified by a follicle-stimulating hormone (FSH) test.\n- Male subjects must be willing to inform their female partners about their participation in the study and use adequate contraceptive methods.\n- The subject must understand the study procedures, provide written informed consent, and be willing to remain in the study unit for the entire duration of the confinement period and return for outpatient visits.\n\nThe exclusion criteria for participants in this trial are as follows:\n- The subject has clinically significant abnormalities indicated by medical tests, medical history, vital signs, or physical examination.\n- The subject has positive serology results for hepatitis B, hepatitis C, or HIV.\n- The subject has marked hypotension or hypertension based on blood pressure measurements.\n- The subject has marked bradycardia or tachycardia based on heart rate measurements.\n- The subject has a current or past history of cardiovascular, cerebrovascular, pulmonary, renal, or liver disease.\n- The subject has a history of hematological disorders in the immediate family.\n- The subject has clinically important conduction abnormalities on ECGs or a history of long QT syndrome.\n- The subject has a current or past history of gastric or duodenal ulcers or other gastrointestinal diseases that could interfere with drug absorption.\n- The subject has active acute or chronic infectious diseases.\n- The subject is unable to discontinue regular use of over-the-counter medication or has taken prescription medication within 14 days prior to the study.\n- The subject consumes alcohol regularly or has a history of alcohol or drug abuse within the previous year.\n- The subject has used alcohol within 48 hours of admission to the study.\n- The subject is an active smoker or tobacco user who cannot discontinue tobacco use or refrain from using tobacco during the study.\n- The subject is unable or unwilling to comply with the study protocol or rules of the clinical research unit.\n- The subject has participated in other clinical studies involving investigational drugs within the previous 30 days.\n- The subject has donated blood or blood products within 8 weeks prior to the first administration of the study drug.\n- The subject has tested positive for drugs of abuse.\n- The subject has a history of allergy to penicillin, sulfonamides, or any other clinically significant drug allergy.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1. The disease mentioned is metastatic breast cancer. The ICDCodes associated with the disease are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The drugs being used in the trial are durvalumab and trastuzumab. The eligibility criteria include various requirements such as histologically confirmed HER-2 positive breast cancer, measurable disease as defined by RECIST 1.1, prior exposure to taxane, trastuzumab, and pertuzumab, and specific laboratory requirements. The sample also includes exclusion criteria such as a history of other malignancies requiring concurrent anticancer therapy, active or prior autoimmune or inflammatory disorders, and previous treatment with PD-1 or PD-L1 inhibitors or other immune-based therapies. Additionally, it mentions that pregnant or lactating women are not eligible for the trial.",
    "The sample from the table is for a phase 1 clinical trial. The diseases being studied are metastatic breast cancer and central nervous system (CNS) metastases. The corresponding ICD-10 codes for these diseases are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The drug being tested is lapatinib in tandem with capecitabine. \n\nThe eligibility criteria for this trial include being at least 18 years old, having histologically-confirmed metastatic adenocarcinoma of the breast with HER2+ status, having received prior trastuzumab or chemotherapy for metastatic breast cancer (except if the patient has CNS as the only site of metastatic disease), and having radiologic evidence of new and/or progressive brain or spinal cord metastasis or leptomeningeal disease. Other criteria include having a life expectancy of more than 12 weeks, an ECOG performance status of 0 to 2, and meeting certain requirements for prior therapies, cardiac function, and organ function. Women of childbearing potential must have a negative pregnancy test and agree to use contraception during the study.\n\nExclusion criteria for this trial include contraindications or allergic reactions to lapatinib or capecitabine, recent major surgery or significant traumatic injury, serious uncontrolled medical conditions, certain cardiac conditions, grade 3 hypertension, recent thrombotic or embolic events, HIV infection or chronic hepatitis B or C, previous or concurrent cancer within 5 years (except for certain types), and use of certain medications or concurrent anti-cancer therapies. Pregnant or breastfeeding women and those unable to comply with the study protocol are also excluded.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease being studied is \"healthy,\" which seems to indicate that the trial is focused on healthy individuals rather than a specific disease. The ICDCodes associated with this disease are \"Z76.3\" and \"Z76.2.\" The drugs being tested in this trial are \"chs-1701\" and \"pegfilgrastim.\" \n\nThe sample also includes the eligibility criteria for participants in the trial. The inclusion criteria state that participants must be adult males or females between the ages of 18 and 45, with a body weight greater than 50 kg and a body mass index (BMI) between 18 and 28 kg/m2. They should also be medically healthy with no significant medical history, as determined by a medical history review, 12-lead ECG, and physical examination. Female participants of childbearing potential must have a negative urine pregnancy test.\n\nThe exclusion criteria specify that individuals who have been previously exposed to pegfilgrastim or filgrastim, or who have current or previous cancer, diabetes, or any clinically significant disorders in various body systems, are not eligible to participate. Other exclusion criteria include a history of respiratory illness, positive urine drug or alcohol screen, unwillingness to abstain from alcohol or recreational drugs during the study, use of prescription or nonprescription drugs during the study, participation in another clinical study within the past 30 days, and a history of known clinically significant drug and/or food allergies, including latex allergies.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is categorized as \"phase 1\" and the disease being studied is \"healthy.\" The corresponding ICD-10 codes for this disease are \"Z76.3\" and \"Z76.2.\" The drugs being used in the trial are \"bi 1026706\" and \"placebo.\" \n\nThe sample also includes the eligibility criteria for participants in the trial. Inclusion criteria include being a healthy male subject, of Chinese or Japanese ethnicity, aged between 20 and 45 years with a BMI between 18.5 and 25 kg/m2. Participants must also provide written informed consent and agree to minimize the risk of their female partners becoming pregnant during and after the trial. \n\nExclusion criteria include any abnormal findings in medical examinations, laboratory values outside the reference range, or evidence of concomitant diseases. Other exclusion criteria include various medical conditions, surgeries, infections, allergies, drug use, smoking, alcohol or drug abuse, recent blood donation, excessive physical activities, inability to comply with dietary regimen, and certain cardiac conditions. \n\nFinally, the sample mentions that male patients who do not agree to minimize the risk of their female partners becoming pregnant are also excluded from the trial. The investigator may also exclude individuals who are deemed unsuitable for inclusion due to their inability to understand and comply with study requirements or if they have a condition that would not allow safe participation in the study.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is multiple myeloma. The ICDCodes associated with this disease are C90.01, C90.02, and C90.00. The drugs being used in the trial are elotuzumab and lenalidomide. The eligibility criteria for this trial include various factors such as age, performance status, prior treatment history, reproductive status, and medical conditions. The sample also includes exclusion criteria, which specify conditions or factors that would disqualify a subject from participating in the trial.",
    "The sample provided is a record from a table that contains information about clinical trials. The table has several columns, including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of diseases being studied, \"icdcodes\" which lists the corresponding ICD-10 codes for the diseases, \"drugs\" which lists the names of drugs being tested, and \"criteria\" which provides the eligibility criteria for the trial.\n\nIn this specific sample, the phase of the trial is phase 1. The diseases being studied are metastatic breast cancer, metastatic colon cancer, and metastatic prostate cancer. The corresponding ICD-10 codes for these diseases are provided. The drug being tested is called \"foxy-5\". The eligibility criteria for the trial are listed, including age requirements, documented diagnosis of the specified cancers, specific tumor characteristics, performance status, life expectancy, and various medical parameters such as blood counts and liver and kidney function. The criteria also include exclusion factors such as bleeding disorders, active infections, certain medical conditions, and previous exposure to the drug being tested.\n\nOverall, this sample provides detailed information about the phase, diseases, drugs, and eligibility criteria for a specific clinical trial.",
    "The sample from the table represents a clinical trial for breast cancer, specifically metastatic breast cancer. The trial is in phase 1/phase 2. The diseases being studied are breast cancer and metastatic breast cancer. The corresponding ICD-10 codes for these diseases are provided. The drugs being investigated in the trial are vinorelbine and trastuzumab emtansine. \n\nThe eligibility criteria for the trial are as follows:\n1. The patient must have histologically or cytologically documented breast cancer.\n2. The patient must have metastatic or unresectable locally advanced/recurrent breast cancer.\n3. The patient must have HER2-positive disease, as determined by positive results from immunohistochemistry (IHC) testing, fluorescence in situ hybridization (FISH) assay(s), or gene copy number analysis.\n4. The patient must have documented disease progression on the last regimen by radiographic measurement.\n5. The patient must have documented disease progression after at least one regimen of HER2-directed therapy in the metastatic or unresectable locally advanced/recurrent setting.\n6. For patients with hormone receptor-positive disease, there must be disease progression or recurrence on prior hormonal therapy, with or without HER2-directed therapy.\n7. The patient must have measurable or bone-only disease.\n8. The patient must have received prior treatment with a taxane.\n9. The patient must have received a minimum of 6 weeks of prior trastuzumab for the treatment of metastatic or unresectable locally advanced/recurrent disease.\n10. Prior use of Pertuzumab or Lapatinib is permitted but not required.\n11. The patient must be at least 18 years old and have a life expectancy of at least 3 months.\n12. The patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n13. The patient must have normal organ and marrow function.\n14. The patient's international normalized ratio (INR) must be less than 1.5 times the upper limit of normal (ULN).\n15. The patient's left ventricular ejection fraction (LVEF) must be at least 50%.\n16. Premenopausal women of reproductive capacity and women < 12 months after menopause must have negative results of a serum pregnancy test. Both men and women of childbearing potential must agree to use two effective non-hormonal forms of barrier contraception throughout the treatment on the study.\n17. The patient must be able to understand and willing to sign a written informed consent and HIPAA document.\n\nThe exclusion criteria for the trial are as follows:\n1. The patient must not have received chemotherapy within 21 days prior to the first dose of study treatment.\n2. The patient must not have received trastuzumab within a specific time frame based on the dose received.\n3. The patient must not have received Lapatinib within 14 days prior to the first dose of study treatment.\n4. The patient must not have received Pertuzumab within 21 days prior to the first dose of study treatment.\n5. The patient must not have received hormone therapy within 7 days prior to the first dose of study treatment.\n6. The patient must not have received investigational therapy or any other experimental therapy within 28 days prior to the first dose of study treatment.\n7. The patient must not have received prior treatment with trastuzumab emtansine.\n8. The patient must not have prior use of vinorelbine in any setting.\n9. The patient must not have received previous radiotherapy for the treatment of unresectable, locally advanced, recurrent, or metastatic breast cancer within a specific time frame or if more than 25% of marrow-bearing bone has been irradiated.\n10. The patient must not have untreated or symptomatic brain metastases or require any radiation, surgery, or continued steroid therapy to control symptoms from brain metastases within 14 days of study enrollment.\n11. The patient must not have a history of intolerance or hypersensitivity to trastuzumab or murine proteins.\n12. The patient must not have a history of exposure to specific cumulative doses of anthracyclines.\n13. The patient must not have current peripheral neuropathy of Grade \u22653.\n14. The patient must have recovered from any other acute toxicity prior to study enrollment.\n15. The patient must not have a history of other malignancy within the last 3 years, except for certain exceptions.\n16. The patient must not meet specific cardiopulmonary function criteria or have certain severe, uncontrolled systemic diseases.\n17. The patient must not have any uncontrolled, intercurrent illness or any other serious medical or psychiatric illness/condition that is likely to interfere or limit compliance with study requirements/treatment.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1. The diseases being studied are ovarian cancer, fallopian tube cancer, and primary peritoneal carcinoma. The ICDCodes associated with these diseases are provided as well. The drugs being used in the trial are paclitaxel, ricolinostat, and bevacizumab. The eligibility criteria for participants in this trial include having a documented history of the specified cancers, measurable disease, previous treatment with platinum-based chemotherapy, recurrence within 12 months of the last treatment, being 18 years or older, having a certain performance status and life expectancy, and meeting specific organ and marrow function requirements. There are also exclusion criteria listed, such as recent chemotherapy or radiotherapy, hormonal therapy, certain medical conditions, and previous treatments or conditions that may contraindicate the trial therapy.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The diseases being studied are \"healthy\" and \"hepatitis, chronic.\" The ICDCodes associated with these diseases are \"Z76.3\" and \"Z76.2.\" The drugs being tested are \"jnj-56136379\" and \"placebo.\" \n\nThe eligibility criteria for this sample include various requirements for inclusion and exclusion. Inclusion criteria state that female participants must either be in a non-childbearing potential state (postmenopausal or permanently sterile) or be of childbearing potential and practicing sexual abstinence or using a highly effective method of contraception. Female participants should also have a negative serum pregnancy test at screening. Healthy participants must have a body mass index (BMI) between 18.0 and 30.0 kg/m2, while chronic hepatitis B participants must have a BMI between 18.0 and 35.0 kg/m2. Chronic hepatitis B participants must also have no advanced liver disease, a HBV DNA level of >= 2,000 IU/mL at screening, and be aged between 18 and 65 years.\n\nExclusion criteria for this sample include past history of cardiac arrhythmias, risk factors for Torsade de Points syndrome, breastfeeding at screening, current HIV-1 or HIV-2 infection, current HCV or HDV infection, positivity of anti-HBs antibodies, and a past history of cardiac arrhythmias for chronic hepatitis B participants.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in the early phase 1 and focuses on chemotherapy symptoms. The associated ICD-10 codes for the disease are 'D61.810', 'Z51.11', 'D64.81', 'D70.1', 'Z92.21', 'P04.11', and 'T80.810S'. The drugs being studied are ginger, lavender, orange, and jojoba. The eligibility criteria for participants include being non-pregnant adults between the ages of 21 to 89 with a cancer diagnosis and scheduled to receive at least three more cycles of chemotherapy. Other criteria include having had at least one chemotherapy cycle in their current prescribed course, a minimum of 12 days between each chemotherapy cycle, and being able to read and understand English. There are also exclusion criteria, such as being under 21 or over 89 years old, being pregnant, being chemotherapy-na\u00efve, having more than four weeks between chemotherapy cycles, undergoing concurrent radiation therapy or interferon treatment, having used or currently using aromatherapy inhalation for symptom management, and having any known allergy to ginger, lavender, orange, citrus, jojoba, or essential oils.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is Tourette Syndrome. The ICDCodes associated with this disease are ['F95.2']. The drug being tested is sd-809. \n\nThe sample also includes the eligibility criteria for participants in this trial. Inclusion criteria include being between the ages of 12 and 18, having a diagnosis of Tourette Syndrome according to the DSM-V, having manifested motor and phonic tics within the past 3 months, having a total tic score of at least 19 on the YGTSS, and having stable tic severity and frequency for at least 2 weeks before the screening visit. Other criteria include willingness to adhere to the medication regimen, being in good general health, providing written informed consent, and using an acceptable method of contraception for female patients of childbearing potential.\n\nExclusion criteria include having a serious untreated or undertreated psychiatric illness, a history of suicidal ideation or behavior, recent use of certain medications, being treated with deep brain stimulation for tic control, having a progressive or degenerative neurological disorder or structural brain disorder, recent participation in another investigational drug or device trial, being pregnant or breastfeeding, and having a history of alcohol or substance abuse in the previous 12 months.\n\nPlease note that there may be additional criteria that apply, and it is recommended to contact the investigator for more information.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The diseases being studied are acute myeloid leukemia and myelodysplastic syndrome. The ICDCodes associated with these diseases are C92.A1, C92.A2, C92.61, C92.62, C92.A0, C92.60 for acute myeloid leukemia, and D46.9, D46.C, D46.Z for myelodysplastic syndrome. The drugs being used in the trial are panobinostat, fludarabine, cytarabine, intrathecal triples, and leucovorin. \n\nThe eligibility criteria for this trial include:\n- Participants must have a diagnosis of AML or MDS and must have disease that has relapsed or is refractory to chemotherapy, or that has relapsed after hematopoietic stem cell transplantation (HSCT).\n- Adequate organ function is required, including specific criteria for bilirubin, AST, ALT, creatinine, serum albumin, and left ventricular ejection fraction or shortening fraction.\n- The age of participants must be 24 years or younger.\n- Patients must be able to swallow capsules.\n- Performance status must meet certain criteria based on age.\n- Patients must have fully recovered from prior therapy, with specific time requirements since the completion of myelosuppressive therapy and low-dose chemotherapy, as well as no evidence of GVHD for patients who have received prior HSCT.\n- Body Surface Area requirements are specified for enrollment at different dose levels.\n\nThere are also exclusion criteria, including not being pregnant or breastfeeding, having certain specific diseases or conditions, recent use of investigational agents, significant concurrent diseases or psychiatric disorders, uncontrolled infection, known HIV infection, diarrhea above a certain grade, impaired cardiac function or significant cardiac diseases, impairment of GI function or disease that may affect the absorption of panobinostat, and the use of medications that may prolong the QT interval or induce torsade de points.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is \"acute coronary syndrome,\" and its corresponding ICDCodes is \"I24.0.\" The drugs being tested are \"mdco-216\" and \"placebo.\" The eligibility criteria for participants are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" The criteria include specific requirements related to recent ACS events, qualifying myocardial infraction, baseline coronary angiogram, target artery conditions, informed consent, and various exclusion factors such as heart disease, liver disease, kidney function, and pregnancy.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is acute myeloid leukemia. The ICDCodes associated with this disease are C92.A1, C92.A2, C92.61, C92.62, C92.A0, and C92.60. The drugs being used in the trial are dasatinib, fludarabine, cytarabine, idarubicin, and intrathecal (it) cytarabine. \n\nThe eligibility criteria for this trial include:\n- Histologically confirmed relapsed or refractory Acute Myeloid Leukemia (AML)\n- \u2265 5% blasts by morphology in the bone marrow or molecular evidence of at least 0.1% leukemic blasts in the bone marrow\n- Definitive evidence of t(8;21) or inv(16) by a CLIA approved cytogenetics laboratory from initial diagnosis\n- Presence of CNS or other sites of extramedullary disease (no cranial irradiation allowed during the protocol therapy)\n- Lansky score \u2265 50 for patients \u2264 16 years old; Karnofsky score \u2265 50 for patients > 16 years old\n- Full recovery from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiation therapy\n- Adequate renal and hepatic functions\n- Shortening fraction \u2265 27% by echocardiogram or ejection fraction \u2265 50% by radionuclide angiogram (MUGA)\n- No evidence of dyspnea at rest, exercise intolerance, and pulse oximetry > 94% at sea level\n- Seizure disorder must be well controlled on anticonvulsants at a stable dose for at least 14 days\n- Female participants of childbearing potential must have a negative pregnancy test and agree not to breastfeed while on the study\n- Male and female participants of child-bearing potential must agree to use effective contraception during the study and for 6 months after treatment\n\nThe exclusion criteria for this trial include:\n- Known allergy to any of the drugs used in the study\n- Ongoing signs/symptoms of systemic fungal, bacterial, viral, or other infection without improvement despite treatment\n- Clinically significant cardiovascular disease\n- Plans to administer non-protocol chemotherapy, radiation therapy, or immunotherapy during the study period\n- Refractory to red blood cell or platelet transfusions\n- Receiving anti-coagulation therapy or drugs that inhibit platelet function\n- Receiving certain potent CYP3A4 inducers or inhibitors\n- Presence of significant concurrent disease, illness, psychiatric disorder, or social issue that would compromise patient safety or compliance with the study\n\nIt is also mentioned that individuals with Down syndrome and DNA fragility syndromes (such as Fanconi anemia, Bloom syndrome) are excluded from the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The diseases being studied are \"synovial sarcoma\" and \"sarcoma, synovial\". The corresponding ICDCodes for these diseases are \"M67.20\", \"M67.211\", \"M67.212\", \"M67.219\", \"M67.231\", \"M67.232\", and \"M67.239\". The drug being tested is \"dhea\". \n\nThe eligibility criteria for this trial include a diagnosis of histologically or cytologically confirmed metastatic or non-resectable synovial sarcoma, having failed at least one line of chemotherapy, having measurable disease, being at least 16 years of age, having an ECOG performance status of 2 or lower, and having normal bone marrow and organ function. Other criteria include using adequate contraception for women of childbearing potential and men, understanding and signing an informed consent document, and meeting certain exclusion criteria such as having a history of other malignancy within the past 3 years, currently receiving other investigational agents, having known brain metastases, and having uncontrolled intercurrent illness.\n\nOverall, this sample provides specific details about the phase, diseases, ICDCodes, drugs, and eligibility criteria for a clinical trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is colon cancer. The ICDCodes associated with this disease are C18.2, C18.4, C18.6, C18.7, C18.9, D12.2, and D12.3. The drug being investigated is niclosamide. \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" Inclusion criteria include a confirmed diagnosis of colon adenocarcinoma, a Karnofsky performance status of 70% or higher, age 18 or older, adequate hematologic, renal, and hepatic function, ability to provide informed consent, and ability to return for follow-up at Duke University Medical Center. \n\nExclusion criteria include concurrent cytotoxic chemotherapy or radiation therapy, active brain or leptomeningeal metastases, serious intercurrent chronic or acute illness, medical or psychological impediment to compliance with the protocol, prior use of niclosamide or allergies to niclosamide, concomitant use of certain medications, pregnancy or nursing, and complete bowel obstruction or high risk for GI perforation or severe hemorrhage.",
    "The sample from the table represents a clinical trial in phase 1 for the treatment of lung adenocarcinoma. The trial involves the use of different doses of the drug apatinib in combination with docetaxel. The eligibility criteria for participants include being between 18 and 65 years old, having an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, and a life expectancy of more than 12 weeks. Other criteria include having a measurable lesion according to RECIST 1.1, histologically/cytologically confirmed advanced/metastatic lung adenocarcinoma of stage IV with wild-type EGFR, and having received one prior platinum-containing chemotherapy. Adequate hepatic, renal, heart, and hematologic functions are also required. Women of child-bearing age must have negative pregnancy test results and use contraception during the study. The sample also includes exclusion criteria such as the presence of coelomic fluid accumulation, other malignancies within the past five years, factors affecting oral medication, recent major injuries or surgeries, and poorly controlled arterial hypertension. Other exclusion criteria include certain cardiac conditions, history of significant bleeding events, active brain metastases, and contraindications for therapy with docetaxel. The sample also lists various other exclusion criteria and conditions that are at the discretion of the investigators.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The phase of the trial, which in this case is Phase 1.\n- Diseases: A list of diseases being studied in the trial, including \"multiple myeloma\" and \"high-risk smoldering multiple myeloma.\"\n- ICD Codes: The ICD-10 codes associated with the diseases, such as \"C90.01\" and \"C90.02\" for multiple myeloma.\n- Drugs: The drugs being used in the trial, including \"ixazomib (mln9708)\" and \"dexamethasone.\"\n- Criteria: The eligibility criteria for participating in the trial, which are listed in a detailed format.\n\nThe inclusion criteria include specific requirements related to the diagnosis of smoldering multiple myeloma, certain laboratory values, absence of certain symptoms, and other factors. The criteria also mention the need for patients to meet the definition of \"high-risk SMM\" according to specific criteria.\n\nThe exclusion criteria outline conditions that would make a patient ineligible for the trial, such as prior therapy with a proteasome inhibitor, certain medical conditions, ongoing infections, and other factors.\n\nOverall, this sample provides a snapshot of the information stored in the table, including the phase, diseases, drugs, and eligibility criteria for a specific clinical trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease being studied is HIV, and the corresponding ICDCodes are ['B20', 'Z71.7', 'O98.72', 'Z21', 'O98.73', 'R75', 'Z11.4']. The drugs being used in the trial are 'microgynon 30\u00ae' and 'evotaz\u00ae'. The eligibility criteria for participants are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". The inclusion criteria include factors such as age, body mass index, liver function, contraception methods, and willingness to comply with study requirements. The exclusion criteria include factors such as medical illnesses, organ dysfunction, positive blood screens for hepatitis B, HIV, or hepatitis C, liver disease, allergies to certain medications, gastrointestinal disease, and recent drug use.",
    "The sample provided is a record from a table that contains information about clinical trials. The trial is in the early phase 1 and focuses on the disease called diabetic nephropathy. The ICD-10 codes associated with this disease are E10.21, E11.21, E13.21, E08.21, and E09.21. The drugs being studied in this trial are resveratrol, placebo, and losartan. The eligibility criteria for participants are as follows:\n\nInclusion Criteria:\n- Type 2 diabetes mellitus (DM)\n- Controlled blood sugar (fasting blood sugar <130mg/dl and glycosylated hemoglobin A1C <7%)\n- Urine albumin >20mg/lit in two separate occasions during the last 3 months period\n- Serum creatinine \u22642mg/dl\n\nExclusion Criteria:\n- Pregnancy\n- Lactation\n- Alcoholism\n- Liver failure (acute or chronic)\n- Renal failure: serum creatinine >2mg/dl\n- Glomerulonephritis\n- Uncontrolled hypertension\n- Congestive heart failure\n- Prostate disease\n- Malignancy\n- Bilateral renal artery stenosis\n- Any systemic disease other than DM\n- Any infection or rheumatologic disorder\n- Use of warfarin",
    "The sample provided is a record from a table that contains information about clinical trials. The phase of the trial is Phase 1. The disease being studied is hypertension. The corresponding ICD-10 codes for hypertension are ['I15.0', 'I97.3', 'K76.6', 'P29.2', 'G93.2', 'H40.053', 'I10']. The drugs being tested in this trial are fimasartan, rosuvastatin, and a combination of fimasartan and rosuvastatin. \n\nThe eligibility criteria for this trial are as follows:\nInclusion Criteria:\n1. The participant must be a Caucasian male between the ages of 19 and 55.\n2. The participant's body mass index (BMI) must be between 18.5 and 32.0 kg/m2 at screening.\n3. The participant must be medically healthy with no significant medical history.\n4. The participant must understand the study procedures outlined in the Informed Consent Form (ICF) and be willing and able to comply with the protocol.\n\nExclusion Criteria:\n1. The participant must not have a history or presence of clinically significant medical or psychiatric conditions or diseases.\n2. The participant must not have tested positive for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV) during screening.\n3. The participant's seated blood pressure must not be less than 90/60 mmHg or greater than 140/90 mmHg at screening.\n4. The participant must not have donated plasma within 7 days prior to the first dose of the study drug.\n5. The participant must not have participated in another clinical trial within 28 days prior to the first dose of the study drug(s).",
    "The sample from the table is a clinical trial for breast cancer patients in phase 1/phase 2. The trial is testing the effectiveness of the drugs entinostat, atezolizumab, and placebo. The eligibility criteria for participants include having confirmed triple negative breast carcinoma that is either metastatic or locally recurrent and not amenable to local curative treatment. Participants must also have received 1-2 prior lines of systemic therapy for locally recurrent and/or metastatic disease. Other criteria include having a performance status of 0 or 1, acceptable laboratory parameters, and being willing to use birth control methods. Exclusion criteria include having immunodeficiency, receiving systemic steroid therapy, or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug. Participants must not have a history of certain conditions or diseases that could confound the study results or interfere with participation. Other exclusion criteria include contraindications to oral agents, recent live vaccine administration, and recent use of certain medications or treatments. Pregnant or breastfeeding individuals, those with HIV or active hepatitis B or C, and those with allergies to specific components of the drugs are also excluded. Additionally, individuals with certain psychiatric or substance abuse disorders that would interfere with study requirements are not eligible to participate.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 1. The diseases being studied are hypertriglyceridemia and familial hypercholesterolemia. The ICDCodes associated with these diseases are \"E78.01\" and \"Z83.42\". The drugs being tested are \"ionis angptl3-lrx\" and \"placebo\". \n\nThe eligibility criteria for all cohorts include providing written informed consent, being between 18 and 65 years old, having a Body Mass Index (BMI) of 35.0 kg/m2 or less, and meeting certain requirements for females regarding pregnancy and lactation. Males must be surgically sterile, abstinent, or using an acceptable contraceptive method.\n\nAdditional inclusion criteria are specified for different cohorts. Cohorts A, D, and AA to DD require fasting triglycerides (TG) of 150 mg/dL or higher and fasting low-density lipoprotein cholesterol (LDL-C) levels above 70 mg/dL. Cohorts B and C have specific TG and LDL-C ranges for inclusion. Cohort EE requires a diagnosis of homozygous FH and fasting LDL-C levels of 190 mg/dL or higher. Cohort FF requires a diagnosis of heterozygous FH and fasting LDL-C levels of 160 mg/dL or higher. Cohorts EE and FF have additional criteria related to LDL-C lowering agents, low-fat diet, and stable weight.\n\nExclusion criteria for all cohorts include a history or positive test for HIV, HCV, or HBV, recent treatment with other study drugs or devices, regular alcohol use, unauthorized concomitant drug use, contraindication or allergy to heparin, smoking more than 10 cigarettes a day, and being deemed unsuitable for inclusion by the Principal Investigator.\n\nAdditional exclusion criteria apply specifically to Cohorts EE and FF, such as recent cardiovascular events, congestive heart failure, uncontrolled type 2 diabetes, prior gene therapy treatment, and recent apheresis treatments.",
    "The sample provided is for a Phase 1 clinical trial. The trial is focused on healthy male subjects. The diseases being studied are listed as \"healthy,\" which indicates that the trial is not specifically targeting any particular disease. The ICD-10 codes provided, \"Z76.3\" and \"Z76.2,\" are codes related to healthcare encounters for other specified counseling and medical advice and encounters for issue of repeat prescription, respectively.\n\nThe trial involves the administration of multiple drugs, including \"dabigatran etexilate tablet e1,\" \"dabigatran etexilate tablet d1,\" \"dabigatran etexilate tablet c1,\" \"dabigatran etexilate tablet b1,\" \"dabigatran etexilate tablet a1,\" and \"dabigatran etexilate capsule.\"\n\nThe eligibility criteria for inclusion in the trial are as follows:\n- The subject must be a healthy male according to the investigator's assessment, based on a complete medical history, physical examination, vital signs, electrocardiogram, and clinical laboratory tests.\n- The subject must be between the ages of 20 and 35.\n- The subject's body mass index (BMI) must be between 18.0 and 25.0 kg/m2.\n- The subject must provide signed and dated written informed consent prior to admission to the study.\n\nThe exclusion criteria for the trial are as follows:\n- Any abnormal findings in the medical examination, including blood pressure, pulse rate, or electrocardiogram, that are considered clinically relevant by the investigator during screening.\n- Blood pressure measurements outside the range of 90 to 140 mmHg systolic and 50 to 90 mmHg diastolic, or pulse rate outside the range of 45 to 90 bpm during screening.\n- Any laboratory values outside the reference range that are considered clinically relevant by the investigator.\n- Any relevant bleeding history as determined by the investigator.\n- Various disorders affecting the gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological, or hormonal systems.\n- Previous gastrointestinal surgery that could interfere with the trial medication's kinetics, except for appendectomy and simple hernia repair.\n- Central nervous system diseases, seizures, stroke, or other relevant neurological or psychiatric disorders.\n- History or evidence of blood disorders, severe thrombocytopenia, bleeding tendencies, or any condition with hemorrhagic tendencies.\n- History of orthostatic hypotension, fainting spells, or blackouts.\n- Chronic or acute infections.\n- Relevant allergies or hypersensitivity, including to the trial medication or its excipients.\n- Any concomitant disease considered clinically relevant by the investigator.\n- Use of drugs with a long half-life within 30 days or less than 10 half-lives prior to trial medication administration.\n- Use of drugs that may influence trial results within 10 days prior to trial medication administration.\n- Use of medication that affects blood clotting within 10 days prior to trial medication administration.\n- Participation in another trial involving an investigational drug within 4 months or 5 half-lives prior to planned trial medication administration.\n- Planned surgeries within four weeks following the end-of-study examination.\n- Smoking more than 10 cigarettes or 3 cigars or 3 pipes per day.\n- Inability to refrain from smoking during in-house confinement at the trial site.\n- Alcohol abuse, defined as consumption of more than 30 g per day.\n- Drug abuse or positive drug screening.\n- Blood donation of more than 100 mL within 30 days prior to trial medication administration or intended donation during the trial.\n- Intention to perform excessive physical activities within one week prior to trial medication administration or during the trial.\n- Inability to comply with the dietary regimen of the trial site.\n- Subject assessed as unsuitable for inclusion by the investigator due to an inability to understand and comply with study requirements or having a condition that would not allow safe participation in the study.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 1 and the disease being studied is \"healthy\". The corresponding ICD-10 codes for this disease are \"Z76.3\" and \"Z76.2\". The drugs being tested in this trial are \"pf-06687234\" and \"placebo\". The eligibility criteria for participants in this trial include being a healthy female of non-childbearing potential or a healthy male, having no evidence of active or latent tuberculosis infection, being able to sign the informed consent document and comply with the schedule of activities. There are also exclusion criteria, such as having clinically significant health concerns, recent treatment with an investigational drug, recent exposure to live vaccines, history of drug/alcohol abuse or tobacco use, history of certain infections, being pregnant, having a sensitivity to heparin, or being unwilling/unable to comply with the lifestyle guidelines outlined in the protocol.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 1 trial and the disease being studied is type 2 diabetes mellitus. The ICD-10 codes associated with this disease are E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, and E11.44. The drugs being tested in this trial are insulin glargine/ lixisenatide fixed-ratio combination hoe901/ave0010, insulin glargine hoe901, and placebo. \n\nThe eligibility criteria for this trial are as follows:\n- Japanese male or female patients with type 2 diabetes mellitus diagnosed for at least 1 year prior to screening.\n- Patients aged 20 to 75 years at screening.\n- Body mass index \u226435 kg/m^2 at screening.\n- Glycohemoglobin \u22657.0% and \u226410.0% at screening.\n- Fasting C-peptide \u22650.6 ng/mL at screening.\n\nThe exclusion criteria for this trial are as follows:\n- Diabetes other than type 2 diabetes mellitus.\n- History of metabolic acidosis, including diabetic ketoacidosis within 1 year prior to screening.\n- History of hypoglycemia unawareness.\n- Hemoglobinopathy or hemolytic anemia.\n- History of myocardial infraction, stroke, or heart failure, history or presence of clinically significant diabetic retinopathy, history or presence of macular edema likely to require laser treatment within the study period.\n- History of unexplained pancreatitis, chronic pancreatitis, pancreatectomy, stomach/gastric surgery, inflammatory bowel disease.\n- Clinically relevant history of gastrointestinal disease associated with prolonged nausea and vomiting, including, but not limited to gastroparesis and gastroesophageal reflux disease requiring medical treatment.\n- Personal or family history of medullary thyroid cancer (MTC) or genetic conditions that predispose to MTC (e.g., multiple endocrine neoplasia syndromes).\n- If female, pregnancy or breast-feeding.\n\nIt is important to note that the provided information may not include all considerations relevant to a patient's potential participation in the clinical trial.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1 and focuses on hepatocellular carcinoma and liver cancer. The ICD-10 codes associated with these diseases are provided. The drugs being studied are \"mtl-cebpa\" and \"sorafenib 200mg\". The record also includes the eligibility criteria for participants, including the requirement of a confirmed diagnosis of advanced HCC, unsuitability for surgery or radiotherapy, and specific laboratory parameters. There are also exclusion criteria listed, such as recent treatment with TACE or chemotherapy, prior investigational drug use, and certain medical conditions. The record concludes with the statement that pregnant or lactating women are not eligible for the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is multiple myeloma. The ICDCodes associated with this disease are C90.01, C90.02, and C90.00. The drugs being used in the trial are tremelimumab, durvalumab, and melphalan. The eligibility criteria for participants in this trial include having histologically confirmed multiple myeloma, measurable disease, available CD34+ stem cells, eligibility for autologous stem cell transplantation, a limited number of prior lines of therapy, and meeting certain organ function requirements. There are also exclusion criteria listed, such as prior exposure to certain drugs, history of severe allergic reactions, autoimmune diseases, and other medical conditions that may prevent compliance with the study or pose unacceptable risks.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2 and is focused on the disease cystic fibrosis. The ICD-10 codes associated with this disease are ['E84.9', 'Z14.1', 'E84.0', 'E84.11', 'E84.8', 'E84.19', 'P09.4']. The drugs being studied are pti-428 and placebo. The eligibility criteria for participants include having a confirmed diagnosis of CF, a forced expiratory volume in 1 second (FEV1) between 40-90% predicted, and being a non-smoker and non-tobacco user for at least 30 days prior to screening. There are also exclusion criteria, such as not participating in another clinical trial within the past 30 days, no history of cancer within the past five years (excluding certain cases), and no history of organ transplantation. Other exclusion criteria include recent sinopulmonary infections or CF exacerbations, history of alcohol or drug abuse or dependence within the past year, and being pregnant or nursing. Participants of child-bearing potential must use highly effective contraception during the study and for 4 weeks after termination.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. \n\nIn this specific sample, the phase of the trial is Phase 1. The diseases being studied are melanoma and skin cancer. The corresponding icd-10 codes for these diseases are provided as well. The drugs being used in the trial are xl888, vemurafenib, and cobimetinib. \n\nThe eligibility criteria for participants in this trial include being 18 years of age or older, having unresectable melanoma with a specific BRAF V600 mutation, meeting certain staging criteria, having adequate hepatic, renal, and bone marrow function, having an Eastern Cooperative Oncology Group (ECOG) performance status of \u22642, being willing to give written informed consent, having a negative pregnancy test (for premenopausal women), using effective contraception, not having received certain inhibitors in the past, having resolved adverse events from prior therapy, having measurable disease, and meeting certain exclusion criteria such as not being pregnant or nursing, not having received certain inhibitors in the past, not having uncontrolled illnesses or infections, and not having certain medical conditions.\n\nIt is important to note that this is just a sample record from the table, and there may be more records with different phases, diseases, drugs, and criteria in the actual table.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is melanoma. The ICDCodes associated with melanoma are ['C43.0', 'C43.31', 'D03.9', 'C43.51', 'C43.9', 'D03.0', 'C43.4']. The drugs being tested in this trial are 'tak-580', 'tak-202', 'vedolizumab', 'nivolumab', and 'ipilimumab'. The eligibility criteria for participants in this trial include being 18 years or older, having histologically confirmed unresectable Stage III or Stage IV melanoma, having an ECOG performance status of 0-1, and meeting certain laboratory parameters for bone marrow reserve, renal function, and hepatic function. There are additional inclusion and exclusion criteria specific to certain drug combinations and expansion cohorts.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is categorized into different phases, with this particular record belonging to phase 1. The trial focuses on the treatment of irritable bowel syndrome. The icd-10 codes associated with the disease are provided as well. The drugs being tested in this phase are \"gsk3179106\" and a placebo. The record also includes the eligibility criteria for participants, which include age requirements, good health, regular bowel habits, and specific contraception requirements for male and female participants. The record also lists exclusion criteria, such as certain medical conditions, history of certain diseases, and substance use.",
    "The sample from the table is for a clinical trial with a phase 1/phase 2 study design. The trial focuses on patients with lymphoma, specifically diffuse large B-cell lymphoma, mantle cell lymphoma, transformed lymphoma, follicular lymphoma, small lymphocytic lymphoma, marginal zone lymphoma, or Hodgkin lymphoma, who have had at least 2 lines of therapy without a curative treatment option. The drug being studied is tak228. \n\nThe eligibility criteria for the trial include patients being 18 years or older, providing voluntary written consent, and meeting certain requirements for contraception for female patients and barrier contraception for male patients. Patients must also have an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or lower and adequate organ function. Measurable disease is also required for enrollment.\n\nExclusion criteria for the trial include patients who are eligible for therapy with a high likelihood of a curative result, lactating or breastfeeding female patients, and patients with serious medical or psychiatric illnesses that could interfere with treatment. Patients with concurrent malignancies, recent treatment with investigational products, or who have not recovered from the reversible effects of prior anticancer therapies are also excluded. Other exclusion criteria include manifestations of malabsorption, poorly controlled diabetes mellitus, and a history of certain cardiovascular or pulmonary diseases.\n\nPatients with certain medical conditions, such as CNS lymphoma, human immunodeficiency virus infection, or hepatitis B or C infection, are also excluded. Patients who have been diagnosed or treated for another malignancy within the past 2 years, except for nonmelanoma skin cancer or carcinoma in situ, are not eligible. Daily or chronic use of a proton pump inhibitor (PPI) or recent use of a PPI is also an exclusion criterion.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase is Phase 1. The diseases listed include adult Hodgkin lymphoma, adult myelodysplastic syndrome, blast phase chronic myelogenous leukemia, childhood chronic myelogenous leukemia, childhood Hodgkin lymphoma, childhood myelodysplastic syndrome, chronic phase chronic myelogenous leukemia, myelofibrosis, primary myelofibrosis, recurrent adult acute lymphoblastic leukemia, recurrent adult acute myeloid leukemia, recurrent adult non-Hodgkin lymphoma, recurrent childhood acute lymphoblastic leukemia, recurrent childhood acute myeloid leukemia, recurrent childhood non-Hodgkin lymphoma, recurrent chronic myelogenous leukemia, refractory chronic myelogenous leukemia, and refractory non-Hodgkin lymphoma. The ICDCodes associated with these diseases are also provided. The drugs mentioned are mycophenolate mofetil and sirolimus. The eligibility criteria include specific disease categories, performance status requirements, HLA mismatched donor criteria, willingness to take oral medications, and exclusion criteria such as prior HSCT, HIV infection, pregnancy or lactation, uncontrolled active infection, and various medical conditions and laboratory values.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase is \"early phase 1\" and the disease is \"carcinoma, renal cell\". The ICDCodes associated with the disease are \"C22.0\", \"C4A.9\", \"C7B.1\", \"C4A.0\", \"C4A.31\", \"C4A.51\", and \"C4A.8\". The drug being studied is \"pazopanib\". The eligibility criteria for this trial include being an adult with unresectable locally advanced or metastatic renal cell carcinoma with a clear cell component, having measurable disease per RECIST 1.1 criteria, not having had prior pazopanib therapy, having an ECOG performance status of less than or equal to 2, and meeting certain organ and marrow function requirements. There are also exclusion criteria listed, such as having certain concurrent health conditions, a history of specific medical events, or being pregnant or nursing.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is breast cancer. The ICDCodes associated with this disease are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The drugs being used in the trial are ribociclib, everolimus, and exemestane. \n\nThe eligibility criteria for this trial include being an adult man or woman, having a confirmed diagnosis of estrogen-receptor positive and/or progesterone receptor positive breast cancer, and having HER2-negative breast cancer. Other criteria include having measurable disease or bone lesions, having an ECOG Performance Status of 0-1, having disease refractory to AI, tamoxifen, or fulvestrant, and having been previously treated with any CDK 4/6 inhibitor. Adequate bone marrow and organ function are also required.\n\nExclusion criteria for this trial include having symptomatic visceral disease or any disease burden that makes the patient ineligible for endocrine therapy, having received more than one line of chemotherapy for advanced disease, having previous treatment with mTOR inhibitors or exemestane for advanced disease, having progressed on more than one CDK 4/6 inhibitor, having CNS involvement unless at least 4 weeks have passed since prior therapy completion, and having clinically significant, uncontrolled heart disease and/or recent cardiac events.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease being studied is metastatic pancreatic cancer. The ICDCodes associated with this disease are C25.3. The drugs being used in the trial are galunisertib and durvalumab. The eligibility criteria for participants include having confirmed recurrent metastatic pancreatic adenocarcinoma, measurable disease, and having received no more than 2 prior systemic regimens for locally advanced or metastatic pancreatic cancer. Other criteria include the ability and willingness to undergo a new tumor biopsy, adequate organ function, a performance status of 0 or 1 on the ECOG scale, and the use of approved contraceptive methods. Exclusion criteria include moderate or severe cardiovascular disease and evidence of interstitial lung disease that may interfere with the detection or management of suspected drug-related pulmonary toxicity or active, noninfectious pneumonitis.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is categorized as either phase I, phase II, or phase III. The specific disease being studied is \"diabetic foot infections,\" and it is associated with a list of ICD-10 codes. The trial involves the use of two drugs, \"bisphosphocin nu-3\" and \"placebo.\" The eligibility criteria for participants are listed, including age requirements, consent, specific diabetes type, and characteristics of the diabetic foot ulcer. Additional criteria for female participants are also mentioned. The exclusion criteria are also provided, which outline conditions that would disqualify a participant from the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 1. The diseases being studied are ovarian cancer, fallopian tube cancer, primary peritoneal cancer, and recurrent ovarian cancer. The ICDCodes associated with these diseases are provided as well. The drug being tested in this trial is nivolumab. \n\nThe eligibility criteria for this trial include having a confirmed pathological diagnosis of one of the specified cancers, having experienced at least one relapse and achieved complete clinical remission after additional chemotherapy, and meeting certain medical parameters such as age, performance status, and hematologic and biochemical parameters. \n\nThere are also specific requirements for the expression of certain proteins (WT1 or NY-ESO-1) in the tumor tissue, as well as exclusions for pregnant or lactating women, patients with active infections or unstable medical conditions, and patients with certain medical history such as HIV, hepatitis B or C, autoimmune diseases, or interstitial pneumonitis.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The diseases being studied are \"healthy\" and \"dermatitis, atopic\". The corresponding ICDCodes for these diseases are \"Z76.3\" and \"Z76.2\" for \"healthy\", and \"L20.89\" and \"L20.9\" for \"dermatitis, atopic\". The drugs being tested in this trial include \"mor106 single ascending doses, intravenous\", \"placebo single ascending doses, intravenous\", \"mor106 multiple ascending doses, intravenous\", and \"placebo multiple intravenous administrations\". \n\nThe eligibility criteria for this trial are divided into inclusion and exclusion criteria. The inclusion criteria for the Single Ascending Dose (SAD) phase include being able and willing to give voluntary written informed consent, having a negative urine drug screen, being a male between 18-50 years of age, having a body mass index (BMI) between 18-30 kg/m\u00b2, and being judged to be in good health. \n\nThe inclusion criteria for the Multiple Ascending Dose (MAD) phase include being a male or female between 18-65 years of age, having a BMI between 18-30 kg/m\u00b2, having a diagnosis of Atopic Dermatitis (AD) for at least 6 months according to the Hanifin and Rajka Criteria, having an EASI score of \u2265 16 and an IGA score \u22653 at the screening and baseline visits, having at least 10% body surface area (BSA) of AD involvement at screening, being willing to continue stable use of an additive-free, basic, bland emollient twice daily for at least 7 days before the baseline visit, being a candidate for systemic therapy and not responding adequately or having a contraindication to topical corticosteroids and/or topical calcineurin inhibitors, having no current active, latent, or history of tuberculosis (TB) infection, having a negative QuantiFERON TB Gold test at screening, having a negative serum pregnancy test at screening and a negative urine pregnancy test at baseline (for female subjects), and using a highly effective method of contraception for at least 24 weeks after the last dose (for female subjects of childbearing potential).\n\nThe exclusion criteria for both phases include known hypersensitivity to study drug ingredients, history of or current immunosuppressive condition, symptoms of clinically significant illness in the 3 months before the initial study drug administration, any concurrent illness, condition, disability, or clinically significant abnormality, treatment with any drug known to have a well-defined potential for toxicity to a major organ in the last 3 months preceding the initial study drug administration, and a history of significant psychological, neurologic, hepatic, renal, endocrine, cardiovascular, gastrointestinal (GI), pulmonary, or metabolic disease.\n\nAdditional exclusion criteria for the MAD phase include having an active (skin) infection requiring systemic antibiotics, receiving immunosuppressive/immunomodulating drugs or phototherapy within 4 weeks prior to baseline, receiving treatment with topical corticosteroids (TCS) or topical calcineurin inhibitors (TCI) within 2 weeks before the baseline, treatment with biologics within 5 half-lives or 12 weeks prior to baseline visit, history of immunosuppression, regular use of a tanning booth/parlor within 4 weeks of the screening visit (more than 2 visits per week), and regular daily use of oral nonsteroidal anti-inflammatory drugs (NSAIDs), except low-dose aspirin (\u2264200 mg/day) for cardioprotection, within 7 days prior to screening.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The trial is in both phase 1 and phase 2.\n- Diseases: The trial is focused on type 1 diabetes mellitus.\n- ICD Codes: The ICD-10 codes associated with the disease are ['E10.65', 'E10.9', 'E10.21', 'E10.36', 'E10.41', 'E10.42', 'E10.44'].\n- Drugs: The trial involves the use of three drugs: 'biochaperone human insulin (hinsbet\u00ae)', 'insulin lispro (humalog\u00ae)', and 'regular human insulin (huminsulin\u00ae normal)'.\n- Criteria: The eligibility criteria for participants in the trial are as follows:\n\n  Inclusion Criteria:\n  - Participants must be male or female aged 18-64 years.\n  - Participants must have been diagnosed with type 1 diabetes mellitus for at least 12 months.\n  - Participants must have been treated with multiple daily insulin injections or continuous subcutaneous insulin infusion (CSII) for at least 12 months.\n  - Participants' current total daily insulin treatment should be less than 1.2 (I)U/kg/day.\n  - Participants' current total daily bolus insulin treatment should be less than 0.7 (I)U/kg/day.\n  - Participants' BMI should be between 18.5 and 28.0 kg/m^2.\n  - Participants' HbA1c levels should be less than or equal to 9.0%.\n  - Participants' fasting C-peptide levels should be less than or equal to 0.30 nmol/L.\n\n  Exclusion Criteria:\n  - Participants with known or suspected hypersensitivity to the investigational medicinal products (IMPs) or related products.\n  - Participants with type 2 diabetes mellitus.\n  - Participants who have previously participated in this trial.\n  - Participants who have participated in any other clinical trial within the past 3 months.\n  - Participants with clinically significant abnormal screening test results for haematology, coagulation, biochemistry, lipids, or urinalysis.\n  - Participants with clinically significant acute gastrointestinal symptoms.\n  - Participants with known slowing of gastric emptying or gastrointestinal surgery that may affect gastrointestinal motility and food absorption.\n  - Participants with unusual meal habits, special diet requirements, or unwillingness to eat the provided food.\n  - Females of childbearing potential who are pregnant, breastfeeding, intend to become pregnant, or are not using highly effective contraceptive methods.\n\nThis information provides an overview of the trial phase, the targeted disease, the associated ICD codes, the drugs involved, and the eligibility criteria for participants.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1 and focuses on neoplasms (a type of tumor). The ICD-10 codes associated with the diseases are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The trial involves several drugs, including caffeine, warfarin, omeprazole, midazolam, digoxin, vitamin k, and rucaparib. The eligibility criteria for participants are listed, including requirements such as having a confirmed advanced solid tumor, measurable disease, a specific performance status, and adequate bone marrow, renal, and liver function. There are also exclusion criteria, such as prior treatment with certain therapies, presence of thrombi or cardiovascular conditions, gastrointestinal disorders that may interfere with drug absorption, and other factors.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 1. The diseases being studied are \"leukemia, lymphocytic, chronic, b-cell\", \"lymphoma, large b-cell, diffuse\", \"lymphoma, follicular\", and \"lymphoma, mantle-cell\". The corresponding ICDCodes for these diseases are \"C91.11\", \"C91.12\", \"C91.10\" for the first disease, and \"S33.110S\", \"S33.111S\", \"S33.120S\", \"S33.121S\", \"S33.130S\", \"S33.131S\", \"S33.140S\" for the rest of the diseases.\n\nThe drugs being used in the trial are \"duvortuxizumab\" and \"ibrutinib\". The eligibility criteria for participants are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include having a B-cell malignancy with tumor progression following prior standard therapies, having a measurable tumor that requires treatment, being able to carry out daily life activities with difficulty, having adequate organ and blood cell counts, and using contraception if sexually active.\n\nExclusion criteria include having a brain tumor or severe side effects from previous anti-cancer treatment, having uncontrolled systemic disease or heart problems, having a history of autoimmune disease or organ transplant, having received specific medications or treatments within a week of starting the study, and being pregnant, breastfeeding, or planning to become pregnant or father a child.",
    "The sample provided is a schema definition of a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this specific sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are ocular hypertension and open-angle glaucoma. The ICDCodes associated with these diseases are provided as well. The drugs being tested are \"mgv354 ophthalmic suspension\" and \"mgv354 placebo\". \n\nThe eligibility criteria for participants in this trial include having documented informed consent, being within a certain age range, being able to communicate well with the investigator, having a specific body mass index (BMI), and meeting certain vital sign requirements. Other criteria include being in good health for healthy volunteers or being diagnosed with open-angle glaucoma or ocular hypertension for patients. \n\nThere are also exclusion criteria, such as a history of hypersensitivity to the study drugs, certain medical conditions, exposure to certain medications, and pregnancy or lactation for women. Additional exclusion criteria may apply as specified in the protocol.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is categorized into different phases, and in this case, it is an early phase 1 trial. The diseases being studied in this trial are hypertension and high blood pressure. The corresponding ICD-10 codes for these diseases are also provided. The drugs being investigated in the trial are losartan, amlodipine, and hydrochlorothiazide. \n\nThe eligibility criteria for participants in this trial are as follows:\n- Age between 21 and 80 years.\n- History of physician-diagnosed hypertension.\n- Currently not treated with antihypertensive medication, but there is a consensus between the patient and their physician that medication should be initiated. Alternatively, participants who are already being treated with one antihypertensive medication are also eligible.\n- No history of suspected or confirmed white coat hypertension.\n- Must have easy access to and regularly use email, as they will need to respond to surveys during the self-monitoring period.\n- Must have an established relationship with an accessible primary care provider who gives permission for participation in the trial.\n\nThe exclusion criteria for participants are as follows:\n- Severe hypertension (office BP = 180/110 mm Hg).\n- History of myocardial infraction, heart failure, atrial fibrillation, or chronic kidney disease.\n- Electrolyte abnormality.\n- Known drug allergy or intolerance to angiotensin receptor blocker, calcium channel blocker, or thiazide diuretic.\n- Prescribed BP medication for indications other than hypertension.\n- Primary care provider permission not obtained.\n- Non-English speaking.\n- No regular access and use of email.\n- Unable to provide informed consent or adhere to the study protocol due to cognitive impairment, mental illness, or other reasons.\n- Unable to monitor BP at home using an automatic BP machine due to physical or mental impairments.\n- Unable to track side effects of medications due to physical or mental impairments, including literacy problems.\n- Arm circumference <9 inches or >17 inches.\n- Unavailable for follow-up during the study period due to severe medical illness or other reasons.",
    "The sample provided is a record from a table that contains information about clinical trials. The record belongs to a trial in phase 1 and focuses on the disease \"carcinoma, non-small-cell lung.\" The associated ICD-10 codes for this disease are \"D02.20,\" \"D02.21,\" and \"D02.22.\" The trial involves the use of two drugs, \"microgynon\" and \"nintedanib.\" \n\nThe eligibility criteria for this trial are as follows:\n- Female patients who are 18 years or older at screening.\n- Female patients who are postmenopausal or surgically sterilized.\n- Patients with locally advanced, metastatic, or locally recurrent non-small cell lung cancer with adenocarcinoma histology.\n- Nintedanib (Vargatef\u00ae) is planned to be prescribed according to the marketing authorization.\n- Patients must provide signed and dated written informed consent in accordance with Good Clinical Practice (GCP) and local legislation prior to admission to the trial.\n\nThe exclusion criteria for this trial are as follows:\n- Any contraindication to nintedanib (Vargatef\u00ae), ethinylestradiol, or levonorgestrel (Microgynon\u00ae) as specified in the respective labels.\n- Use of hormone-containing contraceptives within 30 days prior to the first administration of Microgynon\u00ae.\n- Systemic use of drugs known to induce or inhibit CYP3A4 within 7 days prior to the first trial drug administration until the last pharmacokinetic (PK)-sampling in the trial, with exceptions for corticosteroids as docetaxel (pre)medication.\n- History of major thrombotic or clinically relevant major bleeding event in the past 6 months.\n- Persistence of clinically relevant therapy-related toxicities from previous chemotherapy and/or radiotherapy.\n- Treatment with other investigational drugs or participation in another clinical trial within the past four weeks before the start of therapy or concomitantly with this trial.\n- Gastrointestinal disorders or abnormalities that would interfere with the absorption of the trial drugs.\n- Major surgery performed within 4 weeks prior to the first treatment within the trial and without complete wound healing.\n- Patients who must or wish to continue the intake of restricted medications or any drug considered likely to interfere with the safe conduct of the trial.\n- Patients unable to comply with the protocol.\n- Previous enrollment in this trial.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in the early phase 1 and focuses on the treatment of bipolar disorder. The diseases listed in this sample include \"treatment-resistant bipolar disorder,\" \"bipolar disorder,\" and \"bipolar depressive disorder.\" The corresponding ICD-10 codes for these diseases are ['F31.81', 'F31.89', 'F31.9', 'F25.0', 'F31.0', 'F31.31', 'F31.32']. The drugs being studied in this trial are \"nitrous oxide\" and \"placebo.\" \n\nThe eligibility criteria for this trial include being an adult between 18-65 years of age, having treatment-resistant bipolar depressive disorder without psychosis, and having a baseline MADRS score of >20. Patients must also have a history of being on a mood stabilizer (lithium or valproic acid) for 4 weeks prior to the study and continue taking it during the trial. Additionally, patients must have failed two adequate dose/duration antidepressant courses in their lifetime, including one in the current depressive episode. Good command of the English language is also required.\n\nExclusion criteria for this trial include having schizophrenia, schizoaffective disorder, obsessive-compulsive disorder, or panic disorder. Patients with active or recent substance abuse or dependence (except nicotine use disorders) are also excluded. Patients with a diagnosis of a personality disorder that may interfere with the effectiveness of nitrous oxide, acute medical illnesses that may pose a risk during nitrous oxide administration, active suicidal intention, active psychotic symptoms, significant pulmonary disease, or contraindications against the use of nitrous oxide are also excluded from the trial.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is divided into different phases, and this particular sample is from phase 1. The diseases being studied in this phase include \"healthy\" participants and those with type 2 diabetes mellitus (T2DM). The corresponding ICD-10 codes for these diseases are provided as well.\n\nThe drugs being tested in this phase are \"ly3298176\", \"placebo\", and \"dulaglutide\". The eligibility criteria for participants are listed, including requirements for body mass index (BMI) and the control of T2DM with either diet and exercise or specific medications.\n\nExclusion criteria are also mentioned, such as allergies to certain drugs or compounds, abnormal electrocardiogram (ECG) results, history of pancreatitis or gastrointestinal disorders, and a history of severe hypoglycemia for T2DM participants.\n\nOverall, this sample provides information about the phase, diseases, ICD-10 codes, drugs, and eligibility criteria for participants in a clinical trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is Hepatitis C. The ICDCodes associated with this disease are B18.2, B17.10, B17.11, B19.20, B19.21, B15.0, and B15.9. The drugs being tested in this trial are cdi-31244 and placebo. \n\nThe eligibility criteria for this trial include being male or female aged 18 to 65 years, having a body mass index between 18.5 and 35.0 kg/m2, having a body weight of at least 50 kg, testing negative for alcohol and drugs of abuse, having normal results on a 12-lead electrocardiogram (ECG), and for females, having a negative pregnancy test.\n\nAdditional eligibility criteria specific to Hepatitis C infected subjects include not having received prior direct acting agent (DATA) treatment for Hepatitis C, having a documented clinical history compatible with chronic Hepatitis C, having HCV Genotype 1, having a plasma HCV RNA level of at least 5.0 log10 IU/mL, and having no cirrhosis based on laboratory evidence (negative liver biopsy or fibroscan or FibroTest, F2 or lower) within one year prior to the study.\n\nExclusion criteria for both healthy volunteers and Hepatitis C infected subjects include being pregnant or lactating (for females), being co-infected with Hepatitis B virus (HBV) and/or human immunodeficiency virus (HIV), abusing alcohol and/or drugs that could interfere with adherence to study requirements, testing positive for drugs of abuse or alcohol, having intestinal malabsorption, having clinically significant ECG abnormalities or out-of-range cardiac intervals, having serum creatinine levels above the upper limit of normal, and having any clinically significant medical condition that could jeopardize the subject's safety or impact the validity of the study results.\n\nAdditional exclusion criteria specific to Hepatitis C infected subjects include having clinical or laboratory evidence of cirrhosis, having a history or signs of decompensated liver disease, having a history of hepatocellular carcinoma (HCC) or findings suggestive of possible HCC, and having active clinically significant diseases.",
    "The sample is a record from a table that contains information about clinical trials. The phase of the trial is \"phase 1/phase 2\". The disease being studied is \"esophageal cancer\". The corresponding ICD-10 codes for the disease are \"K22.2\", \"K22.81\", \"Q39.4\", \"P78.83\", \"I85.00\", \"I85.01\", and \"I85.10\". The drug being tested is \"nab-paclitaxel group\". \n\nThe sample also includes the eligibility criteria for the trial. The inclusion criteria are:\n1. The patient must have inoperable locally advanced histologically confirmed esophageal cancer.\n2. The patient's ECOG performance status scale should be 0-1.\n3. The patient must have at least 1 measurable target lesion.\n4. The patient's white blood count, absolute neutrophil count, platelet count, hemoglobin count, serum bilirubin level, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, serum albumin, and serum creatinine should meet certain criteria.\n5. The patient should have normal cardiac function with no severe heart disease.\n\nThe exclusion criteria are:\n1. The patient should not have a history of esophagectomy.\n2. The patient should not be pregnant or breastfeeding.\n3. The patient should not have a past history of other cancers, except for cured non-melanoma skin cancer or cervical cancer.\n4. The patient should not be receiving concomitant treatment with other anticancer drugs.",
    "The sample is a phase 1 clinical trial that focuses on healthy individuals and those with HIV. The trial involves testing the effectiveness of two drugs, \"tenofovir disoproxil fumarate intravaginal ring\" and \"placebo intravaginal ring (ivr)\". The eligibility criteria for participants include being between the ages of 18-45, being in good health without any significant systemic diseases, providing written informed consent, and being willing to avoid certain sexual activities for a week after each biopsy. Participants must also be HIV-negative, using a non-IVR contraceptive method, sexually active, and have a regular sex partner. Exclusion criteria include recent sexual activity with an HIV-positive or unknown status partner, known adverse reactions to certain substances, active hepatitis B infection, vulvar or vaginal symptoms, and various other conditions that may interfere with the study.",
    "The sample provided is a record from a table that contains information about clinical trials. The record is for a phase 1 trial and the disease being studied is \"healthy\". The corresponding ICD-10 codes for this disease are \"Z76.3\" and \"Z76.2\". The drugs being tested in this trial are \"treprostinil\", \"placebo\", \"ly900014\", and \"insulin lispro\". The eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". The inclusion criteria include being overtly healthy, having a BMI between 18.5 and 25 kg/m\u00b2, and having specific blood glucose levels. The exclusion criteria include not being enrolled in any other clinical trial, not having participated in a trial involving the investigational products within the last 30 days, not having previously completed or withdrawn from this study or any other study involving treprostinil or LY900014, and not having any health problems or laboratory test results or ECG readings that could interfere with the study or make it unsafe to participate.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 1. The diseases being studied are diabetes and diabetes mellitus, type 2. The ICDCodes associated with these diseases are E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65 for the first disease, and E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44 for the second disease. The drugs being tested are semaglutide and placebo. \n\nThe eligibility criteria for this trial are as follows:\n- The subject must be male or female, aged 18-75 years.\n- They must have been diagnosed with type 2 diabetes mellitus for at least 90 days prior to screening.\n- They should be treated with diet and exercise and/or metformin monotherapy, with no change in metformin dose for 30 days prior to screening.\n- The subject's body mass index (BMI) should be between 20.0-38 kg/m^2.\n- The HbA1c (glycosylated haemoglobin) level should be between 6.0-9.0%.\n\nThere are also exclusion criteria that would disqualify a subject from participating in the trial. These include being pregnant, having a family or personal history of Multiple Endocrine Neoplasia Type 2 or Medullary Thyroids Carcinoma, a history of pancreatitis, and the presence of gastrointestinal disorders that could affect drug absorption, among others.\n\nOverall, this sample provides information about the phase, diseases, ICDCodes, drugs, and eligibility criteria for a clinical trial related to diabetes.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is biliary tract cancer. The ICDCodes associated with this disease are C24.9 and C24.8. The drug being used in the trial is a combination of mek162 and capecitabine. \n\nThe eligibility criteria for this trial include:\n- The patient must have histologically/cytologically verified, non-resectable, recurrent, or metastatic biliary tract carcinoma, including intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and gallbladder carcinoma.\n- The patient must have previously been treated with gemcitabine-based chemotherapy (up to 2 prior treatment regimens are allowed).\n- The patient must have measurable or evaluable disease according to RECIST 1.1 criteria.\n- The patient's Eastern Cooperative Oncology Group (ECOG) performance status must be 0 or 1.\n- The patient must be at least 20 years old.\n- The patient must have adequate bone marrow function, renal function, and hepatic function.\n- Patients with biliary obstruction can participate if their bilirubin levels correct to the required limit after adequate biliary drainage.\n- Women of childbearing potential must have a negative pregnancy test and both men and women of childbearing potential must be willing to use effective contraception during the trial and for at least 3 months afterward.\n- The patient must be able to understand and sign a written informed consent document.\n\nThe exclusion criteria for this trial include:\n- The patient has evidence of another active cancer that may influence the outcome, except for certain specified types of cancer.\n- The patient has known brain metastases or primary central nervous system tumors with uncontrolled seizures.\n- The patient has uncontrolled intercurrent illness, psychiatric illness/social situations that would limit compliance with study requirements, or is known to be HIV positive.\n- The patient has significant cardiovascular disease, uncontrolled diabetes mellitus, a history of myocardial infraction or stroke within the past 6 months, clinically significant peripheral vascular disease, or has undergone a major surgical procedure within the past 4 weeks.\n- The patient has uncontrolled infection, known or suspected allergy to capecitabine, is pregnant or breastfeeding, has a condition that impairs their ability to swallow whole pills, or has a malabsorption problem that may limit or inhibit the absorption of MEK162.\n- The patient has a history of any organ or bone marrow transplant.",
    "The sample from the table represents a phase 1 clinical trial for patients with head and neck squamous cell carcinoma (HNSCC). The diseases included in the trial are stage III and stage IV HNSCC, involving various regions such as the oral cavity, oropharynx, hypopharynx, and larynx. The trial focuses on patients who have undergone surgical resection of the tumor and have high-risk pathologic features, such as extracapsular nodal extension or invasive cancer at the resection margin.\n\nThe eligibility criteria for the trial include specific requirements for the patient's medical history, physical examination, imaging tests, and laboratory values. Patients must have a Zubrod performance status of 0-1 and meet certain blood count and organ function criteria. Women of childbearing potential must have a negative pregnancy test and both men and women must use contraception during the study.\n\nThere are also exclusion criteria, such as the presence of metastatic disease, prior systemic therapy for the study cancer, and certain severe co-morbidities. Patients with active autoimmune diseases, active infections, or certain electrolyte abnormalities are also excluded. The sample also mentions that patients who are pregnant, nursing, or planning to conceive during the study period are not eligible.\n\nOverall, the sample provides information about the phase, diseases, ICDCodes, drugs, and eligibility criteria for the clinical trial.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is categorized as \"phase 1\" and focuses on the disease \"asthma.\" The ICD-10 codes associated with the disease are listed as \"J45.998,\" \"J82.83,\" \"J45.909,\" \"J45.991,\" \"J45.20,\" \"J45.30,\" and \"J45.40.\" The drugs being studied in this trial include \"abediterol 0.156 \u03bcg,\" \"abediterol 2.5 \u03bcg,\" and \"abediterol 0.05 \u03bcg.\" \n\nThe eligibility criteria for participants in this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" Inclusion criteria include providing informed consent, being between 18 and 75 years old, having a clinical diagnosis of asthma for at least 6 months, being on a stable dose of approved asthma medication, and meeting certain lung function requirements. Exclusion criteria include involvement in the planning or conduct of the study, recent participation in another clinical study with an investigational product, known hypersensitivity to the study drug or its components, recent systemic steroid use, recent hospitalization due to asthma, presence of other active pulmonary diseases, non-compliance with study procedures, recent treatment with certain medications, and various other medical conditions or factors that may affect participation or safety.\n\nThe sample also includes information about procedures for withdrawal of incorrectly enrolled patients and restrictions on concomitant medication use.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The diseases being studied include brain stem neoplasm, pineal region neoplasm, recurrent lymphoma, recurrent malignant solid neoplasm, recurrent primary central nervous system neoplasm, recurrent visual pathway glioma, refractory lymphoma, refractory malignant solid neoplasm, refractory primary central nervous system neoplasm, and refractory visual pathway glioma. The corresponding ICDCodes for these diseases are also provided. The drug being tested in this trial is entinostat. The eligibility criteria include various requirements such as body surface area, ability to swallow tablets, histologic verification of malignancy, measurable or evaluable disease, lack of known curative therapy, performance score, recovery from prior anti-cancer therapy, blood count criteria, absence of bone marrow metastatic disease, and various laboratory values within specified ranges. There are also exclusion criteria listed, such as pregnancy or breastfeeding, use of certain medications, concurrent administration of valproic acid, uncontrolled infection, prior solid organ transplantation, and history of allergy to medications with a benzamide structure.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1. The disease mentioned is pancreatic ductal adenocarcinoma (PDAC). The ICDCodes associated with this disease are C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, and C4A.31. The drug being used in this trial is folfirinox (oxaliplatin, leucovorin, irinotecan). \n\nThe eligibility criteria for this trial include:\n1. Histologic or cytologic diagnosis of adenocarcinoma of the pancreas.\n2. Resectable primary tumor of the head, body, or tail of the pancreas.\n3. Confirmation of resectability by surgical oncology consultation.\n4. No previous therapy for pancreatic cancer.\n5. ECOG performance status of 0 or 1.\n6. Age over 18 years.\n7. No recent stroke or heart attack.\n8. Women of child-bearing potential and men must use contraception.\n9. Negative pregnancy test for females of reproductive age.\n10. Anticoagulation is permitted, but patients cannot be on warfarin.\n11. Patients must have normal organ and marrow function.\n12. Ability to understand and sign a written informed consent document.\n\nThe exclusion criteria for this trial include:\n1. Previous chemotherapy or radiotherapy for pancreatic adenocarcinoma.\n2. Pathologic subtypes other than pure adenocarcinoma.\n3. Patients receiving any investigational agents.\n4. Patients with borderline resectable, locally advanced, or metastatic disease.\n5. History of allergic reactions to specific chemotherapy agents.\n6. Uncontrolled intercurrent illness or psychiatric illness/social situations that would limit compliance.\n7. Pregnant or breastfeeding women.\n8. HIV-positive patients on combination antiretroviral therapy.\n9. Currently active second malignancy, except for non-melanoma skin cancer or carcinoma in-situ of the cervix.\n10. Pre-existing neuropathy greater than grade 1.\n11. Uncontrolled or actively treated inflammatory bowel disease (Crohn's disease, ulcerative colitis).\n\nThis information provides details about the trial phase, the specific disease being studied, the drugs used, and the eligibility criteria for participants.",
    "The sample provided is a schema definition of a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. The \"phase\" column indicates the phase of the trial, which can be phase I, phase II, or phase III. The \"diseases\" column contains a list of disease names. The \"icdcodes\" column contains a list of ICDCodes (ICD-10 codes) associated with the diseases. The \"drugs\" column contains a list of drug names. The \"criteria\" column contains the eligibility criteria for the trial.\n\nIn the provided sample, the phase is \"phase 1\". The diseases associated with this phase are \"accelerated phase chronic myelogenous leukemia (CML)\", \"blast phase chronic myelogenous leukemia (CML)\", \"chronic phase phase chronic myelogenous leukemia (CML)\", and \"Philadelphia chromosome positive (Ph+) phase chronic myelogenous leukemia (CML)\". The ICDCodes associated with these diseases are [\"C95.91\", \"C95.92\", \"Z80.6\", \"Z85.6\", \"C90.11\", \"C90.12\", \"C91.01\"] for the first three diseases and [\"Q99.2\", \"Q99.8\", \"Q95.1\", \"Q98.7\", \"Q92.0\", \"Q92.1\", \"Q93.0\"] for the last disease. The drugs associated with this phase are \"axitinib\" and \"bosutinib\". The eligibility criteria for this phase include specific diagnosis requirements, previous treatment failures, performance status, laboratory values, informed consent, birth control measures, and other exclusion criteria related to prior therapy, medical conditions, psychiatric disorders, hypertension, pregnancy, and medication use.\n\nPlease note that the provided sample is just one entry from the table and may not represent the entire dataset.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease mentioned is \"soft tissue sarcoma\" and its corresponding ICDCodes are ['C46.1']. The drugs being used in this trial are \"olaratumab\" and \"doxorubicin\". The eligibility criteria for participants in this trial include having a histologically confirmed diagnosis of STS, potentially resectable disease, and consent to undergo mandatory serial peripheral whole blood and tumor tissue sampling. There are also exclusion criteria, such as having active central nervous system or leptomeningeal metastasis, prior treatment with certain drugs, or prior participation in an olaratumab trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1. The diseases being studied are \"rheumatoid arthritis\" and \"complication of transplant.\" The corresponding ICDCodes for these diseases are \"M06.9,\" \"M05.9,\" \"M06.08,\" \"M06.00,\" \"M06.011,\" \"M06.012,\" and \"M06.019.\" The drugs being tested are \"fr104\" and \"placebo.\" The eligibility criteria for this sample include various requirements such as age, good health condition, normal ECG, weight range, negative drug and alcohol tests, specific conditions for female subjects, agreement to contraception for male subjects, adherence to study restrictions, signed informed consent, EBV-positive status, and restrictions on smoking. Additionally, there are exclusion criteria listed, which include a history of significant diseases, allergies or intolerances to the study drug, history of severe allergic reactions, alcohol or substance abuse, recent infections, immunological disorders, positive hepatitis or HIV tests, abnormal blood pressure or pulse rate, pregnancy or breastfeeding, recent vaccinations or use of immunosuppressant agents, participation in other clinical trials, recent blood loss or transfusion, and any condition that could compromise the subject's well-being or ability to meet study requirements. There is also a restriction on visiting regions with tuberculosis and mycosis endemicity after dosing.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The diseases being studied are lymphoma and solid tumors (excluding CNS). The ICDCodes associated with these diseases are S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, and S33.140S. The drug being tested is pixantrone. The eligibility criteria for this trial include factors such as patient age, previous treatment history, cardiac function measurements, blood counts, liver function, prior cancer therapy, and willingness to comply with the study protocol. There are also exclusion criteria listed, which include factors such as predicted life expectancy, ability to tolerate treatment, previous anthracycline treatment, infections, recent surgery, hepatitis B or C infection, HIV seropositivity, recent experimental therapy, heart conditions, allergies to investigational drugs, pregnancy or lactation, planned radiotherapy or surgery, and other medical or psychiatric conditions that may hinder participation or interpretation of data.",
    "The sample provided is a record from a table that contains information about clinical trials. The phase of the trial is indicated as \"phase 1/phase 2\". The disease mentioned in this sample is \"nasopharyngeal carcinoma\". The corresponding ICD-10 codes for this disease are listed as \"['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']\". The drug mentioned in this sample is \"cisplatin\". \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include having a confirmed diagnosis of nasopharyngeal carcinoma, completing a course of radiation therapy, having a recurrence diagnosed more than 12 months after the initial treatment, being between the ages of 18 and 70, having a Karnofsky Performance Score of at least 70, being willing to use contraception if applicable, understanding the implications of the trial, and signing the informed consent form.\n\nExclusion criteria include having a local recurrence of nasopharyngeal carcinoma within 12 months of previous radiation therapy, having distant metastasis, using a different technology for the initial treatment, being pregnant or lactating, not having recovered from previous therapies, having a diagnosis of another malignancy within the past 5 years (except for certain types), and refusing to participate in the study.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase is \"early phase 1\" and the disease is \"breast cancer\". The ICDCodes associated with the disease are \"C79.81\", \"D24.1\", \"D24.2\", \"D24.9\", \"D49.3\", \"C44.501\", and \"D48.60\". The drugs being studied are \"oral vinorelbine\" and \"letrozole\". The eligibility criteria for this trial include requirements such as written informed consent, postmenopausal status, specific tumor characteristics, HR-positive and HER2-negative status, adequate organ function, and exclusion of certain conditions or prior treatments.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The phase of the trial is \"early phase 1\".\n- Diseases: The diseases being studied in this trial are \"breast cancer\", \"human epidermal growth factor 2 negative carcinoma of breast\", and \"early-stage breast carcinoma\".\n- ICD Codes: The ICD-10 codes associated with these diseases are [\"C79.81\", \"D24.1\", \"D24.2\", \"D24.9\", \"D49.3\", \"C44.501\", \"D48.60\"] for the first disease, [\"C22.0\", \"C22.1\", \"C4A.9\", \"C7B.1\", \"D09.9\", \"C4A.0\", \"C4A.31\"] for the second disease, and [\"C22.0\", \"C22.1\", \"C4A.9\", \"C7B.1\", \"D09.9\", \"C4A.0\", \"C4A.31\"] for the third disease.\n- Drugs: The drugs being used in the trial are \"me-344\" and \"bevacizumab\".\n- Criteria: The eligibility criteria for participants in the trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". The inclusion criteria include factors such as age, diagnosis, performance status, informed consent, pregnancy status, organ function, cardiac ejection fraction, life expectancy, and willingness to undergo trial procedures. The exclusion criteria include factors such as neuropathy, diabetes mellitus, uncontrolled diseases, participation in other clinical studies, concurrent or active malignant disease, pregnancy or breastfeeding without effective birth control, uncontrolled infection or systemic disease, cardiac disease, concurrent systemic chemotherapy or biologic therapy, hypersensitivity to the drugs being used, HIV or Hepatitis B or C, history of solid organ transplantation, psychiatric disorder or social/geographic situation that would preclude study participation, inability to comply with study procedures, and any other condition that may interfere with evaluation of the study treatment or interpretation of patient safety or results.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is acidosis, and its corresponding ICDCodes are E87.2 and P74.0. The drugs being tested are placebo and trc101. The eligibility criteria for this trial include specific ranges for estimated glomerular filtration rate (eGFR) and serum bicarbonate levels. There are also exclusion criteria listed, such as the presence of severe comorbid conditions, chronic obstructive pulmonary disease, and anticipated changes in doses of certain drugs or drug classes. Additionally, there is a list of drugs and drug classes that are excluded from the trial.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2 and focuses on the treatment of stage III and stage IV skin melanoma. The trial involves the drug imatinib mesylate. The eligibility criteria for participants include having a confirmed diagnosis of melanoma, having a mutation or amplification of the c-KIT gene, providing informed consent, having measurable disease, and meeting certain health requirements such as blood counts, liver function, and kidney function. There are also exclusion criteria, such as not currently participating in another study, not having active tuberculosis, not having hypersensitivity to certain medications, and not having certain medical conditions or infections. The sample also includes information about contraception requirements for female participants and restrictions on prior treatments and vaccinations.",
    "The sample provided is a schema definition of a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this specific sample, the phase of the trial is a combination of phase 1 and phase 2. The disease mentioned is chronic obstructive pulmonary disease (COPD), and the corresponding ICDCodes are J44.9, J44.1, and J44.0. \n\nThe drugs involved in the trial are chf6297 and placebo, with different parts specified for each drug. The eligibility criteria are divided into inclusion and exclusion criteria for different parts of the trial.\n\nFor healthy subjects (parts 1, 2, and 4), the inclusion criteria include being male, aged 18-55 years, non-smokers, having lung function above 80% of the predicted normal value, and being deemed healthy based on medical evaluation. In part 4, the ability to produce an adequate induced sputum sample is also required.\n\nFor COPD patients (part 3), the inclusion criteria include being males or females aged 40-75 years, current or past smokers, having stable lung function with specific FEV1 values, and the ability to produce both spontaneous and induced sputum samples.\n\nThe exclusion criteria for healthy subjects include any clinically relevant abnormalities or uncontrolled diseases, abnormal laboratory values, recent respiratory tract infection, hypersensitivity to the drug or excipients, positive serology results, and positive cotinine, alcohol, or drug abuse tests.\n\nFor COPD patients (part 3), the exclusion criteria include females of childbearing potential, history of asthma, unstable concomitant diseases, abnormal relevant Holter ECG parameters, recent acute exacerbations of COPD or respiratory tract infection, hypersensitivity to the drug or excipients, and positive serology results.",
    "The sample is a record from a table that contains information about clinical trials. In this particular sample, the trial is in phase 1/phase 2. The diseases being studied are Lennox-Gastaut syndrome and Dravet syndrome. The corresponding ICD-10 codes for these diseases are 'G40.813', 'G40.814', 'G40.811', 'G40.812' for Lennox-Gastaut syndrome and 'G40.833', 'G40.834' for Dravet syndrome. The drug being tested in the trial is cannabidiol. The sample also includes the eligibility criteria for the trial, including inclusion and exclusion criteria.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease being studied is HIV-1 infection. The ICDCodes associated with this disease are \"B20\", \"Z71.7\", \"O98.72\", \"Z21\", \"O98.73\", \"R75\", and \"Z11.4\". The drugs being used in the trial are darunavir/cobicistat and etravirine. The eligibility criteria for participants include being at least 18 years old, having documented HIV infection, being on stable antiretroviral treatment with specific drugs for at least 4 weeks, having a plasma HIV-1 RNA load of less than 50 copies/mL for at least 12 weeks, and using a reliable method of birth control for women of childbearing age. The sample also includes exclusion criteria such as inadequate adherence to antiretroviral treatment, recent use of medications with known interactions, acute illness that could interfere with the drugs' effectiveness, active AIDS-defining illness, pregnancy or breastfeeding in women, and the inability to complete the study treatment and protocol.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase is Phase 1. The diseases listed include \"b acute lymphoblastic leukemia with t(9;22)(q34;q11.2); bcr-abl1\", \"recurrent adult acute lymphoblastic leukemia\", \"recurrent childhood acute lymphoblastic leukemia\", \"refractory adult acute lymphoblastic leukemia\", and \"refractory childhood acute lymphoblastic leukemia\". The ICDCodes associated with these diseases are also provided. The drug mentioned in this sample is \"dasatinib\". The eligibility criteria include various requirements such as a confirmed diagnosis of Ph+ ALL, specific genetic markers, prior treatment history, organ and bone marrow function, negative pregnancy test for females, and the ability to understand and sign a consent form. There are also exclusion criteria listed, which include factors such as intolerance to certain medications, medical disorders that may interfere with treatment, and pregnancy or nursing.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is Alzheimer's disease. The ICDCodes associated with Alzheimer's disease are G30.8, G30.9, G30.0, and G30.1. The drugs being used in the trial are placebo and ro7105705. \n\nThe eligibility criteria for participants in this trial include having a total body weight between 45 and 120 kilograms, not donating blood or blood products for the duration of the study and one year after the final dose of the study drug, being in good health based on medical history, physical examination, ECG, laboratory tests, and vital signs, having clinical laboratory evaluations within the reference range, testing negative for selected drugs of abuse, and agreeing to use highly effective contraception measures.\n\nFor healthy participants, they must be between the ages of 18 and 80, have no history of symptomatic cognitive decline, and no concern about clinically significant cognitive impairment.\n\nFor participants with Alzheimer's disease, they must be between the ages of 50 and 80, capable of completing assessments either alone or with the help of a caregiver, have a caregiver who can provide accurate information about their cognitive and functional abilities, have adequate visual and auditory acuity for neuropsychological testing, have a clinical diagnosis of probable Alzheimer's disease dementia, have specific scores on the mini-mental state examination and clinical dementia rating-global score, have a positive florbetapir amyloid PET scan, and be on a stable dose of cholinesterase inhibitor and/or memantine therapy for at least 4 weeks prior to screening.\n\nThe exclusion criteria for all participants include being pregnant or lactating, participating in another clinical trial or using experimental therapies within a certain timeframe, recent surgery or hospitalization, planned procedures or surgeries during the study, recent blood transfusion or blood donation, poor peripheral venous access, testing positive for certain viruses, recent illicit drug or alcohol abuse, administration of certain supplements, history of seizures or certain mental disorders, being at risk of suicide, recent serious infection or medical condition, and being immunocompromised.\n\nFor participants with Alzheimer's disease, additional exclusion criteria include having clinically evident vascular disease potentially affecting the brain, recent stroke or transient ischemic attack, presence of clinically relevant intracranial tumor, presence of infections affecting brain function or resulting in neurologic sequelae, presence of autoimmune disorders potentially causing progressive neurologic disease, presence of other neurologic diseases that may affect cognition, and certain findings on magnetic resonance imaging.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 1 and the disease is schizophrenia. The ICDCodes associated with schizophrenia are ['F20.0', 'F20.1', 'F20.2', 'F20.3', 'F20.5', 'F20.89', 'F20.9']. The drugs being tested in this trial are 'placebo' and 'ro5545965'. The eligibility criteria for participants are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". The criteria include factors such as a diagnosis of schizophrenia, BMI range, language fluency, clinical assessment scores, previous treatments, medical conditions, and medication usage.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1 and focuses on the human immunodeficiency virus (HIV). The trial uses a list of ICD-10 codes to identify specific diseases related to HIV. The drugs being studied are 3bnc117, 10-1074, and a placebo. The eligibility criteria for participants are listed, including age requirements, the need for HIV risk reduction counseling, and the use of contraception for sexually active participants. The exclusion criteria include having a confirmed HIV infection, a history of immunodeficiency or autoimmune disease, and various medical conditions that could affect participation. The sample also includes laboratory abnormalities that would exclude a participant, as well as restrictions on recent vaccinations and previous participation in other clinical studies.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 1 and focuses on cytomegalovirus infections. The ICD-10 code for this disease is \"P35.1\". The trial involves testing several drugs, including \"vbi-1501a 0.5 \u03bcg\", \"vbi-1501a 1.0 \u03bcg\", \"vbi-1501a 2.0 \u03bcg\", \"vbi-1501 1.0 \u03bcg\", and a placebo. The eligibility criteria for participants are listed, including age requirements, serological confirmation of CMV seronegativity, agreement to use contraception for female volunteers, signing an informed consent document, and being generally healthy. The exclusion criteria are also provided, which include having a significant medical illness, abnormal physical examination or laboratory values, previous receipt of a CMV vaccine, allergic reactions to vaccine components, pregnancy or breastfeeding, immunological impairments, recent use of immune-suppressive drugs, participation in other clinical studies, skin abnormalities or tattoos that may interfere with injection site assessment, history of cancer requiring chemotherapy or radiation, and being a family member of study center staff.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease mentioned is \"clostridium difficile infection.\" The ICDCodes associated with this disease are \"A05.2,\" \"A04.71,\" \"A04.72,\" and \"B96.7.\" The drugs being studied are \"ser-262\" and \"placebo.\" \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" Inclusion criteria include the requirement of a signed informed consent, subjects being 18 years or older, and having a primary episode of CDI with documented details. Exclusion criteria include females who are pregnant, breastfeeding, or planning to become pregnant during the study, individuals with known or suspected toxic megacolon or small bowel ileus, those with active irritable bowel syndrome with diarrhea, recent major gastrointestinal surgery, history of inflammatory bowel disease, low estimated glomerular filtration rate, admission or expected admission to an intensive care unit, concurrent intensive induction chemotherapy, radiotherapy, or biologic treatment for active malignancy, and an absolute neutrophil count below 500 cells/mm3.",
    "The sample provided is a schema definition of a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. The table has the following columns: phase, diseases, icdcodes, drugs, and criteria. \n\nThe sample data in the table includes the following information: \n- Phase: Phase 1\n- Diseases: Triple-negative breast neoplasms, carcinoma non-small-cell lung, head and neck carcinoma squamous cell, advanced solid tumors\n- ICDCodes: D02.20, D02.21, D02.22, K74.02, G47.22, H35.3133, H35.3134, H35.3113, H35.3114, H35.3123\n- Drugs: tak-659, nivolumab\n- Criteria: The eligibility criteria for participants in the trial, including age, performance status, contraceptive requirements, consent, laboratory values, previous treatment, and tumor characteristics.\n\nThe sample provides detailed inclusion and exclusion criteria for participants, including specific medical conditions, medications, and substances that may affect eligibility. It also mentions the requirements for tumor",
    "The sample provided is a record from a table that contains information about clinical trials. The table has several columns, including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of diseases being studied, \"icdcodes\" which lists the corresponding ICD-10 codes for the diseases, \"drugs\" which lists the names of drugs being tested, and \"criteria\" which provides the eligibility criteria for the trial.\n\nIn this specific sample, the phase of the trial is phase 1. The diseases being studied include renal cell carcinoma, colorectal adenocarcinoma, non-squamous non-small cell lung cancer, platinum-refractory ovarian carcinoma, and cervical carcinoma. The corresponding ICD-10 codes for these diseases are also provided. The drugs being tested in this trial are nintedanib and bevacizumab. The eligibility criteria for the trial are listed, including age, histological proof of advanced or metastatic solid cancer, life expectancy, performance status, previous treatment history, organ function, and willingness to comply with study procedures. The sample also includes exclusion criteria, such as previous serious toxicities from prior therapy, hypersensitivity to trial drugs, recent treatments, and various medical conditions that may make a patient ineligible for the trial.\n\nOverall, this sample provides detailed information about the phase, diseases, drugs, and eligibility criteria for a specific clinical trial.",
    "The sample from the table represents a phase 1 clinical trial for Alzheimer's disease. The trial includes a list of diseases, with Alzheimer's disease being the only disease mentioned in this sample. The corresponding ICD-10 codes for Alzheimer's disease are also provided. The trial involves the use of two drugs, namely \"bpn14770\" and \"placebo\". The eligibility criteria for participants are listed, including age requirements, body mass index range, and specific criteria for female subjects related to pregnancy and contraception. Other criteria include the ability to understand and consent to the study, willingness to stay in the study unit, and exclusion of individuals with certain medical conditions or abnormalities. The sample also mentions cognitive testing requirements for elderly cohorts, which involve completing various computerized cognitive function assessments.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is bladder cancer. The ICDCodes associated with this disease are D30.3, C67.5, C67.9, C79.11, C67.0, C67.1, and D41.4. The drugs being used in the trial are vinflunine and cisplatin. The eligibility criteria for participants include age between 18 and 75, signed written informed consent, confirmed diagnosis of muscle-invasive urothelial cell carcinoma of the bladder, specific imaging assessments, ECOG performance status of 0 or 1, and various requirements for bone marrow, renal, and hepatic functions. The sample also includes exclusion criteria such as prior systemic chemotherapy, contraindications for imaging, presence of metastasis, and various other medical conditions. Additionally, there are criteria related to pregnancy and contraception for female participants and birth control for sexually active fertile men.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is age-related macular degeneration. The ICDCodes associated with this disease are ['H35.3130', 'H35.3230', 'H35.3110', 'H35.3120', 'H35.3131', 'H35.3132', 'H35.3190']. The drug being tested is elamipretide. The eligibility criteria for this trial include specific age requirements, absence of certain eye conditions, specific visual acuity measurements, and the ability to comply with study visits and examinations. There are also criteria related to contraception for participants of childbearing potential. Additionally, there are exclusion criteria that would disqualify a subject from participating in the study, such as certain ocular conditions, systemic conditions, and previous treatments.",
    "The sample from the table is for a trial in the early phase 1. The disease being studied is acute pain, and the corresponding ICD-10 codes for this disease are G89.12, G89.18, G89.11, and G89.3. The drug being tested is gabapentin. \n\nThe eligibility criteria for inclusion in the trial are:\n- Having more than one rib fracture\n- Requiring hospital admission\n- Enrolled within 24 hours of the injury\n\nThe exclusion criteria for the trial are:\n- Pregnancy\n- Intubation\n- Age below 18 or above 65\n- Inability to tolerate oral medication\n- Patient refusal\n- Inability to obtain consent from the patient or surrogate\n- Renal or Hepatic impairment\n- Allergy or hypersensitivity to gabapentin or any component of the formulation.",
    "The sample is a phase 1 trial for HIV-1 infection. The table includes information about the phase, diseases, icd-10 codes, drugs, and eligibility criteria. In this specific sample, the phase is phase 1, the disease is HIV-1 infection, the icd-10 codes associated with the disease are B20, Z71.7, O98.72, Z21, O98.73, R75, and Z11.4. The drugs being tested are vesatolimod, placebo, and an antiretroviral (ARV) regimen. The eligibility criteria include being aged 18 or older, being on ARV treatment for at least 12 consecutive months, having a plasma HIV-1 RNA level below 50 copies/mL, not having a history of resistance to any components of the current ARV regimen, and meeting various laboratory values such as Hgb, WBC, platelets, ANC, CD4 count, albumin, ALT, AST, and estimated glomerular filtration rate. The sample also includes exclusion criteria such as being positive for hepatitis B surface antigen (HBsAg) or hepatitis C antibody (HCVAb), having a history of pre-ART CD4 nadir below 200 cells/\u00b5L, being diagnosed with a new AIDS-defining condition within 90 days prior to screening, or having an acute febrile illness within 35 days prior to pre-baseline.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is melanoma. The ICDCodes associated with this disease are C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, and C43.4. The drugs being used in the trial are mrx34 and dexamethasone. The eligibility criteria for participants include being 18 years of age or older, having advanced or metastatic cutaneous, acral or mucosal melanoma, having tumor lesions accessible to serial biopsies, having an ECOG score of 1 or lower, and having ANC (Absolute Neutrophil Count) and Plts (Platelets) levels above certain thresholds. The exclusion criteria include having a serious active non-malignant disease and having central nervous system metastasis.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The trial is in Phase 1.\n- Diseases: The trial is focused on two diseases, namely \"healthy volunteers\" and \"ulcerative colitis\".\n- ICD Codes: The ICD-10 codes associated with the diseases are [\"K51.80\", \"K51.813\", \"K51.814\", \"K51.90\", \"K51.913\", \"K51.914\", \"K51.811\"].\n- Drugs: The trial involves two drugs, namely \"bms-986184\" and \"placebo matching bms-986184\".\n- Criteria: The eligibility criteria for the trial are listed, including requirements for women of childbearing potential to have a negative pregnancy test and a confirmed diagnosis of ulcerative colitis. Exclusion criteria include various infections and a history of certain medical conditions. Additional inclusion/exclusion criteria may also apply.\n\nOverall, this sample provides information about a Phase 1 clinical trial focusing on healthy volunteers and individuals with ulcerative colitis.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease mentioned is \"post-menopausal vasomotor symptoms\" and its corresponding ICDCodes is \"J30.0\". The drugs being tested are \"bay3427080\" and \"placebo (for bay3427080)\". The eligibility criteria for this trial include being a post-menopausal female experiencing frequent moderate to severe hot flashes. Exclusion criteria include having a BMI greater than 35kg/m2, having any active comorbid disease or clinically significant ECG or laboratory results, using prohibited medications, or being unable or unwilling to comply with study procedures or requirements.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease being studied is dyspepsia. The ICDCodes associated with the disease are \"K30\". The drugs being tested in the trial are \"abx-1431\" and \"placebo\". The eligibility criteria for this trial include having functional dyspepsia, impaired gastric accommodation, specific symptoms related to dyspepsia, limited episodes of gastrointestinal reflux, being between 18 and 65 years old, having a specific BMI range, having no significant unmanaged diseases or disorders, having no clinically significant abnormality in ECG, being willing to undergo nutrient volume tolerance tests, and meeting certain exclusion criteria such as not being under the age of legal consent, not being pregnant or breastfeeding, not having certain psychiatric disorders or family history of psychosis, not taking specific antidepressant medications or anxiety medications, not having certain gastrointestinal surgeries or illnesses, not having certain abnormal laboratory test results, not having certain neurological disorders or history of seizures, not having certain neoplastic diseases, and not having certain family history or QTc interval abnormalities.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is categorized as \"phase 1\" and focuses on the disease \"asthma.\" The ICD-10 codes associated with this disease are listed as \"J45.998,\" \"J82.83,\" \"J45.909,\" \"J45.991,\" \"J45.20,\" \"J45.30,\" and \"J45.40.\" The drugs being studied in this trial are \"xc8 (histamine glutarimide)\" and \"placebo.\" \n\nThe eligibility criteria for participants in this trial are as follows:\n- Participants must be men and women aged 18 to 50 years.\n- They should be in generally good health.\n- Body mass index should be between 19 and 30 kg/m\u00b2, and body weight should be over 50 kg.\n- Female participants must either be post-menopausal, surgically sterile, or practice a highly effective method of birth control.\n- Male participants with a female partner of child-bearing potential must agree to use contraception during the study and for 3 months after the last intake of study medication.\n- Participants must be willing and able to understand and comply with the study procedures and evaluations.\n- Written informed consent is required.\n\nThe exclusion criteria for participants in this trial are as follows:\n- Participants with hepatic or renal disease or any other condition that may affect the trial results or worsen health.\n- Clinically significant laboratory abnormalities.\n- Use of any medication, including herbal preparations and nutritional supplements, within 1 month before screening.\n- Positive test for HIV, HCV, or HBV at screening.\n- Irregular sleep patterns.\n- History or current evidence of alcohol or drug abuse.\n- History or current evidence of allergic reactions.\n- History or current evidence of symptomatic rhinitis within 2 years before screening.\n- Blood or plasma donation, or surgery within 12 weeks of screening.\n- Lactating or pregnant females.\n- Current or previous treatment with another investigational drug or medical device, or participation in another clinical study within 3 months of enrollment.\n- Previous enrollment in this specific clinical study.\n- Inability to understand or follow protocol instructions.\n- Smoking within 3 months before screening or throughout the study.\n- Lactose intolerance.\n- History of allergic reactions to XC-8 or any inactive ingredients of the trial medication.\n- Employees of the sponsor or subjects who are employees or relatives of the investigator.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are acute myeloid leukemia (AML) and relapse. The ICDCodes associated with these diseases are \"C90.02\", \"C90.22\", \"C90.32\", \"C92.32\", \"C95.92\", \"C90.12\", and \"C91.02\". The drug being tested is called \"chidamide plus dcag regimen\". \n\nThe eligibility criteria for this trial are as follows:\n\nInclusion Criteria:\n- Men and women aged between 18 and 59 years old.\n- Patients diagnosed with AML according to the 2008 WHO myeloid malignant disease diagnosis standard.\n- Patients who have relapsed after remission or have not achieved remission after at least two cycles of systemic therapy.\n- ECOG performance status of 0-3.\n- Expected survival time of more than 3 months.\n- Patients without serious heart, lung, liver, or kidney disease.\n- Patients who have not received any treatment (radiotherapy, chemotherapy, targeted therapy, or hematopoietic stem cell transplantation) within 4 weeks prior to enrollment.\n- Patients who are able to understand and willing to sign informed consent.\n\nExclusion Criteria:\n- Patients who are allergic to the study drug or drugs with a similar chemical structure.\n- Pregnant or lactating women, and women of childbearing age who do not want to practice effective methods of contraception.\n- Patients with active infections.\n- Patients with a history of drug abuse or long-term alcohol abuse that may affect the evaluation results.\n- Patients with mental disorders or conditions that prevent them from giving informed consent or meeting the study's treatment and procedure requirements.\n- Patients with a history of significant QTc interval prolongation, ventricular heart tachycardia, atrial fibrillation, II degree heart block, myocardial infraction attack within the past year, congestive heart failure, or coronary heart disease with clinical symptoms requiring drug treatment.\n- Patients with a diastolic pericardial fluid dark area width greater than 10mm according to cardiac ultrasound.\n- Patients who have received organ transplantation.\n- Patients with active bleeding.\n- Patients with new thrombosis, embolism, cerebral hemorrhage, or other relevant medical history within the past year.\n- Patients who have undergone major organ surgery within the past 6 weeks.\n- Patients with bone marrow hyperplasia and white blood cell count less than 2.0 * 10^9/L.\n- Patients with abnormal liver function (total bilirubin > 1.5 times the upper limit of normal range, ALT/AST > 2.5 times the upper limit of normal range, or patients with liver involvement whose ALT/AST > 1.5 times the upper limit of normal range) or renal anomalies (serum creatinine > 1.5 times the upper limit of normal value).\n- Patients who are not suitable for the study according to the investigator's assessment.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2 and focuses on the treatment of sarcoma. The ICD-10 codes associated with the disease are ['C96.A', 'C46.9', 'C96.22', 'C46.0', 'C46.2', 'C92.31', 'C92.32']. The drug being used in the trial is doxorubicin hydrochloride. The record also includes the eligibility criteria for participants, which include requirements such as providing informed consent, having measurable disease, having a certain performance status, and meeting specific laboratory values. There are also exclusion criteria listed, such as having prior treatment with an anthracycline, having certain sarcoma subtypes, or having active infections or autoimmune diseases.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this specific sample, the phase of the trial is Phase 1. The disease being studied is melanoma. The ICDCodes associated with this disease are C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, and C43.4. The drugs being used in the trial are fludeoxyglucose f 18 and 18f-fluorothymidine. \n\nThe eligibility criteria for this trial include:\n- Patients must have a confirmed diagnosis of unresectable, stage III or metastatic melanoma.\n- Patients must be eligible to receive combined dual immune-checkpoint blockade therapy with ipilimumab and nivolumab, as determined by their referring oncologist.\n- Patients must have a life expectancy of at least 6 months.\n- The disease must be measurable, with lesions measuring at least 10mm on radiologic imaging.\n- The Eastern Cooperative Oncology Group (ECOG) performance status must be 1 or better.\n- Patients must be at least 18 years old.\n- Patients must have normal organ and marrow function, including specific criteria for AST, ALT, bilirubin, hemoglobin, neutrophil count, and platelets.\n- Women of child-bearing potential must have a negative pregnancy test within 7 days of baseline imaging.\n\nThe exclusion criteria for this trial include:\n- Patients who are receiving any other investigational agents.\n- Patients with significant autoimmune disease requiring hospitalization within the past two years or any history of life-threatening autoimmune disease.\n- Patients on immunosuppressive therapy, except for maintenance dosing for adrenal insufficiency.\n- Patients with known additional malignancy that is progressing or requires active treatment, with some exceptions.\n- Patients with active autoimmune disease or a syndrome that requires systemic steroids or immunosuppressive agents, with some exceptions.\n- Patients with active tuberculosis.\n- Patients with uncontrolled intercurrent illness, including ongoing or active infection, autoimmune diseases, congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.\n- Patients with a pacemaker, stainless steel aneurysm clip, or any other magnetic resonance (MR) contraindicated implant or foreign body.\n- Patients with a history of pneumonitis requiring hospitalization or systemic immune suppressive therapy.\n- Pregnant women are excluded from this study.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are \"non-small cell lung cancer,\" \"carcinoma,\" and \"nsclc.\" The corresponding ICDCodes for these diseases are provided as well. The drugs being investigated in this trial are \"ensartinib\" and \"durvalumab.\" The eligibility criteria for this trial are listed, including requirements for histologic confirmation of metastatic NSCLC, measurable disease, provision of a pre-treatment biopsy, absence of certain cardiovascular diseases, and normal laboratory parameters, among others. The sample also includes exclusion criteria, such as recent treatment with investigational agents, prior treatment with certain drugs, autoimmune diseases, and certain medical conditions.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The diseases being studied are glioblastoma and malignant glioma. The icd-10 codes associated with these diseases are \"R18.0\", \"C17.3\", \"G21.0\", \"J91.0\", \"C05.2\", \"C10.0\", and \"C16.0\". The drugs being used in the trial are \"mrz\" and \"tmz\". The eligibility criteria for this trial include various factors such as signed informed consent, age requirements, confirmed diagnosis of G4 MG, Karnofsky Performance Status score, prior tumor resection or biopsy, corticosteroid dosage, previous treatment history, absence of seizures, absence of certain infections, availability of archival tumor tissue, contraceptive measures, adherence to study requirements, and exclusion criteria such as certain medical conditions, previous malignancy, and specific conditions for those enrolled in adjuvant treatment with Optune\u2122.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is Alzheimer's disease, and the corresponding ICDCodes are G30.8, G30.9, G30.0, and G30.1. The drugs being used in the trial are ct1812 and placebo.\n\nThe eligibility criteria for this trial include:\n\n1. The participant must be willing and able to provide written informed consent.\n2. The participant must be between 50 and 80 years old and have a diagnosis of mild to moderate Alzheimer's disease.\n3. The participant must have experienced a decline in cognition for more than six months.\n4. The participant must have undergone a neuroimaging (MRI) scan within the previous 6 months or during screening, which confirms the clinical diagnosis of Alzheimer's disease.\n5. The participant's MMSE (Mini-Mental State Examination) score must be between 18 and 26.\n6. The participant must not have active depression and must have a Geriatric Depression Score (GDS) of less than 6.\n7. The participant's Modified Hachinski Ischemia score must be less than or equal to 4.\n8. The participant must have a formal education of eight or more years.\n9. The participant must be living at home or in a community setting without continuous nursing care and must have a reliable caregiver who can oversee the administration of the study drug and participate in all clinic visits and some study procedures.\n10. If the participant is currently using acetylcholinesterase inhibitors or memantine, the use must have been stable for 90 days prior to screening and not expected to change.\n\nThe exclusion criteria for this trial include:\n\n1. The participant must not have a history of or screening brain MRI scan indicative of significant abnormalities such as hemorrhage, infarct, cerebral contusion, aneurysm, etc.\n2. The participant must not have clinical or laboratory findings consistent with other primary degenerative dementia, other neurodegenerative conditions, seizure disorder, or other infectious, metabolic, or systemic diseases affecting the central nervous system.\n3. The participant must not have a current diagnosis of active major depression, schizophrenia, or bipolar disorder according to DSM-V.\n4. The participant must not have clinically significant, advanced, or unstable disease that may interfere with outcome measures or bias the assessment of their clinical or mental status, or put them at special risk.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 1. The diseases associated with this trial include various types of neoplasms, such as bronchial neoplasms, lung neoplasms, and digestive system neoplasms. The ICDCodes associated with these diseases are also provided.\n\nThe drugs being studied in this trial are entinostat and pembrolizumab. The eligibility criteria for participants are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" Inclusion criteria include having completed a previous study (SNDX-275-0140) and resolving any adverse events or toxicities to Grade 1 or lower. Exclusion criteria include having completed the previous study more than 30 days prior to the start of this study and continuing to meet exclusion criteria from the previous study.\n\nOverall, this sample provides specific details about the phase, diseases, ICDCodes, drugs, and eligibility criteria associated with a clinical trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is prostate cancer. The icd-10 codes associated with this disease are 'C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', and 'Z12.5'. The drug being used in the trial is pyruvate (13c). The eligibility criteria for this trial include having biopsy-proven prostate cancer, progressive castration-resistant disease, planned treatment with an androgen signaling inhibitor, presence of at least one target lesion amenable to hyperpolarized C-13 pyruvate/metabolic MR imaging, ability to comply with study procedures, and meeting certain organ function requirements. There are also exclusion criteria listed, such as patients who cannot give valid informed consent, patients with contra-indications to MRI, patients with certain medical conditions, and patients who may not be able to comply with study procedures.",
    "The sample is a phase 1 clinical trial for the treatment of depression. The trial focuses on patients diagnosed with Major Depressive Disorder (MDD) who are currently experiencing a Major Depressive Episode (MDE) of at least eight weeks in duration. The trial aims to evaluate the effectiveness of the drug naltrexone in treating treatment-resistant depression (TRD).\n\nThe inclusion criteria for the trial include being between 18 to 70 years old, able to provide informed consent, and having a diagnosis of MDD supported by a psychiatrist. Participants must have a history of TRD and be currently on a stable and adequate dose of an SSRI or SNRI antidepressant therapy. They must also meet a threshold on the Hamilton Depression 17-item Scale (HAMD17) score.\n\nOther eligibility criteria include being in good general health, having a body mass index between 18-35kg/m2, and using an acceptable form of birth control for female participants. Concurrent psychotherapy and hypnotic therapy are allowed if they have been stable for a certain period of time.\n\nExclusion criteria include being pregnant or breastfeeding, having a positive pregnancy test, having a total HAMD score below 20, having a current diagnosis of a Substance Use Disorder (except nicotine dependence), having certain Axis I disorders, a history of schizophrenia or psychotic symptoms, a history of eating disorders, or being at significant risk for suicide.\n\nOther exclusion criteria include having certain medical conditions, participating in another clinical trial, having certain heart conditions, chronic lung disease, a history of significant head trauma, abnormal lab results, or a history of drug abuse.\n\nOverall, the sample consists of patients with treatment-resistant depression who meet specific criteria for participation in the phase 1 clinical trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is venous thromboembolism. The ICDCodes associated with this disease are O88.22, O88.23, O88.211, O88.212, O88.213, and O88.219. The drugs being used in the trial are apixaban and clarithromycin. \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include having signed informed consent, being a healthy subject based on medical history, physical examination, and laboratory tests, having a body mass index between 18 and 30 kg/m2, and meeting certain requirements for contraception for women and sexually active men. Exclusion criteria include a history of significant medical illness or drug allergies, coagulopathy or bleeding disorders, recurrent neurological or gastrointestinal disorders, history of antibiotic-induced secondary infections, and evidence of organ dysfunction or clinically significant deviations from normal in physical examination and laboratory tests.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is cancer. The ICDCodes associated with this disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drug being tested is a combination of snx-5422 and ibrutinib. \n\nThe eligibility criteria for this trial include being 18 years of age or older, having a diagnosis of CLL (chronic lymphocytic leukemia) according to IWCLL 2008 criteria, currently being treated with ibrutinib without disease progression, having no more than 4 prior lines of anti-leukemia therapy (excluding ibrutinib), having a certain percentage of mutated BTK in peripheral blood or bone marrow CLL cells, having a life expectancy of at least 9 months, having a Karnofsky performance score of 70, having adequate baseline laboratory assessments, and having signed an informed consent form. \n\nExclusion criteria for this trial include experiencing toxicity with ibrutinib, prior treatment with any Hsp90 inhibitor, major surgery or significant traumatic injury within 4 weeks of starting study treatment, conventional chemotherapy or radiation within 4 weeks, the need for treatment with medications metabolized by the cytochrome P450 (CYP) 3A4 isoenzyme within 3 hours before or after administration of SNX-5422, certain QTc interval measurements on ECG, increased risk for prolonged QT interval, chronic diarrhea or Grade 2 or greater diarrhea despite medical management, gastrointestinal diseases or conditions that could affect drug absorption, gastrointestinal diseases that could alter safety assessment, history of adrenal dysfunction or chronic liver disease, active hepatitis A or B, current alcohol dependence or drug abuse, use of any investigational treatment (except for ibrutinib) within 30 days prior to the first dose, glaucoma, retinitis pigmentosa, macular degeneration, or any clinically important retinal changes, and psychological or social reasons that would hinder compliance with the protocol or compromise the informed consent process.",
    "The sample provided is a record from a table that contains information about clinical trials. The record belongs to a trial in phase 1 and focuses on the disease \"arthroplasty, replacement, knee.\" The associated ICD-10 codes for this disease are \"Z79.890,\" \"Z96.693,\" \"Z47.1,\" \"Z95.4,\" \"Z96.691,\" \"Z96.692,\" and \"T82.320S.\" The drugs being studied in this trial are \"ep=7041\" and \"placebo.\" \n\nThe record also includes eligibility criteria for participants. The inclusion criteria state that participants must be non-smokers, aged between 18 and 60, with a BMI between 18.5 and 32.0 kg/m2, and a weight between 60 kg and 100 kg. They should also be healthy, with no history of abnormal bleeding episodes, normal physical examination and vital signs, and normal laboratory test results. Additionally, participants should not have had any significant illnesses or surgeries within the past 4 weeks and should not have any clinically significant history of various diseases.\n\nThe exclusion criteria state that participants will be excluded if they have any clinically significant abnormality or abnormal laboratory test results during the medical screening, test positive for hepatitis B, hepatitis C, or HIV, have used drugs that affect hepatic drug metabolism within the past 30 days, have a positive pregnancy test, have clinically significant ECG or vital sign abnormalities, have participated in another clinical trial involving drugs within the past 30 days (or 90 days for biologics), or have a hemoglobin or hematocrit level significantly below the lower limits of normal at screening.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 1. The disease being studied is Type 2 Diabetes Mellitus. The icd-10 codes associated with this disease are E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, and E11.44. The drugs being tested in this trial are Biochaperone\u00ae Combo, Humalog\u00ae Mix25, Humalog\u00ae, Lantus\u00ae, and Placebo. \n\nThe eligibility criteria for this trial are as follows:\n\nInclusion Criteria:\n- The subject must be male or female aged 18-70 years.\n- The subject must have been clinically diagnosed with Type 2 Diabetes Mellitus for at least 12 months.\n- The subject's HbA1c level must be between 7.5% and 9.5%.\n- The subject's body mass index must be between 20.0 and 40.0 kg/m2.\n- The subject must have been treated with once daily injections of insulin glargine U-100 for at least 3 months prior to screening.\n\nExclusion Criteria:\n- The subject must not have Type 1 Diabetes Mellitus.\n- The subject must not have a known or suspected allergy to the investigational medicinal products (IMPs) or related products.\n- The subject must not have previously participated in this trial.\n- The subject must not have received any medicinal product in clinical development within 60 days prior to this trial.\n- The subject must not have clinically significant abnormal haematology, biochemistry, urinalysis, or coagulation screening tests, as judged by the Investigator considering the underlying disease.\n- The subject's supine blood pressure at screening must be within the range of 90-160 mmHg for systolic or 50-95 mmHg for diastolic, and their resting supine heart rate must be within the range of 50-90 beats per minute. This exclusion criterion also applies to subjects on antihypertensives.\n- The subject must not be currently treated with premixed or intermediate insulin products, or with long-acting insulins other than insulin glargine U-100. However, the use of short or rapid-acting prandial insulin products is allowed if their use has been stable for at least 3 months prior to screening.\n- The subject must not be using GLP-1 receptor agonists or oral antidiabetic drugs (OADs) other than stable intake of metformin alone or metformin in combination with a DPP-4 inhibitor within 4 weeks prior to screening.\n- Women of childbearing potential must be willing to use contraceptive methods.",
    "The sample from the table represents a clinical trial for the treatment of epithelial ovarian cancer, peritoneal cancer, and fallopian tube cancer. The trial is in phase 1/phase 2. The diseases are identified by their names and corresponding ICD-10 codes. The drugs being tested in the trial are entinostat, avelumab, and placebo. The eligibility criteria for the trial include confirmation of the specified cancers, evidence of measurable disease, previous treatment with platinum-based therapy, acceptable laboratory requirements, and resolution of toxic effects from prior therapy. There are also exclusion criteria, such as non-epithelial ovarian carcinomas, active autoimmune disease, previous treatment with certain inhibitors or antibodies, and enrollment in another investigational drug study. The sample provides detailed inclusion and exclusion criteria for potential participants in the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is melanoma. The icd-10 codes associated with melanoma are ['C43.0', 'C43.31', 'D03.9', 'C43.51', 'C43.9', 'D03.0', 'C43.4']. The drugs being used in the trial are 'digoxin combination', 'dabrafenib', and 'trametinib'. \n\nThe eligibility criteria for this trial include:\n1. Histologic diagnosis of unresectable or metastatic BRAF V600 mutant melanoma.\n2. Age greater than 18 years.\n3. Na\u00efve or any number of prior systemic therapeutic regimens for unresectable stage III or stage IV melanoma, except prior BRAF or MEK inhibitor agents. This includes chemotherapy, immunotherapy, biochemotherapy, or investigational treatments. Patients may also have received therapies in the adjuvant setting.\n4. Performance status ECOG 0-2.\n5. Adequate organ function as defined by specific criteria related to bilirubin, AST/ALT, creatinine, cardiac ejection fraction, QTcF, and PT/INR/aPTT.\n6. Women of child-bearing potential and men must agree to use adequate contraception.\n7. All sites of disease must be evaluated within 4 weeks prior to beginning therapy.\n8. Ability to understand and willingness to sign a written informed consent.\n\nThe exclusion criteria for this trial include:\n1. Recent chemotherapy, radiotherapy, or any systemic therapy for melanoma.\n2. Active infection with hepatitis B or C or HIV.\n3. Active CNS disease, unless previously treated with surgery or radiation therapy and with confirmed stable disease for more than 2 weeks.\n4. History of any other malignancy within the past 2 years, except for certain types of adequately treated and cured cancers.\n5. Uncontrolled inter-current illness, including ongoing or active infection, congestive heart failure, unstable angina, uncontrolled thyroid disease, or psychiatric illness/social situations that would limit compliance with study requirements.\n6. History of predisposition to retinal vein occlusion or central serous retinopathy.\n7. Prior BRAF or MEK inhibitor therapy.\n8. Wolff-Parkinson White syndrome or the presence of an intra-cardiac defibrillator.\n9. Known cardiac metastases.\n10. History of interstitial lung disease or unresolved pneumonitis.\n11. Immediate or delayed hypersensitivity to digoxin.\n12. Inability to switch to reasonable alternative medications listed in section 4.3 if concomitant medications are required.\n\nThis sample provides a detailed description of the trial phase, the specific disease being studied, the associated icd-10 codes, the drugs being used, and the eligibility and exclusion criteria for potential participants.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is lupus erythematosus, systemic. The ICDCodes associated with this disease are M32.9, M32.0, M32.11, M32.12, M32.13, M32.14, and M32.8. The drugs being tested in this trial are jnj-56022473 and placebo. \n\nThe eligibility criteria for this trial include requirements such as the subject having a body weight between 40 to 100 kilograms and a body mass index (BMI) between 18 to 32 kilograms per meter square. The subject must also meet the Systemic Lupus International Collaborating Clinics (SLICC) criteria for diagnosis of lupus and have at least one non-serologic clinical activity defined by the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) within 3 months prior to the first study agent administration. Additionally, the subject must have a positive gene signature score during screening and be using allowed pre-existing lupus treatments, if stable for at least 6 weeks prior to the first dose of study medication.\n\nThere are also exclusion criteria, which include subjects with a history or suspected occurrence of drug-induced systemic lupus erythematosus (SLE), unstable lupus nephritis, active Central nervous system (CNS) lupus, or a history of severe CNS lupus. Subjects who have had major surgery prior to, during, or shortly after the study, or have had an acute illness within 2 weeks prior to the study agent administration, or a major illness or hospitalization within 4 months prior to the screening visit are also excluded. Any other inflammatory diseases that might confound the evaluations of efficacy are also excluded.",
    "The sample from the table describes a clinical trial for the treatment of non-small cell lung cancer. The trial is in phase 1/phase 2. The diseases being studied are specified as non-small cell lung cancer. The corresponding ICD-10 codes for the diseases are provided as ['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']. The drugs being tested in the trial are gedatolisib, paclitaxel, and carboplatin. \n\nThe eligibility criteria for participants in the trial are as follows:\n- Participants must have signed an Institutional Review Board (IRB)-approved informed consent.\n- Participants must be 18 years of age or older.\n- Participants must have advanced-stage unresectable non-small cell lung cancer, confirmed by pathological and/or radiological analysis.\n- Prior chemotherapy is allowed for other invasive malignancies, provided it was completed at least five years before the start of the trial and participants have recovered from all toxicities.\n- Participants may have received prior chemotherapy specifically for non-small cell lung cancer.\n- In the Phase II portion of the trial, subjects must have disease that lacks PTEN expression by immunohistochemistry or has known prior activating PI3K or inactivating PTEN gene mutations.\n- Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status score of less than 2.\n- Life expectancy must be at least 12 weeks.\n- Participants must have measurable disease according to RECIST criteria.\n- Certain blood counts and liver and kidney function tests must meet specific criteria.\n- Women of childbearing potential must be using an adequate method of contraception throughout the trial and for at least 6 months after the last dose of study drug.\n- Men with female partners of childbearing potential must also agree to use physician-approved contraceptive methods throughout the trial and should avoid conceiving children for 6 months following the last dose of study drug.\n\nThe exclusion criteria for participants in the trial are as follows:\n- Uncontrolled cardiac disease, congestive heart failure, angina, arrhythmias, or hypertension.\n- Recent myocardial infraction or unstable angina.\n- Known human immunodeficiency virus (HIV) infection or chronic active Hepatitis B.\n- Active clinically serious infection.\n- Recent thrombotic or embolic events.\n- Recent pulmonary hemorrhage/bleeding event.\n- Any other significant bleeding event.\n- Serious non-healing wound, ulcer, or bone fracture.\n- History of bleeding diathesis or coagulopathy.\n- Recent major surgery, open biopsy, or significant traumatic injury.\n- Women or men of childbearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy.\n- Pregnant or breastfeeding women.\n- History of any other disease or condition that contraindicates the use of the study drug or might affect the interpretation of the study results or put the subject at high risk for treatment complications.\n- Prisoners or subjects who are involuntarily incarcerated.\n- Subjects who are compulsorily detained for treatment of either a psychiatric or physical illness.\n- Subjects demonstrating an inability to comply with the study and/or follow-up procedures.",
    "The sample is a record from a table that contains information about clinical trials. The phase of the trial is specified as \"phase 1/phase 2\". The diseases being studied are \"myelodysplastic syndrome\" and \"myelodysplastic syndromes\". The corresponding ICD-10 codes for these diseases are \"D46.9\", \"D46.C\", and \"D46.Z\". The drugs being used in the trial are \"gsk2879552\" and \"azacitidine\". The eligibility criteria for participants in the trial are listed, including age requirements, specific disease classification, previous treatment history, performance status, organ function, and other medical conditions. Exclusion criteria are also provided, such as the presence of other malignancies, prior treatment with certain drugs, and certain medical conditions.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this specific sample, the phase of the trial is Phase 1. The disease being studied is Major Depressive Disorder. The ICDCodes associated with this disease are F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, and F33.40. The drug being tested is Diprivan. \n\nThe eligibility criteria for this trial are as follows:\n\nInclusion Criteria:\n- The participant must have a diagnosis of Major Depressive Disorder (MDD) or Bipolar Disorder (I or II), with the most recent episode being depression.\n- The participant must have failed at least 2 anti-depressant treatments and not undergone Electroconvulsive Therapy (ETC) in the past 6 months.\n- The participant must be between the ages of 18 and 55.\n- The participant's Body Mass Index (BMI) must be less than 35.\n- The participant's Hamilton Rating Scale for Depression (HRSD) score must be greater than 18.\n- The participant's Quick Inventory of Depression Scale (QIDS) score must be greater than 10.\n\nExclusion Criteria:\n- The participant must not have a diagnosis of primary psychotic disorder, dysthymia, or personality disorder.\n- The participant must not have significant pre-morbid cognitive impairment.\n- The participant must not have hypertension and must not be currently using ACE inhibitor or AR blocker medications.\n- The participant must not have symptomatic coronary artery disease or congestive heart failure.\n- The participant must not have a history of transient ischemic or neurologic signs during the past year.\n- The participant must not have a history of or susceptibility to malignant hyperthermia.\n- The participant must not have a contraindication to isoflurane or propofol anesthesia, as determined by an anesthesiologist.\n- The participant must not have diabetes requiring insulin.\n- The participant must not have poor kidney function.\n- The participant must not have chronic use of benzodiazepines or opioids.\n- The participant must not be incompetent to provide consent, such as being catatonic or psychotic.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is schizophrenia. The ICDCodes associated with this disease are ['F20.0', 'F20.1', 'F20.2', 'F20.3', 'F20.5', 'F20.89', 'F20.9']. The drugs being tested in this trial are 'low dose aut00206 800mg', 'high dose aut00206 2000 mg', 'placebo', and 'ketamine'. The eligibility criteria for participants in this trial include being a male aged 18 to 45 years, being healthy based on various medical assessments, being right-handed, and not being a regular smoker. The exclusion criteria include a history of migraine headaches or head operations and significant claustrophobia.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 1 and focuses on breast cancer. The associated ICD-10 codes for the disease are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The drugs being studied are fulvestrant and tamoxifen. The eligibility criteria for participants are listed, including requirements such as written informed consent, being an adult woman over 18 years old, having a specific performance status, and having a new diagnosis of invasive breast cancer that is cyclin D1 positive, estrogen receptor positive, progesterone receptor positive or negative, and HER2-normal. Other criteria include tumor size, negative pregnancy test, and exclusion criteria such as prior antiestrogen therapy, certain tumor sizes, history of thrombosis or bleeding diathesis, liver disease, neoadjuvant therapy, inflammatory breast cancer, severe or uncontrolled systemic disease, pregnancy or lactation, and prior malignancy within the past 5 years.",
    "The sample from the table is for a Phase 1 clinical trial. The disease being studied is squamous cell carcinoma of the head and neck. The trial is looking at the effectiveness of the drugs avelumab and cetuximab. The eligibility criteria for participants include being willing and able to provide informed consent, being at least 18 years old, having a performance status of 0, 1, or 2 according to the World Health Organization, and having histologically confirmed locally advanced squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx. Participants should be unfit for concurrent chemoradiation with cisplatin and willing to provide tissue for tumor analysis. They should also have at least one measurable lesion, be able to comply with scheduled visits and procedures, and have adequate organ function. Exclusion criteria include prior treatment with certain therapies, immunodeficiency, use of immunosuppressive medication, severe hypersensitivity reactions, known hypersensitivity to the study drugs, recent diagnosis of another malignancy, significant infections, organ transplantation, active autoimmune disease, persisting toxicity from prior therapy, pregnancy or lactation, alcohol or drug abuse, other significant diseases that may affect tolerance of the trial treatment, psychiatric conditions that would hinder understanding or consent, recent vaccination, and certain cardiovascular conditions or brain metastases.",
    "The sample from the table is for a phase 1 clinical trial. The disease being studied is psoriasis, and the corresponding ICD-10 codes for psoriasis are ['L40.0', 'L40.4', 'L40.8', 'L40.9', 'L40.1', 'L40.50']. The drugs being tested in this trial are 'bay1003803', 'clobetasol propionate', and 'betamethasone/calcipotriene'. The eligibility criteria for participants include being male or female (non-childbearing potential) with stable plaque-type psoriasis and being between the ages of 18 and 64. Some exclusion criteria include having had severe disease within the last 4 weeks prior to the trial, using any topical antipsoriatics on the plaques to be treated in this trial (except for salicylic acid), and having received systemic treatment within the specified timeframes. Additionally, participants should not be on concomitant medication that may affect or worsen psoriasis, such as antimalarial drugs, lithium, beta-blockers, or angiotensin-converting-enzyme inhibitors, unless on a stable dose for 3 months before starting the study medication. Clinico-chemical parameters should also not show clinically significant deviation.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in either phase 1 or phase 2. The disease being studied is cancer, and the corresponding ICD-10 codes for the specific types of cancer are provided. The drugs being used in the trial are \"nox66\" and \"carboplatin\". The eligibility criteria for participants in the trial are listed, including requirements such as providing informed consent, being at least 18 years old, having locally advanced or metastatic cancer with no standard treatment options, having a certain performance status, and meeting specific medical criteria related to bone marrow, liver, and kidney function. Female participants must have a negative pregnancy test and agree to use contraception during the study. There are also criteria related to the timing of previous treatments and surgeries. The exclusion criteria include being pregnant or breastfeeding, having uncontrolled infection or systemic disease, having certain cardiac conditions, having a prolonged QTc interval on an electrocardiogram, recent major surgeries or treatments, certain chemotherapy regimens, concurrent use of certain therapies, having HIV or hepatitis B or C, history of solid organ transplantation, having a psychiatric disorder or social/geographic situation that would hinder participation, and being unsuitable for treatment with carboplatin due to renal disease.",
    "The sample from the table represents a phase 1 trial with the disease category being \"healthy\". The ICD-10 codes associated with this category are \"Z76.3\" and \"Z76.2\". The drugs being tested in this trial are \"dabigatran etexilate mesylate\", \"odalasvir (odv)\", and \"simeprevir (smv)\". The eligibility criteria for participants include having a body mass index (BMI) between 18.0 and 32.0 kg/m^2, being healthy based on physical examination and medical history, having normal vital signs and electrocardiogram (ECG), and having a blood pressure within the specified range. Female participants must have a negative pregnancy test. Participants must also be non-smokers for at least 6 months prior to the trial. Exclusion criteria include having a history of liver or renal insufficiency, significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, neoplastic, or metabolic disturbances, and any condition that could prevent or confound the assessments specified in the protocol. Participants with a history of skin diseases or allergies to the drugs being tested are also excluded. Additionally, participants with a history of hepatitis B or C or other liver diseases are excluded.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1 and focuses on breast neoplasms, including breast neoplasms in males and triple negative breast cancer. The ICD-10 codes associated with these diseases are provided. The trial involves the use of drugs such as cyclophosphamide, indomethacin, and omeprazole. The eligibility criteria for participants are listed, including requirements for the type and size of the tumor, previous treatments, organ function, and other medical conditions. There are also exclusion criteria, such as prior neoadjuvant therapy, hypersensitivity to certain medications, and other medical conditions that could interfere with the trial. Pregnancy or lactation, as well as certain infectious diseases, are also exclusion criteria.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is multiple myeloma. The ICDCodes associated with this disease are C90.01, C90.02, and C90.00. The drugs being used in the trial are daratumumab, cyclophosphamide, bortezomib, and dexamethasone. The eligibility criteria for this trial include age between 18 and 70, a documented diagnosis of multiple myeloma, eligibility for high dose therapy and autologous stem cell transplantation, ECOG performance status score of 0-2, and specific pre-treatment clinical laboratory values. There are also exclusion criteria listed, such as previous use of daratumumab or other anti-CD38 therapies, certain diagnoses, peripheral neuropathy grade 2 or higher, and various medical or psychiatric conditions that may interfere with the study.",
    "The sample provided is a record from a table that contains information about clinical trials. The phase of the trial is \"early phase 1\". The disease being studied is \"Crohn's disease\". The corresponding ICD-10 codes for Crohn's disease are \"K50.90\", \"K50.913\", \"K50.914\", \"K50.911\", \"K50.912\", \"K50.918\", and \"K50.919\". The drugs being tested in this trial are \"thalidomide\" and \"placebo (for thalidomide)\". The eligibility criteria for participants in this trial include being between the ages of 18 and 50, having a diagnosis of Crohn's disease, having active disease with a CDA \u2160 score greater than 150 points and visible active lesions on endoscopy, and having failed previous treatment with immunosuppressive drugs or biological agents. There are also exclusion criteria listed, such as having gastrointestinal obstruction symptoms caused by fiber stenosis, being pregnant or lactating, having certain medical conditions or diseases, and having active tuberculosis.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is divided into different phases, and this particular record is from phase 1/phase 2. The diseases being studied in this trial are contraception, liver metabolism, and hemostasis parameter. The corresponding ICD-10 codes for these diseases are ['Z92.0', 'Z30.012', 'Z30.09']. The drugs being tested in the trial are '15 mg e4/3 mg drsp', '30 mcg ee/150 mcg lng', and '20 mcg ee/3 mg drsp'. \n\nThe eligibility criteria for participants in this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include being a healthy adult woman, having a negative pregnancy test, being between the ages of 18-50, having good physical and mental health, having a BMI between 18.0 and 30.0 kg/m\u00b2, and being willing to participate in the study. Exclusion criteria include known hypersensitivity to the investigational product ingredients, smoking if over 35 years old, dyslipoproteinemia or use of antilipidemic agent, known diabetes mellitus, current use of antidiabetic drugs, arterial hypertension, conditions associated with an increased risk of thromboembolism, abnormal uterine/vaginal bleeding, presence of an undiagnosed breast mass, current symptomatic gallbladder disease, history of pregnancy- or COC-related cholestasis, severe hepatic disease, pancreatitis associated with hypertriglyceridemia, porphyria, benign liver tumors, renal impairment, hyperkalemia or conditions predisposing to hyperkalemia, hormone-related malignancy, history of non-hormone-related malignancy within 5 years, use of drugs potentially interacting with COCs, history of alcohol or drug abuse within 12 months, thyroid disorders, participation in another investigational drug clinical study within 1 month, and being affiliated with the study's sponsor, CRO, or PI's site personnel. The final exclusion criterion is being judged unsuitable by the Principal Investigator for any reason.",
    "The sample from the table represents a clinical trial with a combination of phase 1 and phase 2. The trial focuses on two diseases, namely \"healthy volunteers\" and \"asthma\". The corresponding ICD-10 codes for the diseases are provided as well. The trial involves the administration of two drugs, \"rp3128\" and \"placebo\". The eligibility criteria for participants include being male or non-childbearing female subjects with mild asthma or healthy subjects. Other criteria include having a specific body mass index (BMI) range, being a non-smoker or ex-smoker, and adhering to the protocol requirements. Participants should also test negative for drugs of abuse and alcohol. Male subjects should agree not to donate sperm for three months post-dose, and female partners of male subjects should use two highly effective contraception methods for the same duration. Additional criteria are specified for pre-bronchodilator Forced expiratory volume in 1 sec (FEV1) and steroid-na\u00efve subjects with a history of mild asthma. Exclusion criteria include a history of clinically significant medical conditions, tuberculosis, recent immunotherapy, severe hypersensitivity or allergy to any drug, abnormal liver function, and positive screening for hepatitis-B, hepatitis C, or HIV antibodies.",
    "The sample is a phase 1 clinical trial for patients with advanced solid tumor malignancy, specifically non-small cell lung cancer metastatic. The trial is testing the drug ensartinib. The inclusion criteria for the trial include having a confirmed diagnosis of advanced solid tumor malignancy, having ALK genomic alterations positive by FISH or IHC for the expanded cohort, having an ECOG Performance Status score of 0 or 1, and having adequate organ system function. Other criteria include having measurable disease per RECIST, willingness and ability to comply with the trial and follow-up procedures, and providing written informed consent. \n\nThe exclusion criteria for the trial include current use of anticancer therapy, use of an investigational drug within 14 days or 5 half-lives prior to the first dose of ensartinib, recent major surgery, radiotherapy, or immunotherapy, recent chemotherapy regimens with delayed toxicity, recent chemotherapy regimens given continuously or on a weekly basis with limited potential for delayed toxicity, prior stem cell transplant, known allergy or hypersensitivity reaction to drugs related to ensartinib, prior use of ALK TKIs except for crizotinib, presence of primary CNS tumors or meningeal metastasis, pregnancy or breastfeeding, presence of active gastrointestinal disease or conditions that may interfere with the absorption, distribution, metabolism, or excretion of ensartinib, clinically significant cardiovascular disease, psychological, familial, sociological, or geographical conditions that may hinder compliance with the protocol, concurrent conditions that may jeopardize compliance or pose excessive risk associated with study participation, and inability or unwillingness to comply with study and follow-up procedures outlined in the protocol.",
    "The sample from the table is for a phase 1 clinical trial for prostate cancer. The diseases column specifies that the trial is focused on prostate cancer. The icdcodes column contains a list of ICD-10 codes associated with the disease. The drugs column lists the drugs being used in the trial, which include copper, disulfiram, and copper gluconate. The criteria column provides the eligibility criteria for participants in the trial, including age, performance status, laboratory parameters, confirmed diagnosis of prostate cancer, evidence of metastatic disease, ongoing androgen deprivation therapy, evidence of disease progression, previous use of certain therapies, and various other requirements. The exclusion criteria are also listed, which include certain medical conditions, history of certain diseases, and other factors that may preclude participation in the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 1, and the disease being studied is ischemic stroke. The ICDCodes associated with this disease are \"I25.5\", \"H47.013\", \"H93.013\", \"G45.9\", \"H47.011\", \"H47.012\", and \"H47.019\". \n\nThe drugs being tested in this trial are \"0.05 ml/kg ddfpe\", \"0.05 ml/kg placebo\", \"0.10 ml/kg ddfpe\", \"0.10 ml/kg placebo\", \"0.17 ml/kg ddfpe\", and \"0.17 ml/kg placebo\". \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include being between the ages of 18-80, having a diagnosis of AIS (Acute Ischemic Stroke), a body weight of at least 45 kg, NIHSS (National Institutes of Health Stroke Scale) score between 2 and 20, and the patient or their legal authorized representative must be willing and able to understand the study and provide written informed consent. \n\nExclusion criteria include being currently pregnant or breastfeeding, having a history of significantly impaired renal or hepatic function, hemorrhage or hemorrhagic stroke on CT scan, prior stroke, intracranial surgery, or major head trauma within three months prior to enrollment, pre-stroke modified Rankin Scale (mRS) score of 2 or higher, recent myocardial infraction, unstable angina or congestive heart failure, uncontrolled hypertension, known long QT syndrome or prolonged QTc interval, uncontrolled arrhythmia, clinically significant chronic obstructive pulmonary disease (COPD) or other pulmonary conditions, pneumonia or acute respiratory disease, current anticoagulant therapy (except for certain cases), history of allergic reaction to similar compounds, recent use of investigational drugs, inability to comply with study procedures, and any other clinically significant condition that may pose a safety risk or interfere with the study.\n\nThis sample provides a snapshot of the information stored in the table for this particular clinical trial.",
    "The sample from the table represents a clinical trial with a combination of phase 1 and phase 2. The trial is focused on patients with relapsed or refractory solid tumors and non-small cell lung cancer. The diseases are identified by their respective ICD-10 codes. The drugs being studied are lenalidomide and pembrolizumab. \n\nThe eligibility criteria for the trial include having a confirmed metastatic solid tumor malignancy for the phase 1 component, and histologically or cytologically confirmed non-small cell lung carcinoma for the phase 2 component. Patients must have measurable disease according to RECIST criteria v. 1.1 and have completed at least one line of prior therapy for the phase 2 portion, or one or two lines of prior therapy for the phase 1 portion. \n\nOther criteria include age over 18, ECOG performance status of 0 or 1, normal organ and marrow function, ability to understand and sign informed consent, and availability of a core tumor biopsy obtained after progression on the last treatment for the phase 2 portion. Female subjects of childbearing potential must have a negative serum pregnancy test and use contraception during the study. Male subjects of childbearing potential must also use contraception. \n\nExclusion criteria include recent chemotherapy or radiotherapy, ongoing adverse events from previous treatments, active autoimmune disease requiring systemic treatment in the past 2 years, untreated symptomatic brain metastases, interstitial lung disease or active noninfectious pneumonitis, recent live vaccination, uncontrolled intercurrent illness, known hypersensitivity to thalidomide or lenalidomide or pomalidomide, peripheral neuropathy of grade \u22653, and pregnancy or breastfeeding.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in either phase 1 or phase 2. The disease being studied is Duchenne muscular dystrophy. The corresponding ICD-10 code for this disease is G71.01. The drug being tested is (+)-epicatechin. \n\nThe sample also includes the eligibility criteria for participants in the trial. Inclusion criteria include being male, aged between 8 and 17 years, non-ambulatory, weighing less than or equal to 100kg, and having a confirmed diagnosis of Duchenne muscular dystrophy through various tests or having a positive family history. Other criteria include having a cardiac ejection fraction greater than 55% on an echocardiogram, discontinuing the use of certain supplements prior to screening, having stable glucocorticoid and cardiac therapy for a certain period, and having normal hematology and laboratory safety chemistry profiles.\n\nExclusion criteria include the inability to complete certain assessments, current enrollment in another treatment trial, significant concomitant illness or impairment of renal or hepatic function, recent use of medication with antiplatelet effects, and cardiac symptoms suggestive of imminent moderate to severe cardiac events.",
    "The sample is from a table that contains information about clinical trials. It provides details about a specific trial, including the phase (early phase 1), the diseases being studied (follicular lymphoma, follicular lymphoma grade 1, follicular lymphoma grade 2, follicular lymphoma grade iiia), the corresponding ICD-10 codes for the diseases, the drug being tested (ibrutinib), and the eligibility criteria for participants.\n\nThe eligibility criteria include requirements such as having a documented diagnosis of follicular lymphoma, completing a full course of first-line immunochemotherapy including rituximab, achieving a partial response to primary treatment, having residual FDG-PET activity within a certain timeframe, and starting treatment within 90 days of the last dose of immunochemotherapy. Other criteria include age, performance status, measurable disease site, life expectancy, and various medical history exclusions.\n\nThe sample also lists exclusion criteria, such as having central nervous system lymphoma or leptomeningeal disease, a history of other active malignancies, recent organ transplantation, and certain medical conditions or treatments. It further specifies requirements related to cardiovascular health, infections, bleeding disorders, liver function, and other laboratory values. The sample concludes with additional exclusions related to gastrointestinal function, planned major surgery, pregnancy or lactation, inability to comply with study requirements, and certain medical conditions or impairments.\n\nOverall, the sample provides a comprehensive description of the trial, including the phase, diseases being studied, drug being tested, and the specific criteria that potential participants must meet or exclude in order to be eligible for the trial.",
    "The sample is from a table that contains information about clinical trials. In this specific sample, the phase of the trial is Phase 1. The disease being studied is chronic sinusitis, and its corresponding ICD-10 codes are J32.0, J32.1, J32.2, J32.3, J32.8, and J32.9. The drug being tested is called \"480 mometasone furoate sinus drug depot\". \n\nThe sample also includes the eligibility criteria for the trial. The inclusion criteria state that participants must have a diagnosis of chronic sinusitis, female participants of child-bearing potential must have a negative pregnancy test and agree not to become pregnant during the study, participants must be informed about the study and provide written consent, and participants must agree to comply with all study requirements.\n\nThe exclusion criteria state that participants with a known history of intolerance to corticosteroids, oral-steroid dependent condition, recent use of corticosteroids with potential systemic effect, intracranial or orbital complications of chronic rhinosinusitis, history of hypothalamic pituitary adrenal (HPA) axial dysfunction or abnormal morning serum cortisol level, previous pituitary or adrenal surgery, history or diagnosis of glaucoma, ocular hypertension, or cataracts, recent participation in another clinical trial, or current participation in an investigational drug or device study are not eligible to participate in the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 1. The diseases being studied are \"cutaneous melanoma\" and \"melanoma\". The corresponding ICDCodes for these diseases are \"A06.7\", \"A22.0\", \"A26.0\", \"A32.0\", \"A36.3\", \"A43.1\", \"B38.3\" for cutaneous melanoma and \"C43.0\", \"C43.31\", \"D03.9\", \"C43.51\", \"C43.9\", \"D03.0\", \"C43.4\" for melanoma.\n\nThe drug being tested in this trial is \"sonazoid\". The eligibility criteria for inclusion in the trial are:\n\n- Cutaneous melanoma with Breslow depth greater than 1 mm or melanoma Breslow depth of 0.76 - 1.00 mm in the setting of ulceration, extensive regression.\n- Mitotic rate greater than or equal to 1/mm^2.\n- Presence of angiolymphatic invasion.\n- Deep positive margin.\n- No known allergies to contrast material.\n\nThe exclusion criteria for the trial are:\n\n- Pregnant or nursing.\n- Patients with known cardiac shunt.\n- Patients with class II heart failure or worse, per New York Heart Association (NYHA) classification.\n- Patients who have experienced an acute coronary syndrome or angina in the past 6 months.\n- Patients who have undergone coronary artery bypass grafting (CABG) or coronary stenting in the past 3 years.\n- Patients with evidence of moderate or severe cardiac valvular disease on echocardiogram.\n- Patients with evidence of moderate or severe pulmonary hypertension on echocardiogram.\n- Patients with stage II chronic obstructive pulmonary disease (COPD) or worse, per Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification.\n- Patients with hypersensitivity to sonazoid or one of its components.\n- Patients with hypersensitivity to egg or egg products, because sonazoid contains a chicken egg-derived surfactant (hydrogenated egg phosphatidylserine sodium).\n- Patients who cannot consent for themselves.",
    "The sample from the table is for an early phase 1 trial. The diseases being studied are deep-venous thrombosis, pulmonary embolism, and venous thromboembolism. The corresponding ICD-10 codes for these diseases are provided. The drugs being tested are real-time heparin dose adjustment and standard heparin dose. The eligibility criteria for this trial include patients undergoing surgical procedures and initiating a heparin infusion at a rate of 500 units/hour intraoperatively or postoperatively. The exclusion criteria include being under 18 years old, pregnant, incarcerated, or mentally disabled.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is cancer. The ICDCodes associated with this disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drug being tested is a combination of snx-5422 and ibrutinib. \n\nThe eligibility criteria for this trial include being 18 years of age or older, having a diagnosis of CLL (chronic lymphocytic leukemia) according to IWCLL 2008 criteria, currently being treated with ibrutinib for at least 18 months with residual disease and no evidence of disease progression, having no more than 4 prior lines of anti-leukemia therapy (excluding ibrutinib), having a life expectancy of at least 9 months, having a Karnofsky performance score of 70, having adequate baseline laboratory assessments, and having signed an informed consent form. \n\nExclusion criteria for this trial include experiencing toxicity with ibrutinib, prior treatment with any Hsp90 inhibitor, major surgery or significant traumatic injury within 4 weeks of starting study treatment, conventional chemotherapy or radiation within 4 weeks, the need for treatment with medications metabolized by the cytochrome P450 (CYP) 3A4 isoenzyme within 3 hours before or after administration of SNX-5422, screening ECG QTc interval exceeding 470 msec for females or 450 msec for males, being at increased risk for developing prolonged QT interval unless corrected to within normal limits prior to the first dose of SNX-5422, having chronic diarrhea or Grade 2 or greater diarrhea despite medical management, having gastrointestinal diseases or conditions that could affect drug absorption or alter safety assessment, having a history of documented adrenal dysfunction not due to malignancy, having a history of chronic liver disease, having active hepatitis A or B, having current alcohol dependence or drug abuse, using any investigational treatment (except for ibrutinib) within 30 days prior to the first dose, having glaucoma, retinitis pigmentosa, macular degeneration, or any clinically important retinal changes detected by ophthalmological examination, and having psychological or social reasons that would hinder or prevent compliance with the protocol requirements or compromise the informed consent process.",
    "The sample from the table represents a clinical trial with a combination of phase 1 and phase 2. The trial focuses on three diseases: dry eye, ocular graft vs host disease, and meibomian gland dysfunction. The corresponding ICD-10 codes for these diseases are provided as well. The drugs being studied in the trial are brimonidine 0.15%, brimonidine 0.075%, and a placebo. \n\nThe eligibility criteria for participants are as follows:\n- Participants must be 18 years or older.\n- They must be capable of giving informed consent.\n- They should have a diagnosis of Meibomian Gland Disease.\n- Women must be post-menopausal for at least 1 year or surgically sterilized. If not, they need to provide a negative urine pregnancy test within 7 days of receiving the first dose of the study drug. They must also use contraception during the study.\n- Participants should not be allergic to Brimonidine or any similar products, or their excipients.\n- They should not be currently receiving any Brimonidine preparation for glaucoma management.\n- They should not have received any experimental systemic medication within the past 30 days.\n- Participants should not have an active ocular infection or ocular allergies.\n- They should not have undergone eyelid surgery or ocular surgery within the past 3 months.\n- Participants should not have a corneal epithelial defect larger than 1 mm2 in either eye.\n- They should not have a history of active drug/alcohol dependence or abuse.\n- Vulnerable populations such as neonates, pregnant women, children, prisoners, institutionalized individuals, or others who may be considered vulnerable populations are excluded from the trial.\n\nThis information provides an overview of the phase, diseases, ICD-10 codes, drugs, and eligibility criteria for the clinical trial.",
    "The sample from the table is for a phase 1 clinical trial. The trial is focused on patients with hematologic malignancies who have undergone allogeneic stem cell transplantation (SCT) and are currently in remission without evidence of disease relapse or active graft-versus-host disease (GVHD). The trial is specifically looking at patients with high-risk myeloid or lymphoid malignancies following ASBMT criteria. The drug being studied is nivolumab.\n\nThe inclusion criteria for the trial include patients who are at least 18 years old, have an ECOG/Karnofsky performance status of 0 or 1, and meet certain laboratory values such as leukocyte count, absolute neutrophil count, platelet count, and bilirubin levels. Patients must also agree to use contraception if they are of child-bearing potential.\n\nThe exclusion criteria for the trial include patients with a history of allergy to the study drug, active GVHD or history of more than Stage 1 skin acute GVHD, active infection or un-resolving transplant-related toxicities, recent chemotherapy or radiotherapy, and patients receiving any other investigational agents. Patients with certain medical conditions such as severe hypersensitivity reaction to monoclonal antibodies, uncontrolled intercurrent illness, and pregnancy or breastfeeding are also excluded. Patients with certain autoimmune diseases or a history of autoimmune disease that may recur are excluded, although some conditions such as vitiligo, type I diabetes mellitus, and residual hypothyroidism may still be eligible. Patients requiring systemic treatment with corticosteroids or other immunosuppressive medications are also excluded.\n\nAdditionally, patients with certain conditions such as active or acute diverticulitis, intra-abdominal abscess, GI obstruction, and abdominal carcinomatosis are evaluated for potential additional treatment before participating in the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The diseases being studied are hepatocellular carcinoma, unresectable hepatocellular carcinoma, and liver cancer. The corresponding ICDCodes for these diseases are provided as well. The drugs being used in the trial are sorafenib and bavituximab. The eligibility criteria for participants in this trial include having advanced, unresectable hepatocellular carcinoma, being at least 18 years old, having an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, having normal organ and marrow function, having a Childs-Pugh score of A or B7, having measurable/evaluable disease according to RECIST 1.1 criteria, using effective contraception methods, being able to swallow and retain orally administered medication, understanding and signing the informed consent form, and having no more than 10 lesions in the liver. The exclusion criteria include recent radiation therapy or major surgery, prior radiotherapy to the liver region, prior selective internal radiotherapy/hepatic arterial Yttrium therapy, certain tumor size and extension criteria, extrahepatic metastases or malignant nodes above a certain size, use of specific medications, previous use of sorafenib or other systemic therapies for HCC, presence of certain medical conditions, and pregnancy or breastfeeding. The investigator may also exclude patients who they deem unsuitable for trial participation based on their judgment.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 1, the disease is psoriasis, the ICDCodes are ['L40.0', 'L40.4', 'L40.8', 'L40.9', 'L40.1', 'L40.50'], and the drugs are 'drug cocktail' and 'ixekizumab'. The eligibility criteria include various conditions for inclusion and exclusion. For example, participants must have chronic moderate or severe plaque psoriasis for at least 6 months, be candidates for systemic therapy or phototherapy, and have a body mass index (BMI) within a specific range. Exclusion criteria include forms of psoriasis other than chronic plaque-type, pregnancy or nursing, history of certain diseases, recent major surgery, and allergies or hypersensitivity to certain components of the study cocktail or ixekizumab.",
    "The sample from the table represents a phase 1 clinical trial. The trial is focused on studying the effects of different drugs on various diseases. The diseases mentioned in the sample are \"advanced solid tumors.\" The corresponding ICD-10 codes for these diseases are provided as well. The drugs being tested in the trial include \"avelumab,\" \"m9241,\" \"avelumab (once weekly),\" \"m9241 (mtd),\" and \"avelumab (expansion cohort).\" The eligibility criteria for the trial are also mentioned, including age requirements, previous treatment with a checkpoint inhibitor, measurable lesions, performance status, life expectancy, and adequate hematological and hepatic function. The sample also includes exclusion criteria, such as concurrent treatment with non-permitted drugs, prior treatment with IL-12, intolerance to checkpoint inhibitor therapy, history of central nervous system tumors, organ transplantation, and previous malignant diseases. Other exclusion criteria include significant infections, autoimmune diseases, severe hypersensitivity reactions, persisting toxicity from prior therapy, pregnancy or lactation, alcohol or drug abuse, uncontrolled intercurrent illnesses, clinically significant cardiovascular disease, and other significant diseases or chronic medical conditions that may impair the subject's tolerance or interpretation of trial results.",
    "The sample provided is a record from a table that contains information about clinical trials. The table has several columns, including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of the diseases being studied, \"icdcodes\" which contains the corresponding ICD-10 codes for the diseases, \"drugs\" which lists the names of the drugs being tested, and \"criteria\" which provides the eligibility criteria for participants in the trial.\n\nIn this specific sample, the phase of the trial is listed as \"phase 1/phase 2\". The disease being studied is \"psoriasis\" and its corresponding ICD-10 codes are listed as \"['L40.0', 'L40.4', 'L40.8', 'L40.9', 'L40.1', 'L40.50']\". The drugs being tested are \"gsk2981278 ointment\" and \"vehicle ointment\". The eligibility criteria for participants are then listed, including age requirements, specific criteria related to the severity and location of the psoriasis, contraception requirements for male participants with female partners, and criteria for female participants based on reproductive potential and menopausal status. The exclusion criteria are also listed, which include specific conditions, medical history, and test results that would disqualify a participant from the trial.\n\nOverall, this sample provides a detailed description of a specific clinical trial, including the phase, diseases being studied, drugs being tested, and the eligibility and exclusion criteria for participants.",
    "The sample from the table represents a clinical trial study. The table contains information about the different phases of the trial (phase I, phase II, or phase III), the diseases being studied, the corresponding ICD-10 codes for the diseases, the drugs being tested, and the eligibility criteria for participants.\n\nIn this specific sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied include anemia, B-cell prolymphocytic leukemia, various grades of follicular lymphoma, hairy cell leukemia, lymphoplasmacytic lymphoma, mantle cell lymphoma, marginal zone lymphoma, recurrent chronic lymphocytic leukemia, recurrent small lymphocytic lymphoma, refractory chronic lymphocytic leukemia, refractory small lymphocytic lymphoma, and Richter syndrome. The corresponding ICD-10 codes for these diseases are also provided.\n\nThe drug being tested in this sample is entospletinib. The eligibility criteria for participants include specific diagnostic criteria for each disease, previous treatment history, presence of certain symptoms or disease manifestations, and various medical parameters such as performance status, blood counts, liver function, and kidney function.\n\nThe exclusion criteria are also listed, which include prior therapeutic interventions, inadequate recovery from previous therapy, certain medication use, history of certain malignancies, uncontrolled immune conditions, certain infections, pregnancy or lactation, and other medical conditions that may interfere with the study.\n\nOverall, this sample provides detailed information about the phase, diseases, drugs, and eligibility criteria for participants in a clinical trial study.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease mentioned is \"perianal fistula.\" The icd-10 codes associated with this disease are \"K64.5\" and \"A60.1.\" The drug mentioned is \"msc-afp,\" and it is specified that only one arm of the trial involves treatment with this drug. The eligibility criteria for this trial include being between the ages of 12 and 17, being a resident of the United States, having Crohn's disease with single or multiple draining complex perianal fistulae for at least three months despite standard therapy, and having undergone a colonoscopy in the last 12 months to rule out malignant or premalignant conditions, among other criteria. There are also exclusion criteria listed, such as having clinically significant medical conditions, evidence of hepatitis B, C, or HIV, a history of cancer (except localized skin cancers), and being pregnant or breastfeeding, among others.",
    "The sample from the table is a clinical trial for the treatment of non-small-cell lung carcinoma. The trial is in phase 1/phase 2 and involves the drugs atezolizumab and daratumumab. The eligibility criteria for participants include having a performance status of 0 or 1, having advanced or metastatic non-small cell lung cancer, having measurable disease, and specific tumor cell programmed death-ligand 1 (PD-L1) scores. Women of childbearing potential must have a negative pregnancy test. There are also inclusion and exclusion criteria for participants who are eligible for crossover. The exclusion criteria include previous use of certain prescribed medications or therapies, seropositivity for HIV, prior organ transplant, severe allergic reactions to certain antibodies or fusion proteins, and active hepatitis B or C. The exclusion criteria for crossover include receiving subsequent anti-cancer therapies and recent radiation therapy.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is multiple myeloma. The ICDCodes associated with this disease are C90.01, C90.02, and C90.00. The drugs being used in the trial are nivolumab, pomalidomide, dexamethasone, and elotuzumab. The eligibility criteria for this trial include various factors such as patient consent, age, confirmed diagnosis of symptomatic multiple myeloma, performance status, previous treatments, laboratory values, birth control requirements for women of childbearing potential, and exclusion criteria such as previous treatment with specific drugs, certain medical conditions, and pregnancy or breastfeeding.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease being studied is \"healthy,\" which indicates that the trial is focused on individuals who are considered to be in good health. The ICDCodes associated with this disease are \"Z76.3\" and \"Z76.2.\" \n\nThe drugs being tested in this trial are \"ly3192767,\" \"basal insulin peglispro,\" \"insulin glargine,\" and \"placebo.\" \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria.\" Inclusion criteria include being overtly healthy, having a body mass index (BMI) between 18.5 and 30.0 kg/m\u00b2. Exclusion criteria include being currently enrolled in another clinical trial, participating in a clinical trial involving an investigational product within the last 30 days, participating in a first-in-human study within 90 days of the initial dose of the study drug, having known allergies to insulin, heparin, or related drugs, and having a history or presence of certain medical conditions that could significantly affect the absorption, metabolism, or elimination of drugs or interfere with the interpretation of data.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2 and is focused on small cell lung cancer. The ICD-10 codes associated with the disease are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The drugs being studied in the trial are ipilimumab, nivolumab, and rovalpituzumab tesirine. The sample also includes the eligibility criteria for participants. Inclusion criteria include having histologically or cytologically confirmed extensive-stage small cell lung cancer with progressive disease after at least one platinum-based chemotherapeutic regimen and having evaluable or measurable disease. Participants should also have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and adequate hematologic, hepatic, and renal function. Exclusion criteria include having active, known, or suspected autoimmune disease and prior exposure to an immuno-oncology or pyrrolobenzodiazepine (PBD)-based drug.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease being studied is metastatic colorectal cancer. The icd-10 codes associated with this disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drugs being used in the trial are brontictuzumab and trifluridine/tipiracil. The eligibility criteria for this sample include having a histologically confirmed metastatic colorectal cancer previously treated with specific chemotherapy and biological therapies, and having an ECOG performance status of 0 or 1. There are also exclusion criteria listed, such as prior treatment with certain inhibitors, known active HIV infection, uncontrolled diarrhea, and certain gastrointestinal diseases.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are small cell lung cancer and extensive-stage small cell lung cancer. The ICDCodes associated with these diseases are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The drugs being used in the trial are ipilimumab and nivolumab. \n\nThe eligibility criteria for participants in this trial include having a signed written informed consent, being willing and able to comply with scheduled visits and other requirements of the study, having small cell lung cancer confirmed by histology or cytology, presenting with extensive-stage disease at initial diagnosis, having an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1, having received 4-6 cycles of platinum-based first-line chemotherapy and having an ongoing response of complete response, partial response, or stable disease after completion of chemotherapy. Participants must also initiate study treatment with thoracic radiation therapy within 8 weeks from the last dose of chemotherapy. Other criteria include the availability of tumor tissue for biomarker evaluation, re-enrollment of participants who have discontinued the study, and meeting certain age and pregnancy-related requirements.\n\nExclusion criteria for participants in this trial include having previous brain metastases that are not stable, having received prior chest radiation that precludes delivery of protocol radiation therapy, having carcinomatous meningitis, having uncontrollable pleural effusion, having unresolved toxicities from previous anti-cancer therapy, being pregnant or breastfeeding, having active autoimmune disease or requiring immunosuppressive treatment, having received prior therapy with certain antibodies or drugs targeting T cell co-stimulation or checkpoint pathways, having symptomatic interstitial lung disease or requiring supplemental oxygen therapy, having previous malignancies (except certain types), having medical conditions that increase the risk associated with study participation or interfere with safety results, having undergone major surgery or significant traumatic injury within 14 days before the initiation of thoracic radiation therapy, testing positive for hepatitis B or C virus, having a positive test for HIV or AIDS, having inadequate hematologic or hepatic function, having a history of allergy or hypersensitivity to the study drugs or components. Additional criteria may also apply.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, icd-10 codes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease being studied is prostate cancer. The icd-10 codes associated with the disease are C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, and Z12.5. The drugs being used in the trial are docetaxel, cabazitaxel, and clarithromycin. The eligibility criteria for participants in this trial include having metastatic castrate-resistant prostate cancer, having received at least 4 cycles of docetaxel or cabazitaxel, having bone disease documented by imaging or biopsy, being at least 18 years old, having a performance status within a certain range, having normal organ and marrow function, not showing evidence of clinical progression, and being able to understand and sign an informed consent document. There are also exclusion criteria listed, such as having severe toxicities from taxane therapy, receiving other investigational agents, having allergies to certain compounds, taking medications that affect CYP3A4, having uncontrolled illnesses, having received a certain number of cycles of docetaxel or cabazitaxel, and having a history of QT prolongation or ventricular cardiac arrhythmia.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this specific sample, the phase of the trial is Phase 1. The diseases being studied are osteoarthritis, pain syndrome, and intra-articular injection. The corresponding ICDCodes for these diseases are \"M15.4\", \"M15.0\", \"M16.9\", \"M17.9\", \"M19.011\", \"M19.012\", and \"M19.019\". The drugs being tested in this trial are hyaluronic acid and a combination of hyaluronic acid and corticosteroids. \n\nThe eligibility criteria for this trial are as follows:\n- Inclusion Criteria: Patients with knee osteoarthritis for over 3 months, classified as stage II-IV according to the Kellgren-Lawrence (KL) grade by a senior radiologist. The diagnosis of symptomatic knee osteoarthritis is based on the American Rheumatism Association classification criteria for knee osteoarthritis.\n- Exclusion Criteria: Patients with a diagnosis of rheumatoid arthritis or other inflammatory osteoarthritis, presence of trauma or pain-causing diseases, recent treatment with oral medications within the past 3 days, physiotherapy or intra-articular injection of hyaluronic acid or corticosteroids within the past 6 months. Participants who are allergic to any of the medications used in the study or diagnosed with a current systemic infection are also excluded.",
    "The sample from the table represents a clinical trial in the early phase 1. The trial focuses on the diseases of fatigue and overheating. The corresponding ICD-10 codes for these diseases are ['R53.83', 'G93.3', 'R53.82', 'R53.0', 'T67.6XXS', 'T67.6XXA', 'T67.6XXD']. The drugs being tested in the trial are acetylsalicylic acid and placebo. The eligibility criteria for participants include having RRMS, self-reporting overheating during exercise, having low physical disability, being exacerbation-free for 6 weeks, and having a BMI of 35 or lower. The exclusion criteria include uncontrolled hypertension or vascular disease, current medications for heart or blood pressure problems, history of head injury or neurological disease, daily use of antipyretics or pain medication, presence of major depressive disorder or other psychiatric diagnosis, diagnosed sleep disorder, pulmonary or heart disease, diabetes mellitus, lower body weakness or reliance on supportive devices for walking, and contraindications to aspirin use.",
    "The sample is a phase 1 clinical trial for HIV patients. The trial is testing the effectiveness and safety of two drugs, clopidogrel 300mg tablet and prasugrel 60mg. The eligibility criteria for participants include being healthy males over 18 years old, understanding French language, and being able to give informed consent. For HIV patients, they must be on anti-HIV therapy with ritonavir or cobicistat, have stable antiretroviral treatment for at least 2 weeks, and have a viremia level of less than 100 copies/ml. Exclusion criteria include renal failure, hepatic impairment, smoking more than 1 pack per day, hypersensitivity to the drugs used, recent intake of drugs or certain foods that can affect CYP activities, and having pathologies or taking drugs associated with an increased bleeding risk. Additionally, participants with a familial history or previous haemorrhagic disease are also excluded.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is categorized as Phase 1. The specific disease being studied in this trial is low back pain. The corresponding ICD-10 codes for this disease are M54.50, M54.51, and M54.59. The drugs being tested in this trial are sta363 and placebo. \n\nThe eligibility criteria for participants in this trial are as follows:\n\nInclusion Criteria:\n- Participants must provide signed informed consent before any study-related procedures.\n- Participants must have chronic discogenic low back pain for more than 6 months prior to the screening visit.\n- Participants must be between 20 and 60 years old at the screening visit.\n- Participants must have had an insufficient response to at least 6 months of non-operative treatment (such as analgesics, anti-inflammatory medication, or physiotherapy).\n- Participants must have a single lumbar disc suitable for treatment at the L3/4 to L5/S1 level, as determined by the investigator.\n- Participants must have a Pfirrmann grade II-III.\n- Participants must be able to understand the written and verbal information about the study.\n\nExclusion Criteria:\n- Participants must not have received any investigational product within 3 months prior to the screening visit.\n- Participants must not have more than one painful intervertebral disc.\n- Participants must not have a painful intervertebral disc above the L3/4 level.\n- Participants must not have a current infection or a prior history of spinal infection or an active systemic infection.\n- Participants must not have undergone previous lumbar spine surgery.\n- Participants must not have undergone previous disc invasive treatment procedures at the affected level(s).\n- Participants must not have a Pfirrmann grade I, IV, or V.\n- Participants must not have evidence of prior lumbar vertebral body fracture or trauma.\n- Participants must not require spinal decompression, as assessed by the investigator.\n- Participants must not have disc extrusion or sequestration.\n- Participants must not have been previously included in the study.\n- Participants must not suffer from psychosomatic pain, as determined by the investigator.\n- Participants must not have referred leg pain of compressive origin.\n- Participants must not have a known alcohol and/or drug abuse.\n- Participants must not have a severe intercurrent illness or concomitant treatment that may put them at risk or affect their ability to participate in the study, as determined by the investigator.\n- Participants must not have clinically significant abnormalities in clinical chemistry or hematology parameters, as assessed by the investigator.\n- Pregnant or lactating females, or those intending to become pregnant within the study period, are not eligible to participate.\n- Participants must not have a known allergy to any of the components of the drug product or placebo.\n- Participants must not have a known opioid allergy or intolerance.\n- Participants requiring treatment with warfarin or other anticoagulant therapy are not eligible to participate.\n- Participants must be willing to refrain from treatment with non-steroidal anti-inflammatory drugs (NSAIDs) within 5 days before the planned study treatment.\n- Participants must have a body weight of at least 50 kg.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 1, and the disease mentioned is \"diabetes mellitus, type 1\". The ICDCodes associated with this disease are ['E10.65', 'E10.9', 'E10.21', 'E10.36', 'E10.41', 'E10.42', 'E10.44']. The drugs mentioned are 'ly900014' and 'insulin lispro (humalog)'. The sample also includes the eligibility criteria for participants, including inclusion and exclusion criteria. The inclusion criteria specify requirements such as having Type 1 Diabetes Mellitus, a specific BMI range, acceptable medical and laboratory test results, no severe hypoglycemia episodes in the past 6 months, sufficient venous access, and willingness to follow study procedures. The exclusion criteria mention factors such as current or recent participation in incompatible medical research, recent blood loss, allergies to the study drugs, previous participation or withdrawal from the study, and any health problems or medical test results that could interfere with the study or participant safety.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease mentioned is \"small bowel carcinoid tumor.\" The ICDCodes associated with this disease are ['C7A.00', 'C7A.010', 'C7A.011', 'C7A.012', 'C7A.020', 'C7A.021', 'C7A.026']. The drugs mentioned in this sample are 'ga-68-dota-toc' and 'lar octreotide'. The eligibility criteria for this trial include age \u2265 18 years, confirmed diagnosis of small bowel carcinoid tumor, receiving a stable dose of octreotide LAR for at least 3 months, planned for ongoing octreotide treatment for at least 18 months, planned for restaging using contrast-enhanced CT scans, and agreement to use contraception for women of child-bearing potential and men. The sample also includes exclusion criteria such as recent radiotherapy, known brain metastases, allergic reactions to IV contrasts or similar compounds, uncontrolled intercurrent illness, pregnancy or breastfeeding, expected lifespan less than 18 months, previous hypersensitivity reaction to LAR octreotide, and non-removable non-MR compatible placements. Additionally, a history of Meniere's disease is also listed as an exclusion criterion.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 1. The diseases being studied are Tourette Syndrome and chronic motor tic disorder. The ICDCodes associated with these diseases are \"F95.2\". The drugs being used in the trial are abx-1431 and a placebo comparator. \n\nThe eligibility criteria for this trial include the patient being between the ages of 18 and 65, having a diagnosis of Tourette Syndrome or chronic motor tic disorder according to the DSM-5 criteria, and having a Yale Global Tic Severity Scale (YGTSS) total tic sub-scale (TTS) result of at least 18. Patients who are taking daily medications for Tourette Syndrome symptoms must be on a stable dose for at least 30 days before the trial and expected to remain on a stable dose during the study.\n\nThe principal exclusion criteria include patients taking certain medications that may interact with the trial drugs, such as potent cytochrome P450 3A4/5 inducers or strong P450 3A4/5 inhibitors. Patients with certain psychiatric comorbidities or a history of psychosis or schizophrenia are also excluded, unless they have stable OCD or ADHD that does not require alteration in therapy.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in either phase 1 or phase 2. The specific disease being studied is dermatitis, atopic. The corresponding ICD-10 codes for this disease are 'L20.89' and 'L20.9'. The drugs being tested in the trial are hat1 topical cream and vehicle cream. \n\nThe eligibility criteria for participants in the trial are as follows:\n\nInclusion Criteria:\n- Participants must have moderate to severe atopic dermatitis, as determined by the Physician's Global Assessment (PGA > 3).\n- Participants must be between the ages of 12 and 65, inclusive.\n\nExclusion Criteria:\n- Participants who are currently participating or have participated in another interventional clinical study within the past 2 weeks are not eligible.\n- Participants who have been diagnosed or treated for cancer within the past 5 years are not eligible.\n- Participants who require any topical or systemic medications that could affect the course of their atopic dermatitis during the study period (except inhaled steroids and/or stable antihistamines for asthma or allergies) are not eligible.\n- Participants with a known hypersensitivity to any corticosteroid creams are not eligible.\n- Participants with any active infections or who have used antibiotics in the past 7 days are not eligible.\n- Participants with any physical attributes or skin conditions that might interfere with clear visual or instrumental assessments (such as cuts, sunburn, birthmarks, tattoos, extensive scarring, excessive hair growth, or acne) are not eligible.\n- Participants with immunologic or infectious diseases (e.g., hepatitis, tuberculosis, HIV or AIDS, lupus rheumatoid arthritis) that could place them at risk or interfere with the accuracy of the study results are not eligible.\n- Participants who have used any immunosuppressant drugs or immunotherapy within the past 30 days or 5 half-lives are not eligible.\n- Participants who are employees of the sponsor company or clinical testing site are not eligible.\n- Participants who are dependent on oral medication for any skin disease/condition or who, in the opinion of the Investigator, cannot tolerate the restriction of discontinuing the medicine as required in this study are not eligible.\n- Participants who are currently pregnant or lactating or planning to become pregnant in the next 6 months (using double contraception for prevention) are not eligible.\n- Participants with a history of keloid formation following skin injury are not eligible.\n- Participants who are routinely taking anti-coagulant medications (such as Plavix, Coumadin, warfarin, heparin, etc.) are not eligible.\n- Any other condition or factor that the Investigator or their duly assigned representative believes may affect the ability of the subject to complete the study or the interpretation of the results will also make the participant ineligible.",
    "The sample from the table is a clinical trial entry for a phase 1/phase 2 trial. The trial is focused on breast cancer and breast neoplasm. The ICD-10 codes associated with these diseases are C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, and D48.60. The only drug mentioned in the sample is cyclophosphamide. The eligibility criteria for the trial include having histological confirmation of breast cancer with recurrent and/or metastatic lesions, evidence of persistent, recurrent, or progressive disease with no known treatment available, being 18 years of age or older and female, having an expected survival of at least 4 months, and having an adequate performance status (ECOG 0-2). There are also exclusion criteria listed, such as recent chemotherapy or XRT, hypersensitivity to certain components used in the experimental vaccine, abnormal laboratory values, cardiac disease, pregnancy or nursing, HIV positive status, and the use of systemic steroids at a high dose.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is categorized as \"phase 1\" and focuses on the disease \"ulcerative colitis.\" The corresponding ICD-10 codes for this disease are listed as \"K51.80,\" \"K51.813,\" \"K51.814,\" \"K51.90,\" \"K51.913,\" \"K51.914,\" and \"K51.811.\" The drugs being studied in this trial are \"top1288\" and \"placebo to top1288.\" \n\nThe eligibility criteria for participants in this trial are then listed. The inclusion criteria include being a healthy male between the ages of 18 and 55, having a body mass index (BMI) between 18.0 and 29.9 kg/m2, being in good physical and mental health, having normal clinical laboratory test results, and having normal blood pressure and pulse rate. Participants must also be willing to comply with contraception restrictions. Additionally, having regular bowel movements and not having any known hypersensitivity to the study drug are included as inclusion criteria.\n\nOn the other hand, the exclusion criteria state that participants who have recently participated in another study involving investigational medication or medical devices, have made significant blood donations or losses, test positive for HIV, hepatitis B or C, have a history of alcohol or drug abuse, consume excessive alcohol, test positive for alcohol or drugs, have taken certain medications or substances within a specific time frame, have certain medical conditions affecting the colon, rectum, anus, or gastrointestinal motility, have cardiovascular or cerebrovascular diseases, have had recent or serious infections, have a history of tuberculosis or positive tuberculosis test, have received live attenuated vaccinations, have abnormal hematology values or ECG results, have renal or liver impairment, have active or recent neoplastic diseases, have other acute or chronic illnesses that could pose a threat, or have used nicotine-containing products within two weeks prior to the study are excluded from participating.\n\nThis description provides an overview of the sample record and the information it contains about the clinical trial.",
    "The sample provided is for a phase 1 clinical trial. The trial is focused on healthy individuals. The ICD-10 codes associated with the diseases are \"Z76.3\" and \"Z76.2\". The drug being tested is ticagrelor. The eligibility criteria for inclusion in the trial are as follows: the age range is 18-45 years, both males and females are eligible, the ethnicity should be Chinese, participants should be in good health based on physical examination, vital signs, electrocardiogram, and clinical laboratory test results, and written informed consent is required. The exclusion criteria include conditions that may interfere with drug absorption, distribution, metabolism, or excretion, intolerance or hypersensitivity to drugs similar to ticagrelor, recent use of medications, recent blood transfusions or donations, participation in another clinical study within the past 3 months, excessive caffeine, alcohol, or smoking, positive serology for Hbs antigen and HIV, and a history of coagulation disorders.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 1. The diseases being studied are sinusitis and nasal polyps. The ICDCodes associated with these diseases are 'J01.80', 'J01.90', 'J32.0', 'J32.1', 'J32.2', 'J32.3', and 'J32.8'. The drug being tested is verapamil hydrochloride intranasal.\n\nThe eligibility criteria for this trial are as follows:\n- Patients must be presenting to the Mass Eye and Ear Sinus Center.\n- Patients must be between the ages of 18 and 80 years old.\n- Patients must be diagnosed with Chronic Rhinosinusitis with Nasal Polyps according to the EPOS 2012 consensus criteria.\n- Patients must have a post-operative Lund-Kennedy Poly score of less than 4.\n- Patients must have a baseline SNOT-22 Score of 30 or higher.\n\nThe exclusion criteria for this trial are as follows:\n- Patients with certain comorbidities, including GI Hypomotility, Heart Failure, Liver Failure, Kidney Disease, Muscular Dystrophy, Pregnant or Nursing Females, Steroid Dependency, Hypertrophic Cardiomyopathy, and any Atrial or Ventricular arrhythmia.\n- Patients with resting heart rate less than 60 beats per minute.\n- Patients with baseline systolic blood pressure less than 110 mmHg.\n- Patients with baseline diastolic blood pressure less than 70 mmHg.\n- Patients with baseline mean arterial pressure less than 60 mmHg.\n- Patients with PR interval less than 0.12 seconds.\n- Patients taking certain medications, including Aspirin, Beta-blockers, Cimetidine (Tagamet), Clarithromycin (Biaxin), Cyclosporin, Digoxin, Disopyramide (Norpace), Diuretics, Erythromycin, Flecainide, HIV Protease Inhibitors (Indinavir, Nelfinavir, Ritonavir), Quinidine, Lithium, Pioglitazone, Rifampin, and St Johns Wort.\n- Patients with cardiac or conduction abnormality detected by screening EKG.\n- Post-op patients with surgery within 3 months prior to enrollment.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is categorized as phase 1. The disease being studied is bladder cancer. The corresponding ICD-10 codes for the disease are ['D30.3', 'C67.5', 'C67.9', 'C79.11', 'C67.0', 'C67.1', 'D41.4']. The drug being tested in the trial is nivolumab. The eligibility criteria for participants in the trial are listed, including age requirements, specific diagnostic criteria for bladder cancer, previous treatment with BCG, availability of tumor tissue for analysis, performance status, and various laboratory values. There are also criteria related to contraception for females of childbearing potential. The exclusion criteria include certain medical conditions, prior malignancies, autoimmune diseases, previous treatment with specific antibodies or drugs, unresolved toxicities from previous anti-cancer therapy, recent treatment with chemotherapy or radiation, positive tests for hepatitis B or C, HIV or AIDS, allergies to study drug components, pregnancy or breastfeeding, incarceration, and compulsory detention for psychiatric or physical illness.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in either phase 1 or phase 2. The diseases being studied are acute myeloid leukemia and myelodysplastic syndromes. The corresponding ICD-10 codes for these diseases are provided. The drugs being used in the trial are decitabine and digoxin. The sample also includes the eligibility criteria for participants in the trial. These criteria include having a confirmed diagnosis of certain diseases, being at least 18 years old, having a certain performance status, and having normal organ function. There are also exclusion criteria, such as recent chemotherapy or radiotherapy, receiving other investigational agents, and having certain medical conditions. The sample concludes with the requirement that male participants must use effective contraception during sexual activity throughout the treatment and for 2 months after discontinuation, and that pregnant or breastfeeding individuals are not eligible for the trial.",
    "The sample provided is a record from a table that contains information about clinical trials. The table has several columns, including \"phase\" which indicates the phase of the trial (phase I, phase II, or phase III), \"diseases\" which lists the names of diseases being studied, \"icdcodes\" which lists the corresponding ICD-10 codes for the diseases, \"drugs\" which lists the names of drugs being tested, and \"criteria\" which provides the eligibility criteria for the trial.\n\nIn this specific sample, the phase of the trial is phase 1. The disease being studied is Alzheimer's disease, and its corresponding ICD-10 codes are listed as \"G30.8\", \"G30.9\", \"G30.0\", and \"G30.1\". The drugs being tested are \"abvac40\" and \"placebo\". The eligibility criteria for this trial are then listed, including criteria for inclusion and exclusion.\n\nThe inclusion criteria state that participants must have a clinical diagnosis suggesting Alzheimer's disease based on specific criteria, their MRI brain scan must be concordant with the diagnosis, and the severity of Alzheimer's disease must be mild or moderate according to the Mini Mental State Examination (MMSE) scale. Other criteria include specific scores on the Hachinski ischemic scale and the Clinical Dementia Rating Scale (CDR), stable treatment for Alzheimer's disease, and the presence of a stable caregiver.\n\nThe exclusion criteria list various conditions that would make participation in the trial difficult or not allowed, such as pregnancy, poor general health, participation in other clinical trials, allergies to vaccine components, contraindications to MRI examination, recent surgeries, autoimmune diseases, immunodeficiency, recent history of cancer, active infectious diseases, major systemic conditions, poorly controlled diseases, and various other medical conditions.\n\nOverall, this sample provides specific information about a phase 1 clinical trial for Alzheimer's disease, including the diseases being studied, the drugs being tested, and the eligibility criteria for participants.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is small cell lung cancer. The ICDCodes associated with this disease are C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, and C34.2. The drugs being used in the trial are m3814, cisplatin, and etoposide. The eligibility criteria for participants in this trial include being at least 18 years old, having a histological or cytological diagnosis of SCLC, having extensive disease beyond the ipsilateral hemithorax, being eligible for first-line platinum-based chemotherapy, having measurable or evaluable disease according to RECIST v1.1, having an ECOG PS of <= 2, having a life expectancy of >= 3 months, and being willing to avoid pregnancy for female participants of childbearing potential and male participants with female partners of childbearing potential. The sample also includes exclusion criteria such as prior anticancer therapy for extensive disease SCLC, concurrent use of other anticancer therapy within 28 days prior to the first dose of the investigational drug, extensive prior radiotherapy on more than 30% of bone marrow reserves, prior bone marrow/stem cell transplantation within 5 years before study start, major surgical intervention within 28 days prior to the first dose of investigational drug administration, poor vital organ functions, contraindication to the use of etoposide or cisplatin, and current use of medications or herbal supplements known to be potent inhibitors or inducers of specific enzymes.",
    "The sample from the table is for a phase 1 clinical trial for the treatment of nasopharyngeal carcinoma. The eligibility criteria for participants include being between 18-70 years old, having a confirmed diagnosis of primary metastatic nasopharyngeal carcinoma or recurrent NPC that is unfit for local treatment, not having received any systemic chemotherapy or other specific treatments within 6 months prior to the trial, having an ECOG performance status of 0 or 1, and having a life expectancy of more than 12 weeks. Participants must also have measurable lesions according to response evaluation criteria, and meet certain laboratory parameters such as neutrophil count, platelet count, hemoglobin levels, and liver function. Female participants must agree not to be pregnant or lactating during the study and use effective contraception. Exclusion criteria include having any active autoimmune disease, hypersensitivity to the study drug, concurrent medical conditions requiring immunosuppressive medications, active central nervous system metastases, uncontrolled clinically significant medical conditions, active infection or fever, history of immunodeficiency, and other medical or psychiatric conditions that may interfere with the study. Participants must also not have evidence of hepatitis B or hepatitis C infection or risk of reactivation.",
    "The sample is a phase 1 trial that focuses on the treatment of septic shock, shock, septic, lactic acidosis, and thiamine deficiency. The trial involves the use of the drug thiamine and placebos. The eligibility criteria for participants include being over 18 years old, having sepsis (defined as meeting certain criteria related to systemic inflammatory response syndrome and infection), having a lactate level above 3mmol/L, experiencing hypotension after a fluid bolus, and being dependent on vasopressors. Exclusion criteria include having cirrhosis or chronic liver disease, currently taking thiamine supplementation, having a clinical indication for thiamine, having a comfort measures only designation, being unable to provide consent, and having other causes for lactate elevation.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease mentioned is \"healthy,\" and the corresponding ICDCodes are \"Z76.3\" and \"Z76.2.\" The drugs involved in the trial are \"jnj-64155806 150 mg,\" \"ethinylestradiol/drospirenone 0.02 mg/3 mg,\" and \"cocp placebo.\" \n\nThe eligibility criteria for this sample include being a female of childbearing potential with a normal menstrual cycle and not using oral contraceptives in the 30 days prior to screening. The participant must also have a body mass index (BMI) between 18.0 and 30.0 kg/m^2, with a minimum weight of 50.0 kg. They must be willing and able to adhere to the study requirements and likely to complete the study as planned. The participant should be healthy based on physical examination, medical history, vital signs, ECG, and clinical laboratory tests. If any abnormalities are found in the lab tests, they must not be clinically significant according to the investigator. \n\nExclusion criteria include being pregnant, breastfeeding, or planning to become pregnant during the study period. Participants with a creatinine clearance of less than 90 mL/min, significant cardiovascular, respiratory, renal, gastrointestinal, hematologic, neurologic, thyroid, or any other medical illness or psychiatric disorder are also excluded. Additionally, any condition that the investigator believes would not be in the participant's best interest or could interfere with the study assessments is considered an exclusion. Gynecological disorders such as unexplained vaginal bleeding and hyperprolactinemia are also mentioned as exclusion criteria.",
    "The sample from the table represents a clinical trial with different phases (phase I, phase II, or phase III) and focuses on various diseases. The diseases mentioned in the sample include alk-positive non-small cell lung cancer (NSCLC), ret-positive non-small cell lung cancer (NSCLC), and ret-positive thyroid cancer. The diseases are associated with specific ICD-10 codes. The trial also involves the use of a drug called alectinib.\n\nThe eligibility criteria for the trial are described in detail. These criteria include specific tumor types, disease status requirements, the presence of measurable target lesions, organ and marrow function requirements, and recovery from previous treatment toxicities. Other criteria include age, performance status, renal function, pregnancy status, contraceptive methods, ability to understand and sign informed consent, and exclusion of certain medical conditions.\n\nThe exclusion criteria specify conditions that would prevent enrollment in the trial, such as recent chemotherapy or immunotherapy, prior alectinib therapy, certain medications, recent radiation therapy, major surgery, use of other investigational agents, liver disease, symptomatic CNS metastases, hypersensitivity to the drug formulation, uncontrolled intercurrent illness, pregnancy or breastfeeding, gastrointestinal disorders affecting medication absorption, inability to swallow pills, history of second primary malignancy, Grade 3 or higher toxicities from previous therapy, and HIV positivity or AIDS-related illness.\n\nOverall, the sample provides information about the phases of the trial, the diseases being studied, the drugs involved, and the eligibility criteria for participants.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The diseases being studied are non-Hodgkin lymphoma, high-grade B-cell lymphoma, and diffuse large B-cell lymphoma. The corresponding ICDCodes for these diseases are also provided. The drugs being used in the trial are cyclophosphamide and alemtuzumab. The eligibility criteria for participants include having histologically confirmed non-Hodgkin lymphoma and being ineligible for standard curative therapeutic options. There are specific criteria for different subtypes of non-Hodgkin lymphoma, as well as age and organ function requirements. The sample also includes exclusion criteria, such as recent chemotherapy or radiotherapy, use of other investigational agents, and certain medical conditions. Pregnant women and HIV-positive participants on antiretroviral therapy are also excluded from the study.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The diseases being studied are hematologic malignancy and acute myeloid leukemia. The ICDCodes associated with these diseases are provided as well. The drugs being used in the trial are entospletinib, daunorubicin, and cytarabine. The eligibility criteria for participants are listed, including key inclusion criteria such as specific disease criteria and Japanese origin requirements, as well as key exclusion criteria such as central nervous system involvement and certain liver conditions. It is also noted that there may be additional inclusion/exclusion criteria defined in the protocol.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase is \"early phase 1\" and the diseases listed are \"COPD\", \"pulmonary hypertension\", and \"chronic obstructive pulmonary disease\". The corresponding ICDCodes for these diseases are provided as well. The drug mentioned in this sample is \"inhaled nitric oxide 30mcg/kg ibw/hr\". The eligibility criteria for this trial are also included, with both inclusion and exclusion criteria listed. The inclusion criteria include specific requirements such as a confirmed diagnosis of COPD, pulmonary hypertension, and certain age and smoking history. The exclusion criteria include factors such as asthma or other non-COPD respiratory diseases, recent exacerbations requiring hospitalization, left ventricular dysfunction, renal impairment, known allergy to contrast media, and other medical or psychiatric conditions that may make a subject unsuitable for the study.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is asthma. The ICDCodes associated with asthma are listed as ['J45.998', 'J82.83', 'J45.909', 'J45.991', 'J45.20', 'J45.30', 'J45.40']. The drugs being tested in this trial are 'bi 443651' and 'placebo'. \n\nThe eligibility criteria for this trial are listed under \"Inclusion criteria\" and \"Exclusion criteria\". Inclusion criteria include having a diagnosis of asthma, meeting specific spirometric criteria, being within the age range of 18 to 60 years, having a certain ACQ value, PD20 value, and BMI range, and being able to perform study-related procedures and assessments. \n\nExclusion criteria include having significant pulmonary diseases other than asthma, recent respiratory tract infection or asthma exacerbation, recent hospitalization or intubation for asthma, high serum potassium levels, recent blood donation, recent use of certain asthma medications, use of diuretics or drugs that may influence trial results, having a prolonged QT/QTc interval or other relevant ECG findings, having additional risk factors for Torsades de Points, history of relevant allergies/hypersensitivities, and certain smoking history. \n\nIt is important to note that there may be additional exclusion criteria that apply, but they are not specified in this sample.",
    "The sample from the table is for a clinical trial with a phase 1/phase 2 design. The trial focuses on the treatment of renal cell carcinoma, a type of kidney cancer. The trial includes patients with metastatic renal cell carcinoma who have not been previously treated with the drugs tivozanib or nivolumab. The eligibility criteria for the trial include being at least 18 years old, having histologically or cytologically documented renal cell carcinoma with a clear cell component, and having measurable or evaluable disease according to RECIST 1.1 criteria. Other criteria include having an ECOG performance status of 1 or lower, a life expectancy of at least 3 months, and providing written informed consent.\n\nThe exclusion criteria for the trial include being pregnant or lactating, having symptomatic CNS metastases (although stable brain metastases without steroid treatment are allowed), and having certain hematologic or serum chemistry abnormalities. Other exclusion criteria include significant cardiovascular disease, delayed healing of wounds or fractures, serious or active infections, inadequate recovery from prior surgical procedures, and inability to comply with protocol requirements. The trial also excludes patients with a currently active second primary malignancy, concomitant immune suppression diseases such as HIV, recent treatment with systemic hormonal therapy, and recent use of herbal preparations/supplements or CYP3A4 inhibitors or inducers.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is categorized as \"phase 1\" and is related to the treatment of dermatitis, specifically atopic dermatitis and eczema. The diseases are listed as \"dermatitis, atopic,\" \"dermatitis eczema,\" and \"dermatitis, eczematous.\" The corresponding ICD-10 codes for these diseases are \"L20.89\" and \"L20.9.\" The drugs being studied in this trial are \"asn002\" and a \"placebo oral tablet.\" \n\nThe eligibility criteria for participants in this trial are listed under \"Inclusion criteria\" and \"Exclusion criteria.\" Inclusion criteria include obtaining written informed consent, being between 18 and 75 years old with chronic AD for at least 6 months, having at least 10% body surface area (BSA) affected by AD, having a body mass index (BMI) of \u226435 kg/m2, having a history of inadequate response to topical corticosteroids or calcineurin inhibitors, being willing to use a basic bland emollient, complying with discontinuation of certain AD treatments, using medically effective birth control methods, having a negative pregnancy test, and being able to comply with clinic visits and study-related procedures.\n\nExclusion criteria include having clinically infected atopic dermatitis, having certain laboratory abnormalities, having serious uncontrolled conditions such as hypertension, tuberculosis, hepatitis B or C infection, immune deficiency, heart disease, etc., requiring the use of anticoagulants, having a history of hypertrophic scarring or keloid formation, having any medical or psychiatric condition that could interfere with the study, being pregnant or breastfeeding, having hypersensitivity to ASN002 or its excipients, having prior treatment with SYK or JAK inhibitors, using oral or intravenous treatments that could affect atopic dermatitis within 4 weeks prior to Day 1, receiving any biological agent within 12 weeks or 5 half-lives prior to Day 1, currently receiving or having received a non-biological investigational product or device within 4 weeks of Day 1, having excessive sun exposure or not willing to minimize sunlight exposure during the study, planning to receive a live attenuated vaccine within 4 weeks prior to Day 1, and planning a major surgical procedure during the study.\n\nOverall, this sample provides information about the phase, diseases, ICDCodes, drugs, and eligibility criteria for participants in a clinical trial related to the treatment of dermatitis.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease being studied is asthma, and the corresponding ICDCodes are ['J45.998', 'J82.83', 'J45.909', 'J45.991', 'J45.20', 'J45.30', 'J45.40']. The drugs being tested are 'azd9898' and 'matching placebo'. The eligibility criteria are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\" and include factors such as age, gender, body mass index, pregnancy status, asthma diagnosis, lung function, medical history, vital signs, ECG results, substance abuse history, allergies, medication usage, and other health-related factors.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is psoriasis. The ICDCodes associated with psoriasis are ['L40.0', 'L40.4', 'L40.8', 'L40.9', 'L40.1', 'L40.50']. The drugs being tested in this trial are 'abbv-553' and 'placebo'. The eligibility criteria for participants include age restrictions, gender-specific requirements for females, BMI range, general good health, and the need to sign an informed consent form. Additionally, there are specific criteria for Substudy 2, which include a clinical diagnosis of chronic plaque psoriasis, certain scores related to the severity of the disease, and the affected body surface area. The exclusion criteria include restrictions on male participants who may consider fathering a child or donating sperm during the study, history of sensitivity to drugs, various medical conditions, recent infections or medication use, and the requirement for regular use of over-the-counter or prescription medications.",
    "The sample provided is a record from a table that contains information about clinical trials. The record represents a trial in phase 1/phase 2, focusing on the disease \"rheumatoid arthritis (RA)\". The ICD-10 codes associated with this disease are ['M05.9', 'M06.08', 'M06.00', 'M06.011', 'M06.012', 'M06.019', 'M06.021']. The drugs being studied in this trial are \"placebo\", \"niclosamide\", and \"etanercept\". \n\nThe eligibility criteria for this trial are as follows:\nInclusion Criteria:\n- Patients must have RA, as defined by the American College of Rheumatology (ACR) 1987 revised criteria or ACR/EULAR 2010.\n- Patients must have severely active RA, determined by calculating either DAS28 or SDAI or CDAI.\n- Patients must have started etanercept treatment within the last 3 months and still be active.\n\nExclusion Criteria:\n- Patients who have taken nonsteroidal anti-inflammatory drugs (NSAIDs) or methotrexate (MTX) within 2 days before entering the study.\n- Patients with hypersensitivity or severe adverse effects to niclosamide.\n- Patients with renal impairment.\n- Patients with hepatic impairment.\n- Patients who are pregnant or have a desire to become pregnant.\n- Patients who are breastfeeding.\n- Patients with Juvenile RA (16 years old or younger).\n- Patients using other conventional disease modifying antirheumatic drugs (DMARDs).\n- Patients on steroid medication.\n- Patients with coexistence of other connective tissue diseases or hypothyroid disease.\n- Patients with mild or inactive RA.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this specific sample, the phase of the trial is Phase 1. The disease mentioned is \"type 1 diabetes mellitus.\" The ICDCodes associated with this disease are \"E10.65,\" \"E10.9,\" \"E10.21,\" \"E10.36,\" \"E10.41,\" \"E10.42,\" and \"E10.44.\" The drugs mentioned in this sample are \"biochaperone\u00ae insulin lispro,\" \"fiasp\u00ae,\" and \"novorapid\u00ae.\" \n\nThe eligibility criteria for this trial are divided into inclusion and exclusion criteria. The inclusion criteria state that participants must have had Type 1 Diabetes Mellitus for more than 12 months, have a BMI between 18.5 and 28.5 kg/m\u00b2, have an HbA1C level of <=9.0%, and have been treated with insulin for at least 12 months with a total insulin dose of <1.2U/kg/day. \n\nThe exclusion criteria state that participants must not have Type 2 Diabetes Mellitus, must not have a history of severe allergies to drugs or foods, must not have any clinically relevant cardiovascular, pulmonary, respiratory, gastrointestinal, hepatic, renal, metabolic, endocrinological, haematological, dermatological, neurological, osteomuscular, articular, psychiatric, systemic, ocular, gynaecologic, or infectious diseases, or signs of acute illness as determined by the Investigator. Additionally, participants must not have had more than one episode of severe hypoglycemia with seizure, coma, or requiring assistance in the past 6 months. They must also not have proliferative retinopathy or maculopathy and/or severe neuropathy, particularly autonomic neuropathy. Females of childbearing potential who are pregnant, breastfeeding, intend to become pregnant, or are not using highly effective contraceptive methods are also excluded from the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is Alzheimer's disease. The ICDCodes associated with this disease are \"G30.8\", \"G30.9\", \"G30.0\", and \"G30.1\". The drugs being tested in this trial are \"np001\" and \"placebo\". The eligibility criteria for participants in this trial include being 55 years of age or older, having a diagnosis of probable Alzheimer's disease, meeting certain cognitive and memory scores, having certain scores on depression and ischemic scales, and meeting other medical and health-related requirements. There are also exclusion criteria listed, which include having other neurologic disorders, psychiatric disorders, unstable medical illnesses, certain autoimmune disorders, pulmonary diseases, and other specific medical conditions. Additionally, there are criteria related to blood pressure, blood counts, liver function, kidney function, pregnancy, and other factors that may put the participant at risk.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase is \"early phase 1\" and the disease listed is \"squamous cell carcinoma of the head and neck\". The ICDCodes associated with this disease are \"C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8\". The drug mentioned is \"ribociclib\". The eligibility criteria for this trial include various conditions such as the type of cancer, availability of archival tissue, signed informed consent, age, stable central nervous system tumor, adequate bone marrow and organ function, normal laboratory values, normal ECG parameters, contraception for women of childbearing potential, and agreement for men not to impregnate a woman. The exclusion criteria include hypersensitivity to ribociclib, concurrent malignancy requiring treatment, gastrointestinal impairment, HIV infection, other severe medical conditions, uncontrolled heart disease, recent cardiac events, risk factors for Torsades de Pointe, use of certain medications, recent corticosteroid use, use of certain anticoagulants, recent radiotherapy, prior treatment for the current oral cavity malignancy, recent major surgery, incomplete recovery from prior anticancer therapies, Child-Pugh score B or C, history of non-compliance or inability to grant consent, and pregnancy or nursing.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is female infertility. The ICDCodes associated with this disease are N97.9, N97.0, N97.1, N97.2, N97.8, and Z31.81. The drug being tested is sildenafil vaginal suppositories. The eligibility criteria for this trial include women with normal ovarian reserve and at least two prior cycles with FSH levels below 10 mIu/ml, women who have had two or three consecutive failed IVF/ICSI attempts using good quality embryos, women with endometrial thickness below 9 mm in previous attempts, and women with normal endometrial appearance in hysteroscopy, hysterosonography, or hysterosalpingography. The exclusion criteria include women with a history of PCOS, myomectomy, Asherman's Syndrome, and mullerian anomalies.",
    "The sample is a record from a table that contains information about a clinical trial. The phase of the trial is Phase 1/Phase 2. The disease being studied is HIV infections, which is represented by the ICD-10 code 'Z21'. The drugs being used in the trial are disulfiram and vorinostat, along with their respective National Drug Codes (NDC). The eligibility criteria for participants are listed, including age, HIV status, CD4+ T cell count, ability to provide informed consent, and various other factors. There are also exclusion criteria listed, such as current alcohol use disorder, certain medication use, significant medical conditions, and pregnancy. Additionally, there are specific laboratory values that need to be within acceptable ranges for participants.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is \"early phase 1\", the disease is \"urothelial carcinoma\", the ICDCodes are \"['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']\", the drugs are \"atezolizumab\" and \"radium-223\", and the eligibility criteria are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". The inclusion criteria include requirements such as a histologic diagnosis of urothelial carcinoma with evidence of metastatic disease, bone metastasis, specific performance status, progression of disease within a certain timeframe, and other factors related to organ function and previous treatments. The exclusion criteria include restrictions on prior treatments, concurrent malignancies, autoimmune diseases, corticosteroid use, significant medical conditions, severe infections, recent surgical procedures, allergies, and other factors that could affect compliance or interpretation of results.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is cystic fibrosis, and the ICDCodes associated with it are E84.9, Z14.1, E84.0, E84.11, E84.8, E84.19, and P09.4. The drugs being tested in the trial include iva, tez/iva, vx-445, matched placebo, tez, and vx-561. The eligibility criteria for the trial include specific age ranges, body mass index requirements, body weight thresholds, and FEV1 value requirements. There are also exclusion criteria related to drug absorption, recent febrile illness, glucose-6-phosphate dehydrogenase deficiency, cirrhosis, lung infections, and history of organ or hematological transplantation.",
    "The sample provided is a record from a table that contains information about clinical trials. The phase of the trial is \"early phase 1\". The disease being studied is \"nicotine dependence\". The corresponding ICD-10 codes for this disease are \"F17.200\", \"F17.210\", \"F17.208\", \"F17.209\", \"F17.218\", and \"F17.219\". The drugs being tested in this trial are \"mifepristone\" and \"placebo\". The eligibility criteria for participants are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include being a male smoker aged 18 to 55 years, having a history of smoking at least 5 cigarettes daily for the past 12 months, and being in good health as verified by medical history, screening examination, and laboratory tests. Exclusion criteria include having a history of mifepristone allergy, requiring regular psychotropic medication or having recent psychiatric history, having certain medical illnesses or conditions, having specific laboratory test results outside the normal range, using certain medications or substances, and being unable to fulfill all scheduled visits and examination procedures throughout the study period.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase is \"early phase 1\" and the diseases being studied are \"kidney transplant\" and \"hepatitis c\". The ICDCodes associated with these diseases are provided as well. The drugs being used in the trial are \"direct acting anti-viral therapy using epclusa or zepatier\". The eligibility criteria for participants are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\", which include factors such as age, risk factors, willingness to provide informed consent, and absence of certain medical conditions. Additionally, there are specific exclusion criteria for potential donors.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 1, and the disease mentioned is \"neovascular age-related macular degeneration.\" The ICDCodes associated with this disease are ['H35.3211', 'H35.3212', 'H35.3221', 'H35.3222', 'H35.3231', 'H35.3232', 'H35.3291']. The drugs mentioned in this sample are 'gb-102' and 'aflibercept'. The eligibility criteria for this trial include specific age requirements, the presence of an active CNV lesion secondary to AMD, evidence of increased vascular permeability and/or loss of visual acuity. There are also exclusion criteria listed, such as a history of certain cardiac events, uncontrolled hypertension or diabetes, chronic renal disease, abnormal liver function, and pregnancy or lactation for women.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is hepatocellular carcinoma. The ICDCodes associated with this disease are C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, and C4A.8. The drug being used in the trial is meclizine oral tablet. \n\nThe eligibility criteria for this trial include:\n1. Patients must have imaging (MRI or CT abdomen liver protocol) confirmed or highly suspicious for hepatocellular carcinoma.\n2. Patients must have measurable disease, defined as a tumor mass that is >10 mm with a spiral CT scan or MRI.\n3. Patients must have no prior history of treatment for HCC (treatment na\u00efve) on the lesion that is being targeted for biopsy.\n4. Patients must be greater than 18 years of age.\n5. ECOG Performance status must be less than or equal to 2 (Karnofsky greater than 60%).\n6. Patients must have normal organ and marrow function.\n7. Patients must be a candidate for surgical resection, ablation, TACE, Y90, or systemic therapy.\n8. Patients should have a life expectancy greater than or equal to 10 weeks.\n9. Patients must be willing to use contraception.\n10. Patients must be informed of the investigational nature of the study and provide written informed consent.\n\nThe exclusion criteria for this trial include:\n1. Patients may not be receiving any other concurrent anti-cancer therapy.\n2. Patients may not be receiving any other concurrent investigational agents.\n3. Patients taking medications with a narrow therapeutic index should be monitored carefully.\n4. Patients must not be taking Rifampin or St John's Wort.\n5. Patients must not have a history of allergic reactions to compounds of similar composition to Meclizine.\n6. Patients must not be a candidate for liver transplant.\n7. Child Pugh Class B and Class C are excluded.\n8. Antiviral therapy for HCV and HBV is allowed, but patients should not be on interferon.\n9. HIV-positive patients on combination antiretroviral therapy are ineligible.\n10. Patients must not have uncontrolled intercurrent illness.\n11. Pregnant women and breastfeeding mothers are excluded from the study.",
    "The sample from the table is for a clinical trial with a phase 1/phase 2 combination. The trial is focused on patients with myelodysplastic syndromes (MDS), a type of blood disorder. The ICD-10 codes associated with MDS are 'D46.9', 'D46.C', and 'D46.Z'. The trial involves multiple drugs, including nivolumab, azacitidine, fludarabine, cyclophosphamide, cytarabine, all trans retinoic acid, sildenafil, and melphalan. The eligibility criteria for the trial include having MDS with up to 20% blasts, being 18 years or older, having no severe organ dysfunction, having a Karnofsky index of at least 70%, and meeting certain requirements for females of childbearing potential and males with partners of childbearing potential. The exclusion criteria include having another malignancy requiring treatment, a history of interstitial lung disease or pneumonitis, having any other severe and/or uncontrolled medical condition, having an active autoimmune disease requiring treatment, being pregnant or breastfeeding, being unwilling or unable to comply with the protocol, having a somatic or psychiatric disorder that prevents signing informed consent, and having prior treatment with certain therapies.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is \"early phase 1\" and the disease is \"schizophrenia\". The ICDCodes associated with schizophrenia are ['F20.0', 'F20.1', 'F20.2', 'F20.3', 'F20.5', 'F20.89', 'F20.9']. The drugs being tested in this trial are 'vorinostat oral capsule group 1' and 'vorinostat oral capsule group 2'. The eligibility criteria for this trial include being diagnosed with DSM-5 schizophrenia, receiving a stable dose of clozapine (\u2265 300 mg per day) for at least 6 months before entering the study. The exclusion criteria include taking specific psychotropic medications (lamotrigine and valproic acid), current or recent substance use or induced disorder, history of significant neurological or medical disorders, intellectual disability, known contraindications to the administration of vorinostat per product labeling, and women who are currently pregnant, planning to become pregnant, or receiving hormone therapy and refusing any form of birth control.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is \"early phase 1\" and the disease being studied is \"pulmonary hypertension\". The ICDCodes associated with this disease are \"I27.0, I27.20, I27.21, I27.24, I27.29, P29.30, I27.22\". The drugs being tested in this trial are \"albuterol first then placebo\" and \"placebo first then albuterol\". \n\nThe eligibility criteria for this trial are as follows:\nInclusion Criteria:\n- Mean Pulmonary Artery Pressure >25mmHg, Pulmonary Vascular Resistance >3 wood/units, and pulmonary arterial wedge pressure <15mmHg, as documented by right heart catheterization within the last 3 years.\n- Regular use of oral pulmonary vasodilators.\n\nExclusion Criteria:\n- Presence of chronic respiratory disease, cardiovascular disease, or thromboembolic PAH, as documented by prior lung imaging, pulmonary function tests, echocardiography, and/or left heart catheterization.\n- Women of childbearing potential who do not use accepted birth control measures.\n- Pregnant and breastfeeding women.\n- Respiratory infection within 4 weeks of testing.\n- A systemic systolic arterial BP >150 and/or diastolic arterial BP >100 on the experiment day.\n- A resting O2 saturation of <90%.\n- Current smoking.\n- BMI >35 kg/m2 and/or a diagnosis of obstructive sleep apnea.\n- Use of inhaled or intravenous pulmonary vasodilators.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is categorized into different phases, such as phase I, phase II, or phase III. The sample record is from a phase 1 trial. \n\nThe trial focuses on the treatment of chronic hepatitis B. The diseases column specifies the disease being studied, which in this case is \"hepatitis b, chronic.\" The icdcodes column contains the corresponding ICD-10 codes for the disease, which are \"B18.0\", \"B18.1\", \"B18.2\", \"B18.8\", and \"B18.9\".\n\nThe drugs column lists the drugs being used in the trial, which are \"eyp001a\", \"placebo\", \"entecavir\", and \"peg-interferon alfa-2a\". \n\nThe criteria column provides the eligibility criteria for participants in the trial. It includes various conditions that participants must meet, such as having given informed consent, having a documented medical history of chronic HBV infection, being within a certain age range, having specific laboratory test results within normal limits, and abstaining from certain medications.\n\nThe exclusion criteria are also listed, which specify conditions that would disqualify a participant from the trial. These include having certain liver cirrhosis conditions, being currently on anti-HBV treatment, having co-infections with hepatitis C virus or human immunodeficiency virus, receiving or planning to receive certain medications, having substance abuse issues, having certain medical or psychiatric conditions, and having a history of relevant allergies or surgeries.\n\nOverall, the sample record provides detailed information about the phase 1 trial, the disease being studied, the drugs being used, and the eligibility and exclusion criteria for participants.",
    "The sample is a phase 1 clinical trial for patients with pancreatic cancer. The trial is investigating the use of the drug plerixafor. The eligibility criteria for the trial include being 16 years or older (18 years or older in the US), having inoperable, locally advanced or metastatic pancreatic cancer that is refractory to conventional chemotherapy or having declined conventional chemotherapy. The trial also requires tumor lesions that can be accessed for core biopsy and immunostaining assessment, an ECOG performance status of 0-1, and a life expectancy of at least 12 weeks. All women of child-bearing potential and sexually active male patients must agree to use effective contraception methods throughout the trial and for 3 months after the final dose of the trial drug. The exclusion criteria include inadequate hematological, renal, or hepatic function, current treatment with chemotherapy, steroids, or other immunosuppressive drugs, significant medical or psychiatric conditions that would place the patient at undue risk or interfere with the trial, cardiac co-morbidities, active infection, known allergy to plerixafor or its excipients, hepatitis B, hepatitis C, or HIV infection, participation in any other interventional clinical trial, and pregnancy or lactation.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease being studied is metastatic colorectal cancer. The ICDCodes associated with this disease are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, and C17.2. The drugs being used in the trial are irinotecan and capecitabine. The eligibility criteria for this trial include various factors such as age, understanding of the study requirements and risks, confirmed malignancy, performance status, life expectancy, blood counts, liver and kidney function, cardiovascular and pulmonary conditions, prior hypersensitivity reactions, gastrointestinal conditions, ability to swallow tablets, psychiatric conditions, infections, pregnancy status, peripheral neuropathy, and willingness to comply with hospitalization and follow-up visits. The exclusion criteria include simultaneous participation in other studies, symptomatic brain metastases, intake of prohibited medications, and known Dihydropyrimidine dehydrogenase (DPD) deficiency.",
    "The sample from the table is for a clinical trial with a phase 1/phase 2 trial phase. The trial focuses on smoking cessation as the disease. The ICD-10 codes associated with the disease are ['Y36.881S', 'Y36.891S', 'Y36.880S', 'Y36.881A', 'Y36.881D', 'Y36.890S', 'Y36.891A']. The drug being tested is cytisine. \n\nThe eligibility criteria for the trial include being a regular moderate cigarette smoker (at least 10 cigarettes per day) who wants to quit smoking. The participant must have a urine cotinine level greater than 500 ng/mL and an expired air carbon monoxide (CO) level greater than 11 parts per million (with no cigarette 1 hour before the test). The trial is open to healthy males and females aged 18-65+ years. Female participants of childbearing potential must have a negative pregnancy test and be willing to use contraception during the study. Female participants of non-childbearing potential must also have a negative pregnancy test. Male participants must be willing to use contraception. \n\nOther inclusion criteria include having no clinically significant abnormal serum biochemistry, haematology, or urine examination values within 28 days before the first dose of cytisine. The participant must also have a negative urinary drugs of abuse screen, negative HIV, Hep B, and Hep C results, and no clinically significant abnormalities in 12-lead ECG and vital signs. The participant must be available to complete the study and provide written informed consent.\n\nExclusion criteria for the trial include recent treatment with smoking cessation medications or use of other forms of nicotine within 8 weeks of the first dose of cytisine. Participants with known hypersensitivity/allergy reactions to varenicline, other cytisine-derivatives, or any excipients in the Tabex formulation are also excluded. Other exclusion criteria include current treatment with certain medications, history of medical or surgical conditions that may affect drug pharmacokinetics, breastfeeding, difficulty in donating blood, history of alcoholism or drug abuse, use of non-prescription drugs within 14 days prior to the first dose of cytisine, participation in other clinical trials within a certain timeframe, donation of a significant amount of blood or plasmapheresis within 3 months before the first dose of cytisine, inability to communicate well, and any other condition that the Principal Investigator deems unsuitable for the study.",
    "The sample provided is a schema definition of a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this specific sample, the phase of the trial is Phase 1. The diseases being studied include lung diseases, pulmonary disease, cystic fibrosis, and various other related conditions. The ICDCodes associated with these diseases are also provided. The drugs being tested in the trial are \"inhaled snsp113\" and \"inhaled placebo\". \n\nThe eligibility criteria for the trial are divided into two parts, Part A and Part B. In Part A, the inclusion criteria include being a healthy male adult between 18 and 50 years old, having a baseline FEV1 (forced expiratory volume in one second) between 80-120% of predicted, and normal screening laboratory tests. In Part B, the inclusion criteria include being a female or male subject over 18 years old with a confirmed diagnosis of cystic fibrosis, having an FEV1 greater than 50% of predicted, and stable CF pulmonary disease as determined by the investigator. \n\nThe exclusion criteria for Part A include a history of lung or systemic diseases, recent tobacco or cannabis use, and various other chronic conditions. The exclusion criteria for Part B include recent participation in a clinical trial, pregnancy or plans to become pregnant, the need for supplemental oxygen, recent hemoptysis (coughing up blood), and being listed for organ transplantation.",
    "The sample provided is a schema definition of a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. The table has the following columns: phase, diseases, icdcodes, drugs, and criteria.\n\nIn the sample, the phase is described as \"phase 1/phase 2\". The diseases listed are \"cough\". The ICDCodes associated with the disease are \"['R05.1', 'R05.2', 'R05.3', 'R05.4', 'R05.9', 'G44.83', 'J45.991']\". The drugs mentioned are \"bay1817080\" and \"matching placebo\". The eligibility criteria are provided in the \"criteria\" column.\n\nThe eligibility criteria are divided into two parts. In Part 1, the criteria include being a healthy male between the ages of 18-45, a non-smoker for at least 6 months, and agreeing to use contraception if sexually active. In Part 2, the criteria include being over 18 years old, having refractory chronic cough for at least one year, and having a score of >40 mm on the Cough Severity visual analogue scale (WAS) at screening.\n\nThere are also specific criteria for male and female patients regarding contraception and childbearing potential. The exclusion criteria include relevant diseases potentially interfering with the study's aims, febrile illness, taste dysfunction, and recent use of over-the-counter cough mixture in Part 1. In Part 2, the exclusion criteria include respiratory tract infection, smoking history, and significant pulmonary status changes.",
    "The sample is a phase 1 trial for osteoarthritis. The trial is testing the effectiveness of the drug \"glpg1972 cohort 1\", \"glpg1972 cohort 2\", \"glpg1972 cohort 3\", and a placebo. The eligibility criteria for participants include being 50-75 years old, having a diagnosis of osteoarthritis based on symptoms and imaging evidence, having a body mass index (BMI) between 18.0 and 34.9 kg/m2, and being in good health based on medical history, physical examination, vital signs, and laboratory tests. Exclusion criteria include recent administration of certain injections, planned surgeries, known allergies to study drug ingredients, positive serology for certain diseases, immunosuppressive conditions, unstable illness, renal function below a certain level, recent use of certain medications, history of organ or cell transplantation, history of malignancy within the past 5 years, significant abnormalities in the heart's electrical activity, and significant blood loss or transfusion within a certain timeframe.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 1 and focuses on the treatment of pain. The associated ICD-10 codes for the disease are ['N50.82', 'R07.2', 'R07.82', 'R10.13', 'R10.33', 'R14.1', 'R52']. The drugs being studied are 'omnitram', 'tramadol', and 'placebo'. The eligibility criteria for participants are listed, including age requirements, normal vital signs, ability to give informed consent, and compliance with study procedures. Female participants must meet additional criteria related to contraception and pregnancy testing. Various screening tests are required to assess hematologic, liver, renal, and cardiac function. Exclusion criteria include current illness, history of seizures or liver disease, recent alcohol or drug use, and certain medication restrictions. Other factors that could interfere with the study or participant compliance are also considered.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 1, and the diseases mentioned are hypoglycemia and diabetes mellitus, type 1. The ICDCodes associated with these diseases are provided as well. The drugs mentioned in the sample are nasal glucagon and intramuscular glucagon. The eligibility criteria for this trial are listed under inclusion and exclusion criteria, which include requirements and restrictions for participants.",
    "The sample provided is a record from a table that contains information about clinical trials. The record represents a trial for the treatment of Hodgkin's lymphoma in patients who have relapsed or are refractory to previous treatments. The trial is in phase 1/phase 2. The diseases column specifies the disease being targeted, which in this case is Hodgkin's lymphoma. The icdcodes column provides the ICD-10 codes associated with the disease. The drugs column lists the drugs being used in the trial, which are nivolumab and bendamustine hydrochloride. The criteria column includes the eligibility criteria for participants in the trial, such as the requirement of a histologically confirmed diagnosis of Hodgkin's lymphoma, relapse after nivolumab treatment or refractory to nivolumab treatment, age between 18 and 70 years old, and signed informed consent. It also includes exclusion criteria, such as uncontrolled bacterial or fungal infection, requirement for vasopressor support, Karnofsky index below 30%, pregnancy, somatic or psychiatric disorders that prevent signing informed consent, and active or prior documented autoimmune disease requiring systemic treatment.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The diseases being studied are diffuse large B-cell lymphoma and mediastinal B-cell lymphoma. The ICDCodes associated with these diseases are \"S33.110S\", \"S33.111S\", \"S33.120S\", \"S33.121S\", \"S33.130S\", and \"S33.131S\". The drugs being used in the trial are idelalisib, rituximab, ifosfamide, carboplatin, and etoposide. The eligibility criteria for participants include having a confirmed diagnosis of DLBCL or MBCL, relapsed or refractory disease, measurable or evaluable disease, a certain level of performance score, negative pregnancy test for females of childbearing potential, and adequate bone marrow and renal function. There are also exclusion criteria, such as prior therapy with certain drugs, active infections, ongoing or history of certain medical conditions, pregnancy or breastfeeding, and receiving other anti-cancer or investigational drugs.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1 and focuses on the treatment of non-Hodgkin lymphoma. The trial involves the use of drugs such as atezolizumab, emactuzumab, and obinutuzumab. The eligibility criteria for participants include having an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2, a life expectancy of at least 12 weeks, and having measurable nodal lesions of a certain size. Other criteria include adequate hematologic and end-organ function, abstaining from sexual activity or using contraceptive measures, and providing consent for tumor sample collection. The sample also includes exclusion criteria, such as recent treatment with other anti-cancer therapies, participation in other clinical studies, and certain medical conditions or allergies.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is categorized into different phases, such as phase I, phase II, or phase III. The sample record specifically belongs to a trial that is in both phase 1 and phase 2. The trial focuses on the disease \"cough\" and provides the corresponding ICD-10 codes for this disease. The drugs being studied in this trial are \"gsk2798745\" and \"placebo\". The record also includes the eligibility criteria for participants in the trial. The inclusion criteria specify requirements such as age, duration of chronic idiopathic cough, chest imaging results, lung function, cough severity, body weight and BMI, contraception for males, and childbearing potential for females. The exclusion criteria list various medical conditions, history of certain diseases or procedures, recent respiratory tract infection, suicide risk, liver function, QT interval, medication usage, blood loss, exposure to new chemical entities, recent participation in other clinical studies, HIV and hepatitis status, cardiac troponin levels, alcohol and smoking history, and allergies or sensitivities to study treatments or components.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase of the trial is Phase 1, and the disease being studied is hepatocellular carcinoma. The ICDCodes associated with this disease are ['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']. The drugs being used in the trial are nivolumab and bevacizumab. The eligibility criteria for this trial include confirmed unresectable or metastatic hepatocellular carcinoma, previous treatment with a TKI, measurable disease per RECIST1.1, age \u226518 years, ECOG performance status of 0 to 1, life expectancy \u226512 weeks, Childs Pugh A (5-6 points), and adequate organ function. The sample also includes exclusion criteria such as prior treatment with anti-PD1 or anti-PD-L1 antibody therapy, history of arterial thromboembolic event in the past 6 months, ongoing systemic anti-cancer treatment, recent radiotherapy or major surgery, presence of \u2265CTCAE grade 2 toxicity due to prior cancer therapy, and various other medical conditions and factors.",
    "The sample is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease mentioned is \"neoplasm metastasis\" and its corresponding ICDCodes are ['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']. The drugs involved in the trial are 'ds-8201a', 'ritonavir', and 'itraconazole'. The sample also includes the inclusion and exclusion criteria for the trial, which specify the requirements and restrictions for participants.",
    "The sample is a record from a table that contains information about clinical trials. The phase of the trial is \"phase 1/phase 2\". The disease being studied is melanoma. The ICD-10 codes associated with the disease are \"C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, C43.4\". The drugs being used in the trial are \"apr-246\" and \"dabrafenib\". The eligibility criteria for the trial are listed, including requirements such as confirmed BRAF V600 mutation-positive unresectable and/or metastatic malignant cutaneous melanoma, measurable disease according to RECIST 1.1 criteria, ECOG Performance Status of 0 or 1, and signed informed consent. The exclusion criteria are also listed, including the presence of uveal melanoma or other non-cutaneous melanomas, current use of prohibited medications, unresolved toxicity from previous anti-cancer therapy, and various medical conditions that may interfere with the assessment of toxicity. Pregnant or lactating women are also excluded from the trial.",
    "The sample provided is a schema definition of a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. The sample data includes a phase 1 trial with diseases related to anesthesia and analgesia. The ICDCodes for these diseases are also provided. The drugs being tested in this trial are bupivacaine low, bupivacaine high, and neosaxitoxin. The eligibility criteria for this trial include age, body mass index, good health, contraception requirements, and exclusion criteria such as abnormal vital signs, laboratory values, previous drug use, and other medical conditions.",
    "The sample is a phase 1 trial with the disease being studied as \"healthy\". The ICD-10 codes associated with this disease are \"Z76.3\" and \"Z76.2\". The drugs being tested are \"al-794\" and \"placebo\". The eligibility criteria for participants include providing written informed consent, being able to understand and comply with the study requirements, being deemed healthy based on physical examination and medical history, having a body mass index (BMI) between 18 and 32 kg/m^2, with a minimum weight of 50 kg, and having a negative pregnancy test for female participants. Exclusion criteria include being pregnant or planning to become pregnant, having certain laboratory abnormalities, having a creatinine clearance less than 90 mL/min, and testing positive for HIV or hepatitis.",
    "The sample is a record from a table that contains information about a clinical trial. The phase of the trial is Phase 1. The disease being studied is amyloidosis. The ICD-10 codes associated with the disease are E85.89, E85.9, E85.1, E85.2, E85.3, E85.4, and E85.0. The drugs being used in the trial are gsk2315698 (cphpc), gsk2398852 (unlabeled anti-sap mab), and 89zr-gsk2398852 (89zr-labeled anti-sap mab). The eligibility criteria for participants are listed, including age requirements, confirmation of the disease, and other medical conditions that may exclude someone from participating. The exclusion criteria are also listed, which include certain medical conditions, recent medical procedures, and other factors that may prevent someone from participating.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The diseases being studied are neoplasms and lymphoma. The ICDCodes associated with these diseases are C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2 for neoplasms and S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S for lymphoma. The drugs being used in the trial are mln9708 and nelfinavir. The eligibility criteria for participants in this trial include having an advanced or metastatic malignant solid tumor or lymphoma that is not expected to benefit from standard therapy, a life expectancy of more than 3 months, completion of previous chemotherapy and/or radiotherapy at least four weeks before enrollment, recovery from any surgical procedure, and meeting certain laboratory values such as serum creatinine, bilirubin, hemoglobin, neutrophil count, and platelet count. Other criteria include age, Karnofsky Performance Status, and contraception requirements for female and male participants. The sample also includes exclusion criteria such as inability or unwillingness to swallow capsules, active hepatitis B or C, known HIV infection, ongoing or active systemic infection, uncontrolled cardiovascular conditions, serious medical or psychiatric illness, pregnancy or lactation, malabsorption syndromes, participation in other clinical trials, use of certain drugs, recent infection or surgery, known allergies, and previous or concurrent malignancies.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is atopic dermatitis. The ICDCodes associated with this disease are 'L20.89' and 'L20.9'. The drugs being tested in this trial are 'sb414 2%', 'sb414 6%', and 'vehicle'. \n\nThe eligibility criteria for this trial are as follows:\n- Participants must be 18 years of age or older and in good general health.\n- They must have an EASI (Eczema Area and Severity Index) score greater than 1 and less than or equal to 21, with at least 5% of their body surface area affected.\n- They must have at least two target lesions that are at least 5 cm2 in size, with a TLSS (Target Lesion Severity Score) greater than or equal to 5. However, these target lesions cannot be located on the groin, hands, elbows, feet, ankles, knees, face, or scalp.\n- Participants must agree not to use any other products for atopic dermatitis during the study.\n- Women of childbearing potential must have a negative urine pregnancy test before randomization and must use an effective method of birth control during the study and for 30 days after their final study visit.\n\nThe exclusion criteria for this trial are as follows:\n- Participants who have recently used topical or systemic medications without a sufficient washout period are not eligible.\n- Immunocompromised individuals, including those who are known to be HIV positive or receiving immunosuppressive treatment, are excluded.\n- Pregnant or nursing women, as well as those planning to become pregnant during the study, are not eligible.\n- Participants with active acute bacterial, fungal, or viral skin infections within 1 week before the baseline visit are excluded.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1 and focuses on the disease psoriasis. The ICD-10 codes associated with psoriasis are ['L40.0', 'L40.4', 'L40.8', 'L40.9', 'L40.1', 'L40.50']. The drugs being studied are 'sb414 6%' and 'vehicle'. The eligibility criteria for participants include being 18-70 years old, having a clinical diagnosis of stable chronic plaque psoriasis of mild to moderate severity, and having specific target plaques on the trunk and/or extremities. Participants must also agree not to use any other systemic agents or topical products for psoriasis treatment during the study. Women of childbearing potential must have a negative pregnancy test and use effective birth control during the study. The exclusion criteria include having certain types of psoriasis, recent use of medications, being immunocompromised, and being pregnant or planning to become pregnant during the study.",
    "The sample provided is a record from a table that contains information about a clinical trial. The trial is in phase 1 and focuses on the treatment of pulmonary arterial hypertension. The disease is identified by its ICD-10 code, which is \"I27.21\". The drug being studied is \"treprostinil inhalation powder\". \n\nThe sample also includes the eligibility criteria for participants in the trial. The inclusion criteria state that participants must voluntarily consent to participate, be between 18 and 55 years old, and meet certain weight and BMI requirements depending on their gender. Female participants must also be non-pregnant or breastfeeding and either surgically sterile or postmenopausal for at least 1 year, or agree to use birth control during the study.\n\nThe exclusion criteria list various medical conditions or abnormalities that would make a participant ineligible for the trial. These include significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, oncologic, or psychiatric diseases. Other exclusions include a history of chronic lung disease, migraine headaches, bleeding abnormalities, abnormal lung function, hypersensitivity reactions to drugs, recent participation in another clinical trial, use of certain medications or substances, and various other factors that may impact subject safety or the validity of the study results.\n\nOverall, this sample provides a snapshot of the phase 1 clinical trial, including the specific disease being studied, the drug being tested, and the eligibility criteria for participants.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is categorized as Phase 1 and is focused on the disease \"asthma\". The corresponding ICD-10 codes for asthma are provided as well. The trial involves the use of two drugs, \"itraconazole powder\" and \"itraconazole 200 mg\". The eligibility criteria for participants are also listed, including age requirements, lung function measurements, and the ability to demonstrate correct inhalation technique. The criteria are further divided into three parts, with specific requirements for asthmatic subjects. Exclusion criteria are also mentioned, such as recent use of investigational medicinal products, history of drug or alcohol abuse, and certain medical conditions.",
    "The sample provided is a record from a table that contains information about clinical trials. The record includes the following details:\n\n- Phase: The phase of the trial is \"early phase 1\".\n- Diseases: The diseases being studied in this trial are \"pancreatic ductal adenocarcinoma\" and \"pancreatic cancer\".\n- ICD Codes: The ICD-10 codes associated with these diseases are \"C22.0\", \"C22.1\", \"C4A.9\", \"C7B.1\", \"D09.9\", \"C4A.0\", \"C4A.31\" for the first disease, and \"C25.3\" for the second disease.\n- Drugs: The drugs being tested in this trial are \"pegylated recombinant human hyaluronidase (pegph20)\" and \"avelumab\".\n- Criteria: The eligibility criteria for participants in this trial include having a signed, written informed consent form, a confirmed diagnosis of pancreatic ductal adenocarcinoma, accessible tumor for biopsies, progression to first-line treatment for locally advanced or advanced disease, being at least 18 years old, having radiologically measurable disease, having a performance status of ECOG 0-2, having a life expectancy of at least 3 months, resolving acute effects of any prior therapy, meeting certain laboratory requirements, being willing and able to comply with scheduled visits and procedures, and not having certain medical conditions or history.\n\nThe exclusion criteria for this trial include having certain medical conditions or history, current use of specific medications, active infection, known infections with certain viruses, known severe hypersensitivity reactions, history of anaphylaxis or uncontrolled asthma, clinically significant cardiovascular disease, prior cerebrovascular accident/stroke, clinically significant carotid artery disease, inability to comply with study procedures, and known alcohol or drug abuse.",
    "The sample from the table represents a Phase 1 clinical trial. The trial focuses on a single disease called \"healthy,\" which is represented by the ICD-10 codes \"Z76.3\" and \"Z76.2.\" The trial involves several drugs, including \"pb2452 infusion,\" \"placebo - sodium chloride,\" \"ticagrelor oral tablet - pre-treatment,\" and \"ticagrelor oral tablet - pre-treatment and post-treatment.\" \n\nThe eligibility criteria for participants in this trial are as follows:\n1. Participants must be between 18 and 50 years old.\n2. Participants must have a body mass index between 18 and 35 kg/m2 and weigh between 50 kg and 120 kg.\n3. Participants must be in good general health, as determined by medical history, laboratory tests, vital signs, ECG results, and physical examination.\n4. Female participants of childbearing potential must not be pregnant, lactating, or planning to become pregnant during the study. They must have a negative pregnancy test and use two effective methods of birth control.\n5. Participants must agree to comply with all protocol requirements and provide written informed consent.\n\nThere are also exclusion criteria that disqualify participants from the trial, including a history of significant diseases or medical disorders, gastrointestinal, hepatic, or renal diseases, recent illnesses or surgeries, abnormal findings in physical examination or laboratory tests, history of thrombosis or bleeding disorders, positive test results for certain viruses, ongoing medical complaints, and use of certain medications.\n\nAdditionally, participants must not have certain medical conditions, be involved in other studies, have received certain medications within a specific timeframe, have certain allergies or hypersensitivities, or have concerns about their ability to comply with study procedures.\n\nOverall, this sample provides information about the phase, diseases, ICDCodes, drugs, and eligibility criteria for participants in a clinical trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied include coronary artery disease, coronary artery bypass, cardiopulmonary bypass, nitric oxide, and reperfusion injury, myocardial. The corresponding ICDCodes for these diseases are also provided.\n\nThe drug being investigated in this trial is nitric oxide. The eligibility criteria for participants are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria state that participants must have coronary artery disease requiring coronary artery bypass grafting with cardiopulmonary bypass. Exclusion criteria include non-elective surgery, age over 70 years, left ventricular ejection fraction less than 35%, recent history of myocardial infraction, chronic atrial fibrillation, diabetes mellitus, and elevated levels of cardiac specific markers prior to the intervention.",
    "The sample from the table represents a phase 1 clinical trial for patients with multiple myeloma. The trial is focused on patients who have relapsed, relapsed and refractory, or refractory multiple myeloma and have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD28 monoclonal antibody. The eligibility criteria include being NY-ESO-1 positive by immunohistochemistry, HLA-A*0201 (HLA-A2.1) positive by molecular subtyping, and having measurable disease. Measurable disease is defined by certain criteria such as serum monoclonal protein levels, serum free light chain levels, and urine protein levels. The patients must also have adequate bone marrow and major organ function to undergo a peripheral blood stem cell transplant. Other inclusion criteria include Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, willingness to undergo leukapheresis procedures and research PET scans, and ability to provide written informed consent.\n\nThere are also exclusion criteria, such as inability to purify a certain number of CD34-enriched cells from the leukapheresis products, previous allogeneic transplant, hypersensitivity to the study agents, recent systemic treatment for multiple myeloma, and potential requirement for systemic corticosteroids or concurrent immunosuppressive drugs. Other exclusion criteria include HIV seropositivity or other immune deficiency states, hepatitis B or C seropositivity with ongoing liver damage, dementia or altered mental status, clinically active central nervous system involvement, pregnancy or breastfeeding, and certain cardiac or pulmonary abnormalities. Active or recent herpes simplex virus or cytomegalovirus infections are also exclusion criteria.\n\nOverall, the sample represents a phase 1 clinical trial for patients with relapsed or refractory multiple myeloma, with specific eligibility and exclusion criteria outlined.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied include familial partial lipodystrophy, hypertriglyceridemia, fatty liver, and nonalcoholic steatohepatitis (NASH). The corresponding ICDCodes for these diseases are E88.1, K70.0, K76.0, and K75.81, respectively.\n\nThe drugs being tested in this trial are gemcabene, with two different dosages: 300mg and 600mg. The eligibility criteria for participants in this trial include a clinical diagnosis of lipodystrophy, low skinfold thickness in the anterior thigh, a historic genetic diagnosis of familial partial lipodystrophy, hepatic steatosis demonstrated by MRI-PDFF, specific alcohol intake limits, fasting triglyceride levels, stable background lipid lowering medications, contraception requirements for women, weight and BMI restrictions, restrictions on the use of certain medications, and the absence of any conditions or findings that could compromise the patient's safety or participation in the study.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. \n\nIn this particular sample, the phase of the trial is Phase 1. The diseases being studied include solid tumor, hepatocellular carcinoma, gastric cancer, and gastroesophageal junction adenocarcinoma. The corresponding ICDCodes for these diseases are also provided. The drugs being used in the trial are vorolanib, nivolumab, and pembrolizumab. \n\nThe eligibility criteria for this trial include various requirements such as having a confirmed diagnosis of a solid tumor, small cell lung cancer, or other specified diseases. Patients must also have evidence of measurable disease, be at least 18 years old, have a certain performance status, and meet specific criteria for bone marrow and organ function. \n\nThere are also exclusion criteria, which include having a concurrent active, incurable malignancy, receiving other investigational agents within a certain timeframe, and having a history of certain allergic reactions. Other exclusion criteria include having uncontrolled intercurrent illness, certain conditions requiring systemic treatment with corticosteroids or immunosuppressive medications, and a history of certain autoimmune diseases. \n\nThe sample also includes additional exclusion criteria related to bleeding, gastrointestinal conditions, ability to swallow medications, pregnancy or breastfeeding, certain infections, and previous vaccinations. It also mentions criteria related to recent surgeries, radiotherapy, and prior anti-cancer therapy. \n\nFinally, there are criteria related to the presence of cardiovascular diseases or conditions, deep vein thrombosis or pulmonary embolism, and certain QTcF values.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease being studied is castration-resistant prostate cancer. The ICDCodes associated with this disease are \"C61\", \"D29.1\", \"D40.0\", \"Z15.03\", \"Z80.42\", \"Z85.46\", and \"Z12.5\". The drug being used in the trial is cyclophosphamide. \n\nThe eligibility criteria for this trial include the following inclusion criteria:\n- The patient must have histologically or cytologically confirmed adenocarcinoma of the prostate.\n- The patient must have radiographically documented metastatic disease with evidence of disease progression.\n- The patient must be surgically or medically castrate.\n- The patient must have progressed following certain treatments, such as initial therapy, first-line chemotherapy regimen, additional hormonal agent, or pre-chemotherapy abiraterone or enzalutamide.\n\nThe exclusion criteria for this trial include:\n- Patients with neuroendocrine or small cell cancer of the prostate.\n- Patients with a history of other malignant diseases (except primary prostate cancer and non-melanoma skin tumors) in the past 5 years.\n- Patients who have received experimental therapy, immunotherapy, radiopharmaceutical drugs, oncolytic virus treatment, or vaccination with a live virus within specific timeframes.\n- Patients with a history of organ transplantation.",
    "The sample from the table represents a clinical trial for a drug called IRL790 being conducted in patients with Parkinson's disease. The trial is a combination of phase 1 and phase 2. The inclusion criteria for the trial include patients aged 50-85 years, with a diagnosis of idiopathic Parkinson's disease and a clear peak-dose dyskinetic response to regular L-Dopa medication. The patients should also be on stable doses of anti-parkinson treatment for at least one month prior to inclusion. The exclusion criteria include a history of clinically significant diseases or disorders that could put the patient at risk or influence the results, a history of seizures, hepatic or renal disease, and any major surgery planned during the study. Other exclusion criteria include prolonged QTcF, cardiac arrhythmias, severe allergies or hypersensitivity, recent administration of another new chemical entity or participation in another clinical study with drug treatment, history of alcohol abuse or drug use, and patient's likelihood to comply with study procedures.",
    "The sample from the table represents a clinical trial for a drug called lenalidomide. The trial is in phase 1 and is focused on treating patients with recurrent central nervous system lymphoma, recurrent diffuse large b-cell lymphoma, refractory central nervous system lymphoma, and refractory diffuse large b-cell lymphoma. The diseases are identified by their respective ICD-10 codes. The eligibility criteria for the trial include having histological confirmation of the mentioned lymphomas, meeting specific disease progression criteria, having a certain performance status, and meeting various blood and organ function parameters. The criteria also include requirements for prior malignancies, pregnancy testing for females of childbearing potential, and the ability to take aspirin. The exclusion criteria include conditions that would prevent the subject from participating in the study, pregnancy or breastfeeding, certain medical conditions or laboratory abnormalities, use of other experimental drugs or therapies, hypersensitivity to thalidomide, and concurrent use of other anti-cancer agents or treatments. The sample also includes additional exclusion criteria related to specific medical conditions, infections, liver disease, autoimmune disease, and recent major surgery.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are prostate cancer and endometrial cancer. The ICDCodes associated with these diseases are provided as well. The drugs being used in the trial are rucaparib and nivolumab. The eligibility criteria for patients to participate in the trial are listed, including requirements related to consent, disease confirmation, biopsy, previous treatments, medical conditions, and reproductive status. There are also exclusion criteria listed, which specify conditions or situations that would disqualify a patient from participating in the trial.",
    "The sample is from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this specific sample, the phase is Phase 1, and the disease mentioned is knee osteoarthritis. The ICDCodes associated with this disease are M17.9, M17.0, M17.10, M17.11, M17.12, M17.2, and M17.30. The drugs mentioned in this sample are cntx-4975-05, qutenza, and lidocaine (without epinephrine). The eligibility criteria for this trial include specific requirements such as a body mass index (BMI) between 18.0-35.0 kg/m^2, moderate to severe painful osteoarthritis in one knee, confirmation of osteoarthritis based on American College of Rheumatology (ACR) diagnostic criteria, and intact skin at the dosing sites. There are also exclusion criteria mentioned, such as having other forms of arthritis or dermatological conditions that may contraindicate participation.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1, and the disease being studied is hypertension. The ICDCodes associated with this disease are \"I15.0\", \"I97.3\", \"K76.6\", \"P29.2\", \"G93.2\", \"H40.053\", and \"I10\". The drugs being tested in this trial are \"ly3322207\" and \"placebo\". The eligibility criteria for participants are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". The criteria include factors such as age, gender, medical history, physical examination results, laboratory test results, and specific health conditions that would either allow or disqualify individuals from participating in the trial.",
    "The sample is a record from a table that contains information about a clinical trial. The trial is in phase 1/phase 2 and focuses on the treatment of inguinal hernia. The ICD-10 codes associated with the disease are ['K40.11', 'K40.41', 'K40.01', 'K40.21', 'K40.31', 'K40.91', 'K40.10']. The drugs being studied are 'tlc590' and 'naropin'. The sample also includes the eligibility criteria for participants in the trial. The inclusion criteria include being able to provide informed consent, being between 18 and 65 years old, scheduled for a primary, unilateral Lichtenstein inguinal hernia repair, having an ASA Physical Status Classification of 1 or 2, and meeting certain requirements for female and male subjects regarding pregnancy and birth control. The exclusion criteria include having abnormal clinical laboratory test values, evidence of clinically significant 12-lead ECG, history or evidence of certain medical conditions, history of seizures or taking anticonvulsants, hypersensitivity to certain medications, and other specific conditions.",
    "The sample provided is a schema definition of a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. The \"phase\" column indicates the phase of the trial, such as phase I, phase II, or phase III. The \"diseases\" column lists the names of the diseases being studied in the trial. The \"icdcodes\" column contains the corresponding ICD-10 codes for each disease. The \"drugs\" column lists the names of the drugs being used in the trial. The \"criteria\" column provides the eligibility criteria for participants in the trial.\n\nThe sample data in the table includes information for a trial in the early phase 1. The diseases being studied are locally advanced pancreatic cancer, borderline pancreatic inoperable cancer, and pancreatic cancer. The corresponding ICD-10 codes for these diseases are C25.3, A30.3, A30.2, A30.4, F60.3, R41.83, H40.013, H40.023, and C25.3, respectively. The drugs being used in the trial are folfirinox and gemcitabine nab-paclitaxel.\n\nThe eligibility criteria for participants in this trial include having histologically or cytologically proven adenocarcinoma of the pancreas, being staged according to the 2010 AJCC staging system, having a primary tumor of the pancreas, and having a tumor deemed as borderline/unresectable. Other criteria include having measurable disease per RECIST v1.1, having a performance status of at least 70, being over 18 years old, having an estimated life expectancy of more than 12 weeks, and meeting certain blood work requirements.\n\nThere are also exclusion criteria, such as having ineligible histology, having received prior pancreatic surgery, radiation therapy, chemotherapy, or investigational therapy for pancreatic cancer, having tumors extending or invading the duodenum or gastric, having evidence of distant metastasis, having recurrent disease, and having certain medical conditions or infections.",
    "The sample from the table represents a phase 1 trial with various diseases and eligibility criteria. The phase of the trial is phase 1. The diseases included in the trial are \"lymphoma, t-cell, cutaneous\", \"lymphoma, t-cell, peripheral\", \"chronic lymphocytic leukemia\", \"lymphoproliferative disorders\", \"waldenstrom macroglobulinemia\", and \"lymphoplasmacytic lymphoma\", and \"mantle cell lymphoma\". The corresponding ICD-10 codes for these diseases are provided as well. The drug being tested in the trial is \"pacritinib\". The eligibility criteria for the trial include specific diagnosis requirements for each disease, age requirement of 18 or older, ECOG score of 2 or lower, adequate organ and marrow function, ability to take oral medication, immediate need for treatment, ability to understand and provide informed consent, ability to communicate with the investigator and comply with study requirements. The exclusion criteria include various medical conditions, pregnancy or breastfeeding, inability to use contraception, uncontrolled illnesses, HIV infection, positive Hepatitis B or Hepatitis C, recent major surgery, insufficient recovery from previous treatments, use of systemic steroids, prior treatment with pacritinib, autoimmune hemolytic anemia or thrombocytopenia, requirement for anticoagulation, history of significant bleeding, hypersensitivity or allergic reaction to pacritinib or related compounds, concurrent use of certain medications, and gastrointestinal or metabolic conditions that could interfere with medication absorption.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The disease mentioned is \"tumor lysis syndrome,\" and its corresponding ICDCodes is \"E88.3.\" The drug being studied is \"febuxostat.\" \n\nThe eligibility criteria for this trial sample include:\n- Participants must be male and female children aged 6 to less than 12 years, adolescents aged 12 to less than 18 years, and adults aged 18 years and above.\n- Participants must be scheduled for their first cytotoxic chemotherapy cycle due to hematologic malignancies.\n- Participants must be at intermediate or high risk of tumor lysis syndrome (TLS).\n- Participants must not have access to rasburicase.\n\nThe exclusion criteria for this trial sample include:\n- Patients with contraindications as per the febuxostat summary of product characteristics.\n- Patients with severe renal insufficiency.\n- Patients with severe hepatic insufficiency.\n- Patients diagnosed with Laboratory TLS (LTLS) or Clinical TLS (CTLS).",
    "The sample is from a table that contains information about clinical trials. In this particular sample, the phase of the trial is \"early phase 1\". The diseases being studied are \"pain, head\" and \"sleep disturbance\". The corresponding ICD-10 codes for these diseases are \"H53.9\", \"O90.6\", \"F01.50\", \"F01.51\", \"F03.90\", \"F03.91\", and \"O21.1\". The drug being tested in this trial is \"steroids\". The eligibility criteria for this trial include the inclusion criteria of patients with rheumatoid arthritis and MRI findings of atlantoaxial joint inflammation that did not resolve after 2 weeks of systemic steroid administration. The exclusion criteria include coagulopathy, allergy to contrast material, and pregnancy.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The diseases being studied are recurrent squamous cell carcinoma of the head or neck, metastatic squamous cell carcinoma of the head or neck, and squamous cell carcinoma. The ICDCodes associated with these diseases are C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8 for the first two diseases, and C44.520, C44.92, C44.02, C44.321, C44.521, C44.82, C44.42 for the third disease. The drugs being used in the trial are nivolumab and afatinib. The eligibility criteria include various requirements such as no prior immunotherapy for the disease, specific organ and marrow function levels, ECOG Performance Status of 0-1, and the ability to understand and sign a consent document. There are also exclusion criteria listed, such as currently receiving other investigational agents, having brain metastases, known hypersensitivity to the drugs, and various medical conditions that may interfere with the trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The diseases being studied include acute leukemia, acute leukemia in relapse, acute myeloid leukemia, and relapsed or refractory acute leukemia. The corresponding ICDCodes for these diseases are also provided. The drug being tested is an anti-CD123 CAR-T treatment. \n\nThe eligibility criteria for this trial are listed under \"Inclusion Criteria\" and \"Exclusion Criteria\". Inclusion criteria include requirements such as patients having relapsed or refractory CD123+ acute leukemia, availability of bone marrow and/or peripheral blood samples for diagnosis confirmation, a Karnofsky performance status score of at least 70, and various medical measurements falling within specified ranges. Exclusion criteria include conditions such as acute promyelocytic leukemia, pregnancy or lactation, HIV or hepatitis B/C infection, and certain allergies or medical conditions.\n\nOverall, this sample provides specific details about the phase, diseases, drugs, and eligibility criteria for a clinical trial.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is a combination of phase 1 and phase 2. The diseases being studied are \"multiple myeloma in relapse,\" \"multiple myeloma progression,\" and \"multiple myeloma with failed remission.\" The ICDCodes associated with these diseases are \"C90.02.\" The drug being used in the trial is \"tinostamustine.\" \n\nThe eligibility criteria for this trial include having received prior ASCT (autologous stem cell transplantation) after standard first-line induction treatment, evidence of disease progression with a certain progression-free interval, receiving treatment with a limited number of prior therapy lines, and having a certain response to the latest salvage chemotherapy. Other criteria include being a candidate for consolidation therapy with tinostamustine followed by ASCT, having a sufficient number of available autologous peripheral blood stem cells, being within a certain age range, having a specific performance status score, and meeting certain requirements for kidney, heart, lung, and liver function. \n\nThere are also exclusion criteria, such as a history of central nervous system disease involvement, plasma cell leukemia, recent myocardial infraction or stroke, uncontrolled acute infection, high HCT-CI score, concurrent malignant disease (with some exceptions), major coagulopathy or bleeding disorder, other serious medical conditions that could interfere with treatment, lack of cooperation, pregnancy or lactation, recent use of investigational agents, treatment with drugs known to prolong the QT/QTc interval, and a prolonged QTc interval based on ECG readings.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The disease mentioned is \"precursor cell lymphoblastic leukemia-lymphoma.\" The corresponding ICDCodes for this disease are \"S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S.\" The drug mentioned is \"ixazomib.\" The eligibility criteria for this trial include various conditions such as a diagnosis of relapsed/refractory ALL or LLy, a certain percentage of blasts in the bone marrow, measurable disease, specific performance status, adequate organ function, failure of previous therapies, and recovery from prior treatments. The exclusion criteria include isolated extramedullary disease, certain neuropathy conditions, planned administration of other treatments, specific syndromes, Down syndrome, certain ongoing treatments, and recent use of certain medications.",
    "The sample provided is a record from a table that contains information about clinical trial phases, diseases, ICDCodes, drugs, and eligibility criteria. In this particular sample, the phase of the trial is Phase 1. The diseases being studied include her2-positive breast cancer, metastatic breast cancer, locally advanced breast cancer, and unresectable breast cancer. The ICDCodes associated with these diseases are provided as well. The drugs being investigated in this trial are copanlisib and trastuzumab emtansine. The eligibility criteria for participants in this trial are listed, including requirements such as written informed consent, age, confirmation of HER2-positive breast cancer, previous treatment history, measurable lesions, performance status, life expectancy, availability of tissue samples, and various laboratory values. The sample also includes exclusion criteria, which outline conditions that would disqualify a patient from participating in the trial."
]
